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iii. Abstract 
Active Pharmaceutical Ingredients with poor solubility have presented significant difficulties in drug 
product design and development including slow and ineffective absorption leading to inadequate 
and variable bioavailability. Therefore it has become increasingly desirable to overcome the low 
aqueous solubility of drug candidates and develop more novel and innovative formulation 
approaches to increase the dissolution rate of the poorly soluble drugs. This work focuses on the 
formulation of novel amorphous ibuprofen-polymer nanoconjugates based on the polymer-drug 
complexation in order to improve its physical and dissolution characteristics without the use of 
toxic organic solvents. Plain and ibuprofen-loaded binary and ternary nanoconjugates were 
prepared using four modified co-precipitation techniques including melt solubilization; alkaline 
solubilization; surfactant solubilization and hydrotropic complexation techniques. A remarkably 
high loading capacity was achieved ranging from 89.05 to 99.49% across the four techniques and 
polymer-polymer ratio of 50:50 was found to be most efficient. All the four techniques reduced the 
size of ibuprofen (2.87 µm) significantly in the presence of 2.0 x10-3 mM of Diethylaminoethyl 
Dextran (DEAE-Dextran) in the order melt solubilization (203.25 nm) > alkaline solubilization 
(185.68 nm) > surfactant (Tween 80) solubilization (122.17 nm) > hydrotropic complexation (77.92 
nm). 5.0 x 10-4 mM of chitosan also reduced the size of ibuprofen from 2872.12 to 10.70 nm (268-
fold reduction).  The FTIR spectroscopic analysis revealed electrostatic, hydrophobic and hydrogen 
bonding interaction between solubilized ibuprofen and the cationic polymers (DEAE-Dextran and 
chitosan) to form a new product (an amide). Polymer-polymer complexation also occurred between 
DEAE-Dextran and gellan as well as chitosan and gellan to a different extent depending on the 
mixing ratios.  1H and 13C NMR analysis confirmed the conjugation between ibuprofen and each of 
the cationic polymers as well as the formation of a new amide product. DSC thermal analysis 
showed that the nanoconjugates exhibited new broad and diffuse peaks confirming that they did 
exist in amorphous state as multiple complexes. The TGA thermograms of the binary 
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nanoconjugates exhibited one step degradation profile compared with the physical mixture which 
exhibited two steps. However the ternary nanoconjugates exhibited two steps degradation profile 
confirming the formation of multiple complexes. Marked enhancement of drug release was 
achieved by the four techniques compared with the ibuprofen control. All the DG (DEAE-Dextran - 
Gellan) complexes exhibited a higher release profile than ibuprofen control.  Fickian and non-
Fickian anomalous mechanisms were deduced for the drug release of ibuprofen from the binary 
conjugates. The ternary nanoconjugates exhibited non-Fickian (anomalous) diffusion, Fickian 
diffusion and Super Case II transport release mechanisms. The ternary nanoconjugate hydrogels 
exhibited complete release (100%) within 48 h. The lowest concentration of DEAE-Dextran, Gellan – 
Ibuprofen – DEAE-Dextran (GIbDD) 2:0.125, increased the release of ibuprofen by 13.4% however 
higher concentrations of DEAE-Dextran decreased the release profile steadily. It was concluded that 
DEAE-Dextran has potentials in the formulation of modified (extended) release of ibuprofen. The 
most prominent mechanism of release of ibuprofen from the nanoconjugate hydrogel was Super 
Case II transport. SEM and AFM micrographs of the drug loaded composite pharmaceutical films 
exhibited concentric spheres with two and three layers for the binary and ternary films respectively. 
This supports the evidence of internalization of ibuprofen by the polyelectrolyte complex. The FTIR 
and DSC results confirmed electrostatic and hydrophobic interactions between ibuprofen and 
DEAE-Dextran as well as between gellan and DEAE-Dextran. Thermal analysis revealed that plain 
bilayer films were thermally more stable than composite films. The addition of ibuprofen 
significantly increased (p < 0.05, n = 4) the swelling ratio of the films compared with films without 
the drug. The drug loaded bilayer films exhibited Fickian diffusion mechanism while the dominating 
mechanism for composite films was anomalous (Non-Fickian) transport. From the foregoing, it was 
evident that ibuprofen-polymer nanoconjugate present a novel tool for the delivery of ibuprofen 
with potential application for transdermal delivery.  
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CHAPTER ONE 
1.0. Introduction 
1.1. Background of studies 
The delivery of poorly soluble drugs has been a major research concern in the recent past. More 
than 40% of newly discovered drugs and 90% of approved drugs have poor solubility, poor 
permeability or both and approximately 16% have less than optimal performance specifically 
because of poor solubility and low bioavailability [1]. Aqueous solubility of active pharmaceutical 
ingredients is a key parameter in drug design and formulation development because a drug molecule 
has to be water soluble to be readily delivered to the cellular membrane, at the same time they 
need to be hydrophobic to cross the membrane. A balance of both properties can be utilized to 
develop various solubilization systems that can deliver water-insoluble drug to therapeutic target 
sites.   
Poor water solubility of bioactive agents (solubility < 100 µg/mL) has presented significant difficulties 
in drug product development including slow and ineffective absorption leading to inadequate and 
variable bioavailability as well as therapeutic failure. Application of genomics, high – throughput 
screening, combinatorial chemistry, informatics and miniaturization has generated a lot of drug 
candidates however it has been difficult to maximize their biopharmaceutical properties [2]. It has 
therefore become increasingly desirable to overcome the low aqueous solubility of drug candidates 
and develop more robust novel and innovative smart formulation approaches to increase the 
dissolution rates of the poorly soluble drugs. 
Previous formulation research efforts to improve oral and topical bioavailability of poorly soluble 
drugs include addition of release accelerating excipients; invasive sustained release implants which 
can only be used for very low doses; osmotic pump system; solubilization in surfactant systems; 
micronization; formation of water-soluble complexes; pro-drug design; spray drying etc. [3-4]. 
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However for many drugs, these approaches do not lead to a sufficiently high increase in solubility, 
dissolution velocity and subsequent bioavailability. Of significant research interest is the 
development of Indomethacin (Osmosin) tablet with limited gastro intestinal adverse effects. It was 
hailed as formulation breakthrough for non steroidal anti-inflammatory drugs (NSAIDs). The unique 
feature of Osmosin is the release of the active drug via a continuous osmotic pump system over a 
period of 10 to 11 h along the gastro intestinal tract rather than by tablet disintegration. Over 
400,000 prescriptions were written between December 1982 and June 1983 when it was first 
approved. However, bleeding, perforation and death in extreme cases have been reported [5]. This 
could be due to burst release profile which may have exposed certain parts of the gastro intestinal 
tract to high concentrations of indomethacin. The adverse effects of oral non steroidal anti-
inflammatory drugs in general have been recognized as a considerable cost burden. 
Current formulation research approaches are focused on macromolecular assembly of amphiphiles; 
self emulsifying systems; nanonization; nanocrystallization based on top-down and bottom-up 
techniques; co-precipitation; short acting patches as transdermal delivery systems; liposome dermal 
delivery matrix etc. [6-10]. 
Model poorly soluble drug in this study is Ibuprofen. Ibuprofen [(±)-2-4-[2-methylpropyl] phenyl 
propanoic acid] is a derivative of propionic acid which is a naturally occurring carboxylic acid with a 
molecular weight of 206.28 g/mol and molecular formula C13H18O2 shown in Figure 1. Ibuprofen is a 
white crystalline powder highly insoluble in water but readily soluble in organic solvents such as 
ethanol with a melting point between 75 and 78 °C [11]. It has two enantiomers in a racemic mixture 
(R) and (S) – Ibuprofen of which S- is the active form in the human body but R- form can be 
enzymatically converted to the active or vice versa. Ibuprofen has a pKa value of 4.5 to 4.6 [12] and it 
is dissolved at higher pH value because of the ionization of its carboxylic acid group. It is a potent 
non steroidal anti-inflammatory drug (NSAID) widely used in the treatment of rheumatoid arthritis, 
osteoarthritis, ankylosing spondylitis and mild to moderate pains associated with migraine, fever and 
dysmenorrhea. It is considered the safest of the NSAIDs in the treatment of pain due to 
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inflammatory responses and feverish conditions. It is one of the most frequently prescribed and best 
tolerated NSAID, especially in children, because of its high benefit-to-risk profile [13-14].The 
inflammatory activity of ibuprofen is due to the inhibition of cyclooxygenase-2 (COX-2) an enzyme 
responsible for the production of inflammatory mediators such as prostaglandins [15].  
 
Figure 1: The chemical structure of ibuprofen. 
When administered orally, conventional dosage forms of ibuprofen are rapidly and almost 
completely absorbed from the gastro intestinal tract with peak plasma concentrations between 15  
and 25 µg/mL occurring within 1 to 2 h [16]. The excretion is usually complete after 24 h of 
administering the last dose. However ibuprofen has hydrophobic characteristics, practically insoluble 
in water with saturation solubility of 49 µg/mL at room temperature [17]. Therefore it is difficult to 
formulate as aqueous solution and the dosage release from aqueous based hydrogels could be 
variable and unpredictable. Ibuprofen also has a short biological half-life (approximately 2 h) and its 
solubility and permeability are pH dependent [18]. It is poorly soluble at acidic pH of the stomach 
but solubilizes at alkaline pH of the small intestine. Its poor solubility (log P value 3.6) in the stomach 
limits its absorption before gastric emptying (30 min to 2 h) occurs. Although ibuprofen solubilizes in 
the small intestine, its ionized species cannot permeate through the intestinal membrane [19]. It 
follows that when administered orally, ibuprofen tends to be eliminated from the gastro-intestinal 
tract before having the opportunity to dissolve fully and be absorbed into the circulation, resulting in 
incomplete absorption as well as low and erratic bioavailability with a consequent poor dosing 
proportionality [1]. This phenomenon translates to low systemic bioavailability requiring the use of 
high and multiple daily dosing to maintain the required plasma concentration for effective 
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therapeutic activity. The usual consequence includes wasted dosing as well as potentially serious 
gastro intestinal side effects such as bleeding and ulceration. Ibuprofen belongs to the 
Biopharmaceutics Classification System (BCS) class II which exhibits poor water solubility and high 
membrane permeability [20]. The rate limiting step for BCS class II drugs is dissolution. BCS which 
was proposed by Amidon et al. is a system that classifies orally administered drugs into four classes 
based on their solubility and intestinal permeability [21]. Attempts to enhance drug solubility of BCS 
class II drugs have been shown to correlate well with increased bioavailability [22]. It has also been 
reported that rapid absorption rate of oral formulations of ibuprofen enhanced its analgesic 
properties [23]. 
The high dose requirement and poor solubility of ibuprofen have limited its application in 
transdermal drug delivery and all efforts in this regard have not been successful. Although ibuprofen 
is available as bulk topical gels, the drug loading efficiency has been limited by its poor solubility and 
the dosage is highly variable. Presently, it is difficult to quantify the effective dose for pain relief in 
the existing ibuprofen topical gels and other drug patches due to inadequate skin penetration 
profiles. Formulation strategies are still required to design fixed dose topical ibuprofen gel with 
enhanced dissolution profile adaptable for transdermal delivery in the management of pain.  
Pain is the most common symptom for which patients seek help. Over 10 million adults (6 million 
women and 4 million men) in the UK consult their GP each year with arthritis and related conditions. 
The prevalence increases with age with 1 in 10 people aged between 15 and 24 years consulting 
their GP each year with a musculoskeletal problem increasing to 1 in 3 people over the age of 75 
years [24]. Between 2006 and 2007 in England and Wales, a total of 58,952 hip replacements and 
62,150 knee replacements were carried out with between 94 and 97% due to osteoathritis [25]. Pain 
relief is a significant part of arthritis treatment and varieties of commercial topical formulations 
containing ibuprofen are available to manage arthritic conditions.  
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In most developed economies, adults are living longer and they continue to make frantic efforts to 
lead an active lifestyle. This tends to expose them to continuous incidence of pain as a result of 
muscle and joint injury or underlining disease condition. It has been projected that half of the adult 
UK population will be aged over 50 years within the next 20 years [26]. It follows that the demand 
for pain management will continue to increase hence further research into optimization of ibuprofen 
delivery is inevitably a continuous process. 
The delivery of NSAIDs through the skin for soft tissue and joint pain has been shown to be as 
equally effective as and preferred over the oral route in randomized clinical studies because they 
offer fast onset of actions as they are applied directly to the target site with fewer side effects. Local 
irritation of the skin such as pruritus and dermatitis which resolved on withdrawal of the therapy 
was also reported [27]. Literature is replete of randomized clinical studies that demonstrate the 
superiority of topical NSAIDs over placebo however comparison with oral NSAIDs has not been 
conclusive. It was reported that topical NSAIDs are highly effective in relieving pain functions and 
stiffness during the first few weeks of treatment of osteoarthritis compared with placebo but were 
less effective than oral NSAIDs at any given week [28]. However it was evident that topically applied 
NSAIDs presented far less ‘common side effects’ than the oral route [29]. The group on oral route 
had more severe respiratory adverse effects. The authors opined that topical NSAIDs diffuse directly 
into the target joints and tissues [30]. This may imply high concentration of the drug at the site of 
action but low plasma concentration which is the reverse of oral administration. Furthermore over 
80% of orally administered drug is removed by the digestive system with a consequent reduced 
therapeutic effect and severe localized side effects due to increased dose [28]. 
Transdermal route of drug delivery has gained significant attention recently because it avoids the 
pre-systemic metabolism and instability in acidic environment of the stomach when administered 
orally. It also provides consistent levels of drug at the site of action for prolonged period of time. 
Transdermal formulations are designed to facilitate diffusion through the layers of the skin into the 
systemic circulation [31], while for topical drug formulations, the site of action is the tissue directly 
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underlying the application site, including the soft tissue and peripheral nerves [29]. The skin offers 
diverse advantages as a site of drug administration however due to its natural properties as a 
protection barrier and the intrinsically poor permeability of the drug, permeation of poorly soluble 
drug through the skin is difficult. It is therefore necessary to search for new strategies to enhance 
the penetration of drugs [32]. Drug carrier systems have been proposed in order to favour the 
transport of drugs through the skin, enabling drug retention and in some cases allowing a controlled 
release [33-36]. Polymeric nanoparticles have also been reported to form a depot in the hair 
follicles, giving a targeted drug controlled drug delivery [37].    
New research efforts are being focused on lipid coated microgels [38] and short acting patches as 
transdermal delivery systems but both have been limited by poor transcutaneous absorption with 
inaccurate and unpredictable dosages.  
Hydrogels have been of great value in topical administration of many drugs based on their high 
water content (95%) [39], reduced surface tension with water, soft and rubbery consistency 
characteristics.  Their water holding capacity is based on the presence of hydrophilic groups such as 
amino, carboxyl and hydroxyl groups in the polymer chains. Their three dimensional polymer 
networks are capable of absorbing and retaining large amount of water and swelling; this could 
modulate their biocompatibility, permeability and hydrodynamic, surface and mechanical 
properties. These properties could be modified to control the movement of drug molecules of 
different sizes to diffuse into the polymer network (drug loading) and design intelligent controlled 
release systems for site specific drug delivery. Hydrogels have been used to develop oral, nasal, 
ocular, rectal, transdermal and implantable drug delivery systems (DDS) [40]. The concept of 
‘intelligent’, ‘smart’ or ‘stimuli’-responsive DDS is based on the swelling and permeability 
characteristics of hydrogels and their ability to undergo structural changes in response to physical, 
chemical and biological stimuli (bio mimetic).  
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Hydrogels liquefy on contact with the skin without visible stain compared with cream, ointment or 
pastes. Their high proportion of water allows free movement of drug molecules as in pure water. 
Generally the mobility of aqueous solutions predisposes them to absorption problems and erratic 
bioavailability because they only allow a short contact time with the skin or mucosa. Research 
efforts to solving this problem include distribution of the drug in micelles and liposomes, 
electrostatic interaction of the drug with the gel polymer and suspending the drug in the gel matrix 
[41]. However the rheological properties of gel formulations could increase contact time via 
mucoadhesion (mucosa) resulting to increased absorption if there is sufficient amount of active drug 
in the hydrogel throughout the contact period. Research efforts to date have not been able to 
establish the desired improvement in drug loading efficiency, absorption and bioavailability profiles 
of hydrogels therefore research interest in this area is continuous. 
1.2. Previous research efforts in delivering poorly soluble drugs 
Formulation approaches used in delivering poorly soluble drugs include traditional methods of 
solubility enhancement through particle size reduction via comminution, solvent recrystallization 
and spray drying; addition of surfactants such as tweens and poloxamer; polymer inclusion 
complexation (e.g. cyclodextrin); inorganic complexation; coordination and chelation etc. Other 
novel techniques include self-emulsifying systems; nanoparticularization by solvent evaporation, co-
precipitation, emulsion polymerization and co-crystallization as well as nanoconjugation or nano-
complexation [42-53]. 
Particle size reduction by micronization generally increases the surface area of drug powder leading 
to increase in total surface area and improved dissolution properties of the drug [42]. However 
various disadvantages of these technique have been reported including formation of coarse drug 
powder with broad particle size distribution due to particle re-aggregation and scaling in the spiral 
jet mills; contamination of particles with toxic solvents; degradation of products due to thermal or 
mechanical stress and its unsuitability for drugs with high dose since it does not alter the saturation 
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solubility of drug [42]. Liversidge and Conzentino prepared a nanoparticulate dispersion of naproxen 
using pearl milling technique. They used Zirconium Oxide beads in the roller mill to produce 
naproxen nanocrystals with reduced particle size from 20 µm to 270 nm and improved stability 
against agglomeration in gastric fluid as well as reduced gastric irritation and improved absorption 
rates in rats [43].  
Peters et al. produced clofazimine nanosuspension with particle size suitable for intravenuous 
injection and passive targeting of the reticuloendothelial system using high pressure homogenization 
technique [44].  Velaga et al. also used solutions enhanced dispersion by supercritical fluids (SEDS) to 
prepare hydrocortisone particles from acetone and methanol solvents. The authors were able to 
control the crystallinity of the particles and characterize the morphology and aerodynamic 
properties of the particles which maybe adaptable for the preparation of inhalation powders for 
pulmonary delivery [45-46]; Rapid expansion from supercritical to aqueous solution (RESAS) 
technique was adapted by Young et al. to prepare stable suspensions of submicron particles of 
cyclosporine with particle sizes between 400 and 700 nm. The particle growth and agglomeration 
was impeded by  surfactant (tween 80)-mediated steric stabilization [47]. Spray freezing to liquid 
(SFL) technique was used by Hu et al. to produce micronized carbamazepine powders with 
significantly enhanced dissolution rates when compared with the bulk carbamazepine [48]. 
Ibuprofen nanoparticles were formed by rapid expansion of supercritical fluid in a liquid solvent 
(RESOLV) [49] however, the ibuprofen nanoparticles formed were quick to agglomerate into large 
aggregates leading to broad particle size distribution. A post production stabilization scheme which 
involved the use of polymeric or oligomeric stabilization agent - poly (N-vinyl-2-pyrrolidone) was 
required to reduce the aggregation of the ibuprofen nanoparticles. The authors reported that the 
carrier-free solid drug nanoparticles obtained from RESOLV exhibited high drug loading capacity with 
increased efficacy at reduced excipient concentration. The strength of this technique is that RESOLV 
does not utilize any surfactant or organic solvent.  
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Surfactants have been used to improve the dissolution of poorly soluble drugs by lowering the 
surface tension and increasing the solubility of the drug within the solvent. They are also used to 
stabilize drugs dissolved in microemulsions and suspensions. Kayser et al. used tween 80 as 
surfactant to develop amphothericin nanosuspension using high pressure homogenization 
technique. The resulting nanosuspension exhibited significant reduction in liver parasite (Leishmania 
amastigotes) load by 28.6% indicating an improved oral absorption and systemic efficacy when 
compared with commercial formulations available [50]. 
Drug inclusion complexation with cyclodextrin has been reported to solubilize high dose drug 
products and drugs with high melting points. Cyclodextrins (CDs) are cyclic oligosaccharides with its 
natural derivatives possessing limited aqueous solubility however the synthetic CDs have improved 
solubility but limited drug inclusion capacity. The solubilizing effects of CDs have been improved by 
their addition to hydrophilic polymers.  Maestrelli et al. prepared two hydrophobic drugs, triclosan 
and furosemide, complexed with cyclodextrin and further entrapped in the chitosan nanocarrier. 
The authors found that the drug-cyclodextrin complex was efficiently entrapped in the nanoparticle 
system [34] and the drug release profile of the drugs was biphasic with an initial fast release 
followed by a delayed release phase. This nanosystem offered a potential in transmucosal delivery of 
hydrophobic drugs.  
Nanoconjugation or nano-complexation has also been used in the delivery of poorly soluble drugs. 
Nanoparticles as drug carriers can be formed from biocompatible and biodegradable materials such 
as polymers. In recent years, biodegradable polymeric nanoparticles have attracted considerable 
attention as potential drug delivery devices in view of their applications in the controlled release of 
drugs; targeting particular organs/tissues; as carriers of DNA (Deoxyribonucleic acid) in gene 
therapy, and in their ability to deliver proteins, peptides and genes through the per oral route. 
Nanosizing of poorly soluble drugs is a rapidly developing technique in the field  of medicine to 
achieve safe and effective drug delivery [51]. Their potential applications include enhanced molar 
solubility, increased dissolution velocity, controlled release, tissue targeting in cancer therapy, 
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carrier action for the delivery of peptides, enhanced cell penetration, improved efficacy and reduced 
side effects etc.[52-53]. 
Nanoscale drug delivery systems enhance solubility and dissolution rates due to massive increase in 
specific surface area; they can also cross the capillary barriers and flow freely in blood circulation 
enhancing the bioavailability of the drug. Polymeric nanoparticles have high structural integrity due 
to the rigidity of the polymer matrix. 
Nanoparticles for the purpose of drug delivery are amorphous or crystalline submicron (< 1 µm) 
solid, colloidal particles including nanospheres and nanocapsules of sizes between 10  and 1000 nm 
[54]. Nanocapsules are vesicular systems in which the drug is confined to a cavity (aqueous or oily 
core) surrounded by a unique polymer membrane or shell like wall, while nanospheres are matrix 
systems in which the drug is physically and uniformly dispersed [55]. Polymer nanoparticle is a 
collective term used for any type of polymer nanoparticle, particularly for both nanocapsules and 
nanospheres. 
First polymer nanoparticles for pharmaceuticals were prepared in the late 1960’s and early 1970’s 
[56]. Different techniques have been employed in the production of polymeric nanosized drug 
particles based on preformed polymers or by direct polymerization of monomers. Polymerization of 
monomers involves techniques such as micro-emulsion, mini-emulsion, surfactant-free emulsion and 
interfacial polymerization. Preformed polymers utilize techniques such as solvent evaporation, 
salting out, dialysis and supercritical fluid technology. 
Solvent evaporation was the first method and the most widely used in the preparation of polymeric 
nanoparticles. The method of preparation involves the dispersion of the polymer  in volatile solvents 
by high speed homogenizers or ultrasonication to form emulsions on addition of the aqueous phase 
containing stabilizers, which gives a nanosuspension on evaporation of the solvent, diffusing through 
the continuous phase, by continuous stirring, heat or vacuum [57]. The emulsions are either 
prepared as single emulsions (oil-in-water emulsion) or double emulsions (water-in-oil-in-water 
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emulsion). The nanosuspension formed is then ultra-centrifuged and washed with distilled water to 
remove additives and lyophilized. The organic solvent should be able to dissolve both the oil and 
polymer, be partially water soluble to aid the diffusion step and be safely removed under reduced 
pressure [58]. Ethyl acetate has been used to replace dichloromethane and chloroform based on its 
better toxicological profile [59]. Lemoine and Preat prepared poly (D, L-lactide-coglycolide) (PLGA) 
nanoparticles loaded with hemagglutinin (HA) by the single and double emulsion methods to achieve 
200 nm particle size [60]. Poly vinylalcohol PVA (emulsion) or Span 40 (double emulsion) was used as 
surfactants. Increased concentration of PVA resulted in marked decrease of particle size. PVA 
decreased the particle size compared to Span 40. The particle size was influenced by the surfactant 
type and concentration; homogenizer speed and evaporation. The PLGA nanoparticles were easily 
resuspended after freeze drying without variation in size. HA was well encapsulated, however, it was 
difficult to quantify the amount of HA encapsulated within the nanoparticles. 
The simplicity of the solvent evaporation method has been overwhelmed by the possibility of the 
nano droplets coalescing during evaporation thereby affecting the final particle size and morphology 
and the method being time consuming [61]. 
Salting-out method involves the separation of water miscible solvent from aqueous solvent. It could 
also be described as a modified emulsification/solvent diffusion method. Alleman et al. prepared 
polymeric nanoparticles by adding a high concentration of electrolyte (sodium chloride, calcium 
chloride, and magnesium chloride or magnesium acetate) containing water soluble stabilizing 
polymer (polyvinylpyrrolidone or hydroxyethlcellulose) to acetone polymer solution under 
continuous stirring. The acetone was prevented from mixing with water by the saturated aqueous 
solution via salting out. Addition of excess water facilitated the complete diffusion of acetone into 
the aqueous phase resulting in the production of nanospheres [62]. The authors avoided the use of 
surfactants and chlorinated solvents in the preparation. 
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Salting-out is non-dependent on temperature, which makes it useful in the preparation of heat 
sensitive substances [63]. It also minimizes stress to protein encapsulants [64]. However, it is applied 
exclusively to lypophilic drugs and its cumbersome extensive washing up steps has limited its use 
[65].  
Nanoprecipitation method developed by Fessi et al. [66] is also referred to as solvent displacement 
method. It is based on the interfacial deposition of a polymer after displacement of a semi-polar 
solvent, miscible with water from a lipophilic solution. Solvent diffusing rapidly into non-solvent 
phase causes a decrease in the interfacial tension between the two phases, increasing the surface 
area and ultimately forming small droplets of organic solvent [66]. The slow addition of the organic 
phase to the aqueous phase under moderate stirring results in polymeric nanoparticles.  Yordanov 
and Dushkin prepared poly (butylcyanocrylate) nanoparticles loaded with chlorambucil coated with 
three stabilizers (Polysorbate-80, Pluronic-F68 and Dextran 40) [67]. The solvent used was acetone 
with nanoparticle sizes in the range of 210 to 269 nm. The authors suggested that the polysorbate-
80 coated nanoparticles could overcome blood-brain barrier and multi drug resistance in cancer 
therapy. Nehilla et al. prepared surfactant free ubiquinone (CoQ10) loaded PLGA nanoparticles with 
acetone as solvent [68]. Particle sizes of about 165 nm were achieved with sustained release for two 
weeks. It has great potential in antioxidant therapy. 
There are three stages in the process of particle formation in nanoprecipitation method : nucleation, 
growth and aggregation as described by Lince et al. [69]. Nucleation is the creation of a new solid 
phase from a super-saturated solution where small clusters are initiated; molecular growth is the 
attachment of the single molecules into the particle matrix after diffusion from the bulk of the 
supersaturated solution to the particle surface and it is the continuous rate of change of particle 
size; while aggregation occurs when individual nuclei coalesce into larger clusters and is based on 
the frequency of collisions and their stability. The particle size distribution is determined by the rate 
of each stage and this principle is based on super-saturation which is the ratio of polymer 
concentration and the solubility of the polymer in the solvent mixture [69]. Barichello et al. assessed   
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the drawback and advantages of this method and found that hydrophilic drugs such as vancomycin 
and phenobarbital were poorly encapsulated by PLGA nanoparticles with encapsulation efficiency of 
12.1% and 9.1% respectively while lipophilic drugs such as cyclosporin A and indomethacin had good 
encapsulation efficiency of 83.7% and 93.9% respectively [70]. Encapsulation had been increased 
from 2.6 to 9.3% , by modifying the solubility of cloricromene (anti-ischemic drug) in poly (D,L-
lactide)–PLA nanoparticles by changes in pH to 11; increasing the aqueous pH from 5.8 to 9.3 
increased the encapsulation efficiency from 11 to 58% for procaine hydrochloride PLGA 
nanoparticles [71-72].  
Ibuprofen nanoparticles were  prepared based on dextran-drug conjugates applying in situ activation 
of N,N(‘)-carbonyldiimidazole (CDI) by nanoprecipitation method via dialysis and dropping technique 
[73]. The molecules self assembled into nanoparticles in the absence of surfactants. However, 
improved stability of the nanoparticles can be obtained by the addition of non-ionic polymeric 
surfactant. A remarkably high loading capacity was achieved with the drug content obtained varying 
from 37 to 71%. The authors assumed that the hydrophobic ibuprofen moieties are located in the 
interior of the particles because it is established that nanoparticles based on dextran esters possess 
a hydrophobic core [74]. Nanoprecipitation is a simple and reproducible method, but the low 
polymer concentration in the organic phase has posed a formulation challenge which is a drawback. 
Dialysis involves dissolving the polymer in organic solvent and placing it inside a dialysis tube with 
proper molecular weight cut off performed against a non-solvent miscible with the former miscible 
solvent. Lee et al. prepared carboxylic acid poly (ethylene oxide)-poly (lactide) (PEO-PLA) block 
nanoparticles with particle size range of 30 to 40 nm suitable for injectable drug carrier and drug 
loading efficiency increased when carboxylic acid content was increased in the block copolymer [75].  
Co-precipitation method is a modification of complex coarcervation method. Complex coarcervation 
is formed in a system with two dispersed hydrophilic colloids of oppositely charged electrolytes 
when mixed in an aqueous solution. The colloid-rich phase is called the coarcervate phase while the 
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phase with the little colloid is called the equilibrium fluid [76]. Micrometric or nanometric particles 
are formed based on process variables which include temperature, pH, ionic strength, molecular 
weight and polyelectrolyte concentration. 
Co-precipitation is used in the preparation of nano-scale core-shell particles and it enhances the 
dispersion stability of poorly soluble drugs during storage. It is a technique used in 
microencapsulation. Co-precipitation can be induced in systems which contain anionic and cationic 
hydrophilic colloids. Ibuprofen sodium salt nanoparticles stabilized by diethylaminoethyl dextran, 
DEAE-Dextran (Ddex) were prepared via the co-precipitation method [8]. DEAE-Dextran was 
deposited unto precipitated ibuprofen (Ib) particles from a supersaturated solution through 
electrostatic interaction. The authors found the particles had a core-shell structure formed at pH 6 
for Ddex/Ib weight ratio of 5:1 containing 32% of ibuprofen. Ibuprofen was further identified as the 
core and DEAE-Dextran as the shell. Electrostatic complexation was found to dominate the Ddex/Ib 
particles instead of the co-precipitation mechanism. 
Emulsion polymerization involves the polymerization of monomers. Water can be used as the 
dispersing medium. Based on surfactant, it can be grouped as conventional emulsion polymerization 
or surfactant-free emulsion polymerization [77]. Conventional emulsion polymerization utilizes 
water, a monomer of low water solubility, water soluble initiator and a surfactant in its formulation 
reaction to produce polymeric nanoparticles containing many polymer chains. Four differentially 
charged surfactants (sodium dodecyl sulphate-(SDS); cetyltrimethylammonium bromide-(CTAB); 3-
(N,N-dimethylmyristylammonio)propanosulfonate-(DMMA-PS) and dodecanoic acid 2(2-
hydroxyethoxy)ethyl ester-(DDA-HEEE)) were used to prepare poly (butyl acrylate-styrene) 
nanoparticle emulsions loaded with antibacterial agent penicillin  with particle size range of 42 to 
332 nm [78].   Removal of surfactants is time consuming with additional cost burden a drawback. 
Therefore, surfactant-free emulsion polymerization has been used as alternative. Surfactant-free 
polymerization utilizes deionized water, a water soluble initiator (potassium persulfate) and 
monomers (vinyl or acryl monomers), where stabilization of polymeric nanoparticles occurs through 
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the use of ionizable initiators [61]. Bao and Zhang prepared  poly (methyl metacrylate) – PMMA 
nanoparticles by polymerization of methyl metacrylate (MMA) using microwave irradiation [79]. The 
particle size obtained was controlled by the concentration of MMA (monomer). The particle size 
increased linearly from 103 to 215 nm as MMA increased from 0 to 0.3 mol/L. Monodisperse and 
superfine PMMA microspheres were achieved by the polymerization reaction. 
The use of most synthetic surfactants has been limited by their toxicity. Therefore this research 
focuses on using novel, natural, safe and biodegradable polymers to prepare polymeric nano-
complex carrier systems to enhance the solubility, dissolution, permeability, release profiles as well 
as predictable bioavailability of poorly soluble drugs. 
1.3. Polymers used in the preparation of nano-conjugates 
Natural polymers have attracted attention as potential vehicles for the sustained/controlled release 
of bioactive materials in recent years. Natural polymers are used more when compared with various 
synthetic and semi synthetic polymers due to safety issues associated with synthetic polymers 
although they can be tailored to give a wider range of properties. 
Gellan gum is a water soluble, linear anionic polysaccharide gelling agent produced by 
Sphingomonas elodea. It consists of tetrasaccharide repeating units of glucose, glucuronic acid and 
rhamnose in the 2:1:1 ratio [80] shown in Figure 2.  
 
Figure 2 The chemical structure of gellan gum [81]. 
The gelation of gellan gum is either temperature dependent or cation (monovalent or divalent) 
induced [82]. The gelation process starts with the formation of double helical junctions from random 
coil chains, then the aggregation of the double helical segments forming a three dimensional 
Glucose    Glucuronic acid      Glucose              Rhamnose 
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network by complexation with cations and hydrogen bonding with water [83]. Gellan gum is stable 
over a wide pH range of 2 to 10 [84]. The pKa value of gellan gum is 3.06 [85]. Its molecular weight is 
greater than 70 000 Daltons with 95% above 500 000 Daltons. Gellan gum is mainly used as stabilizer 
or thickening agent. Gellan gum has been reported to be completely safe for use in food. The 
European Union has permitted its use as an additive (E418) with generally recognized as safe (GRAS) 
status in the United States [86] . Miyazaki et al. exploited the in situ gelling characteristics of gellan 
in the stomach of animal models (rats and rabbits) in the oral delivery of theophylline [87]. The 
sustained release of theophylline was achieved for over a period of at least 6 h.  Recently, Yang et al. 
prepared chitosan-calcium-gellan beads for controlled release of bovine serum albumin (BSA) 
protein by combining of ionic gelation and polyelectrolyte complexation methods [88]. Its 
encapsulation efficiency was in the range of 62 to 85%. The authors found the release of BSA was 
mainly triggered by Fickian diffusion mechanism with a potential of being a new carrier for the 
controlled release of protein.  
Diethylaminoethyl-Dextran (DEAE-Dextran) is a water soluble polycationic derivative of Dextran 
produced by reacting diethylaminoethyl chloride with Dextran shown in Figure 3. It is supplied in 
hydrochloride form. It is freely soluble in water and salt solutions and biodegradable [89]. It has 
mean molecular weight > 500 000. The solubility is unaffected by pH within the range of 4 to 10. The 
high amount of hydroxyl groups facilitates the introduction of drugs into its structure [73]. 
 
Figure 3 The chemical structure of DEAE-Dextran. 
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Chitosan is an amino-polysaccharide derived from alkaline deacetylation of chitin, present in the 
fungal cell walls and exoskeleton of arthropods [90]. Chitosan  consists  of linear copolymers of 
(1→4)-2-amino-2-deoxy-β-D-glucan (GlcN) shown in Figure 4. Chitosan is insoluble in water, but 
soluble in acidic aqueous media due to the protonation of the chitosan amino groups. Chitosan has 
been used in the preparation of nanoparticles and microparticles due to its characteristics which 
include its cationic nature, biodegradability, biocompatibility, non toxicity and mucoadhesive 
character. Low molecular weight chitosan used in this study has a molecular weight in the range of 
50 000 to 190 000 Daltons. Chitosan is a positively charged polymer at low pH values (below its pKa) 
value. The reported pKa value of chitosan is 6.5 [91].  Addition of a strong base beyond pH 6.2 leads 
to the formation of a gel-like precipitate which is due to the neutralization of chitosan amino groups, 
and the removal of repulsive inter-chain electrostatic forces. This therefore allows for extensive 
hydrogen bonding and hydrophobic interactions between chains [92]. It spontaneously associates 
with negatively charged polyions in solution to form polyelectrolyte complexes. The positively 
charged amino groups of chitosan interact electrostatically with the negatively charged carboxylic 
acid group of the glucuronic acid unit in gellan gum to form a chitosan-gellan polyelectrolyte 
complex by self-assembly of their counter ions [93]. 
 
Figure 4 The chemical structure of chitosan. 
Various methods for producing chitosan nanoparticles are described in the literature [94-95]. Mao et 
al. prepared chitosan-DNA nanoparticles by complex coarcervation method [91]. The optimized 
particle size was in the range of 100 to 250 nm with a narrow distribution. The encapsulated plasmid 
DNA was partially protected from nuclease degradation by the chitosan-DNA nanoparticles. The 
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nanoparticles were further loaded with chloroquine (CQ) and the drug loading of CQ was found to be 
5.2%. The authors reported that in vitro drug release could not be accurately determined due to 
small sample size obtained. Fernadez-Urrusuno et al. prepared insulin-loaded chitosan nanoparticles 
by ionic gelation via mixing insulin with tripolyphosphate (TPP) solution and chitosan solution. 
Particle size range of 300 to 400 nm with positive surface change in the range of +54 to +25 mV was 
obtained.  The drug loading obtained was up to 55%. The authors found that insulin association was 
mediated by an ionic interaction mechanism. The nasal absorption of insulin was enhanced by the 
chitosan nanoparticles. 
1.4. Polymer Therapeutics 
Polymer Therapeutics entities was first defined as nanomedicines by Prof Ruth Duncan [96]. Polymer 
therapeutics is made up of complex systems with rationally designed covalent chemical bond 
between a water soluble carrier and the bioactive molecule(s) [97]. These include polymeric drugs, 
polymer-drug conjugates, polymer-protein conjugates, polymeric micelles covalently bound to drugs 
and polyplexes for gene and protein delivery. Drug-polymer conjugates enhance aqueous solubility 
and also changes the pharmacokinetics of the whole organism and at sub-cellular level thereby 
possibly enhancing drug therapeutic value [98-99]. The physical properties of polymers have been 
found to have unique properties useful in the treatment of human diseases, improved drug targeting 
and circulation, leading to polymer drugs currently being used in routine clinical use [98]. 
It has been demonstrated that polymer-drug conjugation engenders nano-sized multi-component 
constructs (nanomedicine) [100]; enhances drug’s aqueous solubility, permeability and retention 
[97, 101]; promotes accumulation and preferential uptake by targeted cells [102]; decreased 
toxicity; improved pharmacokinetics and programmed drug release profile [103]. These polymer-
drug conjugates are considered as New Chemical Entities (NCEs) not conventional pharmaceutical 
dosage formulation or drug delivery systems that simply physically entrap the drug [97]. 
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In 1990, Maeda et al. developed the first polymer-protein conjugate. It consisted of two polymer 
chains of styrene-co-maleic anhydride (SMA) covalently bound to the antitumor protein 
neocarzinostatin (NCS) [104]. This conjugate was known as Zinostatin stimalmer (SMANCS). Oily 
SMANCs was shown to inhibit tumour growth by a range of 63 to 82% in mice bearing various solid 
tumours [105]. A large number of hepatoma patients treated with SMANCS in the first clinical 
evaluation showed that 95% had tumour shrinkage and 86% had a  decreased concentration of α-
fetoprotein level [104]. Polyethylene Glycol conjugated with protein (PEGylated proteins) in the case 
of PEG-catalase has been reported to retain 93% of its enzyme activity, resisted digestion by 
enzymes from Streptomyces griseus, and enhanced circulating lives in the blood of acatalasemic 
mice during repetitive intravenous injection [106]. There has also been an increase in the use of 
responsive polymer-protein bioconjugates (RPPB) for biotechnological applications. These types of 
polymers respond to different environmental stimuli such as a change in temperature, pH, ionic 
strength or presence or absence of a specific metabolite in solution etc. They undergo rapid yet 
reversible macroscopic physical and/or chemical changes. The conjugation between responsive 
polymers and proteins is said to improve functional stability of the protein in different reaction 
microenvironments, effectively allowing diversification of drug functions.  Research has stressed the 
importance of site-directed bioconjugation, as random conjugation of polymer to protein was shown 
to lead to heterogeneity which causes denaturation of the protein. However the attachment of 
polymer to a specific site on the protein may lead to functional stability with better conjugation 
efficiency. The improvement in functional stability is underpinned by the polymer's ability to protect 
the protein from its local microenvironment until it reaches its target, at which point the polymer 
releases the protein and enhances the desolvation properties involved in the protein's binding to its 
target.  
The conjugation between polymer and enzyme has been researched in depth over the past couple of 
decades. The first polymer-enzyme (PEGylated enzyme) to be approved for clinical use was the 
conjugation between PEG and L-asparaginase, also known as Oncaspar® [107]. In 1994, Oncaspar®, 
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an anti-tumour PEGylated protein, was approved for the treatment of acute lymphoblastic 
leukaemia. This conjugate involved the formation of multiple PEG chains linked to the enzyme with 
advantages of reduced hypersensitivity, longer plasma half life and slower total clearance. The 
conjugation between PEG and recombinant arginine deaminase (PEG-rhArg) has been developed to 
treat hepatocellular carcinoma as a single agent or combined with 5-fluorouracil (5-FU) [108]. It was 
noted that the activity and stability of orderly-arranged enzyme bioconjugates is typically higher 
than for the randomly-conjugated enzyme because specific conformations of the bioconjugate may 
optimize availability of substrate without, on the other hand, modifying the active site. PEG-
granulocyte stimulating factor (PEG-GCSF), neulasta has also been used to prevent cancer 
chemotherapy induced neutropenia with benefit of less frequent administration [109]. It was noted 
that polymer-cytokine conjugates, like polymer-protein conjugates generally, display enhanced 
activity as a result of enhanced bioavailability without loss of function. Polymer-proteins are now 
used routinely anti-cancer therapeutics as an adjunct to chemotherapy [96]. 
Due to the clinical success of polymer-protein conjugates and polymer-peptide conjugates, research 
has focused on developing strategies to form equally effective polymer-drug conjugates. Polymer-
drug conjugates are defined as nano-sized hybrid constructs that bind with the biomolecule 
covalently to ensure efficient delivery and adequate availability at the site of action [110]. The 
combination of drug and polymer has been shown to be effective in cancer therapy, and is becoming 
accepted as a new class of antitumour agents [99]. In contrast with the bioavailability-enhancing 
effects of polymers on proteins, the enhancement of drugs by polymers appears to be due to 
increased stability, which leads to enhanced permeability and retention [111]. This type of 
conjugation has the ability to improve the therapy of common drug-resistant solid tumours by 
decreasing toxicity and improving activity in chemotherapy-refractory patients. The modification is 
often mediated by the formation of stable bonds such as ester, amide, and disulphide. These bond 
linkages must be stable enough to prevent the early release of the drug, i.e. during transport before 
cellular localization of the drug. Covalent bonds (e.g. ester or amide) are stable and could deliver the 
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drug at the targeted site, but such bonds may only easily release the targeting agent (peptides) 
under the influence of acceptable environmental change [112]. N-(2-Hydroxypropyl) 
methacrylamide (HPMA) copolymers were used as carriers for most of the anticancer drug 
conjugates. Two HPMA copolymer-doxorubicin conjugates were produced in the early 1980s by 
Duncan et al. which progressed into phase I/II evaluation [113]. In terms of physical stability, 
Williams et al.  investigated the use of polymer-drug conjugates to modify the physical properties 
(improving aqueous stability) of the cytotoxic drug, 7-ethyl-10-hydroxycamptothecin (SN-38) using 
reversible addition fragmentation chain transfer [114]. The research emphasized the importance of 
growing a water soluble polymer of defined size, composition and shape from hydrophobic 
antitumour agents. This offers a means of improving the physical properties of the drug while 
simultaneously introducing specific targeting elements. This work also stressed the importance of 
the site at which the polymer is attached to the drug to the success of the conjugate formed, as has 
been found for polymer-protein conjugates. 
Polyethylene glycol (PEG) and N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers used as the 
polymer components in polymer-protein and polymer-drug conjugates respectively are non-
biodegradable. A number of polymer-protein conjugates have been in the market since the 90’s 
however none of the polymer-drug conjugates under intensive research efforts have yet reached the 
market [97]. The slow progression of transforming polymer-drug conjugates into clinically useful 
medicines for clinical evaluation for regulatory approval has been due to clinical failure owing to 
‘wrong conjugate rational design’ that yielded unspecific drug release [115-116]. 
Polymer–protein conjugates are in the market or in the clinical development phase [117]. Issues of 
great consideration regarding the suitability of polymers or their conjugates for development 
include; safety following acute or chronic use, primary metabolites that could be formed and their 
fate, reproducibility, possibility of achieving validated characterization of all components, acceptable 
stability and suitability for patients, reproducible efficacy, cost effectiveness and variability based on 
the physical attributes of the polymers and terminologies used [117].  
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1.5. Polyelectrolyte Complexation (PEC) 
Polyelectrolytes are macromolecular species with repeating units bearing charged groups. Positively 
or negatively charged entities are formed when the charged group dissociate in aqueous solution. 
Polyelectrolyte complexes (PECs) are association complexes formed due to electrostatic attraction 
between oppositely charged polyions (polymer-polymer, polymer-drug and polymer-drug-polymer 
[118]. PECs circumvents the use of chemical crosslinking agents, thereby reducing the toxicity and 
other side effects associated with the cross-linkers. 
Polyelectrolytes are classified based on electrochemistry as cationic (DEAE-Dextran and chitosan), 
anionic (gellan) and zwitterionic (proteins). They are also classified based on origin as natural, 
synthetic and chemically modified biopolymers. 
Polymeric self-assembly or polyelectrolyte complex is formed by the spontaneous association of 
oppositely charged polyelectrolytes in solution. The complex formed is insoluble in aqueous 
solution. The use of chemical cross-linking is avoided, which reduces the possible toxicity and 
unwanted side effects that may be caused by the potential cross-linkers.  
PEC could be formed by using a possible mechanism of electrostatic forces  and Flory-Huggins mixing 
free energies of the polyelectrolytes [119-121].  PECs formed are applied in different dosage forms 
for the formulation of stable aggregated macromolecules. 
The formation of polyelectrolyte complexes involves 3 steps as shown in Figure 5 [118]. A primary 
complex is formed in the first step based on Coulomb forces. This undergoes intracomplex formation 
in the second step based on new bonds formation and correction of the polymer chains distorted. 
And finally undergoes intercomplex aggregation process in the third step based on aggregation of 
secondary complexes via hydrophobic interactions. 
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Figure 5 Schematic representation of the formation and aggregation of PECs (a) Primary complex formation (b) 
Formation process within intracomplexes (c) Inter complex aggregation process [118]. 
Factors affecting the formation and stability of polyelectrolyte complexes include: the density of the 
charges on the polyelectrolytes, the charge distribution over the polymeric chains, the degree of 
ionization of each of the oppositely charged polyelectrolytes, the concentration of the 
polyelectrolytes, the molecular weight of the polyelectrolytes, the order of mixing, the ratio of mix, 
time taken for interaction to be completed, the nature of the ionic groups,  the charge distribution 
over the polymeric chains, the position of the ionic groups on the polymeric chains, the polymer 
chain flexibility, the temperature; ionic strength and pH of the reaction medium [122-124].  
The occurrence of charge to charge interaction of polymer-drug and polymer-polymer has been 
investigated for controlled release of drugs [125-126]. Genta et al. prepared oxychitin-chitosan 
microcapsules with encapsulation efficiency of 49 to 67% [125]. The microcapsules exhibited 
external layer of polyelectrolyte complex and a core of oxychitin with miconazole crystals and it 
delayed the release of miconazole. Macleod et al. also investigated the polyelectrolyte complex 
between pectin and chitosan loaded with paracetamol in the film preparation [126]. The results 
suggested that a bimodal drug release of paracetamol can be achieved when applied as a film coat 
to tablets for an increased rate of release in the colon.  
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Four possible mechanisms of complexation of the active drug with the PEC include: entrapment of 
the active drug during complex formation; incorporation of the drug into the complex after it has 
formed; binding of the drug to one polyelectrolyte before complexation; and the drug forming a PEC 
itself by acting as a poly-ion [127]. Drug release can be by solution equilibrium, ion exchange, charge 
interactions, de-complexation or degradation of the complex [118]. Soluble non-stoichiometric 
complexes are formed when PECs are made with excess of one charge while insoluble stoichiometric 
complexes or precipitate are formed when the PECs has equal amounts of both charges [128]. 
These PECs have been characterized using different techniques including measurements of turbidity, 
ionic strength, pH [129] viscosity [130], weight polymer ratio in the solution [131], light scattering 
[132], infrared spectroscopy, thermal analysis, NMR, pKa and powder X-ray diffraction [133]. 
Swellable drug-polyelectrolyte matrices (SDPM) were investigated by Jimenez-Kairuz et al. by 
loading different basic drugs-atenolol, lidocaine and metoclopramide onto carbomer. The basic 
drugs were slowly released from the matrix with release rates observed in water remaining almost 
constant over time approaching zero order kinetics.  When water was replaced with sodium chloride 
(NaCl) solution, the release rate was not modified in NaCl solution with the kinetics exhibiting a 
departure from zero order kinetics but was raised in acidic media (0.1 N HCl) with a moderate burst 
effect. They found that lidocaine and atenolol matrices showed delivery properties based on the 
proportion of drug loading [134]. Interfacial polyelectrolyte complexation method was used by Liao 
et al. to prepare drug loaded chitosan-alginate fibers [135]. This method showed great potentials for 
producing drug loaded fibers with high encapsulation efficiency of 72 to 92% and sustained release 
kinetics exhibited by avidin and platelet-derived growth factor-bb (PDGF-bb) with sustained release 
of up to 3 weeks. The prolonged release of diltiazem clorhydrate from two polymer matrices system 
chitosan-alginate and chitosan-carrageenan PECs or mixtures were compared by Tapia et al. [136]. 
They found that chitosan-alginate systems exhibited a better prolonged release profile of diltiazem 
clorhydrate than chitosan-carrageenan systems because the drug release is controlled at low 
percentage of the polymers in the formulation. For the chitosan-alginate systems, the swelling 
25 | P a g e  
 
behaviours of the polymer controlled the drug release from the matrix while for the chitosan-
carrageenan the release mechanism was disintegration instead of the swelling of matrix. The effect 
of polymer-polymer and polymer-drug interaction; and the release profile of amoxicillin trihydrate 
and amoxicillin sodium from different copolymer concentration of chitosan and polyacrylic acid  
were studied by de la Torre et al. [137]. The swelling degree of amoxicillin sodium was found to be 
higher than the amoxicillin trihydrate hydrogels. The degree of ionization highly controlled the water 
uptake properties of the hydrogels. Amoxicillin sodium exhibited a slightly faster release profile than 
the amoxicillin trihydrate formulations. Non-Fickian or anomalous release mechanism was exhibited 
by both amoxicillin sodium and amoxicillin trihydrate formulations. 
Ionotropic gelation method was used by Win et al. to prepare ibuprofen loaded phosphorylated 
chitosan (PCS)-tripolyphosphate (TPP) PEC gel beads [138].  The release rate of ibuprofen from PCS 
gel beads in different dissolution medium was found to be higher at pH 7.4 than at pH 1.4 due to the 
electrostatic repulsion between negatively ionized carboxyl group of ibuprofen and phosphate group 
in PCS in pH 7.4 media; and higher solubility of ibuprofen at pH 7.4 (alkaline medium). Solid 
interpolymer complex as controlled release matrix for oral delivery was prepared by Rolfes et al. 
[139]. The method was based on either encapsulating the drug in the interpolymer complex before 
spay drying or adding it at a later stage of the formulation process. 
PEC nanoscale hydrogels have also been studied for the purpose of poorly soluble drug delivery. 
Dispersed nanogel particles are of particular interest because they exhibit intrinsic properties of gels 
combined with the properties of colloids, such as micro heterogeneous structure, small size and high 
surface to volume ratio. Drug delivery from colloidal systems dispersed in a hydrogel appears to be 
unique when compared with the delivery from traditional topical and dermatological formulations.  
Solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) enriched hydrogels were 
developed for transdermal delivery of nitrendipine [140]. The developed gels increased the efficacy 
of nitrendipine for the therapy of hypertension in comparison with oral nitrendipine. Carbopol SLN 
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and carbopol NLC gels significantly controlled hypertension from the first hour. Both the Solid Lipid 
Nanoparticle (SLN) and the Nanostructured Lipid Carrier (NLC) dispersions and the gels enriched with 
SLN and NLC possessed a sustained drug release over a period of 24 h. 
Patel et al. developed cationic hydrogels with specific delivery for antibiotics in the treatment of H. 
pylori infection in peptic ulcer disease [141]. Drug release from the freeze-dried chitosan-poly 
(ethylene oxide) (PEO) semi-inter penetrating network (IPN) hydrogels after 2 h in simulated gastric 
fluid (SGF) for amoxicillin and metronidazole were 65% and 59% respectively. The results suggested 
that the freeze dried chitosan-PEO semi-IPN could be used for local delivery of antibiotics in the 
acidic environment of the gastric fluid. 
PEC multi-layer is an example of PECs on the surface scale. One polycation/polyanion layer is called 
double layer or bilayer. On immersion of polyanion layer of film into polycation solution, there is a 
diffusion of the polycation chain towards the film which strongly interacts with the outer negative 
layer to form polyelectrolyte complexes. PEC nanoparticles are examples of PEC in the field of 
dispersions. 
The interaction between oppositely charged polymers, copolymers and surfactants in aqueous 
media could give rise to the formation of association nano-structures or complexes which exhibit a 
core-shell in form of dense coarcervate of micelles surrounded by the polymer. Drugs can be 
covalently bound or physically entrapped in the core of the polymeric nano-complexes. In the 
present study, advantage is being taken of the electrostatic interaction between oppositely charged 
polymers and surfactants, formation of polymer micelles and the finite sizes of the complexes to 
develop different biomaterials in the form of nanoparticles, hydrogels and pharmaceutical films as a 
delivery tool for poorly soluble drugs. 
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1.6. Gaps in knowledge 
Literature is replete of vast concerted multidisciplinary research efforts to optimize the delivery of 
poorly soluble drugs by the use of nanotechnology and polyelectrolyte complexation techniques as 
outlined above. However research on amphiphilic drug-polyelectrolyte and polymer-drug-polymer 
complexation and their influence on the physicochemical behaviour and drug release mechanism of 
ibuprofen are limited. To our knowledge the influence of cationic polysaccharide on the crystal habit 
and micromeritic properties of ibuprofen as well as development of pharmaceutical films and 
hydrogel of Gellan-DEAE-Dextran nanoconjugate for the delivery of ibuprofen have not been 
reported.  Literature reports on the fixed dose nanoparticle hydrogel for extended delivery of 
ibuprofen are also lacking. 
Furthermore most of the techniques used in literature involve the use of high concentrations of toxic 
chemical crosslinking agents which are subsequently removed by various techniques including 
evaporation, vacuum drying, spray drying, fluidized bed drying, lyophilization etc. making the 
process more tedious and expensive. Most reports on these techniques did not address the amount 
of residual crosslinker present in the final product which could be of great safety concerns. There are 
also concerns about environmental impact of the chemical crosslinkers as well as the reproducibility 
and scale up difficulties of the technique. Therefore, there is an urgent need to develop new 
concepts and techniques that can preclude the use of chemical crosslinkers.  
1.7. Research intention 
The electrostatic interaction of drug molecules with the polymer gel (drug-polymer conjugates) is a 
relatively new concept of polymer therapeutics where therapeutic agents are covalently attached to 
a water soluble polymer in order to optimize drug delivery efficiency as well as the therapeutic 
quality of the final product.  As a weak organic acid amphiphile, ibuprofen ionizes at high pH in 
aqueous environment to facilitate electrostatic interaction and hydrogen bonding with oppositely 
charged molecules especially hydrophilic cationic polysaccharides with glucosidic backbone.  
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In the present study, the knowledge of drug-polymer and polymer-drug-polymer solubilization-
complexation techniques have been envisioned to prepare bio mimetic nanoconjugate hydrogels 
and pharmaceutical films without any organic cross linkers for the extended delivery of ibuprofen as 
a model poorly soluble drug. The study intended to answer whether nanosize dimensions of 
ibuprofen could be achieved via the drug-polymer complexation technique and to investigate the 
mechanism of complexation; the structure of the product formed; the complexation efficiency and 
the impact of complexation on the physicochemical and morphological characteristics; changes in 
ibuprofen crystal habit and thermal stability as well as mechanism of release of ibuprofen from the 
nanoconjugate hydrogels and pharmaceutical films. It was hypothesized that this technique would 
provide extended and predictable dosage delivery. 
This technique would overcome the use of various toxic chemical cross linkers which could be 
harmful and provide foundation knowledge on the characteristics of binary ibuprofen-polymer and 
ternary polymer-ibuprofen-polymer nanoconjugates as prospective active pharmaceutical 
ingredients. In the same vein understanding of the change in crystal habit; isothermal stability; 
micromeritic and spectroscopic properties of the polymer-drug conjugate would shed light on the 
type of interaction (physical or chemical) and the capacity of the polymer combination to achieve 
the desired drug payload as well as other features that govern clinical risk-benefit ratio which are 
key indices to optimization of polymer-drug conjugate design in order to achieve effective delivery of 
poorly soluble drugs. 
1.7.1. Specific Objectives 
 To formulate and characterize oppositely charged polymer-polymer nanocomplexes for the 
delivery of poorly soluble drugs. 
 To formulate and characterize drug loaded polymer nanoconjugates. 
 To determine the drug encapsulation efficiency of the nanoconjugates. 
 To study the in vitro release profile and kinetics of the drug from the nanoconjugates. 
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 To formulate and characterize nanoconjugate hydrogels. 
 To study the in vitro release kinetics of ibuprofen from the hydrogels. 
 To formulate and characterize pharmaceutical nanoconjugate films. 
 To study the in vitro release kinetics of ibuprofen from the pharmaceutical films. 
1.8. Novelty of research 
Development of pharmaceutical nanoconjugate film for the extended delivery of ibuprofen is novel 
and would have significant application in the management of pain when drug-loaded pharmaceutical 
films are used to coat medical devices and pharmaceutical implants which could be adapted for 
contraceptives and Hormone Replacement Therapy. The polymer-drug binary nanoconjugate 
technique reduced the particle size of ibuprofen significantly thereby enhancing solubility and 
extended release of ibuprofen while the ternary nanoconjugate provided some controlled release 
profiles which could be adaptable to solid dosage form design. The enhanced, extended and 
controlled drug release from these delivery systems could provide reduction in therapeutic doses of 
ibuprofen with consequent reduced side effects.   
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CHAPTER TWO 
2.0. Formulation and characterization of Ibuprofen – Polymer nano 
conjugates 
2.1. Introduction 
Ibuprofen is a weak organic acid amphiphile that is soluble in high pH aqueous environment in its 
ionized form [1]. This ionized species has propensity for electrostatic interaction with oppositely 
charged molecules. Hydrophilic cationic polysaccharides with glucosidic backbone have a particularly 
adequate structure to interact with amphiphilic molecules like ibuprofen and the presence of 
charged or hydrophilic groups in their substituents provides strong affinity for the oppositely 
charged molecule or hydrogen bonding capacity [2]. A combination of spontaneous electrostatic and 
hydrophobic interactions between polyelectrolyte and the ionized drug underpins the formation of 
amphiphile-polyelectrolyte complexes of various structures and sizes depending on the type of 
amphiphile [3-4]. Literature is replete of reports on the role of polyelectrolyte-ionic surfactant 
(amphiphile) complexation in solubilization of poorly soluble drugs in a review by Langevin [5] 
however research on amphiphilic drug-polyelectrolyte complexation is limited. Few reports found in 
literature include elucidation of the factors underpinning the complexation of amitriptyline, 
chlorpromazine and doxepin to polyelectrolyte in aqueous phase however the drug delivery and 
nanoscale applications were not evident from the report [6-8]. Hughert and Sunderlof studied the 
effect of polyelectrolyte counterion specificity, charge density and conformation on the interaction 
between carrageenan/furcelleran and amitriptyline by means of dialysis equilibrium technique but 
did not give a report on its drug delivery potentials [8]. Persson et al. studied the interaction of 
dextran sulphate and hydrophobicity of cationic amphiphiles in the order doxepin-HCl < 
amitriptyline HCl < chlorpromazine-HCl [7]. The data reported indicated that the polyelectrolyte-
amphiphile interaction depended on both the hydrophobicity of the amphiphile and the charge 
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density of dextran sulphate. The amorphous forms of highly water insoluble drugs are known to 
exhibit higher saturation solubility, enhanced dissolution and bioavailability as well as nanoscale 
formulation than the crystalline form [9]. Cheow and Hadinomoto prepared freeze-dried amorphous 
ciprofloxacin-dextran sulfate nanoplex via drug-polyelectrolyte complexation. The nanoplex powders 
exhibited about twice the dissolution rate (50% at 1 h) and solubility (0.3 mg/mL) when compared 
with raw ciprofloxacin crystals (25% at 1 h and 0.14 mg/mL respectively) [9]. The authors however 
acknowledged that the rapid crystallization of ciprofloxacin from the supersaturated solution could 
erode its solubility advantage. Therefore, to prolong the supersaturation period, crystallization 
inhibitors such as polyvinylpyrrolidone (PVP) have to be included. 
Polymer-surfactant complexes have been reported to form nanoscopic core-shell structures above 
the critical micelle concentration (CMC) [10]. In this case poorly soluble drugs are entrapped in the 
hydrophobic core while the hydrophilic part serves as the interface between the bulk aqueous phase 
and the hydrophobic domain. The polymeric micelles therefore serve as nanoscopic depot or 
stabilizers for poorly water soluble drugs [11]. Barreiro-Iglesias et al. studied the capability of 
pluronic conjugated with poly (acrylic acid) to enhance the solubility and stability of camptothecin 
[10]. The authors found that camptothecin solubility in polymer micellar solution was three to four-
folds higher than in water at pH 5. A review of drug loaded polymeric micelles for the enhancement 
of the solubility of the drug has been presented by Jones and Leroux [12]. 
The present study aims to investigate a novel drug-polyelectrolyte complexation technique of 
preparing amorphous ibuprofen nanoconjugate. This technique entails using various techniques to 
solubilize ibuprofen, including alkaline solubilization at pH above its pKa 4.5; melt solubilization 
above melting point of ibuprofen; micellar solubilization using non ionic surfactant and hydrotropic 
complexation. The respective solutions were mixed with a solution of oppositely charged 
polyelectrolyte to initiate drug-polymer interaction. Charge neutralization leads to spontaneous 
precipitation and formation of nanoscale drug-polyelectrolyte complex. The combination of strong 
electrostatic interactions between the drug and the polyelectrolyte as well as the spontaneous 
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precipitation prevent the drug from reverting back into the ordered crystalline form hence 
amorphous drug-polyelectrolyte nanocomplex is formed. The cationic polyelectrolytes employed in 
this study are Diethylaminoethyl-Dextran (DEAE-Dextran) and chitosan which are natural 
biocompatible and biodegradable polycations. The high positive charge in the chitosan backbone has 
been reported to interact with negatively charged biomolecules [13].  
Melt solubilization technique is usually preferred when the starting materials are crystalline (solid 
dispersions)  [14]. Sekiguchi and Obi prepared the first solid dispersions consisting of sulphathiazole 
and urea as matrix by the fusion method [15]. The physical mixture at the eutectic composition was 
melted and cooled with a simultaneous crystallization of drug and matrix obtained during the 
cooling step. In this method, a poorly soluble drug is dispersed in a highly soluble hydrophilic matrix 
which enhances the solubility of the drug. Limitations of fusion method include incompatibility 
between the drug and matrix at the heating temperature which can lead to inhomogeneous solid 
dispersion with two liquid phases or a suspension being observed in the heated mixture [16]. 
Greenhalgh et al. prepared solid dispersions of ibuprofen and xylitol by fusion method [16]. The 
authors reported that large solubility parameter differences existed between the drug and carrier, 
laying evidence for possible incompatibilities. Another drawback is phase separation which can occur 
during cooling when the drug miscibility of the drug-matrix miscibility changes. Slow cooling yielded 
crystalline drug while fast cooling gave amorphous solid dispersions in the preparation of nifedipine-
polyethylene glycol solid dispersions [17]. The third drawback is the possibility of degradation of the 
drug or matrix occurring during heating to temperatures required to fuse drug and matrix.  
Alkaline solubilization involved the use of sodium hydroxide (NaOH) as solvent in the enhancement 
of solubility of ibuprofen. Ibuprofen was solubilized in alkaline medium (NaOH) above its pKa 4.5 to 
form a solution of anionic species and was mixed with positively charged polyelectrolyte solution to 
initiate drug-polymer interaction and the concurrent charge neutralization giving rise to 
spontaneous precipitation and formation drug-polyelectrolyte complex in the nanometre range. 
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Surfactant solubilization is one of the important methods of formulating by solubilizing in surfactant 
solution above the critical micelle concentration (CMC) of 0.02 mM in the case of tween 80 [18]. 
Surfactants tend to lower the surface tension and improve the dissolution of hydrophobic drugs in 
aqueous medium.  Micelles are formed when the concentration of surfactants exceeds their critical 
micelle concentration. In this study, tween 80 also known as polysorbate 80, a non-ionic surfactant 
was used to entrap the drug within the micelle. Seedher and Kanojia studied the enhancement of 
solubility of seven antidiabetic drugs such as glicazide and glyburide using cationic (cetyl 
trimethylammonium bromide-CTAB), anionic (sodium dodecyl sulphate-SDS), non-ionic surfactants 
(tween 80) and their mixtures [19]. The authors found that the non-ionic surfactant (tween 80) could 
be a better solvent as compared to ionic surfactants. In this study, polymers (DEAE-Dextran and 
chitosan) were used to control the rheology of the formulations and surfactant (tween 80) was used 
to control the surface properties or wettability. 
Hydrotropy is a molecular phenomenom whereby adding a second solute (the hydrotrope) results in 
an increase in the aqueous solubility of poorly soluble drugs. Nicotinamide aggregates via self 
assembly distinct from the surfactant self assembly since hydrotropes form planar or open-layer 
structures distinct from spheroids formed by surfactants [20-21]. Hydrotropy is considered to be 
superior to other solubilization methods such as surfactant or micellar solubilization [22]. In this 
study nicotinamide was used as the hydrotropic agent and tween 80 as surfactant in addition to the 
ibuprofen-polyion nano conjugate. 
The intention of this research was to maximize the solubility of ibuprofen in order to ensure fixed 
dose and control its release using varying complexation techniques based on electrostatic 
interaction. It is expected that understanding of the intrinsic capacity of polymer-drug conjugates in 
terms of phase solubility behaviour of poorly soluble drugs, conjugation efficiency, physicochemical 
characteristics and thermal stability would shed light on the type of interaction (physical or 
chemical/agonist or synergistic), the best polymer-drug ratio, the capacity of the polymer to achieve 
the desired drug payload and other features that govern clinical risk-benefit ratio which are key 
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indices to optimization of polymer-drug conjugate design and a consequent effective and efficient 
drug delivery. Presently there is not sufficient research information on the quantitative contribution 
of drug–polyion nanoconjugates to the biopharmaceutical characteristics of poorly soluble drugs 
justifying the need for this study to be carried out. Therefore the aim of this phase was to prepare a 
stabilized amorphous ibuprofen-polyion nanoconjugate using a fast, minimum energy and organic 
solvent-free technique.  
2.2.  Materials and Methods 
2.2.1. Materials 
Ibuprofen was purchased from Fagron, UK while gellan gum (Phytagel®), chitosan (low molecular 
weight), DEAE-Dextran hydrochloride, nicotinamide, tween 80 and pluronic F-68 were purchased 
from Sigma-Aldrich, UK. They were all used as received without further modification. Other reagents 
such as glacial acetic acid, hydrochloric acid, sodium hydroxide were of analytical grade. 
2.2.2. Formulation of drug-polymer nanoconjugates 
2.2.2.1. Melt solubilization 
Co-precipitation technique previously reported by Jiang et al. [23] was adapted with modifications. 
Varying amount of DEAE-Dextran was dissolved and made up to 50 mL with 0.1% w/v pluronic 
solution to produce double strength of the required ratio ranging from 0.2 to 3.2% w/v solutions and 
heated to 80 oC under magnetic stirring on a hot plate (Jenway 1000 stirrer). 4 mg/mL ibuprofen 
(double strength) dispersion was also prepared in 0.1% w/v pluronic solution and heated to 80 oC 
under magnetic stirring.  Equal volume of the melted ibuprofen dispersion was added drop-wisely 
into the DEAE-Dextran solution at the same temperature under magnetic stirring for 10 min. The 
Ibuprofen-DEAE-Dextran nanoconjugates produced contain a final ibuprofen concentration of 2 
mg/mL and Ibuprofen-DEAE-Dextran ratios of 1:0, 1:0.5, 1:1, 1:2, 1:4 and 1:8 labelled as IbMelt-
control, IbD1Melt, IbD2Melt, IbD3Melt, IbD4Melt and IbD5Melt respectively.  
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The pH of the drug polymer complex mixture was adjusted to 6.0 with the Mettler Toledo pH meter 
using 1 M NaOH [23].  The nanosuspension obtained was dialysed in distilled water through Visking 
dialysis tube (Visking Medicell, London UK) with molecular weight cut off 12000 for 24 h. The 
distilled water was changed three times within 24 h. The nanosuspension was kept at room 
temperature prior to particle size and zeta potential analysis. The process was repeated in the 
preparation of Ibuprofen-Chitosan nanoconjugates however chitosan was hydrated in 1%  glacial 
acetic acid and was adjusted to pH 5.0 using 1 N HCl [24] as precipitation of chitosan occurred above 
pH of 6.2. Also the final drug-polymer ratio were 1:0.125, 1:0.25, 1:0.5, 1:1, 1:2  as gelatinous mass 
was formed beyond ratio 1:2. They were labelled as IbMelt-control, IbCh1Melt, IbCh2Melt, 
IbCh3Melt, IbCh4Melt and IbCh5Melt respectively.  
2.2.2.2. Alkaline Solubilization 
The concentrations of ibuprofen, DEAE-Dextran and Ibuprofen-DEAEDextran ratio are same as 
presented in section 2.2.2.1. 200 mg ibuprofen was dissolved in 10 mL of 0.2 M NaOH, made up to 
50 mL with 0.1% w/v pluronic solution and added drop-wisely into equal volume of the varying 
concentrations of DEAEDextran in pluronic solution at room temperature under continuous 
magnetic stirring for 10 min (Jenway 1000 hotplate and stirrer).  The pH of the drug polymer 
complex mixture was adjusted to 6.0 (Mettler Toledo pH meter) using 1 N HCl [23]. The Ibuprofen-
DEAE-Dextran nanoconjugate prepared were dialysed as described in section 2.2.2.1 and labelled as 
IbNaOH-control, IbD1NaOH, IbD2NaOH, IbD3NaOH, IbD4NaOH and IbD5NaOH respectively. The 
nanosuspension formed was kept at room temperature prior to analysis. The process was repeated 
in the preparation of Ibuprofen-Chitosan nanoconjugates however chitosan was hydrated with 1%  
glacial acetic acid and adjusted to pH 5.0 [24] with 1 N HCl. The final drug-polymer ratio were 1:0, 
1:0.125, 1:0.25, 1:0.5, 1:1, 1:2 drug-polymer ratio labelled as IbNaOH-control, IbCh1NaOH, 
IbCh2NaOH, IbCh3NaOH, IbCh4NaOH and IbCh5NaOH respectively. 
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2.2.2.3. Surfactant Solubilization 
The concentrations of ibuprofen, DEAE-Dextran and Ibuprofen-DEAE-Dextran ratio are same as 
presented in section 2.2.2.1. 200 mg ibuprofen was dissolved in 10 mL of tween 80, made up to 50 
mL with 0.1% w/v pluronic solution and added drop-wisely into equal volume of the varying 
concentrations of DEAE-Dextran in 0.1% w/v pluronic solution at room temperature under 
continuous magnetic stirring for 10 min (Jenway 1000 hotplate and stirrer). The pH of the drug 
polymer complex mixture was adjusted to 6.0 (Mettler Toledo pH meter) using 1 M NaOH [23]. The 
Ibuprofen-DEAE-Dextran nanoconjugate prepared were dialysed as described in section 2.2.2.1 and 
labelled as IbTw80-control, IbD1Tw80, IbD2Tw80, IbD3Tw80, IbD4Tw80 and IbD5Tw80 respectively. 
The nanosuspension formed was kept at room temperature prior to analysis. The process was 
repeated in the preparation of Ibuprofen-Chitosan nanoconjugates however chitosan was hydrated 
with 1% glacial acetic acid and adjusted to pH 5.0 [24] with 1 N HCl. The final drug-polymer ratio 
were 1:0, 1:0.125, 1:0.25, 1:0.5, 1:1, 1:2 drug-polymer ratio labelled as IbTw80-control, IbCh1Tw80, 
IbCh2Tw80, IbCh3Tw80, IbCh4Tw80 and IbCh5Tw80 respectively.  
2.2.2.4. Hydrotropic Complexation 
The concentrations of ibuprofen, DEAE-Dextran and Ibuprofen-DEAE-Dextran ratio are same as 
presented in section 2.2.2.1. 200 mg ibuprofen was dissolved in 10 mL of 10% w/v nicotinamide 
solution, made up to 50 mL with 0.1% pluronic solution and heated up to 60 oC on a hot plate 
(Jenway 1000 hotplate and stirrer, UK). It was added drop-wisely into equal volume of the varying 
concentrations of DEAE-Dextran in 0.1% w/v pluronic solution at the same temperature under 
continuous magnetic stirring for 10 min (Jenway 1000 hotplate and stirrer). The pH of the drug 
polymer complex mixture was adjusted to pH 6.0 (Mettler Toledo pH meter) with 1 M NaOH [23]. 
The Ibuprofen-DEAE-Dextran nanoconjugate prepared were dialysed as described in section 2.2.2.1 
and labelled as IbNic-control, IbD1Nic, IbD2Nic, IbD3Nic, IbD4Nic and IbD5Nic respectively. The 
nanosuspension formed was kept at room temperature prior to analysis. The process was repeated 
in the preparation of Ibuprofen-Chitosan nanoconjugates however chitosan was hydrated with 1%  
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glacial acetic acid and adjusted to pH 5.0 [24] with 1 N HCl. The final drug-polymer ratio were 1:0, 
1:0.125, 1:0.25, 1:0.5, 1:1, 1:2 drug-polymer ratio labelled as IbNic-control, IbCh1Nic, IbCh2Nic, 
IbCh3Nic, IbCh4Nic and IbCh5Nic respectively.  
The composition of ibuprofen-DEAE-Dextran and ibuprofen-chitosan conjugates was presented in 
Tables 1 and 2. 
Table 1 Composition of ibuprofen-DEAE-Dextran conjugates  
Formulation Drug-Polymer Ratio Ibuprofen (%w/v) DEAE-Dextran (%w/v) 
IbMelt-control 1:0 0.2 - 
IbD1Melt 1:0.5 0.2 0.1 
IbD2Melt 1:1 0.2 0.2 
IbD3Melt 1:2 0.2 0.4 
IbD4Melt 1:4 0.2 0.8 
IbD5Melt 1:8 0.2 1.6 
Table 2 Composition of ibuprofen-chitosan conjugates  
Formulation Drug-Polymer Ratio Ibuprofen (%w/v) Chitosan  (%w/v) 
IbMelt-control 1:0 0.2 - 
IbCh1Melt 1:0.125 0.2 0.025 
IbCh2Melt 1:0.25 0.2 0.05 
IbCh3Melt 1:0.5 0.2 0.1 
IbCh4Melt 1:1 0.2 0.2 
IbCh5Melt 1:2 0.2 0.4 
 
2.2.3. Preparation of plain and drug loaded polymeric nanoconjugates 
2.2.3.1. Formulation of plain polymer-polymer binary nanoconjugates 
The DEAE-dextran-gellan complex was prepared by modifying the ionic gelation technique previously 
described by Santucci et al. [25]. 0.1% w/v of gellan was prepared in 0.1% w/v pluronic solution in 
distilled water and adjusted to pH 6.0 with 1 M NaOH. The dispersion was heated up to above 90 ˚C 
until solution became clear. It was added dropwise to 0.1% aqueous solution of DEAE-Dextran in 
0.1% pluronic and adjusted to pH 6.0 with 1 M NaOH using Mettler Toledo pH meter [23] at the 
same temperature under continuous magnetic stirring (Jenway 1000 hotplate and stirrer) for 10 min. 
The DEAE-Dextran-Gellan nanoconjugate prepared was dialysed as described in section 2.2.2.1 and 
were labelled appropriately. The nanoconjugates were collected by centrifugation (Denley BS 400 
Crompton) at 5000 rpm for 1 h and dried in the oven at 40 ˚C overnight. The weight ratios of DEAE-
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Dextran to gellan were 0:100, 25:75, 50:50, 75:25 and 100:0. The same process was repeated for the 
chitosan-gellan complex with 0.1% aqueous solution chitosan prepared in 1% glacial acetic acid 
containing 0.1% pluronic (adjusted to pH 5.0 with 1 M NaOH) [24] used in place of DEAE-Dextran. 
The weight ratios of chitosan to gellan were 0:100, 25:75, 50:50, 75:25 and 100:0. 
2.2.3.2. Formulation of polymer-drug-polymer ternary nanoconjugates with drug  
The method described by Santucci et al. [25] was adapted and modified as presented in section 
2.2.3.1.  100 mg ibuprofen (4.85 mM) was dispersed in 0.1% aqueous solution of gellan in 0.1% w/v 
pluronic solution with continuous stirring and adjusted to pH 6 with 1 M NaOH [23]. The dispersion 
was heated up to above 90 ˚C (Jenway 1000 hotplate and stirrer) until solution became clear. The 
solution was added dropwisely into varying concentrations of aqueous solution of DEAE-Dextran at 
the same temperature to give final polymer-polymer ratios of 0:100, 25:75, 50:50, 75:25 and 100:0 
and adjusted to pH 6.0 with 1 M NaOH on Mettler Toledo pH meter under continuous magnetic 
stirring (Jenway 1000 hotplate and stirrer) for 10 min. The DEAE-Dextran-ibuprofen-Gellan 
nanoconjugate prepared was dialysed as described in section 2.2.2.1 and were labelled 
appropriately.  The nanoconjugates were collected by centrifugation (Denley BS 400 Crompton) at 
5000 rpm for 1 h and dried in the oven at 40 ˚C overnight. The control was prepared by dispersing 
0.1% ibuprofen in distilled water adjusted to pH 6.0 and heated up to above 90 ˚C. The same process 
was repeated for the chitosan-gellan complex with 0.1% aqueous solution chitosan prepared in 1% 
glacial acetic acid containing 0.1%  pluronic (adjusted to pH 5.0 with 1 M NaOH) [24] used in place of 
DEAE-Dextran. The weight ratios of chitosan to gellan were 0:100, 25:75, 50:50, 75:25 and 100:0. 
2.2.4. Characterization of Ibuprofen nanoconjugates 
2.2.4.1. Measurement of Conductivity 
The conductivity measurements of the nanoconjugates were performed on the nanoconjugate 
suspensions before centrifugation using conductivity meter (Oakton CON 110 Series) with a cell 
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constant of 1 cm-1 at 25 ˚C. The conductivity measurements were an average of at least six 
determinations. 
2.2.4.2. Surface tension determination 
The torsion balance for surface and interfacial tension measurements with rings of circumference 4 
cm (White Elec. Inst, Co. Ltd) was used to determine the surface tension at 20 ˚C. The method 
involved measurement of the force required to detach a platinum wire ring immersed at the liquid 
surface, which was proportional to the surface tension [26]. The surface tension measurements 
were an average of at least six determinations. 
2.2.4.3. Measurement of Viscosity 
Viscosity of the nanoconjugates was measured by SV 10 Vibro Viscometer (A&D Company Ltd 
Japan). Viscosity was measured at 25 ˚C. 10.0 g of the sample was poured into the cup until the 
surface reached between the level gauges. The cup was attached on the table along guides. The 
grips were pinched and the sensor was gently lowered above the sample surface. The lever was 
lowered to secure the sensor plates. The knob of the table was turned so as to adjust the surface of 
the narrow part of sensor plates. The start key was pressed to start the viscosity measurement till 
25 ˚C was reached and the reading was taken. The viscosities obtained were the average of at least 
six determinations. 
2.2.4.4. Measurement of Transmittance/Turbidity 
The absorbance/transmittance of the nanoconjugates was measured at 420 nm (ThermoFischer 
Evolution 60S UV Spectrophotometer) against a blank of distilled water. The measurements 
obtained were the average of at least six determinations. 
2.2.4.5. Determination of particle size and zeta potential of nanoconjugates 
The mean particle size and zeta potential of the nanoconjugates were determined by ZetaPlus Zeta 
Potential Analyser (Brookhaven Instruments Corporation). Samples were diluted appropriately with 
distilled water and injected into the sample cell. Particle size measurements were carried out at a 
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scaling angle of 90° and a temperature of 25 °C. Apparent z-average hydrodynamic diameter and 
polydispersity index (PDI) were obtained. Zeta potential was determined by measuring the 
electrophoretic mobility of the dispersed particles in a charged field. Zeta potential measurements 
were done in aqueous solutions at 25 °C and the electric field strength was about 14.95 V/cm. All 
measurements of individual samples were a mean of six determinations for particle size and 10 runs 
for zeta potential. 
2.2.4.6. Drug conjugation capacity/efficiency 
Conjugation efficiency (equation 1) is the mass percentage of ibuprofen that forms the Ibuprofen 
complex relative to the initial amount of ibuprofen added. The amount of ibuprofen that forms the 
ibuprofen complex was calculated as the difference between the amount of ibuprofen added and 
the amount of non-conjugated ibuprofen in the supernatant after centrifugation. The ibuprofen 
concentration was measured by UV (ThermoFischer Evolution 60 UV Spectrophotometer, UK)  after 
passing it through 0.45 µm filter (Sartorius, Germany) at 264 nm wavelength [27]. All measurements 
were an average of six determinations. 
                       
     
  
                                                                        (1) 
Where M0 is the initial amount of ibuprofen added and Mi is the amount of nonconjugated 
ibuprofen in the supernatant after centrifugation. 
2.2.4.7. Morphology and size- Scanning electron microscopy 
The surface characteristics of the reference compound and nanoconjugates were examined by Carl 
Zeiss SEM EVO High Definition 15 Scanning Electron Microscope (Carl Zeiss, Germany) using variable 
pressure technology at low voltages with beam deceleration and high definition backscattered 
electron (BSE) imaging. The samples were mounted on double sided carbon tabs that were 
previously secured to aluminium stubs and then analysed at different magnifications and a pressure 
of 10 Pa. The accelerating voltage was 10 KV with probe current of 400 pA. The particle sizes of the 
reference compounds and the nanoconjugate images were determined. 
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2.2.4.8. Spectroscopic analysis - Fourier Transform Infra-red 
FTIR was conducted using Perkin-Elmer Precisely Spectrum One FTIR Spectrometer and a Universal 
ATR Sampling Accessory (Perkin Elmer, USA). The samples were mounted directly on the diamond 
surface and the arm was placed over it by applying enough pressure in the range of 100 to 120 units. 
The spectrum was recorded in the wavelength region of 4000 to 650 cm-1.  All spectra were then 
collected at an average of 16 scans at a resolution of 4 cm-1. All measurements were taken in 
replicates of four determinations. 
2.2.4.9. Nuclear Magnetic Resonance (NMR) Spectroscopy 
All Proton Nuclear Magnetic Resonance (1H-NMR) studies were performed on the Bruker AV-400 
(Ultrashield, Germany) spectrometer equipped with a pulsed field gradient accessory (490 mT m-1 z-
field gradient) at 25 oC (298 K) using a probe tuned at 5.13 MHz. The samples were prepared in 
Dimethyl sulfoxide (DMSO) and equilibrated in the probe for about 30 min at 25 oC before the NMR 
experiments. 1H-NMR spectra of the pure ibuprofen; ibuprofen loaded Dextran-Gellan and Chitosan-
Gellan nanoconjugates were studied in 5 mm quadruple nucleus probe (QNP) (1H/15) tubes and 
recorded at room temperature; frequency 399.94 MHz; 45o pulse; relaxation delay of 1 sec; 
acquisition time of 7.9168 sec and spectra width of 8.278 kHz. One hundred and twenty eight scans 
were recorded for each sample. 13C-NMR analysis was also performed on the same set of samples at 
frequency of 399.94 MHz; acquisition time of 1.3665 sec and spectra width of 23.980 kHz. All 
chemical shifts were assigned relative to Tetramethylsilane (TMS) as external reference. One 
thousand and twenty four scans were recorded for each sample. 
2.2.4.10. Thermal studies  
2.2.4.10.1.  Differential scanning calorimetry 
DSC was performed using Perkin Elmer Precisely Jade DSC machine with a Perkin Elmer Intracooler 
SP cooling Accessory (Perkin Elmer, USA) to study the thermal behaviour of the pure ibuprofen, 
DEAE-Dextran, chitosan, physical mixtures and ibuprofen nano-conjugates. The sample sizes in the 
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range of 8 to 10 mg were heated in hermetically sealed aluminium pans under nitrogen flow 
(40mL/min) using a scanning rate of 20 ˚C/min from -50 to 300 ˚C. Empty aluminium pan was used as 
a reference. Indium was used as the standard reference material to calibrate the DSC instrument. All 
measurements were an average of four determinations and expressed as mean ± S.D. 
2.2.4.10.2. Thermogravimetric analysis 
TGA was performed using Perkin Elmer Pyris 1 Thermogravimetric Analyser (Perkin Elmer, USA) to 
monitor the mass of the pure starting materials and nanoconjugates as a function of temperature or 
time as the sample specimen is subjected to a controlled temperature program at atmospheric 
pressure. The weight of the empty reference pan placed in the crucible was zeroed and then 
removed. Samples of known weight in the range of 18 to 25 mg were placed in aluminium pans and 
measurements performed at a scanning rate of 10 ˚C/min in the range of 25 to 500 ˚C. All 
measurements were an average of four determinations and expressed as mean ± S.D. 
2.2.5. Dissolution and drug release studies 
Calibration curve (Figure 156 in the Appendix) was constructed by using pure ibuprofen reference 
standard (secondary standard) dissolved in buffer solution (pH 7.4) within the concentration range 
1.56 and 50 µg/mL (7.56 to 242.39 mM). The correlation was linear (r2 = 0.9953) and the 
measurements at six levels of concentration were reproducible with limit of quantification (LOQ = 10 
x standard error of the intercept/slope) of 0.37 µg/mL (1.79 mM). The concentrations of ibuprofen 
were derived from this calibration curve. Thereafter the dissolution profile of the ibuprofen-loaded 
nanoconjugates was studied using the USP dissolution method. 90 mL of the ibuprofen-DEAE-
Dextran and ibuprofen-chitosan nanoconjugates (Melt, NaOH, Tween 80 and nicotinamide batches) 
containing 1 mg/mL ibuprofen was put in a dialysis tubing (Visking Medicell Ltd London UK with 
diameter 18/32ʺ and exclusion size 12000 to 14000 Da). Both ends were tied. The dialysis tubing was 
suspended in 900 mL of PBS pH 7.4, rotated at 50 rpm and maintained at 37 ± 0.5 ˚C using Pharma 
Test PT DT7 USP Apparatus II Dissolution Test Instrument - paddle method (Pharma Test Ltd, 
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Germany). At pre-determined time intervals 10, 20, 30, 60 min, 1, 2, 4, 6 and 24 h, 5 mL aliquots 
were withdrawn and replaced with 5 mL PBS pH 7.4. Drug concentrations were quantified using UV 
(ThermoFischer Evolution 60 UV-Visible Spectrophotometer, UK) after filtering through 0.45 µm 
filter (Sartorius, Germany) at 264 nm. All measurements were an average of four determinations and 
expressed as mean ± S.D. This procedure was repeated for ternary nanoconjugates. A calibration 
curve was produced using a series of dilution of reference standard ibuprofen in PBS pH 7.4 and 
analysed by UV at 264 nm shown in the Appendix I (Figure 156). The calibration curve was linear at 
concentrations between 1.56 and 50 µg/mL with R2 value of 0.99. The absorbance values obtained 
from the drug release of the complexes were correlated with the calibration curve and the amount 
of ibuprofen released was determined.  
2.2.6. Drug release kinetics 
Data obtained from in vitro release studies were fitted to various kinetic equations. The kinetic 
models used are zero order, first order and Higuchi equation.  
The zero order rate equation (2) describes the systems were the drug release rate is independent of 
its concentration [28]. The cumulative % drug release vs. time plot is made. 
                            (2)  
Where k0 is zero order rate constant expressed in units of concentration/time and t is the time. 
The first order rate equation (3) describes the release from the systems where release rate is 
concentration dependent [29]. The log cumulative % drug release vs. time plot is made. 
                                                                                   (3) 
Where C0 is the initial concentration of drug and K is first order constant. 
Higuchi described the release of drugs from insoluble matrix as a square root of time dependent 
process based on Fickian diffusion: equation (4) [30]. The cumulative % drug release vs. square root 
of time is made.  
50 | P a g e  
 
                                                                                                                                     (4)  
Where K, is the constant and it reflects the design variables of the system. 
Korsemeyer et al. derived a simple relationship which described drug release from a polymeric 
system: equation (5). To find out the mechanism of drug release, first 60 % drug release data was 
fitted in Korsemeyer-Peppas model: 
         
                                                                                                                       (5)  
Where Mt/M∞ is a fraction of drug released at time t, K is the rate constant and n is the release 
exponent. The n value is used to characterize different release mechanisms [31]. The log cumulative 
% drug release vs. log time plot is made. The criterion for selecting the appropriate model is the 
highest R2 value which indicates linearity of dissolution data [32]. 
2.2.7. Similarity factors 
The similarity fit factor denoted f2 was used to compare the dissolution profiles of the drug–polymer 
conjugates (test) and ibuprofen control (reference). The similarity f2 factor is defined by equation (6) 
proposed by Moore and Flanner [33]: 
 
              
 
 
            –    
 
          
                                                    (6) 
Where n is the number of dissolution sample times, and Rt and Tt are the individual or mean percent 
dissolved at each time point, t, for the reference and test dissolution profiles, respectively. The f2 
value greater than 50 suggests that the two profiles are similar. The f2 value of 100 suggests that the 
test and the reference profiles are identical and as the value becomes smaller the dissimilarity 
between release profiles increases [34]. 
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2.2.8. Statistical analysis 
Quantitative data are presented as mean ± standard deviation. The significance of the differences 
between means was assessed using Analysis of Variance (ANOVA) and Post hoc Tukey Test with a 
statistical significance level set at p < 0.05 using IBM SPSS (Statistical Package for Social Science) 20. 
2.3. Results and Discussions 
2.3.1. Formulation and optimization of Drug-Polymer nanoconjugates 
Process optimization was based on preliminary studies carried out (results not presented) to 
determine the optimal formulation variables such as pH, concentration of polymers and drug, drug-
polymer and polymer-polymer mixing ratio, mixing time, mixing speed, temperature, salt 
concentration and the order of polymer addition. Physicochemical properties of the drug, polymers 
and their binary and ternary conjugates such as surface tension, conductivity, contact angle, 
turbidity, viscosity and pH were evaluated to determine the critical association concentration and 
polymer saturation point which in turn was used to determine the appropriate polymer-polymer and 
drug-polymer ratio for the formulation of the nanoconjugates. The direct effect of the polymeric 
ingredients on the physicochemical characteristics, solubility, and dissolution profile of ibuprofen-
polyelectrolyte nanoconjugates was also investigated.  
Two polycation (chitosan and DEAE-Dextran) and two polyanion (sodium alginate and gellan) 
polymers were used in the pre-formulation study. The final pH chosen for DEAE-Dextran and 
chitosan formulations based on the preliminary studies was pH 6.0 and 5.0 respectively. In a similar 
study Jiang et al. prepared ibuprofen nanoparticles stabilized by DEAE-Dextran by co-precipitation 
method at pH 6.0 [23]. Arora et al. also reported the use of pH 5.0 for the chitosan solution in the 
preparation of chitosan-alginate nanoparticles based on ionotropic gelation process [24]. They noted 
that the nanoparticles obtained at pH 5.0 in chitosan solutions did not aggregate. However, 
precipitation occurred beyond pH 5.0, particularly when the pKa value of chitosan (6.5) is 
approached. 
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The binary conjugates (Ibuprofen-DEAEDextran and Ibuprofen-Chitosan) were prepared by melt 
solubilization, solubilization (ibuprofen solubilized in NaOH or Tween 80) and hydrotropic 
complexation methods. The intention was to design a technique that can dissolve ibuprofen 
completely to facilitate maximum interaction with cationic polymer and ensure formation of 
conjugates of nano size dimension with predictable fixed dose as well as complete release. Further 
interaction with anionic polymer (ternary conjugate) is expected to reinforce the conjugate with a 
view to controlling and extending the drug release. The use of stainless steel homogenizer during 
preparation of the conjugates shed some silvery colour contaminants into the sample at high 
temperature hence magnetic stirrer was used throughout the study.  
Reddy and Gudsookar prepared gliclazide-Polyethylene glycol conjugate using the solid dispersion by 
solvent method [35]. The authors reported a reduction in particle size resulting in enhancement of 
surface area and increase in gliclazide wettability. However this method involved the use of solvent-
ethanol to dissolve the drug and polymer followed by evaporation of the solvent. The method used 
in this study avoided the use of organic solvents due to safety issues and the increasing need to 
deliver safe drugs to patients. It also avoids the laborious process of evaporation.  
Alkaline solubilization and surfactant solubilization were adapted to enhance the propensity of 
interaction between ibuprofen and the respective polymers. Hydrotropic complexation was also 
carried out to solubilize ibuprofen using 10% w/v nicotinamide. The research intention is to enhance 
the solubility of ibuprofen by the combined advantage of hydrotropic solubilization and the 
solubilization effect of the polymeric carrier. Hydrotropic agents have been reported to enhance the 
aqueous solubility of various poorly water-soluble compounds due to the presence of large amount 
of additives such as sodium benzoate, sodium-o-hydroxy benzoate, sodium-p-hydroxy benzoate, 
sodium salicylate, urea, nicotinamide, sodium citrate and sodium acetate [37]. They also increase 
the number of hydrogen bridges in the water clusters making the water more hydrophobic, 
therefore a better solvent for the poorly soluble drug or due to change in solvent character known 
as hydrotrope solubilization phenomenon [38]. Ahuja et al. prepared urea with nicotinamide as 
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hydrotrope in varied proportions by hydrotropy solid dispersion method to enhance the dissolution 
of rofecoxib [39]. 
DEAE-Dextran was prepared in distilled water containing pluronic used as stabilizer to prevent 
aggregation. It is well documented that the use of appropriate stabilizers can prevent the induction 
of agglomeration or aggregation of the drug particles due to the high surface energy of the 
nanoparticles yielding physically stable formulations by providing steric or ionic barriers [40].  
 Chitosan solution was prepared under acidic condition due to its poor solubility in neutral and 
alkaline pH conditions. Ibuprofen can either interact (electrostatic) with the end groups of chitosan 
or DEAE-Dextran or can be encapsulated in the interior of the polymers (weak interactions) [23]. It is 
expected that the ibuprofen with a carboxylic group may form a complex with the amine (–NH2) 
groups of DEAE-Dextran or chitosan. 
2.3.2. Preparation of polymer-polymer, polymer-drug-polymer nanoconjugates 
DEAE-Dextran-Ibuprofen-Gellan conjugates and Chitosan-Ibuprofen-Gellan conjugates were 
prepared by modified ionic gelation method. On addition of ibuprofen dispersed in gellan solution to 
DEAE-Dextran solution, the mixture became turbid instantly indicating the occurrence of 
electrostatic interaction. A similar reaction was observed when ibuprofen-loaded gellan was added 
to chitosan solution. Low molecular weight chitosan was used in this study since it has been 
suggested that it reacts more completely with polyanions compared with chitosan of higher 
molecular weight [41]. For optimum interaction and polyelectrolyte complex formation, the amine 
group of chitosan  and DEAE-Dextran have to be protonated and the carboxyl group of gellan ionized 
[42]. This was ensured by keeping the final pH of chitosan, gellan and DEAE-Dextran solutions at pH 
5.0, 6.0 and 6.0 respectively. 
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2.3.3. Physicochemical characteristics of nanoconjugates 
2.3.3.1. Conductivity 
Conductimetry has been used in the study of transport process in electrolytic solutions due to its 
high accuracy [44] hence it has been used to investigate the potential ibuprofen-polymer interaction 
in this study. The conductivity measurements of ibuprofen in distilled water from preliminary studies 
ranged from 0.10 to 0.50 mS/cm decreasing with increasing concentration (2.5 to 40.0 µg/mL) of 
ibuprofen. The critical micelle concentration of ibuprofen was obtained from the plot of conductivity 
as a function of drug concentration. The cmc values were taken as the break point intercepts of the 
linear portions on the graph.  In the presence of the DEAE-Dextran, increase in concentration of the 
polymer increased specific conductivity with one or more break points depending on the method of 
preparation (Figure 6).  The melt and surfactant (tween 80) solubilization techniques showed two 
break points which signify two types of aggregation phenomena. The first break at lower DEAE-
Dextran concentration was assigned the critical association concentration (cac) of DEAE-Dextran 
where the interaction between ibuprofen and DEAE-Dextran starts while the second break point was 
assigned the critical micelle concentration (cmc) which is attributed to the saturation of the polymer 
with the drug (polymer saturation point, psp). As concentration of the drug increases beyond the psp 
polymer-free aggregates are formed. It was noted that the presence of DEAE-Dextran decreased the 
cac of ibuprofen significantly in all the four techniques used in this study (p < 0.05, n = 6) confirming 
the interaction between DEAE-Dextran and ibuprofen in all the techniques studied. However the 
melt solubilization technique showed the lowest cac at 1.0 mg/mL and cmc at 3.76 mg/mL compared 
with cac at 2.34 mg/mL and cmc at 8.0 mg/mL respectively for Tween 80.  Sodium hydroxide 
solubilization and nicotinamide hydrotropic complexation showed only one break point at 0.95 
mg/mL and 1.32 mg/mL respectively within the studied concentrations of DEAE-Dextran. It was 
opined that alkaline solubilization and hydrotropic complexation may reduce the amphiphilic 
properties of ibuprofen. In a similar research, Khan et al. [43] reported that a cationic polymer, 
hydroxyethyl cellulose ethoxylate quaternized (HECEQ), reduced the cac of ibuprofen sodium and 
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was credited to strong affinity for ibuprofen and evidence of interaction between them. Therefore 
the electrostatic interaction between DEAE-Dextran and ibuprofen was evident. 
 
Figure 6 Conductivity of IbDMelt, IbDNaOH, IbDTw80 and IbDNic conjugates based on DEAE-Dextran content in the 
conjugates. Each data point represents mean ± SD (n = 6). 
Table 3 Conjugation efficiency, conductivity, surface tension; viscosity and absorbance/transmittance of ibuprofen-
DEAE-Dextran conjugates (melt solubilization). Each value represents mean ± SD (n = 6). 
Formulation Conjugation 
Efficiency (%) 
Conductivity 
(mS/cm) 
Surface tension 
(dynes/cm) 
Viscosity 
(mPaS) 
Absorbance/Transmittance 
IbMelt-control - 0.1±0.001 56.60±1.15 1.28±0.01 0.009±0.0005 
IbD1Melt 98.82±1.37 5.53±0.1 36.75±1.12 1.72±0.02 0.011±0.001 
IbD2Melt 98.40±1.08 6.12±0.04 32.15±1.06 1.82±0.01 0.014±0.001 
IbD3Melt 98.23±1.22 10.66±0.09 34.88±1.48 2.86±0.03 0.003±0.001 
IbD4Melt 98.47±1.35 14.08±0.07 36.03±1.25 4.29±0.03 0.015±0.001 
IbD5Melt 98.40±1.76 22.95±0.19 37.35±0.83 6.61±0.02 0.008±0.001 
 
Table 4 Conjugation efficiency, conductivity, surface tension, viscosity and absorbance/transmittance of ibuprofen-
DEAE-Dextran conjugates (solubilization). Each value represents mean ± SD (n = 6). 
Formulation Conjugation 
Efficiency (%) 
Conductivity 
(mS/cm) 
Surface tension 
(dynes/cm) 
Viscosity 
(mPaS) 
Absorbance/Transmittance 
IbNaOH-control - 3.84±0.06 62.38±1.32 1.38±0.03 0.001±0.001 
IbD1NaOH 97.37±0.97 14.88±0.06 36.88±1.09 1.52±0.01 0.016±0.001 
IbD2NaOH 97.90±1.05 15.89±0.05 33.43±0.98 1.74±0.01 0.017±0.001 
IbD3NaOH 98.14±1.87 16.20±0.04 35.78±0.99 2.09±0.01 0.014±0.001 
IbD4NaOH 98.05±1.92 18.30±0.06 33.00±0.80 3.06±0.08 0.017±0.001 
IbD5NaOH 97.88±1.73 25.55±0.31 33.95±1.57 5.44±0.03 0.015±0.001 
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Table 5 Conjugation efficiency, conductivity, surface tension, viscosity and absorbance/transmittance of ibuprofen-
DEAE-Dextran conjugates (solubilization). Each value represents mean ± SD (n = 6). 
Formulation Conjugation 
Efficiency (%) 
Conductivity 
(mS/cm) 
Surface tension 
(dynes/cm) 
Viscosity 
(mPaS) 
Absorbance/Transmittance 
IbTw80-control - 2.43±0.07 47.25±1.22 2.39±0.05 0.075±0.001 
IbD1Tw80 90.26±0.95 3.16±0.02 38.30±1.00 3.04±0.01 0.056±0.002 
IbD2Tw80 90.26±1.03 4.76±0.03 39.68±1.04 4.01±0.02 0.047±0.004 
IbD3Tw80 89.05±0.91 6.25±0.04 37.78±1.09 5.09±0.02 0.033±0.003 
IbD4Tw80 91.30±1.35 10.40±0.08 40.65±0.39 7.57±0.03 0.033±0.003 
IbD5Tw80 96.34±1.46 12.78±0.04 39.58±0.81 11.83±0.16 0.030±0.003 
Table 6 Conjugation efficiency, conductivity, surface tension, viscosity and absorbance/transmittance of ibuprofen-
DEAE-Dextran conjugates (hydrotropy). Each value represents mean ± SD (n = 6). 
Formulation Conjugation 
Efficiency (%) 
Conductivity 
(mS/cm) 
Surface tension 
(dynes/cm) 
Viscosity 
(mPaS) 
Absorbance/Transmittance 
IbNic-control - 0.29±0.01 50.63±1.07 1.12±0.03 0.000±0.000 
IbD1Nic 95.68±1.32 3.62±0.02 34.70±0.37 1.80±0.01 0.001±0.0005 
IbD2Nic 95.64±1.47 6.47±0.03 30.78±0.65 2.12±0.01 0.005±0.001 
IbD3Nic 95.48±1.56 9.56±0.03 34.08±1.27 2.92±0.02 0.010±0.0005 
IbD4Nic 95.61±1.65 14.42±0.02 36.70±0.79 4.73±0.02 0.005±0.002 
IbD5Nic 95.54±1.67 28.98±0.28 38.23±0.70 7.01±0.02 0.005±0.002 
 
The specific conductivity profile of ibuprofen in the presence of chitosan is presented in Tables 7 to 
10 and Figure 7.  Conductivity also increased with increasing concentration of chitosan to a 
maximum value. All the four techniques have one break point each at the same concentration of 
chitosan in the range of 0.25 to 0.27 mg/mL which is relatively lower than the cac of ibuprofen alone 
in pure aqueous solution but significantly lower than the DEAE-Dextran values (p < 0.05, n = 6). 
There was no significant difference among the four techniques (p > 0.05, n = 6). Therefore it could be 
deduced that DEAE-Dextran has more affinity and stronger interaction towards ibuprofen than 
chitosan. It was opined that larger amount of ibuprofen is required to saturate DEAE-Dextran 
compared with chitosan hence the interaction may be stronger than in ibuprofen-chitosan 
conjugates. Although the values of cac in chitosan are smaller than in DEAE-Dextran, a decrease in 
cac compared with ibuprofen alone was evident which is a good indication of drug-polymer 
interaction. The stronger interaction in DEAE-Dextran may be due to its greater hydrophobic 
characteristics or possible Coulombic repulsion among the counterions of ibuprofen and the cationic 
DEAE-Dextran. In a similar study, Polyvinyl pyrrolidone (PVP) which is more hydrophobic than 
polyethylene glycol (PEG) has been reported to exhibit stronger interaction with amphiphilic drugs 
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[43]. Rodriguez et al. [2] also reported that the presence of apolar regions and ammonium groups in 
the cationic polysaccharides increases the intensity of interactions with aromatic ring and 
hydrophilic carboxylic acid group of NSAIDs hence the interaction involves both hydrophobic 
association and electrostatic interaction. The presence of these groups in DEAE-Dextran explains its 
stronger interaction with ibuprofen than chitosan.  
 
Figure 7 Conductivity of IbChMelt, IbChNaOH, IbChTw80 and IbChNic conjugates based on chitosan content in the 
conjugates. Each data point represents mean ± SD (n = 6). 
Table 7 Conjugation efficiency, conductivity, surface tension; viscosity and absorbance/transmittance of ibuprofen-
chitosan conjugates (melt solubilization). Each value represents mean ± SD (n = 6). 
Formulation Conjugation 
Efficiency (%) 
Conductivity 
(mS/cm) 
Surface 
tension 
(dynes/cm) 
Viscosity 
(mPaS) 
Absorbance/ 
Transmittance 
IbMelt-control - 0.1 ±0.001 56.60 ±1.15 1.28 ±0.01 0.009 ±0.0005 
IbCh1Melt 99.49 ±1.88 92.63 ±0.45 45.53 ±0.46 1.47 ±0.01 0.001 ±0.0005 
IbCh2Melt 98.87 ±1.65 100.58 ±0.22 45.00 ±0.91 1.64 ±0.03 0.005 ±0.0005 
IbCh3Melt 98.73 ±1.93 104.20 ±0.37 46.5 ±2.16 2.27 ±0.02 0.008 ±0.001 
IbCh4Melt 98.09 ±1.27 108.70 ±0.32 41.55 ±0.71 2.90 ±0.01 0.015 ±0.0006 
IbCh5Melt 98.04 ±1.36 112.15 ±0.26 48.38 ±0.85 3.22 ±0.02 0.022 ±0.001 
Table 8 Conjugation efficiency, conductivity, surface tension, viscosity and absorbance/transmittance of ibuprofen-
chitosan conjugates (solubilization). Each value represents mean ± SD (n = 6). 
Formulation Conjugation 
Efficiency (%) 
Conductivity 
(mS/cm) 
Surface tension 
(dynes/cm) 
Viscosity 
(mPaS) 
Absorbance/ 
Transmittance 
IbNaOH-control - 3.84±0.06 62.38±1.32 1.38±0.03 0.001±0.001 
IbCh1NaOH 98.68 ±1.35 71.33 ±0.25 36.63 ±0.63 1.55 ±0.03 0.055 ±0.004 
IbCh2NaOH 98.56 ±1.48 73.15 ±0.31 37.38 ±1.41 1.70 ±0.01 0.082 ±0.003 
IbCh3NaOH 98.51 ±1.37 75.38 ±0.39 41.55 ±1.21 1.71 ±0.01 0.123 ±0.003 
IbCh4NaOH 98.38 ±1.28 79.30 ±0.61 40.15 ±0.53 2.29 ±0.02 0.167 ±0.002 
IbCh5NaOH 97.98 ±1.32 93.53 ±0.25 41.43 ±0.83 3.33 ±0.02 0.219 ±0.002 
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Table 9 Conjugation efficiency, conductivity, surface tension, viscosity and absorbance/transmittance of ibuprofen-
chitosan conjugates (solubilization). Each value represents mean ± SD (n = 6). 
Formulation Conjugation 
Efficiency (%) 
Conductivity 
(mS/cm) 
Surface tension 
(dynes/cm) 
Viscosity 
(mPaS) 
Absorbance/ 
Transmittance 
IbTw80-control - 2.43±0.07 47.25±1.22 2.39±0.05 0.075±0.001 
IbCh1Tw80 90.26 ±0.94 73.00 ±0.61 43.78 ±0.96 2.49 ±0.03 0.021 ±0.001 
IbCh2Tw80 89.74 ±0.96 76.50 ±0.22 40.15 ±1.08 2.58 ±0.01 0.021 ±0.001 
IbCh3Tw80 89.74 ±0.99 81.60 ±0.22 40.35 ±1.30 2.96 ±0.02 0.027 ±0.002 
IbCh4Tw80 89.74 ±1.02 89.76 ±0.17 40.80 ±0.57 3.34 ±0.01 0.025 ±0.001 
IbCh5Tw80 89.22 ±0.89 95.73 ±0.17 42.30 ±0.57 4.84 ±0.04 0.038 ±0.001 
Table 10 Conjugation efficiency, conductivity, surface tension, viscosity and absorbance/transmittance of ibuprofen-
chitosan conjugates (hydrotropy). Each value represents mean ± SD (n = 6). 
Formulation Conjugation 
Efficiency (%) 
Conductivity 
(mS/cm) 
Surface tension 
(dynes/cm) 
Viscosity  
(mPaS) 
Absorbance/ 
Transmittance 
IbNic-control - 0.29±0.01 50.63±1.07 1.12±0.03 0.000±0.000 
IbCh1Nic 91.99 ±1.03 81.45 ±0.13 43.50±0.91 1.65 ±0.01 0.001 ±0.00 
IbCh2Nic 91.30 ±0.98 83.40 ±0.29 48.55 ±0.66 1.77 ±0.02 0.005 ±0.0005 
IbCh3Nic 90.95 ±0.87 84.35 ±0.29 45.93 ±0.81 1.80 ±0.01 0.006 ±0.0005 
IbCh4Nic 90.78 ±0.92 89.90 ±0.37 44.00 ±0.91 2.29 ±0.01 0.013 ±0.0005 
IbCh5Nic 90.26 ±0.85 92.58 ±0.22 44.25 ±1.32 3.49 ±0.01 0.028 ±0.001 
 
The physical properties of binary polymer-polymer [DEAE-Dextran-Gellan (DG), Chitosan-Gellan (CG)] 
and ternary polymer-drug-polymer [DEAE-Dextran-Ibuprofen-Gellan (DGIb); Chitosan-Ibuprofen-
Gellan (CGIb)] conjugates are shown in Tables 11 to 14. Effective release of active pharmaceutical 
substances from polymeric materials requires that the concentration of the drug should be high 
enough at the site of action to facilitate therapeutic effect at the same time it should not be too high 
to elicit undesirable side effects. However the general drawback of polysaccharides as a delivery 
system is low complexation efficiency consequently a significantly high amount of water soluble 
polymers are frequently needed to solubilize small amount of poorly soluble drugs. Ribeiro et al. 
reported a dramatic improvement in drug solubility when a suitable third component (α-hydroxy-
acids and water-soluble polymers) was added to cyclodextrin followed by heating [45]. Therefore, 
oppositely charged polymers were combined to reinforce the initial drug-cationic polymer conjugate 
so that the release of the solubilized ibuprofen can be enhanced, controlled, extended and 
complete. Extended and complete release could also allow for dose reduction and consequently 
reduced side effects without compromising the therapeutic values. Therefore choosing the 
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appropriate polymer-polymer ratio would be of great value to achieving efficient release profile 
from the polymer combinations. 
Interaction between DEAE-Dextran and Gellan revealed characteristic pattern in each of the 
parameter studied (Table 11 and Figure 8) exhibiting break points at critical conjugation 
concentration ratio of the polymers. Break point was prominent at DEAE-Dextran/Gellan ratio 50:50 
for conductivity, surface tension and viscosity while turbidity exhibited two breakpoints at ratio 
25:75 and 50:50. The Chitosan/Gellan profile was similar to the DEAE-Dextran/Gellan exhibiting 
critical conjugation at ratio 50:50 for surface tension and viscosity while break point was observed at 
Chitosan/Gellan ratio 25:75 for conductivity and turbidity. It was concluded that ratio 50:50 is the 
critical conjugation concentration for both DEAE-Dextran/Gellan and Chitosan/Gellan interaction. 
Therefore in order to optimize the conjugation process in the presence of ibuprofen DEAE-
Dextran/Gellan and Chitosan/Gellan ratio of 2:1 was used in this study to account for the ibuprofen-
DEAE-Dextran or Ibuprofen-Chitosan interaction. 
Table 11 Conductivity, surface tension, viscosity and absorbance/transmittance of DEAE-Dextran-gellan conjugates. Each 
value represents mean ± SD (n = 6). 
Formulation Conductivity 
(µS/cm) 
Surface tension  
(dynes/cm) 
Viscosity 
 (mPaS) 
Absorbance/Transmittance 
DG 0:100 142.23±1.05 55.27±0.25 3.61±0.02 0.008±0.001 
DG 25:75 194.43±1.21 54.17±0.15 1.70±0.01 0.771±0.006 
DG 50:50 235.75±1.08 52.73±0.64 1.39±0.01 0.756±0.001 
DG 75:25 254.13±0.67 54.33±0.42 1.83±0.01 0.039±0.001 
DG 100:0 286.83±0.75 54.50±0.50 2.02±0.02 0.001±0.000 
 
Table 12 Conductivity, surface tension, viscosity and absorbance/transmittance of chitosan-gellan conjugates. Each 
value represents mean ± SD (n = 6).  
Formulation Conductivity 
(mS/cm) 
Surface tension  
(dynes/cm) 
Viscosity 
 (mPaS) 
Absorbance/Transmittance 
CG 0:100 0.15±0.001 55.23±0.25 3.78±0.03 0.006±0.001 
CG25:75 2.50±0.018 54.07±0.12 1.98±0.06 0.243±0.011 
CG50:50 4.28±0.026 53.50±0.87 1.60±0.01 0.214±0.002 
CG75:25 5.84±0.010 53.67±0.58 1.30±0.01 0.105±0.003 
CG 100:0 7.55±0.019 52.77±0.25 1.58±0.02 0.001±0.000 
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Physical characteristics and conjugation efficiency of the ibuprofen loaded conjugates are presented 
in Table 13. Breakpoints for surface tension and viscosity of DEAE-Dextran/Ibuprofen/Gellan were at 
DEAE-Dextran/Gellan ratio 50:50 while conductivity and turbidity were at 75:25 and 25:75 
respectively. It showed that the requirement for cationic polymer increased in the presence of 
ibuprofen especially in the conductivity experiment. However the difference between polymer-
polymer ratios in the plain and ibuprofen-loaded nanoconjugate was not statistically significant (p > 
0.05, n = 6). 
Table 13 Conjugation efficiency, conductivity, surface tension, viscosity and absorbance/transmittance of ibuprofen-
DEAE-Dextran-gellan conjugates (ternary). Each value represents mean ± SD (n = 6). 
Formulation Conjugation 
Efficiency (%) 
Conductivity 
(µS/cm) 
Surface tension 
(dynes/cm) 
Viscosity 
(mPaS) 
Absorbance/Transmittance 
IbDW-pH6 - 307.17±1.47 52.33±1.04 1.32±0.01 0.015±0.001 
DG0:100 98.57±0.89 175.22±0.17 49.00±0.5 3.29±0.02 0.164±0.005 
DG25:75 98.73±0.84 186.10±0.36 47.67±0.76 1.48±0.01 1.162±0.006 
DG50:50 97.71±0.82 199.55±0.39 40.17±0.58 1.41±0.01 0.472±0.004 
DG75:25 98.22±0.76 211.00±3.34 43.50±1.00 1.75±0.01 0.177±0.003 
DG100:0 99.10±0.92 255.15±0.80 47.83±0.58 2.43±0.02 0.062±0.004 
 
 
Figure 8 Conductivity of DG polymer-polymer complexes and ibuprofen loaded DG-Ib based on DEAE-Dextran content in 
the complexes. Each data point represents mean ± SD (n = 6). 
Conductivity measurements showed that the DG polymer-polymer and DG-Ib loaded complexes 
exhibited increase in conductivity values as the DEAE-Dextran content increased: DG 100:0 > DG 
75:25 > DG 50:50 > DG 25:75 > DG 0:100. However the rate of increase in conductivity was faster in 
100 
150 
200 
250 
300 
0 25 50 75 100 
C
o
n
d
u
ct
iv
it
y 
(µ
S/
cm
) 
DEAEDextran (%w/v) 
DG-Ib loaded 
DG polymer-polymer 
61 | P a g e  
 
the plain than the drug loaded conjugates (Figure 8). The plain conjugate exhibited breakpoint at 
DEAE-Dextran/Gellan ratio 50:50 while the drug loaded conjugates exhibited breakpoint at 75:25. It 
was opined that the presence of ibuprofen reduced the affinity between DEAE-Dextran and Gellan 
probably due to preferential affinity of ibuprofen for DEAE-Dextran because of its higher 
hydrophobicity. It is well documented in literature that the amphiphilic drugs like ibuprofen have 
ability to self-associate in aqueous solutions and be adsorbed onto polymer backbone through 
hydrophobic and electrostatic bonds [2]. Also considering the lowest ibuprofen concentration used 
in this study (1 mg/mL) which is 4.85 mM, the molar ratio of the carboxylic acid group to quarternary 
ammonium polymer group on the maximum DEAE-Dextran concentration (0.02 mM) was 242.5  
(greater than 1). It follows that there are sufficient ibuprofen molecules in all the systems to 
neutralize all the cationic groups on DEAE-Dextran. This explains the initial high conductivity of the 
drug loaded conjugate however as the concentration of DEAE-Dextran increased further interaction 
occurred probably displacing gellan which can form association below its cmc leading to the 
observed lowered break point. In a similar study, Rodriguez et al. reported that near cmc ibuprofen 
caused phase separation of ethylhydroxyethyl cellulose (EHEC) dispersions because of a strong 
hydrophobic interaction that shrinks the polymer chain and its micelle solubilised the hydrophobic 
part of the polymer above cmc. This reaction is possible between ibuprofen and the 
Diethylaminoethyl- (hydrophobic) group of DEAE-Dextran and explains the difference between the 
plain and drug loaded conjugates. 
Table 14 Conjugation efficiency, conductivity, surface tension, viscosity and absorbance/transmittance of ibuprofen-
chitosan-gellan conjugates (ternary). Each value represents mean ± SD (n = 6). 
Formulation Conjugation 
Efficiency (%) 
Conductivity 
(mS/cm) 
Surface tension 
(dynes/cm) 
Viscosity 
(mPaS) 
Absorbance/Transmittance 
IbDW-pH5 - 0.31±0.001 52.33±1.04 1.32±0.01 0.015±0.001 
CG0:100 98.94±0.84 0.16±0.003 47.83±1.15 4.61±0.04 0.158±0.006 
CG25:75 98.97±0.75 2.33±0.02 47.67±0.76 1.54±0.01 0.104±0.004 
CG50:50 97.01±0.90 4.07±0.01 46.17±0.58 1.33±0.01 0.297±0.001 
CG75:25 98.60±0.89 5.71±0.01 47.17±0.58 1.54±0.01 0.120±0.003 
CG100:0 98.47±0.91 6.95±0.01 44.33±0.76 1.58±0.02 0.077±0.003 
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Figure 9 Conductivity of CG polymer-polymer complexes and ibuprofen loaded CG-Ib based on chitosan content in the 
complexes. Each data point represents mean ± SD (n = 6). 
Conductivity measurements showed that the CG polymer-polymer and CG-Ib complexes exhibited in 
the order CG 100:0 > CG 75:25 > CG 50: 50 > CG 25:75 > CG 0:100. Conductivity increased with 
increase in chitosan content shown in Figure 9. Li and co-workers reported the conductivity 
behaviours of chitosan solution showed that there is transforming process of chitosan solution 
conformation and charge conduction mechanism in 0.1 M acetic acid solution with the increase of 
chitosan concentrations [46]. The specific electrolytic conductivity increased as chitosan 
concentration increased and more complexes are formed.  
As an amphiphilic substance, ibuprofen can form micelles or micelle-like aggregates above a critical 
micelle concentration and can interact with polymers in a similar way to surfactant-polymer 
interaction [43]. 
2.3.3.2. Surface tension 
The surface activity of the drug-polymer was studied by the evaluation of the surface tension 
measurements of the nanoconjugates as a function of polymer concentration. The surface tension of 
ibuprofen in distilled water obtained from preliminary studies ranged from 49.20 to 53.99 N/m 
decreasing with increasing concentration (2.5 to 40.0 µg/mL) of ibuprofen. The surface tension 
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behaviour of Ibuprofen with cationic DEAE-Dextran is shown in Figure 10. Surface tension 
measurements showed that the IbDMelt ranged from 32.15 to 37.35 N/m, exhibiting lower surface 
tension than the control (56.6 N/m). The profile showed an initial decrease till minima was reached 
at IbD2Melt (0.2% DEAE-Dextran), this was followed by a little increase which remained constant 
over the increasing concentration of DEAE-Dextran. Addition of DEAE-Dextran caused a reduction in 
surface tension at the air/water interface indicating its ability to adsorb at the air/water interface in 
preference to the bulk of the medium. In theory, when surface active agents adsorb at the water 
interface they replace some water molecules thereby reducing the intermolecular (cohesive) forces 
of attraction between water molecules hence surface tension is reduced. 
 
Figure 10 Surface tension of IbDMelt, IbDNaOH, IbDTw80 and IbDNic conjugates based on DEAE-Dextran content in the 
conjugates. Each data point represents mean ± SD (n = 4). 
The amount of DEAE-Dextran present at the water surface, in excess of those in the bulk for the melt 
solubilization technique was 1.97 x 10-4 mol/dm3 as calculated using the Gibbs equation (equation 7): 
     
 
  
  
  
  
                                                                                                                         (7) 
In which Г is the surface excess concentration of DEAE-Dextran; R is the Gas constant (8.314 J mol-1K-
 1; T is the temperature in kelvin; C is the concentration of DEAE-Dextran in mol/dm3; dγ is the 
change in surface tension and dC is the change in concentration. The surface excess of DEAE-Dextran 
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for alkaline solubilization, Tween 80 (non ionic surfactant) solubilization and hydrotropic 
complexation are 2.34 x 10-4; 7.23 x 10-5 and 1.60 x 10-4 mol/dm3 respectively. Comparing the four 
processes used in this study the surface excess of DEAE-Dextran was in the order alkaline 
solubilization > melt solubilization > hydrotropic complexation > non ionic surfactant solubilization 
technique. It was also observed that the cmc of DEAE-Dextran was same in three of the methods 
(0.004 mM) but lower in the surfactant solubilization technique (0.002 mM). Two break points were 
also observed in this technique while there was only one in the others. It was opined that the 
adsorption of Tween 80 was preferentially favoured until the surface was saturated leading to the 
first cmc at lower concentration of DEAE-Dextran. The effect of DEAE-Dextran became prominent 
afterwards however the cac was increased to 0.008 mM. Contrary to this finding, Lee et al. have 
noted that micelle formation of polymers can compete with surface adsorption and that 
polymer/surfactant combination is often considered to have synergistic effect due to co-adsorption 
[47]. 
The surface tension behaviour of Ibuprofen with cationic chitosan is shown in Figure 11. Surface 
tension measurements showed that the IbChMelt ranged from 41.55 to 48.38 N/m, exhibiting lower 
surface tension than the control (56.6 N/m). The profile showed an initial decrease till minima was 
reached at IbCh2Melt (0.2% chitosan), this was followed by a little increase, a decrease and a final 
increase over the increasing concentration of chitosan. 
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Figure 11 Surface tension of IbChMelt, IbChNaOH, IbChTw80 and IbChNic conjugates based on chitosan content in the 
conjugates. Each data point represents mean ± SD (n = 4). 
The IbChNaOH nanoconjugates ranged from 36.63 to 41.55 N/m, exhibiting lower surface tension 
than the control (62.38 N/m). The profile showed an initial decrease till minima was reached at 
IbCh1NaOH (0.1% chitosan), this was followed by an increase, then a decrease which remained 
constant over the increasing concentration of chitosan. 
The IbChTw80 nanoconjugates ranged from 40.15 to 43.78 N/m exhibiting lower surface tension 
than the control (62.38 N/m). The profile showed an initial decrease till minima was reached at 
IbD1Tw80 (0.1% DEAE-Dextran), this was followed by a little increase, then a decrease and a final 
increase which was followed by a decrease over the increasing concentration of chitosan. 
While IbChNic nanoconjugates from 43.50 to 48.55 N/m conjugates exhibited lower surface tension 
than the ibuprofen control (56.6 N/m). No predictable pattern was observed in the trend based on 
the increasing concentration of chitosan. However the surface excess for melt solubilization; alkaline 
solubilization; surfactant solubilization and hydrotropic complexation are 9.36 x 10-5; 2.08 x 10-4; 
1.79 x 10-4 and 1.06 x 10-4 mol/dm3 respectively. The highest surface excess was present in the 
alkaline solubilization which also had very low cmc (0.025% ie 0.0005 mM) while the melt 
solubilization had the lowest amount with cmc of 0.05% (0.001 mM). Tween 80 did not show any 
visible effect on the surface activity of chitosan unlike DEAE-Dextran and the chitosan surface excess 
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was 2.5 times the amount of DEAE-Dextran in the presence of Tween 80. It was evident that both 
DEAE-Dextran and chitosan showed surface activity and were adsorbed significantly at the water 
surface with high probability of forming micelles and reducing the surface free energy of the system 
which in turn could facilitate solubility.       
Surface tension measurements showed that the DG polymer-polymer loaded complexes exhibited in 
the order DG 0:100 > DG 100:0 > DG 75:25 > DG 25:75 > DG 50:50 (Table 11). Figure 12 showed the 
surface tension plot with an initial decrease in surface tension with increasing concentration of 
DEAE-Dextran up to DG 50:50 exhibiting the minima; beyond which it increased till it reached a 
constant surface tension value. 
 
Figure 12 Surface tension of DG polymer-polymer and ibuprofen loaded DG-Ib complexes based on DEAE-Dextran 
content in the complexes. Each data point represents mean ± SD (n = 4). 
Surface tension measurements showed that the DG-Ib loaded complexes exhibited lower surface 
tension than the ibuprofen control in the order: Ibuprofen control > DG 0:100 > DG 100:0 > DG 25:75 
> DG 75:25 > DG 50:50 (Table 13). Figure 12 showed the surface tension plot with DG 50:50 
exhibiting the minima. 
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Figure 13 Surface tension of CG polymer-polymer and ibuprofen loaded CG-Ib complexes based on chitosan content in 
the complexes. Each data point represents mean ± SD (n = 4). 
Surface tension measurements showed that the CG complexes exhibited in the order CG 0:100 > CG 
25:75 > CG 75:25 > CG 50:50 > CG 100:0 (Table 12). The surface tension plot showed a decrease, a 
minima (CG 50:50) followed by a maxima (CG 75:25) and a further decrease in surface tension in 
Figure 13. Surface tension measurements showed that the ibuprofen loaded CG complexes exhibited 
lower surface tension than the ibuprofen control in the order: ibuprofen control > CG 0:100 > CG 
25:75 > CG 75:25 > CG 50:50 > CG 100:0 (Table 14). The surface tension plot showed a decrease, a 
minima (CG 50:50) followed by a maxima (CG 75:25) in Figure 13. This cmc of DEAE-Dextran: Gellan 
conjugate (50:50) coincides with its cac indicating conjugation equilibrium at the weight ratio.  
2.3.3.3. Viscosity 
The viscosity of the drug-polymer solutions is an important parameter due to its association with the 
hydrodynamic stabilization of the particles formed [48]. The viscosity of ibuprofen in distilled water 
obtained from preliminary studies ranged from 1.12 to 1.17 mPas decreasing with increasing 
concentration (2.5 to 40.0 µg/mL) of ibuprofen. The viscosity of DEAE-Dextran in distilled water 
ranged from 1.2 to 1.41 mPaS increasing slowly with increasing concentration (0.005 to 0.1% w/v). 
The viscosity behaviour of the drug-polymer nanoconjugates was studied by the evaluation of the 
viscosity measurements of the nanoconjugates as a function of polymer concentration. Viscosity 
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measurements in Table 4 showed that the IbDMelt nanoconjugates from 1.72 to 6.61 mPas, 
exhibiting higher viscosity than the control 1.28 mPas.  Viscosity increased gradually with increasing 
concentration of DEAE-Dextran in Figure 14. 
 
Figure 14 Viscosity of IbDMelt, IbDNaOH, IbDTw80 and IbDNic conjugates based on DEAE-Dextran content in the 
conjugates. Each data point represents mean ± SD (n = 6). 
 The IbDNaOH nanoconjugates in Table 5 ranged from 1.52 to 5.44 mPas, exhibiting higher viscosity 
than the control (1.38 mPas). The IbDTw80 nanoconjugates in Table 6 ranged from 3.04 to 11.83 
mPas, exhibiting higher viscosity than the control (2.39 mPas). While IbDNic nanoconjugates in Table 
7 ranged from 1.80 to 7.00 mPaS conjugates exhibiting higher viscosity values than the ibuprofen 
control (1.21 mPas). Viscosity increased with increase in DEAE-Dextran concentration for all the 
batches. The intrinsic viscosity of IbDMelt, IbDNaOH, IbDTw80 and IbDNic were 1.36 (R2 = 0.99), 1.21 
(R2 = 0.99), 2.63 (R2 = 0.99) and 1.4 (R2 = 0.99) mPas respectively. The intrinsic viscosity of IbDTw80 
batch was considerably higher when compared to the other techniques in the order: IbDTw80 > 
IbDNic > IbDMelt > IbDNaOH. 
The viscosity of chitosan in glacial acetic acid ranged from 1.16 to 17.7 mPaS, increasing with 
increasing concentration (0.005 to 1% w/v) of chitosan. The viscosity measurements in Table 8 
showed that the IbChMelt ranged from 1.47 to 3.22 mPas, exhibiting higher viscosity than the 
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control (1.28 mPas). Viscosity increased with increase in chitosan concentration, gradually reaching a 
constant in Figure 15. 
 
Figure 15 Viscosity of IbChMelt, IbChNaOH, IbChTw80 and IbChNic conjugates based on chitosan content in the 
conjugates. Each data point represents mean ± SD (n = 6). 
The IbChNaOH nanoconjugates in Table 9 ranged from 1.55 to 3.33 mPas, exhibiting higher viscosity 
than the control (1.38 mPas). The IbChTw80 nanoconjugates in Table 10 ranged from 2.49 to 4.84 
mPas, exhibiting higher viscosity than the control (2.39 mPas). While IbChNic nanoconjugates in 
Table 11 ranged from 1.65 to 3.49 mPas exhibiting higher viscosity values than the ibuprofen control 
(1.12 mPas). Viscosity increased with increase in chitosan concentration for all the batches. The 
intrinsic viscosity of IbChMelt, IbChNaOH, IbChTw80 and IbChNic were 1.49 (R2 = 0.88), 1.38 (R2 
=0.99), 2.31 (R2 = 0.99) and 1.34 (R2 = 0.96) respectively. The intrinsic viscosity of IbChTw80 batch 
was considerably higher when compared to the other techniques in the order IbChTw80 > IbChMelt 
> IbChNaOH > IbChNic. 
Viscosity measurements showed that the DG complexes exhibited a decrease in viscosity in the 
order DG 0:100 > DG 100:0 > DG 75:25 > DG 25: 75 > DG 50:50. It was obvious that gellan is more 
viscous than DEAE-Dextran by a factor of 1.8. The binary conjugate of the two showed a steady 
decrease in viscosity to a minimum value of 1.39 ± 0.01 mPaS at DEAE-Dextran/Gellan conjugate 
ratio 50:50 which also coincides with the conjugation concentration. The viscosity increased again 
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beyond the minimum value. The viscosity curve of the plain and ibuprofen loaded conjugates 
crossed at DEAE-Dextran/Gellan 50:50 hence, it was concluded that process of conjugation 
accounted for the reduction in viscosity (Figure 16) and that the addition of ibuprofen in the 
conjugate did not interfere with the process of conjugation. Although the viscosity profile of the 
ibuprofen-loaded conjugates was slightly lower than the plain, the difference was not statistically 
significant (p > 0.05, n = 6). 
 
Figure 16 Viscosity of DG polymer-polymer and ibuprofen loaded DG-Ib complexes based on DEAE-Dextran content in 
the complexes. Each data point represents mean ± SD (n = 6). 
Figure 17 shows the viscosity profle of plain and ibuprofen loaded chitosan-gellan conjugate. 
Viscosity measurements decreased in the order CG 0:100 > CG 25:75 > DG 50:50 > CG 100:0 > CG 
75:25 (Table 12). The viscosity plot showed an initial decrease to a minimum followed by a slight 
increase with increasing concentration of chitosan similar to DEAE-Dextran. Ibuprofen-loaded 
chitosan-gellan conjugates exhibited higher viscosity than the ibuprofen control in the order CG 
0:100 > CG 100:0 > CG 75:25 > CG 25:75 > DG 50:50 > ibuprofen control (Table 14). However, the 
viscosity decreased to almost a constant value as the chitosan content increased. The minimum 
viscosity of the drug loaded conjugates was lower than the plain conjugates (Figure 17). 
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Figure 17 Viscosity of CG polymer-polymer and ibuprofen loaded CG-Ib complexes based on chitosan content in the 
complexes. Each data point represents mean ± SD (n = 6). 
2.3.3.4. Turbidity  
Turbidity is used to measure polyelectrolyte complex formation. The turbidity profile of the 
Ibuprofen-DEAE-Dextran nanoconjugates is shown in Figure 18 and Tables 4 to 7. Turbidity profile of 
surfactant solubilized Ibuprofen-DEAE-Dextran conjugates decreased steadily to constant value of 
0.033 at 0.4% DEAE-Dextran concentration while others exhibited a net increase of turbidity to a 
maximum (Figure 18). The melt solubilized Ibuprofen-DEAE-Dextran conjugates showed two 
inflection points indicating multiple complex phenomena. The low turbidity values in Tables 4, 5 and 
7; and Figure 18 for IbDMelt, IbDNaOH and IbDNic respectively may indicate formation of soluble 
complexes which are often reversible and unstable while the ones with higher turbidity values may 
indicate formation of insoluble complexes which are usually irreversible. 
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Figure 18 Absorbance at 420 nm of IbDMelt, IbDNaOH, IbDTw80 and IbDNic conjugates based on DEAE-Dextran content 
in the conjugates. Each data point represents mean ± SD (n = 6). 
The turbidity profile of the Ibuprofen-Chitosan nanoconjugates is shown in Figure 19 and Tables 8 to 
11. Turbidity profile of IbChNaOH increased steadily as the concentration of chitosan increased while 
others exhibited a net decrease to a minimum in Figure 19. The IbChNaOH exhibited high turbidity 
due to its cloudiness when compared to the other techniques. The low turbidity in other techniques 
may be due to formation of soluble complexes which are reversible. 
 
Figure 19 Absorbance at 420 nm of IbChMelt, IbChNaOH, IbChTw80 and IbChNic conjugates based on chitosan content in 
the conjugates. Each data point represents mean ± SD (n = 6). 
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Turbidity values for the DG complexes ranged between 0.001 and 0.771. The order of increase in 
turbidity: DG 25:75 > DG 50:50 > DG 75:25 > DG 0: 100 > DG 100:0. Maximum turbidity was achieved 
by DG 25:75 shown by the maxima in Figure 20. 
Turbidity values for the ibuprofen loaded DG complexes ranged between 0.062 and 1.162 much 
higher than the control formulation. The order of increase in turbidity: DG 25:75 > DG 50:50 > DG 
75:25 > DG 0:100 > DG 100:0 > ibuprofen control. Maximum turbidity was achieved by DG 25:75 
shown by the maxima in Figure 20. It was noted that the plain conjugates exhibited a normal 
distribution shape while the drug-loaded conjugates was skewed to lower concentration of DEAE-
Dextran indicating that smaller quantities of DEAE-Dextran is required to achieve conjugation 
equilibrium in the presence of ibuprofen. It follows that the addition of a third component may have 
synergistic effect in this case. The area under the curve (AUC) measures the extent of complexation. 
The AUC of the plain DEAE-Dextran/Gellan conjugate (31.6 unit2) was less than that of the ibuprofen-
loaded conjugates (57.5 unit2). This finding corresponds to the stronger interaction between DEAE-
Dextran and ibuprofen due to a combination of hydrophobic and electrostatic interaction as 
discussed under conductivity and surface tension.   
 
Figure 20 Absorbance at 420 nm of DG polymer-polymer and ibuprofen loaded DG-Ib complexes based on DEAE-Dextran 
content in the complexes. Each data point represents mean ± SD (n = 6). 
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Turbidity measurements showed that CG complexes ranged between 0.001 and 0.243 in the order: 
CG 25:75 > CG 50:50 > CG 75:25 > CG 0:100 > CG 100: 0. The turbidity plot showed an initial decrease 
followed by maxima and then a decrease as the chitosan content increased. Maximum turbidity was 
achieved by CG 25:75 shown by the maxima in Figure 21. 
The ibuprofen loaded CG complexes showed higher turbidity than the ibuprofen control in the order: 
CG 50:50 > CG 0:100 > CG 75:25 > CG 25:75 > CG 100:0 > ibuprofen control. The turbidity plot 
showed an initial decrease followed by maxima shown by CG 50:50 and then a decrease as the 
chitosan content increased in Figure 21. The plain and the drug-loaded conjugates exhibited slightly 
skewed conjugate distribution with AUC of 12.5 and 15 unit2 respectively which are significantly 
lower than the DEAE-Dextran conjugates (p < 0.05, n = 6). The plain conjugate was skewed to the 
lower concentration of chitosan while the drug-loaded type was near normal distribution. In 
contrary to the DEAE-Dextran conjugates, the plain binary chitosan-gellan mixture formed 
conjugates at lower concentration of chitosan than the drug-loaded type. It was opined that addition 
of a third reacting component delayed the process of conjugation and may have antagonistic effect. 
 
Figure 21 Turbidity at 420 nm of CG polymer-polymer and ibuprofen loaded CG-Ib complexes based on chitosan content 
in the complexes. Each data point represents mean ± SD (n = 6). 
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2.3.3.5. Particle size, poly-dispersity index and zeta potential 
Poorly soluble drugs are commonly associated with critical problems of slow dissolution and erratic 
absorption with a consequent low and variable bioavailability. Preparation of dosage forms with 
particle size of less than 1 µm (nano-medicines) has been identified as an approach to enhance the 
dissolution as well as the rate and extent of absorption for poorly soluble drugs [49]. Literature is 
replete of particle size reduction techniques to enhance drug dissolution and hence the 
bioavailability of poorly soluble drugs [50-51] by increasing the effective surface area [52]. The 
relationship between rate of solution and surface area has been described by the Noyes Whitney 
equation (equation 8): 
  
   
                                                                                                                           (8) 
where dC/dT is the rate of dissolution (concentration with respect to time), k is the dissolution rate 
constant, S is the surface area of the particles, Cs is the concentration of the drug in the immediate 
proximity of the dissolving particle (solubility of the drug) and Ct is the concentration of the drug in 
the bulk [53]. 
The particle size of ibuprofen control (processed without polymer) was found to be 2.87 µm (Table 
15). Miyadai et al. reported that raw ibuprofen has a mean particle size of 27 µm [54]. This shows 
that the process of melt solubilization alone reduced the particle size significantly by a factor of 9 (p 
< 0.05, n = 6). Introduction of DEAE-Dextran at 0.1% (2.0 x 10-3 mM) concentration formed 
conjugates with further 14-fold size reduction to 203.25 nm. Drug-polymer nanoconjugates of size 
range 203.25 to 321.42 nm were obtained with DEAE-Dextran concentrations of 2.0 x 10-3 to 8.0 x 
10-3 mM. Further increase in DEAE-Dextran concentration increased the conjugate size steadily up to 
2351.68 nm at 1.6% (3.2 x 10-2 mM) (Table 15, Figure 22). In a similar study Lemarchand et al. 
reported smaller nanoparticle size of 104 nm and 165 nm from coprecipitation and emulsion 
polymerization of DEAE-Dextran with iron oxide and polyalkylcyanoacrylate (PACA) respectively 
however the amount of the polysaccharide at the surface was not quantified [55]. It was opined that 
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the smaller particle size in the complexation of DEAE-Dextran with metallic ion (FeO) may be due to 
formation of stronger bond than DEAE-Dextran with ibuprofen used in this study. Hornig et  al.[56] 
also prepared dextran-ibuprofen conjugates by in situ activation of the carboxylic acid group with 
N,N’-carbonyldiimidazole (CDI), they obtained nanoparticles in the range of 102 to 287 nm. 
Nonetheless it was remarkable to note that nanoparticles could be prepared from DEAE-Dextran-
Ibuprofen conjugate without any addition of surfactants or activators which are generally required 
for the preparation of polymeric nanoparticles. The increase in particle size at higher concentrations 
of DEAE-Dextran in this study was attributed to increase in the coating layer of DEAE-Dextran on 
ibuprofen. Jiang et al. [23] found that hydrodynamic diameter of ibuprofen particles decreased 
slowly with increase in pH values as ibuprofen was solubilized with NaOH in this study. The 
surfactant solubilized technique produced the smallest particle sizes ranging from 13.02 to 122.17 
nm (Table 17 and Figure 22). Also unlike the other techniques used in this study, the nanoconjugate 
size decreased steadily to a minimum (13.02 nm) with increase in concentration of DEAE-Dextran 
confirming the synergistic effect of polymer surfactant combination which is consistent with surface 
tension findings in section 2.3.3.2. Hydrotropic complexation with nicotinamide also produced 
nanoconjugates at all concentrations of DEAE-Dextran used in this study as shown in Table 18 and 
Figure 22. The nanoconjugate sizes ranged from 77.92 to 994.27 nm and the size increased with 
increase in DEAE-Dextran concentrations. Comparing the four techniques, the initial conjugate size 
produced at the lowest concentration of DEAE-Dextran (2.0 x 10-3 mM) was in the order melt 
solubilization (203.25 nm) > alkaline solubilization (185.68 nm) > surfactant (Tween 80) solubilization 
(122.17 nm) > hydrotropic (nicotinamide) complexation (77.92 nm). The impact of hydrotropic 
complexation on particle size reduction was statistically significant (p < 0.05, n = 12) compared with 
other techniques. Sanghvi et al. [57] have reported the use of nicotinamide as potent solubility 
enhancing agent for poorly soluble drugs. They reported significant improvement in solubility up to 
4000-fold (Benzophenyl urea derivative) with 20% nicotinamide however the effect on particle size 
was not investigated. The only NSAID on the list of the drugs they investigated was ketoprofen with 
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solubility enhancement of 12-fold. 10% w/v nicotinamide was used in this study based on the 
preliminary study which showed that the cmc of nicotinamide is 10% w/v, it was opined that higher 
concentrations could lead to self-association which could interfere with the conjugation process.   
 
Figure 22 Effect of DEAE-Dextran concentration on particle sizes of the drug-polymer conjugates. 
Polydispersity index (PDI) is the size or width of particle size distribution of the sample and has a 
scale which ranges from 0 to 1. PDI value of 0.1 to 0.25 which has been assigned to a narrow size 
distribution while PI value greater than 0.5 indicates a very wide or broad size distribution [40, 58].  
High PI values indicate less homogenous size distribution hence PDI should be as low as possible for 
the long term stability of formulations.  
The PDI of ibuprofen control was 0.67 (Tables 15 to 18) which indicated a broad and non 
homogeneous size distribution. The PDI of nanoconjugates in the melt solubilization technique 
(IbDMelt conjugates) ranged from 0.35 to 0.42 (Table 15, Figure 23) which indicated a medium 
homogeneous size distribution. Also the PDI of nanoconjugates in alkaline solubilization (IbDNaOH); 
surfactant solubilisation (IbDTw80) and hydrotropic complexation (IbDNic) ranged from 0.29 to 0.39; 
0.15 to 0.37 and 0.23 to 0.55 respectively (Figure 23) which indicated a net medium homogeneous 
size distribution. This suggests that all the techniques used in this study exhibited semi homogenous 
size distribution which may translate to medium stabilization of the particles formed. However at 
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higher concentrations of DEAE-Dextran (1.6 x 10-2 and 3.2 x 10-2 mM), the surfactant solubilization 
technique produced PDI of 0.16 and 0.15 respectively indicating narrow particle size distribution, 
high homogeneity and stabilization. The hydrotropic complexation technique also produced PDI of 
0.23 at DEAE-Dextran concentration of 3.2 x 10-2 mM suggesting narrow particle size distribution and 
high homogeneity. 
 
Figure 23 Effect of DEAE-Dextran on polydispersity indices of drug-polymer conjugates.  
Zeta potential is a measure of the charge of the particle which is an index for particle stability. It is 
the potential difference between the dispersion medium and the stationary layer of fluid attached to 
the dispersed particle. The minimum zeta potential  of ±30 mV is required and can be used to assure 
the stability by electrostatic repulsion of nanoparticulate suspensions [59]. However, if stability is 
based on electrostatic and steric stabilizer, the zeta potential of ±20 mV suffices [60]. Low zeta 
potential values can lead to decrease in electrostatic repulsion between the particles thereby 
increasing the propability of particle aggregation [61]. The aim of this study is to reduce the particle 
size of ibuprofen using the four techniques to increase the dissolution rate of ibuprofen.The particle 
size, polydispersity index values and zeta potential for the four methods of preparing the drug-
polymer conjugates were presented in Tables 15 to Table 22.  
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The zeta potential of the ibuprofen/DEAE-Dextran nanoconjugates increased from -7.251 mV in the 
control batch to steady maximum values of +4.79; -1.18; +3.45 and +13.87 mV in melt solubilization, 
alkaline solubilization, surfactant solubilization and hydrotropic complexation techniques 
respectively (Figure 24, Tables 15 to 18) however the overall profile showed low values close to 
neutrality in all the four techniques used in this study. The negative zeta potential in the ibuprofen 
control indicates electrostatic repulsion between ibuprofen molecules and therefore higher physical 
stability of the colloidal suspension in the absence of DEAE-Dextran. The positive values of zeta 
potentials suggest surface modification of the nanoparticles by the cationic DEAE-Dextran. It was 
noted that zeta potential in the hydrotropic complexation technique tended to reduce towards 
neutrality after attaining the maximum value (Figure 24) probably because of aggregation of the 
nano conjugates which may occur when the particles overcome the energy barrier of electrostatic 
repulsion and approach each other to form bigger aggregates. Plakkot et al. [49] suggested that if 
the kinetic energy or velocity of the particles is sufficiently high they will collide with a consequent 
growth in particle size. This may explain the increase in conjugate size with increasing concentration 
of DEAE-Dextran except in the surfactant solubilization technique where conjugate sizes decreased 
steadily from 122.17 to 13.2 nm with a corresponding decrease in zeta potential from 3.45 to 1.02 
mV respectively. The values of zeta potential observed in this study were relatively low (-3.04 to 
+13.87 mV) indicating low repulsion stabilization probably because stabilization of the 
nanoconjugates is by steric effect rather than electrostatic repulsion as reported by Plakkot et al. 
[49]. 
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Figure 24 Effect of DEAE-Dextran on zeta potential measurements of drug-polymer conjugates. 
Table 15 Particle size, polydispersity index and zeta potential for melt (IbDMelt) nanoconjugates. Each value represents 
mean ± SD (n = 6). 
Formulation Ibuprofen 
(%w/v) 
DEAE-Dextran 
(%w/v) 
Particle size (nm) Polydispersity 
Index 
Zeta Potential 
(mV) 
IbMelt-control 0.2 - 2872.12±128.9 0.67±0.08 -7.251±1.3 
IbD1Melt 0.2 0.1 203.25±3.7 0.36±0.05 -0.79±0.11 
IbD2Melt 0.2 0.2 239.80±6.34 0.35±0.02 0.96±0.24 
IbD3Melt 0.2 0.4 321.42±2.86 0.42±0.05 1.56±0.23 
IbD4Melt 0.2 0.8 2055.58±19.5 0.39±0.09 2.56±0.26 
IbD5Melt 0.2 1.6 2351.68±12.6 0.42±0.07 4.79±0.24 
Table 16 Particle size, polydispersity index and zeta potential of solubilised (IbDNaOH) nanoconjugates. Each value 
represents mean ± SD (n = 6). 
Formulation Ibuprofen 
(%w/v) 
DEAE-Dextran 
(%w/v) 
Particle size (nm) Polydispersity 
Index 
Zeta Potential 
(mV) 
IbNaOH-control 0.2 - 2872.12±128.9 0.67±0.08 -7.25±1.3 
IbD1NaOH 0.2 0.1 185.68±17.61 0.32±0.04 -3.04±2.39 
IbD2NaOH 0.2 0.2 203.90±12.78 0.29±0.03 -2.65±1.97 
IbD3NaOH 0.2 0.4 204.48±17.02 0.33±0.03 -1.76±0.03 
IbD4NaOH 0.2 0.8 882.77±110.8 0.39±0.03 -1.18±0.17 
IbD5NaOH 0.2 1.6 1118.55±142.57 0.35±0.04 2.64±0.30 
Table 17 Particle size, polydispersity index and zeta potential of tween 80 (IbDTw80) nanoconjugates. Each value 
represents mean ± SD (n = 6). 
Formulation Ibuprofen 
(%w/v) 
DEAE-Dextran 
(%w/v) 
Particle size (nm) Polydispersity 
Index 
Zeta Potential 
(mV) 
IbTw80-control 0.2 - 2872.12±128.9 0.67±0.08 -7.251±1.3 
IbD1Tw80 0.2 0.1 122.17±4.65 0.37±0.02 3.45±0.2 
IbD2Tw80 0.2 0.2 104.08±4.99 0.37±0.01 3.30±0.46 
IbD3Tw80 0.2 0.4 19.92±1.59 0.32±0.04 1.84±0.12 
IbD4Tw80 0.2 0.8 13.02±0.92 0.16±0.14 1.37±0.16 
IbD5Tw80 0.2 1.6 13.02±1.19 0.15±0.14 1.02±0.21 
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Table 18 Particle size, polydispersity index and zeta potential of hydrotrope (IbDNic) nanoconjugates. Each value 
represents mean ± SD (n = 6). 
Formulation Ibuprofen 
(%w/v) 
DEAE-Dextran 
(%w/v) 
Particle size (nm) Polydispersity 
Index 
Zeta Potential 
(mV) 
IbNic-control 0.2 - 2872.12±128.9 0.67±0.08 -7.251±1.3 
IbD1Nic 0.2 0.1 77.92±1.61 0.48±0.03 1.24±0.42 
IbD2Nic 0.2 0.2 107.75±5.28 0.56±0.09 2.23±0.59 
IbD3Nic 0.2 0.4 753.12±22.19 0.50±0.09 4.95±0.26 
IbD4Nic 0.2 0.8 858.47±27.21 0.55±0.13 13.87±0.23 
IbD5Nic 0.2 1.6 994.27±91.85 0.23±0.02 2.84±0.18 
  
Similar to DEAE-Dextran, initial concentration (5.0 x 10-4 mM) reduced the particle size of ibuprofen 
from 2872.12 nm to 216.7, 502.93, 10.70 and 336.93 nm in melt solubilization; alkaline 
solubilization; surfactant (Tween 80) solubilization and hydrotropic (nicotinamide) complexation 
techniques respectively (Tables 19 to 22; Figure 25). The greatest impact of initial concentration of 
chitosan was observed in the surfactant solubilization technique where particle size was reduced 
from 2872.12 to 10.70 nm (268-fold reduction) at lower concentration suggesting a more potent 
synergism with surfactant (Tween 80) compared with DEAE-Dextran.   All the techniques used in this 
study produced nanoconjugates (below 1000 nm) except the alkaline solubilization technique which 
produced greater than 4000 nm particles at chitosan concentration of 8.0 x 10-3 mM (Table 20). It 
was noted that the nanoconjugate sizes decreased to a minimum value (cac) at chitosan 
concentration of 0.05% (1.0 x 10-4 mM) in all the four techniques used in this study suggesting that 
method of preparation did not affect the critical association concentration of ibuprofen/chitosan 
nanoconjugates (ratio of 1:0.5). Beyond this ratio, chitosan nanoconjugates exhibited steady 
increase in size with increasing chitosan concentration. This similar trend was reported by Gan et al. 
in their investigation of chitosan-tripolyphosphate nanoparticles where a linear relationship was 
exhibited between the size and the concentration of chitosan within the tested range (0.05 to 3%) 
[61]. The authors suggested that the increase in particle size may be due to the dense spatial 
distance among chitosan molecules at higher concentration which led to the formation of larger 
particles.  
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Unlike the DEAE-Dextran, the conjugate size increased after cac in the surfactant solubilization 
technique. In a similar study polyalkylcyanoacrylate (PACA) and poly (lactic acid) (PLA) nanoparticles 
were coated with chitosan using emulsion polymerization and adsorption respectively to achieve 60 
and 500 nm sizes respectively [55]. However the effect of different nanoparticularization technique 
was not evaluated.   
 
Figure 25 Effect of chitosan concentration on particle sizes of drug-polymer conjugates. 
Table 19 Particle size, polydispersity index and zeta potential of melt (IbChMelt) nanoconjugates. Each value represents 
mean ± SD (n = 6). 
Formulation Ibuprofen 
(%w/v) 
Chitosan (%w/v) Particle size (nm) Polydispersity 
Index 
Zeta Potential 
(mV) 
IbMelt-control 0.2 - 2872.12±128.9 0.67±0.08 -7.251±1.3 
IbCh1Melt 0.2 0.025 216.7±99.15 0.51±0.17 1.89±0.59 
IbCh2Melt 0.2 0.05 252.92±75.78 0.62±0.25 2.27±0.33 
IbCh3Melt 0.2 0.1 338.15±104.76 0.57±0.2 2.51±0.08 
IbCh4Melt 0.2 0.2 446.07±73.15 0.35±0.09 2.84±0.24 
IbCh5Melt 0.2 0.4 450.83±29.69 0.45±0.09 3.03±0.21 
Table 20 Particle size, polydispersity index and zeta potential of solubilised (IbChNaOH) nanoconjugates. Each value 
represents mean ± SD (n = 6). 
Formulation Ibuprofen 
(%w/v) 
Chitosan (%w/v) Particle size (nm) Polydispersity 
Index 
Zeta Potential 
(mV) 
IbNaOH-control 0.2 - 2872.12±128.90 0.67±0.08 -7.251±1.3 
IbCh1NaOH 0.2 0.025 502.93±37.93 0.41±0.10 0.42±0.22 
IbCh2NaOH 0.2 0.05 271.05±12.06 0.69±0.20 1.27±0.18 
IbCh3NaOH 0.2 0.1 292.81±25.80 0.65±0.06 1.88±0.02 
IbCh4NaOH 0.2 0.2 649.50±11.39 0.42±0.08 2.07±0.02 
IbCh5NaOH 0.2 0.4 4216.70±129.70 0.53±0.11 2.68±0.03 
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Table 21 Particle size, polydispersity index and zeta potential of surfactant solubilization (IbChTw80) nanoconjugates. 
Each value represents mean ± SD (n = 6). 
Formulation Ibuprofen 
(%w/v) 
Chitosan (%w/v) Particle size (nm) Polydispersity 
Index 
Zeta Potential 
(mV) 
IbTw80-control 0.2 - 2872.12±128.90 0.67±0.08 -7.25±1.30 
IbCh1Tw80 0.2 0.025 10.70±0.97 0.25±0.07 1.27±0.20 
IbCh2Tw80 0.2 0.05 9.93±2.19 0.35±0.06 2.05±0.62 
IbCh3Tw80 0.2 0.1 10.90±1.58 0.41±0.20 2.11±0.04 
IbCh4Tw80 0.2 0.2 12.40±1.20 0.28±0.11 2.13±0.02 
IbCh5Tw80 0.2 0.4 15.13±2.40 0.33±0.08 2.33±0.03 
Table 22 Particle size, polydispersity index and zeta potential of hydrotrope (IbChNic) nanoconjugates. Each value 
represents mean ± SD (n = 6). 
Formulation Ibuprofen 
(%w/v) 
Chitosan (%w/v) Particle size (nm) Polydispersity 
Index 
Zeta Potential 
(mV) 
IbNic-control 0.2 - 2872.12 ±128.9 0.67 ±0.08 -7.25 ±1.30 
IbCh1Nic 0.2 0.025 336.93 ±15.3 0.30 ±0.04 2.57 ±0.18 
IbCh2Nic 0.2 0.05 295.82 ±18.01 0.33 ±0.06 2.69 ±0.28 
IbCh3Nic 0.2 0.1 378.55 ±62.97 0.32 ±0.03 2.74 ±0.03 
IbCh4Nic 0.2 0.2 551.27 ±33.51 0.33 ±0.01 3.11 ±0.17 
IbCh5Nic 0.2 0.4 869.17 ±77.9 0.31 ±0.033 4.39 ±1.54 
 
The PDI of ibuprofen/chitosan nanoconjugates are presented in Tables 19 to 22; Figure 26. The PDI 
of IbChMelt; IbChNaOH; IbChTw80 and IbChNic was in the range of 0.35 to 0.62; 0.41 to 0.69; 0.25 to 
0.41 and 0.30 to 0.33 repectively with no specific pattern with respect to concentration of chitosan. 
This suggests medium to broad and non homogeneous particle size distribution with low probability 
of stabilization. 
 
Figure 26 Effect of chitosan concentration on polydispersity indices of drug-polymer conjugates. 
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Similar to the ibuprofen/DEAE-Dextran nanoconjugates, the zeta potential of ibuprofen/chitosan 
nanoconjugates exhibited relatively low values but the values increased to a maximum with 
increasing concentrations of chitosan (Figure 27). The zeta potential of IbChMelt; IbChNaOH; 
IbChTw80 and IbChNic was in the range of 1.89 to 3.03; 0.42 to 2.68; 1.27 to 2.33 and 2.57 to 4.39 
repectively (Tables 19 to 22). The presence of positive charge in the nanoconjugates also suggests 
modification of the nanoconjugate surface with chitosan and the low zeta potential values indicates 
high probability of particle aggregation. However the stabilization of the nanoconjugates may be due 
to steric effect rather than electrostatic repulsion. The difference between the zeta potentials of 
ibuprofen/DEAE-Dextran and ibuprofen/chitosan nanoconjugates was not statistically significant (p > 
0.05, n = 24).  
 
Figure 27 Effect of chitosan on zeta potential measurements of drug-polymer conjugates. 
The preliminary studies showed that DEAE-Dextran and Chitosan interacted individually with gellan 
to form colloidal DEAE-Dextran-Gellan complex and Chitosan-Gellan complex. Therefore ternary 
DEAE-Dextran-Ibuprofen-Gellan conjugates were prepared, characterized and evaluated for 
controlled release potentials. The particle size, polydispersity index and zeta potential for ibuprofen 
loaded DEAE-Dextran-gellan and chitosan-gellan ternary conjugates are presented in Tables 23 and 
24 respectively. The mean particle size of ibuprofen/DEAE-Dextran control conjugate was 4.23 µm 
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while those of ibuprofen loaded DEAE-Dextran-gellan complexes ranged from 552.87 to 972.38 nm 
in the order DG 50:50 < DG 75:25 < DG 25:75 < DG 0:100 < DG 100:0 < Ib-control (Table 23 and 
Figure 28). It was obvious that the mean particle size of the ternary DEAE-Dextran-Ibuprofen-Gellan 
nanoconjugate was significantly higher than the binary DEAE-Dextran-Ibuprofen nanoconjugates (p < 
0.05, n = 6). For instance at ibuprofen/DEAE-Dextran ratio 1:1, the nanoconjugate size was 203.25 
nm (Table 15) and 552.87 nm (Table 23) for the binary and ternary nanoconjugates respectively. It 
was opined that addition of anionic polyelectrolyte (gellan) could reduce the zeta (repulsion) 
potential of DEAE-Dextran-ibuprofen nanoconjugates leading to particle aggregation and growth. 
Gellan may also coat the nanoconjugate to increase the particle size. Wang et al. have reported the 
unique characteristics of gellan which include temperature-dependent hydrogen bonding and 
cation-induced electrostatic incorporation [62]. Since high temperature was used in the presence of 
cationic polymer during the preparation of ternary nanoconjugates, both electrostatic interaction 
and hydrogen bonding which might have occurred could increase the particle size. Increasing 
concentration of DEAE-Dextran decreased conjugate size steadily to a minimum value of 552.87 nm 
at critical conjugation DEAE-Dextran concentration of 1 x 10-3 mM (DEAE-Dextran/Gellan weight 
ratio 50:50), suggesting a single complexation phenomenon. Higher concentrations of DEAE-Dextran 
increased the conjugate size steadily (Figure 28).  
Table 23 Particle size, polydispersity index and zeta potential for ibuprofen loaded DEAE-Dextran-gellan complexes. Each 
value represents mean ± SD (n = 6). 
Formulation Particle size (nm) Polydispersity Index Zeta Potential (mV) 
Ib-control 4233.33±154.7 0.13±0.04 -0.97±0.28 
DG 0:100 924.35±96.43 0.41±0.05 -32.14±3.75 
DG 25:75 721.07±35.40 0.34±0.06 -30.31±8.10 
DG 50:50 552.87±28.00 0.22±0.03 34.15±2.10 
DG 75:25 635.98±29.69 0.19±0.02 44.63±2.17 
DG 100:0 972.38±48.34 0.38±0.05 47.23±2.92 
Table 24 Particle size, polydispersity index and zeta potential for ibuprofen loaded chitosan-gellan complexes. Each 
value represents mean ± SD (n = 6). 
Formulation Particle size (nm) Polydispersity Index Zeta Potential (mV) 
Ib-control 4233.33±154.7 0.13±0.04 -0.97±0.28 
CG 0:100 869.07±64.40 0.72±0.09 -30.36±3.00 
CG 25:75 725.66±42.68 0.27±0.04 -24.81±2.73 
CG 50:50 783.40±36.55 0.31±0.06 29.67±3.88 
CG 75:25 1017.3±42.10 0.04±0.01 31.22±6.96 
CG 100:0 1046.33±134.69 0.20±0.01 32.16±2.98 
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Similar results were obtained for ibuprofen loaded chitosan-gellan complexes as shown in Table 24 
and Figure 28. The ternary conjugate sizes ranged from 725.66 to 1046.33 nm in the order CG 25:75 
< CG 50:50 < CG 0:100 < CG 75:25 < CG 100:0 < Ib-control. The mean particle size of the ternary 
Chitosan-Ibuprofen-Gellan nanoconjugate was also significantly higher than the binary Chitosan-
Ibuprofen nanoconjugates (p < 0.05, n = 6). For instance at ibuprofen/chitosan ratio 1:1, the 
nanoconjugate size was 338.15 nm (Table 19) and 783.40 nm (Table 24) for the binary and ternary 
nanoconjugates respectively. The conjugate size also decreased to a minimum value of 725.66 nm at 
chitosan concentration of 5 x 10-4 mM (Figure 29) suggesting a mono complexation phenomenon.  
 
Figure 28 Effect of DEAE-Dextran and chitosan concentration on particle sizes of ibuprofen loaded DEAE-Dextran-gellan 
and chitosan-gellan complexes. 
The PDI for DEAE-Dextran ternary conjugates exhibited only one breakpoint (cac) at 1.5 x 10-3 mM of 
DEAE-Dextran while chitosan ternary conjugates exhibited two breakpoints at 5 x 10-4 and 1.5 x 10-3 
mM of chitosan indicating mono- and multiple-complexation phenomena respectively. Ibuprofen 
control has a PDI of 0.13 while those of ibuprofen loaded DEAE-Dextran-gellan and chitosan-gellan 
complexes ranged from 0.19 to 0.41 (Figure 29) and 0.04 to 0.72 (Figure 29) respectively. The PDI for 
DEAE-Dextran-ibuprofen-gellan conjugates decreased steadily to a minimum value of 0.19 with 
increase in DEAE-Dextran concentration indicating homogeneous monodispersed particle size. 
Further increase in DEAE-Dextran concentration beyond the cac increased PDI steadily indicating 
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polydispersed system at higher concentrations. On the other hand chitosan-ibuprofen-gellan 
conjugates exhibited two inflection points (Figure 29) with increasing concentration of chitosan 
indicating multiple complexation and polydisperse systems. 
 
Figure 29 Effect of DEAE-Dextran and chitosan concentration on polydispersity indices of ibuprofen loaded DEAE-
Dextran-gellan and chitosan-gellan complexes. 
The zeta potential of ibuprofen is -0.97 mV while those of ternary ibuprofen loaded DEAE-Dextran-
gellan complexes ranged from -30.31 to 47.23 mV (Figure 30). The zeta potential of the ternary 
nanoconjugates were significantly higher (p < 0.05, n = 6) than those of binary nanoconjugates 
(Figures 24 and 27) suggesting high repulsion potential and better physical stability of the ternary 
nanoconjugates. The increased stability was ascribed to the interaction between cationic (DEAE-
Dextran) and anionic (gellan) polyelectrolytes. Similar zeta potential was observed with chitosan-
ibuprofen-gellan conjugates ranging from -30.36 to 32.16 mV (Figure 33) which was also higher than 
the corresponding zeta potentials for binary chitosan/ibuprofen nanoconjugates (Figure 27). The 
enhanced stability was ascribed to the presence of gellan.  
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Figure 30 Effect of DEAE-Dextran and chitosan concentration on zeta potential of ibuprofen loaded DEAE-Dextran-gellan 
and chitosan-gellan complexes. 
2.3.3.6. Drug conjugation capacity/efficiency 
The efficiency of attaching drugs to the polymer carrier is very important for the success of polymer 
therapeutics. It is desirable to achieve higher conjugation efficiency for clinical applications.  The 
drug conjugation efficiency of the nano-conjugates is shown in Table 3 toTable 10. The conjugation 
efficiency of IbDMelt conjugates was in the range of 98.22 to 98.81%; IbDNaOH conjugates 97.38 to 
98.14%; IbDTw80 conjugates 89.05 to 96.33% and IbDNic conjugates from 95.48 to 95.68%. It 
appeared that the concentration of DEAE-Dextran did not affect the conjugation efficiency of the 
four techniques studied. The conjugation efficiency was relatively constant, thus independent of 
DEAE-Dextran concentration. High conjugation efficiency was achieved by all the method studied. 
This was higher than the findings of Jiang et al. which stated a maximum entrapment efficiency of 
72.20% for ibuprofen-DEAE-Dextran complex [23]. 
The conjugation efficiency of IbChMelt conjugates was in the range of 98.03 to 98.73%; IbChNaOH 
conjugates 97.98 to 98.68%; IbChTw80 conjugates 89.21 to 90.26% and IbChNic conjugates from 
90.26 to 91.99%. High conjugation efficiency was achieved by all the methods studied. 
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The conjugation efficiency of the ibuprofen-DEAE-Dextran-gellan complex was found to be between 
97.35 and 99.1% in the order DG 100:0 > DG 25:75 > DG 0:100 > DG 75:25 > DG 50:50 as shown in 
Table 11. The conjugation efficiency was highest for DG 100:0.  
The conjugation efficiency of the ibuprofen-chitosan-gellan complex was found to be in the range of 
97.01 and 98.97% in the order CG 25:75 > CG 0:100 > CG 75:25 > CG 100:0 > CG 50:50 in Table 12. 
CG 25:75 complex showed the highest conjugation efficiency. 
2.3.3.7. Morphology and size – Scanning electron microscopy 
The SEM micrographs of ibuprofen, DEAE-Dextran, chitosan and the respective nanoconjugates are 
presented in Figures 31 to 38. Ibuprofen had a distinct long needle-like crystalline structure and 
rough surface with particle size of 145.08 ± 56.63 x 32.82 ± 12.06 µm and aspect ratio (length to 
width of 4.42) in Figure 31G. This was similar to the SEM image of ibuprofen crystals reported by 
Plakkot et al. with aspect ratio range of 4 to 6 [49].  While DEAE-Dextran, had rough surface and 
irregular structures in Figure 31H. The surface morphology of ibuprofen control showed almost 
spherical shaped particles in aggregates (Figure 31F).  
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Figure 31 Scanning electron micrographs of ibuprofen-DEAE-Dextran conjugates (melt solubilization) (A) IbD1Melt, (B) 
IbD2Melt, (C) IbD3Melt, (D) IbD4Melt, (E) IbD5Melt, (F) IbMelt-control, (G) ibuprofen powder-reference and (H) DEAE-
Dextran powder-reference. 
All the four techniques produced particles of nano-size dimensions. The nanoparticles where 
observed to be either distinct, spherical particles or as clusters/aggregates. All the IbDMelt 
conjugates showed spherical particles in aggregates with particle size range of 122.7 to 807.1 nm 
except IbD3Melt which was spherical and appeared singly with particle size of 315.3 nm in Figure 
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31A to Figure 31E. They appeared to be homogenous in size under the SEM. The particle sizes 
increased with increasing concentration of DEAE-Dextran with the exception of IbD5Melt which 
exhibited the smallest particle size (Table 100 in the Appendix). It was observed that raw ibuprofen 
powder changed from a needle like shape to spherical particles in the processed ibuprofen (IbMelt 
control) and drug polymer (IbDMelt) nanoconjugates. 
All the particle sizes measurements from the SEM images of the IbDMelt conjugates were in the 
nanometre range. This is in contrast with the particle size analyzer measurements which showed 
that the IbD4Melt and IbD5Melt were in the micrometer range. The discrepancy between the 
particle size measurement by SEM and particle size analyzer has been justified by Prabha et al. to be 
due to the fact that particle size analyzer measures the apparent size (hydrodynamic radius) of a 
particle, and this includes the hydrodynamic layers composed of the polymers formed around the 
hydrophilic particle, causing an overestimation of nanoparticles size [63]. 
IbD1NaOH and IbD3NaOH showed single spherical shaped particles with two concentric rings with 
particle sizes 364.9 nm and 249.73 nm respectively, while IbD2NaOH, IbD4NaOH and IbD5NaOH 
showed spherical shaped particles in aggregates with particle sizes 109.1 nm, 89.9 nm and 60.4 nm 
respectively in Figure 32A to 32E. The particle sizes were all in the nanometre range, which 
decreased with increasing concentration of DEAE-Dextran. 
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Figure 32 Scanning electron micrographs of ibuprofen-DEAE-Dextran conjugates (solubilization) (A) IbD1NaOH, (B) 
IbD2NaOH, (C) IbD3NaOH, (D) IbD4NaOH, (E) IbD5NaOH and (F) IbNaOH-control. 
The surface morphologies of IbDTw80 conjugates were all spherical in shape and in aggregates 
(Figures 33A to 33E). The particle sizes decreased with increasing concentration of DEAE-Dextran in 
the range of 38.76 to 111.6 nm. This was comparable to that observed with the particle size analyzer 
in this study. It was observed that the surfactant solubilization technique exhibited the highest 
tendency to coalesce when compared to other techniques. 
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Figure 33 Scanning electron micrographs of ibuprofen-DEAE-Dextran conjugates (solubilization) (A) IbD1Tw80, (B) 
IbD2Tw80, (C) IbD3Tw80, (D) IbD4Tw80, (E) IbD5Tw80 and (F) IbTw80-control.  
The surface morphology of IbDNic conjugates were single and spherical in Figure 34A to 34E. The 
particle sizes increased with increasing concentration of DEAE-Dextran in the range of 77.52 to 162.7 
nm. The values of the particle sizes were smaller when compared to the particle size analyzer 
measurements. 
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Figure 34 Scanning electron micrographs of ibuprofen-DEAE-Dextran conjugates (hydrotropy) (A) IbD1Nic, (B) IbD2Nic, 
(C) IbD3Nic, (D) IbD4Nic, (E) IbD5Nic and (F) IbNic-control.  
The surface morphology of IbCh1Melt was almost spherical, IbCh2Melt, IbCh3Melt and IbCh5Melt 
were spherical and in aggregates while IbCh4Melt showed spherical particles on interconnected 
strands in Figure 35A to Figure 35E. The particle sizes increased with increasing chitosan 
concentration were in the range of 261.3 to 602.37 nm (Table 101 in Appendix I). This was 
comparable to the particle size analyzer measurements. 
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Figure 35 Scanning electron micrographs of ibuprofen-chitosan conjugates (melt solubilization) (A) IbCh1Melt, (B) 
IbCh2Melt, (C) IbCh3Melt, (D) IbCh4Melt, (E) IbCh5Melt, (F) IbMelt-control, (G) ibuprofen powder-reference and (H) 
chitosan powder-reference. 
The surface morphology of IbChNaOH conjugates showed single and near spherical particles in 
Figure 36A to Figure 36E.  The particle sizes increased with increasing concentration of chitosan with 
the exception of IbCh2NaOH in the range of 2.3 to 9.84 µm. The particle sizes were within the 
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micrometre range compared with the nanometre range obtained from the particle size analyzer 
measurements. 
 
Figure 36 Scanning electron micrographs of ibuprofen-chitosan conjugates (solubilization) (A) IbCh1NaOH, (B) 
IbCh2NaOH, (C) IbCh3NaOH, (D) IbCh4NaOH, (E) IbCh5NaOH and (F) IbNaOH-control. 
The surface morphology of IbChTw80 conjugates showed spherical and monodisperse particles in 
Figure 37A to 37E. The particle sizes increased with increasing chitosan concentration in the range of 
166.2 to 498.9 nm. The sizes were larger than the measurements obtained from the particle size 
analyzer. 
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Figure 37 Scanning electron micrographs of ibuprofen-chitosan conjugates (solubilization) (A) IbCh1Tw80, (B) 
IbCh2Tw80, (C) IbCh3Tw80, (D) IbCh4Tw80, (E) IbCh5Tw80 and (F) IbTw80-control. 
The surface morphology of IbChNic conjugates showed spherical particles in aggregates (Figures 38A 
to 38E). The particle sizes increased with increasing chitosan concentration in the range of 114.8 nm 
to 2.6 µm with IbCh5Nic in the micrometer range. The particle sizes were all in the nanometre range 
for particle size analyzer measurements. 
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Figure 38 Scanning electron micrographs of ibuprofen-chitosan conjugates (hydrotropy) (A) IbCh1Nic, (B) IbCh2Nic, (C) 
IbCh3Nic, (D) IbCh4Nic, (E) IbCh5Nic and (F) IbNic-control.  
The surface morphology of gellan, DEAE-Dextran and chitosan exhibited particles with irregular form 
and sharp edges in Figures 39 and 40.  The surface morphology of binary complexes DG 0:100, DG 
25:75, DG 50:50, DG 75:25 and DG 100:0 showed that the complexes were spherical and appeared 
singly. 
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Figure 39 Scanning electron micrographs of DEAE-Dextran-gellan conjugates (binary)  (A) DG 0:100, (B) DG 25:75, (C) DG 
50:50, (D) DG 75:25, (E) DG 100:0, (F) DEAE-Dextran powder-reference and (G) Gellan powder-reference. 
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Figure 40 Scanning electron micrographs of gellan conjugates (binary) (A) CG 0:100, (B) CG 25:75, (C) CG 50:50, (D) CG 
75:25, (E) CG 100:0, (F) Chitosan powder-reference and (G) Gellan powder-reference. 
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The surface morphology of binary complexes CG 0:100, CG 25:75, CG 50:50, CG 75:25 and CG 100:0 
showed that the complexes were spherical and appeared singly (Figure 40). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The surface morphology of ibuprofen loaded DG 0:100, DG 25:75, DG 50:50, DG 75:25 and DG100:0 
were found to be spherical and monodisperse. IbDW (processed ibuprofen in distilled water), the 
control formulation showed that ibuprofen remained crystalline and angular shaped arranged in 
cross pattern in Figure 41. The particle sizes were in the range of 171.4 to 499.5 nm exhibiting initial 
increase with increasing concentration of DEAE-Dextran in the DG weight ratio up to DG 50:50 
beyond which there was a decrease in particle sizes.  
 
Figure 41 Scanning electron micrographs of ibuprofen-DEAE-Dextran-gellan conjugates (ternary)  (A) DG 0:100, 
(B) DG 25:75, (C) DG 50:50, (d) DG 75:25, (E) DG 100:0 and (F) ibuprofen control. 
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For the ibuprofen-gellan-chitosan complexes shown in Figure 42, CG 0:100, CG 25:75, CG 50:50, CG 
75:25 and CG 100:0 complexes were spherical and appeared singly. IbDW, the control formulation 
showed that ibuprofen remained crystalline and angular shaped arranged in cross pattern. The 
particle sizes ranged from 162.1 nm to 1.45 µm with the CG 75:25 only in the micrometer range. 
2.3.3.8. Spectroscopic studies- Fourier Transform Infrared  
FTIR is the preferred method of infrared spectroscopy due to its highly accurate and reproducible 
frequency determinations. The resulting spectrum represents the molecular absorption and 
transmission, creating a molecular fingerprint of the sample. Like a fingerprint, no two unique 
molecular structures produce the same infrared spectrum. This makes infrared spectroscopy useful 
 
Figure 42 Scanning electron micrographs of ibuprofen-chitosan-gellan conjugates (ternary) (A) CG 0:100, (B) CG 
25:75, (C) CG 50:50, (D) CG 75:25, (E) CG 100:0 and (F) ibuprofen-control. 
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for several types of analysis including drug formulations. The unique fingerprint is required in this 
study to readily dinstinguish the absorption patterns of all drug-polymer nanoconjugate samples in 
comparison to pure references of drugs and polymers. 
FTIR spectra of the samples were generated to identify any potential intrinsic molecular interaction 
between functional groups of ibuprofen and DEAE-Dextran; Chitosan; Gellan or any local 
disturbances to the basic backbone spectrum of their structure due to neighbouring electrostatic 
effects. The assignments of peaks of drug and polymers used are summarized in Table 25 and the 
changes in peak positions and intensities of absorption bands are summarized in Tables 26 to 35 and 
Figures 43 to 52. The spectra of raw ibuprofen showed characteristic broad absorption peaks at 3020 
and 2954 cm-1 corresponding to OH group usually from carboxylic acid which has strong tendency to 
form hydrogen bonded dimers and methyl CH-stretching respectively. Broad absorption bands at 
3500 to 2500 cm-1 have been ascribed to OH group from carboxylic acid [64]. The hydrogen bonded 
dimer is also evident between 3309 and 2632 cm-1 (Figure 43). This was consolidated by strong and 
sharp C-O stretching at 1230 cm-1 as well as strong and sharp carbonyl band absorption peak at 
1706  cm-1 with high intensity due to large dipole moment of the carbonyl bond (C = O) stretching of 
the carboxylic acid (COOH) group. Major band in the region of 1750 to 1700 cm-1 have been reported 
to correspond to substances containing simple carbonyl compounds such as aldehyde, ketone, ester 
or carboxylic acid [65]. It also includes absorption peaks at 2954 cm-1, 2923 cm-1 and 2859 cm-1 which 
are characteristic for linear aliphatic C-H stretching as well as the presence of aromatic ring vibration 
(C = C) observed at bands 1507 cm-1 which supports the presence of aromatic structure of ibuprofen. 
DEAE-Dextran spectra contain characteristic broad absorption band at 3295 cm-1 corresponding to 
normal polymeric –OH stretching [65]. The N-H deformation vibration at 1641 cm-1 was assigned to 
tertiary amine (NH bend: 1650 to 1550 cm-1) and C-N stretching at 1342 cm-1 (1340 to 1250 cm-1). 
Chitosan showed characteristic amine absorption peak at 3279 cm-1 accompanied with NH- bending 
at 1651 cm-1 while gellan exhibited OH- stretching, CH- stretching and carboxyl stretching at 3306 
cm-1, 2897 cm-1  and 1602 cm-1 respectively.  In the FT-IR spectrum of 1:1 physical mixture of 
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ibuprofen and DEAE-Dextran (Figure 43, Table 26) the band features correspond to the bands in the 
individual components of the mixture however the carbonyl group peak at 1706 cm-1 shifted to 
1716  cm-1 and a new peak appeared at 1844 cm-1 indicating a possible intermolecular interaction in 
solid state.  Also absorption peaks at 3610, 3749 and 3902 cm-1 corresponds to monomeric hydroxyl 
groups which indicate a strong tendency to form intermolecular hydrogen bonding. The Ibuprofen-
DEAE-Dextran nanoconjugates obtained from melt solubilization exhibited only two peaks at 3309 to 
3334 cm-1 and 1634 to 1639 cm-1 at all concentrations of DEAE-Dextran (Figure 43). The 
characteristic aromatic and the fingerprint features completely disappeared while the hydroxyl 
group became a broad Gaussian-shaped peak at around 3334 cm-1 indicating intermolecular 
hydrophobic and hydrogen-bonded hydroxyl interactions respectively. Also the carbonyl group at 
1706 cm-1 disappeared and a new peak appeared at 1634 cm-1 which corresponds to amide 
functional group as reported by Coates (1680 to 1630 cm-1) [65]. It was hypothesized that melt 
solubilization of ibuprofen (-COOH) in the presence of cationic DEAE-Dextran (-N+HR2) produced an 
amide probably through condensation reaction.  
The nanoconjugates prepared by alkaline solubilization technique showed similar peaks to the melt 
solubilization process showing broad Gaussian-shaped hydroxyl and CH-stretching absorption peak 
at 3335 to 3324 cm-1 as well as amide group at 1635 cm-1. However a new peak appeared at 2149 to 
2111 cm-1 which increased to a maximum of 2149 cm-1 at ibuprofen/DEAE-Dextran ratio 1:2 (Figure 
44).  Harwood and Claridge have assigned sharp absorption peaks at around 3300 cm-1 accompanied 
by absorption around 2100 cm-1 which was due to disubstituted alkynes stretching [64]. This may not 
be applicable in this case because the peak was particularly broad and intense due to the strong 
tendency of carboxylic acids to form hydrogen-bonded dimers. The broad hydroxyl absorption peaks 
shifted to higher values in the physical mixture and nanoconjugates, this has been linked with 
hydrogen bond interaction or amorphous transformation by Coates [65] although the shift in the 
peaks was not statistically significant (p > 0.05, n = 4). All the characteristic bands for secondary 
amine and polymeric hydroxyl groups on DEAE-Dextran also disappeared from all the treated 
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samples which supports the potential interaction of the –R2NH groups of DEAE-Dextran with 
ibuprofen. Amino groups (present on DEAE-Dextran) have been reported to have strong propensity 
to form hydrogen bond network with carboxylic groups (present on ibuprofen) due to the van der 
Waals forces of attraction which forces the hydrophobic organic molecules to interact during the 
process of crystallization to produce multiple layered crystals [66]. In corollary, only the tertiary 
amine group of the DEAE-Dextran with pKa 9.5 is totally protonated [67] at the formulation pH (6.0) 
and can interact with ibuprofen. The tertiary amine with pKa 5.5 has little or no protonation while 
the quaternary amine group with pKa of 14 could protonate but is not very accessible due to steric 
hindrance effects. Complex formation between ibuprofen and DEAE-Dextran involving electrovalent 
as well as hydrogen bonding was therefore hypothesized.   
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Table 25 Functional groups and vibrations assigned to the major peaks of pure components observed in the FTIR spectra 
displayed in Figures 46 to 53. 
Material Assignment / group Group frequency 
Wave number/ cm-1 
Ibuprofen Aromatic C-H asymmetric stretching 
Hydroxyl O-H stretching 
Methyl –CH stretch 
Methylene C-H stretching 
Methyne C-H stretching 
Carboxylic acid C=O stretching  
Aromatic ring C=C-C stretching 
Methyl –CH bend 
Methyne C-H bending 
Skeletal C-C vibration 
Aromatic C-H in plane bending 
Aromatic C-H bend out of plane bending 
3088 and 3040 
3020 
2954 
2923 
2859 
1706 
1563, 1507, 1461 and 1450 
1462, 1450 and 1442 
1320 
1268, 1230, 1183 
1183, 1168, 1123, 1091, 1073, 1007 and 969 
880, 865, 849, 834, 820, 779, 746 and 690 
DEAE-Dextran N-H stretching, O-H stretching 
C-H stretching 
N-H bending (C=O in amide group) 
C-C stretching 
Methyne C-H bending 
C-O-C stretching 
C-N stretching 
C-O stretching 
C-Cl stretching 
3295 
2921 
1641 
1456 
1342 
1144 
1007 
915 
760 
Chitosan O-H stretching 
NH stretching 
Methyl C-H symmetrical stretch 
N-H bending (C=O in amide group) 
Amine –NH2 (NH2 in amino group) 
Methyl C-H symmetrical bending 
C-O-C stretching 
C-N stretching 
C-C stretching 
3279 
3279 
2873 
1651 
1583 
1300 
1161 
1025 
672 
Gellan O-H stretching 
C-H stretching 
Aromatic carboxyl COO- stretching 
C-O-C stretching for alkyl ether 
C-O stretching 
C-C stretching 
3306 
2897 
1602 
1191 
1020 
672 
 
DEAE-Dextran showed peaks at 3295 cm-1 (NH and OH), 2921 cm-1 (CH), 1641 cm-1 (NH), 1456 cm-1 
(C-C), 1342 cm-1 (C-H), 1144 cm-1 (C-O-C), 1007 cm-1 (C-N), 915 cm-1 (C-O) and 760 cm-1 (C-Cl). 
Dermibilek and Dinc reported  similar peaks for  DEAE-Dextran at 3394 cm-1, 2926 cm-1, 1643 cm-1, 
1467 cm-1, 1157 cm-1, 1013 cm-1, 918 cm-1 and 765 cm-1 [68]. The bands assigned as the  finger prints 
of ibuprofen in literature include 2992 cm- 1 (CH), 1706 cm-1 (C=O), 1230 cm-1 (C-C) and 779 cm-1 (CH) 
[69-70]. Ibuprofen-DEAE-Dextran physical mixture showed peaks at 3610 cm-1 (OH), 2921 cm-1 (CH), 
1716 cm-1 (CO), 1646 cm-1 (NH), 1319 cm-1 (CH), 1230 cm-1 (C-C), 1007 cm-1 (CN) and 778 cm-1 (CH) 
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which are basically a combination of peaks present in ibuprofen and DEAE-Dextran with slight 
variations. 
Table 26 FTIR spectral characteristics at various wavelengths for ibuprofen-DEAE-Dextran conjugates (melt 
solubilization) ibuprofen control, ibuprofen-reference, DEAE-Dextran-reference and ibuprofen-DEAE-Dextran physical 
mixture. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Ibuprofen-reference 3089 
3045 
3020 
2992 
2980 
 
2954 
2923 
2859 
2727 
2632 
2542 
1911 
1804 
1706 
1507 
1462 
1450 
1442 
1418 
1379 
1365 
1329 
1321 
1305 
1268 
1231 
1183 
1168 
1123 
1091 
1073 
1007 
969 
934 
880 
865 
849 
834 
820 
779 
746 
690 
DEAE-Dextran-reference 3295 2921  1641 
1456 
1342 
1144 
1007 
915 
760 
Ibuprofen-DEAE-Dextran physical mixture 3902 
3749 
 
3610 
2921 
 
1844 
1716 
1675 
1646 
1555 
1542 
1524 
1456 
1319 
1230 
1007 
778 
IbMelt-control (IbD 1:0) 3309   1634   
IbD1Melt (IbD 1:0.5) 3324   1635   
IbD2Melt (IbD 1:1) 3327   1635   
IbD3Melt (IbD 1:2) 3324   1635   
IbD4Melt (IbD 1:4) 3334   1639   
IbD5Melt (IbD 1:8) 3334   1634   
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Figure 43 The FTIR spectra of ibuprofen-DEAE-Dextran conjugates (melt solubilization) ibuprofen control, ibuprofen-
reference, DEAE-Dextran-reference and ibuprofen-DEAE-Dextran physical mixture. 
Table 27 FTIR spectral characteristics at various wavelengths for ibuprofen-DEAE-Dextran conjugates (solubilization) 
ibuprofen control, ibuprofen-reference, DEAE-Dextran-reference and ibuprofen-DEAE-Dextran physical mixture. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Ibuprofen-reference 3089 
3045 
3020 
2992 
2980 
2954 
2923 
2859 
2727 
2632 
2542 
1911 
1804 
1706 
1507 
1462 
1450 
1442 
1418 
1379 
1365 
1329 
1321 
1305 
1268 
1231 
1183 
1168 
1123 
1091 
1073 
1007 
969 
934 
880 
865 
849 
834 
820 
779 
746 
690 
DEAE-Dextran-reference 3295 2921 1641 
1456 
1342 
1144 
1007 
915 
760 
Ibuprofen-DEAE-Dextran physical mixture 3902 
3749 
 
3610 
2921 
 
1844 
1716 
1675 
1646 
1555 
1542 
1524 
1456 
1319 
1230 
1007 
778 
IbNaOH-control (IbD 1:0)  3288 2122  1635   
IbD1NaOH (IbD 1:0.5) 3325 2132  1635   
IbD2NaOH (IbD 1:1) 3322 2144  1634   
IbD3NaOH (IbD 1:2) 3324 2140  1635   
IbD4NaOH (IbD 1:4) 3335 2125  1635   
IbD5NaOH (IbD 1:8) 3326 2111  1635   
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
Ib:D1:0.5
Ib:D1:1
Ib:D1:2
Ib:D1:4
Ib:D1:0
Ib:D1:8
Ibuprofen reference
DEAEDextran reference
Ibuprofen-DEAEDextran physical mixture
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Figure 44 The FTIR spectra of ibuprofen-DEAE-Dextran conjugates (solubilization) ibuprofen control, ibuprofen-
reference, DEAE-Dextran-reference and ibuprofen-DEAE-Dextran physical mixture. 
Table 28 FTIR spectral characteristics at various wavelengths for ibuprofen-DEAE-Dextran conjugates (solubilization) 
ibuprofen control, ibuprofen-reference, DEAE-Dextran-reference and ibuprofen-DEAE-Dextran physical mixture. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Ibuprofen-reference 3089 
3045 
3020 
2992 
2980 
2954 
2923 
2859 
2727 
2632 
2542 
1911 
1804 
1706 
1507 
1462 
1450 
1442 
1418 
1379 
1365 
1329 
1321 
1305 
1268 
1231 
1183 
1168 
1123 
1091 
1073 
1007 
969 
934 
880 
865 
849 
834 
820 
779 
746 
690 
DEAE-Dextran-reference 3295 2921 1641 
1456 
1342 
1144 
1007 
915 
760 
Ibuprofen-DEAE-Dextran physical mixture 3902 
3749 
 
3610 
2921 
 
1844 
1716 
1675 
1646 
1555 
1542 
1524 
1456 
1319 
1230 
1007 
778 
IbTw80-control (IbD 1:0) 3496 2922 
2836 
1735 
1643 
 
1436 
1349 
1296 
1248 
1095 
946 
845 
712 
IbD1Tw80 (IbD 1:0.5) 3336   1635 1087  
IbD2Tw80 (IbD 1:1) 3337   1635 1086  
IbD3Tw80 (IbD 1:2) 3335   1635 1086  
IbD4Tw80 (IbD 1:4) 3342   1635 1086  
IbD5Tw80 (IbD 1:8) 3343   1639 1086  
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
cm-1
%T 
IbD1:0.5
IbD1:1
IbD1:2
IbD1:4
IbD1:8
IbD1:0
Ibuprofen reference
DEAEDextran reference
Ibuprofen-DEAEDextran physical mixture
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Figure 45 The FTIR spectra of ibuprofen-DEAE-Dextran conjugates (solubilization) ibuprofen control, ibuprofen-
reference, DEAE-Dextran-reference and ibuprofen-DEAE-Dextran physical mixture. 
Nanoconjugates derived from the surfactant (Tween 80) solubilization technique; exhibited similar 
FT-IR absorption profile to the melt and alkaline solubilization techniques. However in the absence 
of DEAE-Dextran, the broad hydroxyl absorption became very weak and the aromatic as well as the 
fingerprint peaks of ibuprofen was more prominent (Figure 45). This effect was attributed to Tween 
80, the non ionic surfactant. Also the intensity of the amide peak reduced and shifted to 1643 cm-1 
while the carbonyl peak reappeared at 1735 cm-1 which may indicate the formation of ester or six-
membered ring lactone [65]. A new peak also appeared at 1350 cm-1 suggesting the formation of 
carboxylic acid salt (carboxylate).  It was opined that carboxylic acid salt, ester and amide as well as 
hydrogen bonding were formed during surfactant solubilization of ibuprofen in the absence of DEAE- 
Dextran. 
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Table 29 FTIR spectral characteristics at various wavelengths for ibuprofen-DEAE-Dextran conjugates (hydrotropy) 
ibuprofen control, ibuprofen-reference, DEAE-Dextran-reference and ibuprofen-DEAE-Dextran physical mixture. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Ibuprofen-reference 3089 
3045 
3020 
2992 
2980 
 
2954 
2923 
2859 
2727 
2632 
2542 
1911 
1804 
1706 
1507 
 
1462 
1450 
1442 
1418 
1379 
1365 
1329 
1321 
1305 
1268 
1231 
1183 
1168 
1123 
1091 
1073 
1007 
969 
934 
880 
865 
849 
834 
820 
779 
746 
690 
DEAE-Dextran-reference 3295 2921 1641 
1456 
1342 
1144 
1007 
915 
760 
Ibuprofen-DEAE-Dextran physical mixture 3902 
3749 
 
3610 
2921 
 
1844 
1716 
1675 
1646 
1555 
1542 
1524 
1456 
1319 
1230 
1007 
778 
IbNic-control (IbD 1:0) 3382 2127  1635   
IbD1Nic (IbD 1:0.5) 3326 2100  1635   
IbD2Nic (IbD 1:1) 3321 2090  1635   
IbD3Nic (IbD 1:2) 3327 2143  1635   
IbD4Nic (IbD 1:4) 3324 2147  1635   
IbD5Nic (IbD 1:8) 3324 2149  1635   
 
 
 
Figure 46 The FTIR spectra of ibuprofen-DEAE-Dextran conjugates (hydrotropy) ibuprofen control, ibuprofen-reference, 
DEAE-Dextran-reference and ibuprofen-DEAE-Dextran physical mixture. 
Ibuprofen/DEAE-Dextran nanoconjugates prepared by hydrotropic complexation technique 
exhibited three peaks at 3327 to 3312 cm-1; 2149 to 2090 cm-1 and 1635 cm-1 corresponding to 
hydrogen bonding, transition metal carbonyls (2100 to 1800 cm-1) and amide respectively (Figure 
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112 | P a g e  
 
46).  The disappearance of the carbonyl peak also suggests its involvement in electrostatic interacton 
with the DEAE-Dextran. Similar to other techniques hydrogen bonding and formation of amide was 
evident. 
The FTIR spectra of ibuprofen/chitosan nanoconjugates (Figure 47)  prepared by melt solubilization 
were quite similar to the ibuprofen/DEAE-Dextran nanoconjugates (Figure 46) producing only two 
peaks at 3335 cm-1 and 1635 cm-1 corresponding to hydrogen bonding and amide respectively. The 
ibuprofen/chitosan physical mixture also reflected the spectra of the components and the 
disappearance of the N-H stretching absorption peak at 3279 cm-1 as well as the broadness of the 
hydroxyl peak suggest hydrogen bonding. 
Table 30 FTIR spectral characteristics at various wavelengths for ibuprofen-chitosan conjugates (melt solubilization) 
ibuprofen control, ibuprofen-reference, chitosan-reference and ibuprofen-chitosan physical mixture. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Ibuprofen-reference 3089 
3045 
3020 
2992 
2980 
2954 
2923 
2859 
2727 
2632 
2542 
1911 
1804 
1706 
1507 
1462 
1450 
1442 
1418 
1379 
1365 
1329 
1321 
1305 
1268 
1231 
1183 
1168 
1123 
1091 
1073 
1007 
969 
934 
880 
865 
849 
834 
820 
779 
746 
690 
Chitosan-reference 3279 2918 1583 1300 1161 672 
Ibuprofen-Chitosan physical mixture 3902 
3854 
3749 
 
2954 
2922 
2868 
2631 
1715 
1555 
 
1542 
1508 
1462 
1418 
1379 
1365 
 
1320 
1268 
1229 
1183 
1167 
1122 
1091 
1072 
1008 
969 
935 
880 
865 
849 
820 
779 
746 
690 
667 
IbMelt-control (IbCh 1:0) 3309   1634   
IbCh1Melt (IbCh 1:0.125) 3333   1635   
IbCh2Melt (IbCh 1:0.25) 3335   1635   
IbCh3Melt (IbCh 1:0.5) 3326   1634   
IbCh4Melt (IbCh1:1) 3324   1639   
IbCh5Melt (IbCh 1:2) 3324   1635   
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Figure 47 The FTIR spectra of ibuprofen-chitosan conjugates (melt solubilization) ibuprofen control, ibuprofen-reference, 
chitosan-reference and ibuprofen-chitosan physical mixture. 
The FTIR spectra of ibuprofen/chitosan nanoconjugates prepared by alkaline solubilization were 
similar to the ibuprofen/DEAE-Dextran nanoconjugates. Three characteristic new peaks appeared at 
a range of 3324 to 3325 cm-1 ascribed to bonded hydroxyl group, 2099 to 2149 cm-1 ascribed to 
cyanide and 1635 cm-1 ascribed to amide for IbChNaOH nanoconjugates in Figure 48. There was a 
shift of peak at 1418 cm-1 in ibuprofen and DEAE-Dextran to 1412 cm-1 in the IbChNaOH 
nanoconjugates. The C=O and C-C stretching peak at 1706 cm-1 and 1230 cm- 1 for pure ibuprofen 
disappeared in the spectra of IbChNaOH nanoconjugates.The disappearance in peaks suggested 
there is a possible interaction between the polymer and the drug. Hydrogen bonding and formation 
of amide was evident. 
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Table 31 FTIR spectral characteristics at various wavelengths for ibuprofen-chitosan conjugates (solubilization) ibuprofen 
control, ibuprofen-reference, chitosan-reference and ibuprofen-chitosan physical mixture. 
Formulation  Position of absorption band (Wavenumber) / cm-1 
Ibuprofen-reference 3089 
3045 
3020 
2992 
2980 
 
2954 
2923 
2859 
2727 
2632 
2542 
1911 
1804 
1706 
1507 
1462 
1450 
1442 
1418 
1379 
1365 
1329 
1321 
 
1305 
1268 
1231 
1183 
1168 
1123 
1091 
1073 
1007 
 
969 
934 
880 
865 
849 
834 
820 
779 
746 
690 
Chitosan-reference 3279 2918  1583 
1300 
1161 672 
Ibuprofen-Chitosan physical mixture 3902 
3854 
3749 
 
2954 
2922 
2868 
 
2631 
1715 
1555 
1542 
1508 
1462 
1418 
1379 
1365 
1320 
1268 
1229 
1183 
1167 
1122 
1091 
1072 
1008 
969 
935 
880 
865 
849 
820 
779 
746 
690 
667 
IbNaOH-control (IbCh 1:0)  3288 2122  1635   
IbCh1NaOH (IbCh 1:0.125) 3324 2099  1635 1412  
IbCh2NaOH (IbCh 1:0.25) 3324 2122  1635   
IbCh3NaOH (IbCh 1:0.5) 3324 2115  1635 1412  
IbCh4NaOH (IbCh 1:1) 3325 2147  1635 1412  
IbCh5NaOH (IbCh 1:2) 3324 2149  1634 1412  
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Figure 48 The FTIR spectra of ibuprofen-chitosan conjugates (solubilization) ibuprofen control, ibuprofen-reference, 
chitosan-reference and ibuprofen-chitosan physical mixture. 
The FTIR spectra of ibuprofen/chitosan nanoconjugates were also similar to the corresponding 
ibuprofen/DEAE-Dextran nanoconjugates. Four characteristic peaks appeared in the range of 3335 to 
3337 cm-1 ascribed to bonded hydroxyl group, 2100 to 2149 cm-1 ascribed to cyanide, 1635 cm-1 
ascribed to amide and 1086 to 1092 cm-1 ascribed to aromatic C-H in plane bend for IbChTw80 
nanoconjugates in Figure 49. The C=O and C-C stretching peak at 1706 cm-1 and 1230 cm-1 for pure 
ibuprofen disappeared in the spectra of IbChTw80 conjugates. The disappearance in peaks 
suggested there is a possible interaction between the polymer and the drug. 
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Table 32 FTIR spectral characteristics at various wavelengths for ibuprofen-chitosan conjugates (solubilization) ibuprofen 
control, ibuprofen-reference, chitosan-reference and ibuprofen-chitosan physical mixture. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Ibuprofen-reference 3089 
3045 
3020 
2992 
2980 
2954 
2923 
2859 
2727 
2632 
2542 
1911 
1804 
1706 
1507 
1462 
1450 
1442 
1418 
1379 
1365 
1329 
1321 
1305 
1268 
1231 
1183 
1168 
1123 
1091 
1073 
1007 
969 
934 
880 
865 
849 
834 
820 
779 
746 
690 
Chitosan-reference 3279 2918 1583 1300 1161 672 
Ibuprofen-Chitosan physical mixture 3902 
3854 
3749 
2954 
2922 
2868 
2631 
1715 
1555 
1542 
1508 
1462 
1418 
1379 
1365 
1320 
1268 
1229 
1183 
1167 
1122 
1091 
1072 
1008 
969 
935 
880 
865 
849 
820 
779 
746 
690 
667 
IbTw80-control (IbCh 1:0) 3496 
2922 
 
2836 
1735 
1643 
1436 
1349 
1296 
 
1248 
1095 
946 
845 
712 
IbCh1Tw80 (IbCh 1:0.125) 3337 2100 1635 1555 1086  
IbCh2Tw80 (IbCh 1:0.25) 3337 2149 1635  1091  
IbCh3Tw80 (IbCh 1:0.5) 3337 2147 1635 1555 1088  
IbCh4Tw80 (IbCh1:1) 3336 2146 1639 1555 1456 1091 
IbCh5Tw80 (IbCh 1:2) 3335 2145 1639 1555 1092  
 
 
Figure 49 The FTIR spectral characteristics at various wavelengths for ibuprofen-chitosan conjugates (solubilization) 
ibuprofen control, ibuprofen-reference, chitosan-reference and ibuprofen-chitosan physical mixture. 
Three characteristic peaks appeared at a range of 3310 cm-1 to 3336 cm-1 ascribed to bonded 
hydroxyl group, 2090 to 2146 cm-1 ascribed to cyanide and 1635 cm-1 ascribed to amide for IbChNic 
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nanoconjugates in Figure 50. There was a shift of peak at 1418 cm-1 in ibuprofen to 1412 cm-1 in the 
IbChNic nanoconjugates. The C=O and C-C stretching peak at 1706 cm-1 and 1230 cm-1 for pure 
ibuprofen disappeared in the spectra of IbChNic nanoconjugates. The disappearance in peaks 
suggested there is a possible interaction between the amino group of the polymer and the -COOH 
group of the drug. 
Table 33 FTIR spectral characteristics at various wavelengths for ibuprofen-chitosan conjugates (hydrotropy) ibuprofen 
control, ibuprofen-reference, chitosan-reference and ibuprofen-chitosan physical mixture. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Ibuprofen-reference 3089 
3045 
3020 
2992 
2980 
 
2954 
2923 
2859 
2727 
2632 
2542 
1911 
1804 
1706 
1507 
1462 
1450 
1442 
1418 
1379 
1365 
1329 
1321 
1305 
1268 
1231 
1183 
1168 
1123 
1091 
1073 
1007 
969 
934 
880 
865 
849 
834 
820 
779 
746 
690 
Chitosan-reference 3279 2918  1583 
1300 
1161 672 
Ibuprofen-Chitosan physical mixture 3902 
3854 
3749 
 
2954 
2922 
2868 
 
2631 
1715 
1555 
1542 
1508 
1462 
1418 
1379 
1365 
1320 
1268 
1229 
1183 
1167 
1122 
1091 
1072 
1008 
969 
935 
880 
865 
849 
820 
779 
746 
690 
667 
IbNic-control (IbCh 1:0) 3382 2127  1635   
IbCh1Nic (IbCh 1:0.125) 3310 2116  1634 1555  
IbCh2Nic (IbCh 1:0.25) 3336 2146  1635 1555 1412 
IbCh3Nic (IbCh 1:0.5) 3335 2091  1634  1412 
IbCh4Nic (IbCh1:1) 3310 2090  1635 1555 1412 
IbCh5Nic (IbCh 1:2) 3312 2114  1634  1412 
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Figure 50 The FTIR spectral characteristics at various wavelengths for ibuprofen-chitosan conjugates (hydrotropy) 
ibuprofen control, ibuprofen-reference, chitosan-reference and ibuprofen-chitosan physical mixture. 
The FTIR spectra of ibuprofen-DEAE-Dextran-gellan complex, pure ibuprofen, gellan gum, DEAE-
Dextran, chitosan are shown in Figures 51 and 52; and Tables 34 and 35. Gellan showed significant 
peaks at 3306 cm-1, 1602 cm-1 1408 cm-1 and 1020 cm-1. The peaks at 1602 cm-1 and 1408 cm-1 are 
assigned to the characteristic absorption band of carboxyl in gellan gum [71]. The peak assignments 
of gellan has also been described by Sudhamani et al. [72]. They reported significant absorption 
peaks of gellan at 3273 cm-1, 1611 cm-1 and 1035 cm-1.  The peak at 3306 cm-1 is assigned to hydroxyl 
stretching. Gellan gum has hydroxyl and carboxyl groups in its structure capable of undergoing a 
nucleophilic substitution reaction with DEAE-Dextran as described for the methacrylation of gellan 
gum (GG-MA) with the most favourable reaction being with the carboxyl group [73]. FTIR spectrum 
of the complexes DG 25:75, DG 50:50 and DG 75:25 showed the disappearances of 1641 cm-1 peak of 
DEAE-Dextran, 1602 cm-1 in gellan and slight shift of  1706 cm-1 ibuprofen peak to a range of 1710 to 
1713 cm-1 in the complexes which appeared to be of lesser intensities. The characteristic peaks of 
ibuprofen were present in the complexes with slight variations. This confirms the chemical stability 
of ibuprofen in the DEAE-Dextran-gellan complex. Since ibuprofen interacted with DEAE-Dextran in a 
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binary mixture (Figures 43 to 46) it was opined that polyelectrolyte complexation between DEAE-
Dextran and gellan was favoured in the ternary mixture rather than the ibuprofen/DEAE-Dextran 
conjugation. 
Table 34 FTIR spectral characteristics at various wavelengths for  ibuprofen incorporated into DEAE-Dextran-gellan 
conjugate in ratios, DG 0:100, DG 25:75, DG 50:50, DG 75:25 and DG 100:0; pure ibuprofen, gellan and DEAE-Dextran. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Ibuprofen-reference 3089 
3045 
3020 
2992 
2980 
2954 
2923 
2859 
2727 
2632 
2542 
1911 
1804 
1706 
1507 
1462 
1450 
1442 
1418 
1379 
1365 
1329 
1321 
1305 
1268 
1231 
1183 
1168 
1123 
1091 
1073 
1007 
969 
934 
880 
865 
849 
834 
820 
779 
746 
690 
Gellan-reference 3306 1602 1300 1191 1020 672 
DEAE-Dextran-reference 3295 2921 1641 
1456 
1342 
1144 
1007 
915 
760 
IbDW-pH6 
  
2954 
2921 
2868 
2727 
2631 
1712 
1507 
1462 
1451 
1379 
1365 
1268 
1230 
1183 
1168 
1123 
1092 
1073 
1007 
969 
934 
880 
865 
849 
820 
779 
746 
691 
667 
DG 0:100 3089 
3046 
3020 
2954 
2922 
2869 
 
2727 
2632 
2542 
1911 
1701 
1507 
1461 
1450 
1442 
1418 
1379 
1365 
1329 
1320 
1268 
1230 
1183 
1168 
1122 
1091 
1072 
1008 
969 
935 
880 
865 
849 
834 
820 
746 
690 
667 
DG 25:75 2991 
2980 
2954 
2922 
2868 
 
2727 
2632 
1710 
1507 
1462 
 
1451 
1418 
1379 
1365 
1321 
 
1268 
1230 
1183 
1168 
1122 
1091 
1072 
1008 
969 
935 
880 
865 
849 
834 
819 
746 
690 
668 
DG 50:50 2992 
2980 
2954 
 
 
2922 
2869 
2727 
2632 
1713 
1507 
1462 
1451 
1418 
1379 
1365 
1321 
1268 
1230 
1183 
1168 
1123 
1091 
1073 
1008 
969 
935 
880 
866 
849 
834 
820 
746 
690 
668 
DG 75:25  2991 
2980 
2954 
2922 
2868 
2725 
2631 
1711 
1507 
1461 
1450 
1418 
1375 
1365 
1320 
1268 
1230 
1122 
1091 
1072 
DG 100:0 3020 
2992 
 
2980 
2954 
2923 
2868 
2727 
2632 
1910 
1703 
1507 
1462 
1450 
1418 
1379 
1365 
1329 
1321 
1230 
1305 
1268 
1183 
1168 
1122 
1091 
1072 
1008 
934 
880 
969 
865 
849 
834 
820 
746 
690 
668 
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Figure 51 The FTIR spectra of ibuprofen incorporated into DEAE-Dextran-gellan conjugate in ratios: DG 0:100, DG 25:75, 
DG 50:50, DG 75:25 and DG 100:0; pure ibuprofen, gellan and DEAE-Dextran powder references.  
Chitosan showed significant peaks at 3279 cm-1, 2918 cm-1, 1583 cm-1 and 1300 cm-1. Chitosan 
exhibits main characteristic band O-H and N-H stretching at 3279 cm-1 and methyl C-H symmetrical 
stretch at 2981 cm-1 (Figure 52). The band at 1583 cm-1 is due to the NH3
+ absorption band. The band 
at 1300 cm-1 is due to the methyl C-H symmetrical bend. The band at 1025 cm-1 is attributed to the 
alkyl substituted ether C-O-C. Gellan peaks at 3306 cm-1 and 1602 cm-1 disappeared in the 
complexes. Chitosan peaks at 3279 cm-1 and 1583 cm-1 disappeared in the complexes. The absence 
of the absorption band at 3279 cm-1 indicated that hydroxyl and amino groups are apparently 
substituted on the monosaccharide units of the chitosan chains. FTIR spectra of the CG 25:75, CG 
75:25 and CG 100:0 complexes showed a new peak at a region of 1557 to 1563 cm-1 which was 
absent in CG 50:50 and CG 0:100 suggesting the formation of carboxylate salt. The characteristic 
peaks of ibuprofen were present in the complexes with slight variations. This confirms the chemical 
stability of ibuprofen in the chitosan-gellan complex and a preferential interaction between chitosan 
and gellan. 
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Table 35 FTIR spectra at various wavelengths for ibuprofen incorporated into chitosan-gellan conjugate in ratios, CG 
0:100, CG 25:75, CG 50:50, CG 75:25 and CG 100:0; pure ibuprofen, gellan and chitosan. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Ibuprofen-reference 3089 
3045 
3020 
2992 
2980 
2954 
2923 
2859 
2727 
2632 
2542 
1911 
1804 
1706 
1507 
1462 
1450 
1442 
1418 
1379 
1365 
1329 
1321 
1305 
1268 
1231 
1183 
1168 
1123 
1091 
1073 
1007 
969 
934 
880 
865 
849 
834 
820 
779 
746 
690 
Gellan-reference 3306 1602 1300 1191 1020 672 
Chitosan-reference 3279 2918 1583 1300 1161 672 
IbDW-pH5 2954 
2921 
2868 
2727 
 
2631 
1712 
1507 
1462 
1451 
1379 
1365 
1268 
1230 
1168 
1123 
1092 
1073 
1007 
969 
934 
880 
865 
849 
820 
779 
746 
691 
667 
CG 0:100 3020 
2992 
2980 
2954 
2922 
2869 
 
2767 
2632 
1910 
1705 
1507 
1462 
 
1450 
1418 
1379 
1365 
1329 
1321 
 
1305 
1268 
1230 
1183 
1168 
1123 
1091 
1072 
1008 
969 
934 
880 
 
865 
849 
834 
820 
746 
690 
667 
CG 25:75 3089 
3045 
3019 
2991 
2979 
2954 
2922 
2868 
2727 
2632 
1910 
1710 
1557 
1507 
1461 
1451 
1418 
 
1379 
1364 
1321 
1305 
1268 
1230 
1183 
 
1168 
1122 
1091 
1072 
1020 
1007 
969 
934 
880 
865 
849 
834 
819 
746 
690 
667 
CG 50:50  2992 
2954 
2922 
2868 
2727 
2632 
1708 
1507 
 
1462 
1450 
1418 
1379 
1365 
1320 
1268 
1230 
1183 
1167 
1122 
1091 
1072 
1008 
969 
935 
880 
865 
849 
834 
820 
746 
690 
667 
CG 75:25 3019 
2991 
2954 
2922 
2868 
2725 
2631 
1910 
1705 
1563 
1507 
1461 
 
1450 
1418 
1379 
1365 
1320 
1304 
1267 
1229 
1183 
1167 
1122 
1091 
 
1072 
1020 
1007 
969 
934 
880 
865 
849 
834 
819 
746 
690 
667 
CG 100:0 3019 2991 
2954 
2922 
2868 
2727 
2632 
1910 
1706 
1563 
1507 
1461 
1451 
1418 
1379 
1320 
1305 
1268 
1230 
1183 
1167 
1122 
1091 
1072 
1007 
969 
934 
880 
865 
849 
834 
820 
746 
690 
667 
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Figure 52 The FTIR spectra of ibuprofen incorporated into chitosan-gellan conjugate in ratios: CG 0:100, CG 25:75, CG 
50:50, CG 75:25, CG 100:0; pure ibuprofen, gellan and chitosan powder references. 
2.3.3.9. 1H- and 13C- Nuclear Magnetic Resonance 
1H NMR technique was chosen to confirm the suspected interaction between ibuprofen and DEAE-
Dextran/Chitosan. The 1H NMR spectra of the pure ibuprofen, DEAE-Dextran, chitosan and their 
ternary nanoconjugate assembly are presented in Figure 55. Pure ibuprofen exhibited typical signals 
of the isopropyl methyl protons (C10 and C11);  methyl doublet proton (C3); nonet CH proton (C9); 
doublet CH proton (C8); quartet CH proton (C2) and the aromatic ring proton (C4 to C7) which were 
detected at 0.87; 1.36; 1.65; 2.51; 3.66 and 7.21 ppm respectively (Figure 55). Complete 1H and 13C 
chemical shifts assigned to pure ibuprofen, DEAE-Dextran-ibuprofen-gellan and Chitosan-ibuprofen-
gellan nanoconjugates are presented in Table 36. The 1H-NMR spectra of DEAE-Dextran showed 
signals in both anomeric (4.4 to 5.5 ppm) region indicating the presence of amines (-R3N
+H) and 
RCH2O- group as well as the bulk (3.0 to 4.2 ppm) proton resonance regions in chitosan suggesting 
the presence of amino (RNH2) groups. The OH-signal detected at 12.24 ppm from the pure ibuprofen 
is characteristic of the proton from carboxylic acid group. The peak was completely absent from the 
binary ibuprofen-DEAE-Dextran and ibuprofen-chitosan nanoconjugates but was present in 
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ibuprofen-gellan mixture (Figure 53). This confirms the interaction between the carbonyl group of 
ibuprofen and the cationic polyelectrolytes but no visible interaction with gellan which is an anionic 
polymer. The OH-signal from the carbonyl group was also completely absent in all the ternary DEAE -
Dextran-ibuprofen-gellan and Chitosan-ibuprofen-gellan nanoconjugates prepared in this study 
confirming electrostatic interaction that involved the carboxylic acid group of ibuprofen and the 
amino group of the cationic polymers. Ibuprofen-DEAE-Dextran conjugate exhibited an exceptionally 
broad multiplet signals between 3.0 and 5.5 ppm which overlapped the quartet CH proton signal on 
C2 indicating the presence of amino group from DEAE-Dextran and formation of hydrogen bond. 
Proton chemical shift of δ 6.9, 7.9 and 8.4 ppm was also observed in the ibuprofen-DEAE-Dextran 
nanoconjugates which indicate the formation of amide (δ 4.0 to 8.5 ppm) [74]. It was evident that 
electrovalent interaction between ibuprofen and DEAE-Dextran occurred confirming the FTIR data 
that an amide was formed from the interaction between Ibuprofen and DEAE-Dextran. Multiplicity 
(splitting and duplication) of signals were also observed at the isopropyl methyl protons (C10 and 
C11); methyl doublet proton (C3); doublet CH proton (C8) and quartet proton (C2) which overlapped 
with the signals of the DEAE-Dextran suggesting hydrophobic interaction or formation of hydrogen 
bonding network with the carboxylic groups due to van der Waals forces of attraction. Multiplicity 
(or duplication) of proton signals of racemic enantiomers of ibuprofen has been reported in the 
presence of chiral cyclodextrin [66]. The authors assert that this phenomenon underpins the spatial 
arrangement of ibuprofen molecules and formation of inclusion complex with β-cyclodextrin. Similar 
proton signal multiplicity and absence of the hydroxyl group were observed for the ibuprofen-
chitosan nanoconjugates indicating electrovalent and hydrogen bonding interaction between 
ibuprofen and chitosan. The amide proton signals from the ibuprofen-chitosan nanoconjugates were 
more prominent and stronger (δ 7.89, 8.08 and 8.46 ppm) than ibuprofen-DEAE-Dextran 
nanoconjugates (δ 6.99, 7.38, 7.91 and 8.38 ppm). There was no visible interaction between the 
proton signals of ibuprofen and gellan however the 13C NMR of binary mixtures of ibuprofen with 
each of the three polymers including gellan exhibited extensive carbon multiplicity and split of peaks 
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into singlets with varying chemical shifts (Figure 54) suggesting dipole-dipole interaction within 
racemic ibuprofen molecule and confirms the result of FT-IR analysis in this regard [66]. The ternary 
DEAE-Dextran-ibuprofen-gellan and ibuprofen-chitosan-gellan nanoconjugates prepared with 
varying weight ratios of DEAE-Dextran/Gellan and chitosan/gellan exhibited increased intensities of 
amide proton signals with increasing concentrations of the cationic polymers. There was no 
noticeable shift in the resonance of the H- bonded proton of the aromatic portion of ibuprofen 
(Figure 55). It was opined that the aromatic proton signal of ibuprofen may not be involved in the 
complexation reaction however it was evident that the amino groups on DEAE-Dextran and chitosan 
interacted with the carbonyl group of ibuprofen in agreement with the FT-IR data.  
The 13C-NMR spectra and assignments of pure ibuprofen and the ibuprofen-DEAE-Dextran 
nanoconjugates are presented in Table 36 and Figure 56. The peak assignment of chemical shifts (δ) 
for pure ibuprofen with a signal at 175.44 ppm corresponding to the carbonyl group was prominent 
in all the binary nanconjugates but the ibuprofen-DEAE-Dextran and ibuprofen-chitosan 
nanoconjugates shifted downfields to δ 175.68 and 176.39 ppm respectively. An upfield chemical 
shift was also observed at δ 172.77 ppm in ibuprofen-chitosan nanoconjugates (Figure 54). 
Multiplicity of the aromatic carbon (δ: 127 to 147 ppm) and aliphatic carbons (δ: 18.50 to 44.25 
ppm) of ibuprofen was very prominent in ibuprofen-chitosan nanoconjugates with upfield and 
downfield chemical shifts. This suggests that both aliphatic and aromatic carbon atoms of ibuprofen 
experienced reduced freedom of rotation due to complexation with DEAE-Dextran or chitosan. 
Similar findings have been reported for ibuprofen complexation with hyperbranched polymers and 
cyclodextrin [75].  This confirms the 1H NMR and FT-IR findings and that complexation of ibuprofen 
with DEAE-Dextran and chitosan respectively was evident.   
 
 
125 | P a g e  
 
Table 36 1H and 13C chemical shift assignments for ibuprofen and Ibuprofen nanoconjugates. 
Carbon 
No. 
Proton 
Type 
Ibuprofen DEAE-Dextran-Ibuprofen-
Gellan Nanoconjugates 
Chitosan-Ibuprofen-Gellan 
Nanoconjugates 
1H Chemical 
Shift 
13C Chemical 
Shift 
1H Chemical 
Shift 
13C Chemical 
Shift 
1H Chemical 
Shift 
13C Chemical 
Shift 
1 COOH 12.24 175.44 - 195.38 - 175.64 
2 CH 3.66 44.26 3.64; 3.52 44.42; 69.75 3.68; 3.58; 
3.56; 3.52 
44.58; 69.76 
3 CH3 1.36 18.50 1.35; 1.24 18.57 1.35; 1.32; 
1.24; 1.11; 
1.10 
18.65 
4 C - 138.46 - 138.65 - 138.87; 
146.63 
5, 5’ CH 7.11 127.07 7.11 127.08 7.09 127.09 
6, 6’ CH 7.20 128.93 7.20 128.89 7.21 128.84 
7 C - 139.51 - 139.43 - 139.32 
8 CH2 2.43 44.26 2.42 44.42 2.42 44.58 
9 CH 1.85 40.11 1.83; 1.91 40.11 1.84; 1.89 40.11 
10 CH3 0.85 18.50 0.85 18.57 0.85; 0.71; 
0.69 
18.65 
11 CH3 0.87 22.14 0.87 22.15 0.85; 0.87; 
0.94; 0.92 
22.15 
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Figure 53 1H NMR spectra of binary nanoconjugates of Ibuprofen. 
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Figure 54 13C- NMR spectra of binary nanoconjugates of Ibuprofen. 
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Figure 55 1H NMR spectra of ternary nanoconjugates of Ibuprofen. 
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Figure 56 13C- NMR spectra of ternary nanoconjugates of Ibuprofen. 
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2.3.3.10. Thermal studies 
2.3.3.10.1. Differential scanning calorimetry 
Differential Scanning Calorimetry (DSC) is a well established rapid thermal analytical technique 
commonly used for the evaluation of potential physical and chemical interactions between drugs 
and excipients during preformulation studies stage of product development [76]. It has also found 
wide applications in detection of polymorphism, incompatibility between drugs and excipients of a 
dosage form, measurement of interaction and decomposition kinetics [77], and more recently in the 
determination of the solubility of Active Pharmaceutical Ingredients (API) within semi-solid and solid 
matrix systems [78] as well as estimating the binding or complexation parameters in multiligand 
binding proteins [79]. DSC measures the differences in heat flow into a substance compared with a 
reference as a function of controlled sample temperature and heat (enthalpy) capacity [80]. It was 
intended to use DSC technique to evaluate the complexation between ibuprofen and DEAE-Dextran 
or chitosan in binary conjugates as well as the ternary DEAE-Dextran-ibuprofen-gellan and chitosan-
ibuprofen-gellan nanoconjugates. 
The DSC thermograms of the nanoconjugates and their components are presented in Tables 37 to 44 
and Figures 57 to 66. The DSC thermograms of Ibuprofen showed characteristic sharp endothermic 
peak at 80.07 °C suggesting its crystallinity, with enthalpy of fusion of 118.64 J/g in Figure 56. This 
melting peak is higher than the literature value for pure ibuprofen in the range of 75 to 78 °C [81]. 
This could be due to some impurity in the ibuprofen sample however in a similar study, Kumar et al. 
reported that the melting peak of ibuprofen was 82.76 °C [82]. The second peak of the pure 
ibuprofen was ascribed to the degradation of ibuprofen at 237.51 °C with enthalpy of fusion 2241.34 
J/g. DEAE-Dextran showed a glass transition temperature (Tg) at 57.26 °C; a broad endothermic 
melting peak at 124.05 °C due to its amorphous characteristic; a small peak was noted at 201.21 °C 
probably due to the semi crystalline component of the polymer and a final peak at 268.50 °C 
attributed to the decomposition of DEAE-Dextran. The physical mixture of DEAE-Dextran and 
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Ibuprofen showed peaks at 59.58 °C, 79.99 °C, 116.86 °C, 200.58 °C and 237.63 °C which represented 
peaks from individual components (ibuprofen and DEAE-Dextran). It was observed that the Tg of 
DEAE-Dextran increased by 2.32 °C in the physical mixture while the melting peak of ibuprofen did 
not change to any great extent (79.99 °C). However, the melting peak of the DEAE-Dextran 
decreased by 5.80% while the degradation peaks remained almost constant.    
The melt solubilization technique produced nanoconjugates (IbDMelt) with only three endothermic 
peaks which did not correspond to any of the peaks in the physical mixture. The new peaks exhibited 
significantly lower melting temperatures (5.42 to 9.69 °C; 39.24 to 85.98 °C and 92.49 to 105.48 °C) 
compared with five peaks in the physical mixture which ranged from 59.58 to 237.63 °C (Table 37; 
Figure 58). The appearance of new multiple endothermic peaks suggests formation of multiple 
complexes and the reduced melting temperatures indicates the existence of the newly formed 
product in amorphous state. The peak at the lowest temperature decreased to a minimum of 5.42 °C 
at ibuprofen/DEAE-Dextran weight ratio 1:1 and increased steadily beyond this ratio (Figure 59) 
indicating the critical complexation concentration of DEAE-Dextran. It was opined that this peak may 
be attributed to the melt of water ice crystals since the DSC temperature range was -50 to 300 °C. 
The Tg of ibuprofen has been reported to be -42.3 °C [83] hence the process of melt solubilization 
may have increased the Tg of ibuprofen. The second peak of each of the nanoconjugate (39.24 to 
85.98 °C) was broad and diffuse due to loss of residual water. This peak also decreased to a 
minimum of 39.24 °C at ibuprofen/DEAE-Dextran weight ratio 1:1 and increased steadily beyond this 
concentration confirming the critical complexation concentration of DEAE-Dextran. The increase in 
the melting temperature of the third peak (92.49 to 108.16 °C) suggests increased isothermal 
stability of the nanoconjugate. These peaks increased with increasing concentration of DEAE-
Dextran to a maximum of 108.16 °C at ibuprofen/DEAE-Dextran weight ratio 1:4. The degradation 
peak of pure ibuprofen at 237.51 °C disappeared completely in all the IbDMelt nanoconjugates 
suggesting the isothermal stability of the nanoconjugates.   
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Figure 57 DSC thermograms of (A) ibuprofen (B) DEAE-Dextran (C) Ibuprofen-DEAE-Dextran physical mixture. 
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Table 37 DSC of ibuprofen-DEAE-Dextran conjugates (melt solubilization) and ibuprofen control. Each value represents 
mean ± SD (n = 4). 
Formulation Onset (°C) Peak (°C) End (°C) Delta H (J/g) Area (mJ) 
Ibuprofen-
reference 
76.52±1.42 
193.66±7.73 
80.07±1.94 
237.51±9.93 
83.23±1.78 
243.03±9.57 
118.64±0.96 
2241.34±51.03 
949.15±38.72 
309.29±11.21 
DEAE-Dextran-
reference 
53.55±0.85 
87.43±1.22 
187.42±8.23 
245.83±12.74 
57.86±0.76 
124.05±4.16 
201.54±10.58 
268.50±11.78 
63.97±0.92 
158.87±5.34 
210.60±11.45 
281.53±13.66 
5.10±0.08 
139.17±5.64 
12.72±0.84 
70.84±0.92 
35.16±0.41 
960.30±40.48 
87.74±1.25 
488.852±21.22 
Ibuprofen-DEAE-
Dextran physical 
mixture 
55.30±0.76 
75.83±1.40 
90.83±1.35 
179.65±7.43 
233.64±10.75 
59.58±0.92 
79.99±1.84 
116.86±2.76 
200.58±10.68 
237.63±10.96 
66.17±0.88 
83.83±1.91 
154.50±5.58 
211.36±10.54 
245.06±10.84 
3.37±0.02 
31.48±0.95 
37.13±0.86 
10.93±0.22 
67.67±0.81 
20.57±0.43 
192.03±9.47 
226.48±10.82 
66.68±0.81 
412.78±18.64 
IbMelt-control 
(IbD 1:0) 
1.57±0.04 
52.64±1.08 
8.31±0.23 
89.00±2.32 
12.93±0.58 
97.04±2.64 
193.68±7.3 
1220.79±38.22 
1278.28±52.78 
8057.21±105.77 
IbD1Melt  
(IbD 1:0.5) 
2.13±0.04 
29.59±0.88 
84.99±1.98 
5.57±0.18 
56.44±1.33 
92.49±2.25 
8.94±0.30 
63.39±1.45 
95.40±2.37 
139.69±6.48 
566.35±20.14 
39.94±0.85 
391.12±11.65 
1585.78±58.69 
111.82±4.07 
IbD2Melt  
(IbD 1:1) 
2.69±0.02 
28.67±0.65 
91.75±1.32 
5.42±0.07 
39.24±0.84 
99.53±1.62 
8.53±0.15 
44.00±0.96 
103.06±1.74 
32.67±0.61 
76.29±0.81 
71.65±0.76 
127.40±1.36 
297.51±12.18 
279.44±11.23 
IbD3Melt  
(IbD 1:2) 
1.92±0.03 
51.78±1.27 
102.06±2.65 
8.75±0.22 
81.16±1.95 
106.63±3.78 
13.05±0.58 
91.03±2.14 
110.39±3.32 
124.21±4.35 
567.13±22.18 
64.56±2.09 
1179.95±51.57 
5387.69±68.74 
613.29±25.22 
IbD4Melt  
(IbD 1:4) 
1.93±0.04 
46.45±1.01 
101.63±2.24 
8.78±0.28 
81.81±1.96 
108.16±3.02 
13.56±0.69 
89.81±2.05 
110.91±3.21 
158.72±5.77 
10.04±35.44 
98.97±2.52 
1460.15±61.54 
7452.36±96.38 
910.49±38.34 
IbD5Melt  
(IbD 1:8) 
2.07±0.05 
51.26±1.11 
101.36±2.55 
9.69±0.35 
85.98±2.08 
105.34±2.98 
14.66±0.77 
94.90±2.33 
107.65±3.11 
212.46±7.22 
1277.84±48.23 
28.75±0.96 
1763.41±65.22 
10606.04±130.78 
238.63±7.63 
 
 
Figure 58 DSC thermograms of ibuprofen-DEAE-Dextran conjugates (melt solubilization), ibuprofen control, pure 
ibuprofen, DEAE-Dextran and physical mixture of ibuprofen and DEAE-Dextran. 
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Figure 59 The DSC melting peak profile of IbDMelt, IbDNaOH, IbDTw80 and IbDNic nanoconjugates. 
The nanoconjugates obtained from the alkaline solubilization technique (IbDNaOH nanoconjugates) 
exhibited similar profile with the melt solubilization technique. However only two endothermic 
peaks were shown (in the range of 3.16 to 11.06 °C and 70.16 to 104.71 °C) except IbD4NaOH which 
showed three peaks (Table 38). The peak with the lowest melting temperature did not show any 
particular pattern with increasing concentration of the DEAE-Dextran however low values of 3.16 °C 
and 2.78 °C were observed at ibuprofen/DEAE-Dextran weight ratios of 1:1 and 1:2 respectively. It 
was opined that nanoconjugates were formed at similar ratio of ibuprofen/DEAE-Dextran as in the 
melt solubilization technique. The second peak also decreased to a minimum of 87.85 °C at 
ibuprofen/DEAE-Dextran weight ratio of 1:1 beyond which it became unpredictable. It was opined 
that the endothermic melting peak of pure ibuprofen which appeared at 80.07 °C had shifted to 
higher temperatues ranging from 87.85 to 106.10 °C for IbDNaOH nanoconjugates (Figure 60). The 
thermal decomposition peak of pure ibuprofen at 237.51 °C also disappeared in all the IbDNaOH 
nanoconjugates.  All the endothermic peaks shown in this technique were broad with higher melting 
temperatues than the melt solubilization technique suggesting the existence of the nanoconjugates 
formed in the amorphous state with better isothermal stability. It was concluded that multiple 
complexes were also formed in this technique. 
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Table 38 DSC of ibuprofen-DEAE-Dextran conjugates (solubilization), ibuprofen control, pure ibuprofen, DEAE-Dextran 
and physical mixture of ibuprofen and DEAE-Dextran. Each value represents mean ± SD (n = 4). 
Formulation Onset (°C) End (°C) Peak (°C) Area (mJ) DeltaH (J/g) 
Ibuprofen-reference 76.52±1.42 
193.66±7.73 
83.23±1.78 
243.03±9.57 
80.07±1.94 
237.51±9.93 
949.15±38.72 
309.29±11.21 
118.64±0.96 
2241.34±51.03 
DEAE-Dextran-
reference 
53.55±0.85 
87.43±1.22 
187.42±8.23 
245.83±12.74 
63.97±0.92 
158.87±5.34 
210.60±11.45 
281.53±13.66 
57.86±0.76 
124.05±4.16 
201.54±10.58 
268.50±11.78 
35.16±0.41 
960.30±40.48 
87.74±1.25 
488.852±21.22 
5.10±0.08 
139.17±5.64 
12.72±0.84 
70.84±0.92 
Ibuprofen-DEAE-
Dextran physical 
mixture 
55.30±0.76 
75.83±1.40 
90.83±1.35 
179.65±7.43 
233.64±10.75 
66.17±0.88 
83.83±1.91 
154.50±5.58 
211.36±10.54 
245.06±10.84 
59.58±0.92 
79.99±1.84 
116.86±2.76 
200.58±10.68 
237.63±10.96 
20.57±0.43 
192.03±9.47 
226.48±10.82 
66.68±0.81 
412.78±18.64 
3.37±0.02 
31.48±0.95 
37.13±0.86 
10.93±0.22 
67.67±0.81 
IbNaOH-control 
(IbD 1:0)  
0.54±0.04 
101.07±1.18 
10.48±0.58 
119.18±1.37 
5.91±0.23 
114.02±1.41 
966.66±42.78 
5166.17±58.77 
322.22±14.30 
1722.07±35.37 
IbD1NaOH  
(IbD 1:0.5) 
1.87±0.03 
59.58±1.18 
16.17±0.82 
106.33±2.28 
11.06±0.42 
94.04±1.92 
2262.32±70.58 
14792.58±128.09 
128.90 ±7.22 
842.88 ±1.21 
IbD2NaOH  
(IbD 1:1) 
1.28±0.04 
70.37±1.52 
5.52±0.13 
92.39±1.90 
3.16±0.09 
87.85±1.86 
96.06±1.93 
317.06±17.48 
16.85 ±0.61 
55.62±1.21 
IbD3NaOH  
(IbD 1:2) 
0.50±0.01 
99.10±2.08 
5.65±0.15 
108.41±2.37 
2.78±0.78 
103.62±2.41 
129.03±3.25 
614.60±22.17 
14.34±0.58 
68.29±1.26 
IbD4NaOH  
(IbD 1:4) 
1.98±0.05 
52.34±1.11 
101.53±2.27 
9.47±0.36 
78.18±1.54 
109.22±2.58 
6.06±0.17 
70.16±1.58 
106.10±2.11 
614.08±22.84 
3448.78±69.87 
332.35±18.66 
45.55±0.93 
255.84±8.74 
24.66±0.85 
IbD5NaOH  
(IbD 1:8) 
0.69±0.02 
100.48±2.58 
6.56±0.25 
108.72±2.61 
3.60±0.14 
104.71±2.33 
234.80±8.22 
757.37±35.47 
14.14±0.64 
45.62±0.98 
  
 
Figure 60 DSC thermograms of ibuprofen-DEAE-Dextran conjugates (alkaline solubilization), ibuprofen control, pure 
ibuprofen, DEAE-Dextran and physical mixture of ibuprofen and DEAE-Dextran. 
Nanoconjugates obtained from the surfactant solubilization technique (IbDTw80) showed three 
peaks in the range of -14.15 to 8.64 °C; 37.47 to 82.55 °C and 104.45 to 106.31 °C (Table 39). The 
melting temperature of the first peak was observed at -14.00 °C in the absence of DEAE-Dextran but 
increased with increasing concentration of DEAE-Dextran to a maximum value of 6.35 °C at 
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ibuprofen/DEAE-Dextran weight ratio of 1:2 beyond which it became unpredictable. The second 
peak did not show any particular pattern with increase in the concentration of DEAE-Dextran but 
exhibited two minima values of 45.65 °C and 37.47 °C at ibuprofen/DEAE-Dextran weight ratios 1:1 
and 1:4 respectively suggesting formation of multiple complexes. The broad and diffused peaks with 
reduced melting temperatures of the nanoconjugates produced in this technique also signify the 
amorphous state of the new product. There was a shift of melting peak of ibuprofen to a range of 
37.47 to 82.55 °C for IbDTw80 conjugates in Figure 61. The thermal decomposition peak of ibuprofen 
at 237.51 °C also disappeared in all the IbDTw80 nanoconjugates suggesting isothermal stability. 
Table 39 DSC of ibuprofen-DEAE-Dextran conjugates (solubilization), ibuprofen control, pure ibuprofen, DEAE-Dextran 
and physical mixture of ibuprofen and DEAE-Dextran. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Peak (oC) Area (mJ) Delta H (J/g) 
Ibuprofen-reference 76.52±1.42 
193.66±7.73 
83.23±1.78 
243.03±9.57 
80.07±1.94 
237.51±9.93 
949.15±38.72 
309.29±11.21 
118.64±0.96 
2241.34±51.03 
DEAE-Dextran-
reference 
53.55±0.85 
87.43±1.22 
187.42±8.23 
245.83±12.74 
63.97±0.92 
158.87±5.34 
210.60±11.45 
281.53±13.66 
57.86±0.76 
124.05±4.16 
201.54±10.58 
268.50±11.78 
35.16±0.41 
960.30±40.48 
87.74±1.25 
488.852±21.22 
5.10±0.08 
139.17±5.64 
12.72±0.84 
70.84±0.92 
Ibuprofen-DEAE-
Dextran physical 
mixture 
55.30±0.76 
75.83±1.40 
90.83±1.35 
179.65±7.43 
233.64±10.75 
66.17±0.88 
83.83±1.91 
154.50±5.58 
211.36±10.54 
245.06±10.84 
59.58±0.92 
79.99±1.84 
116.86±2.76 
200.58±10.68 
237.63±10.96 
20.57±0.43 
192.03±9.47 
226.48±10.82 
66.68±0.81 
412.78±18.64 
3.37±0.02 
31.48±0.95 
37.13±0.86 
10.93±0.22 
67.67±0.81 
IbTw80-control 
(IbD 1:0) 
-25.29±0.14 
120.42±1.08 
-7.35±0.22 
131.83±3.64 
-14.15±0.23 
125.11±3.32 
207.06±12.13 
262.84±11.77 
28.76±0.53 
36.51±0.52 
IbD1Tw80  
(IbD 1:0.5) 
1.35±0.01 
42.00±0.88 
100.49±5.24 
6.75±0.02 
58.59±1.03 
109.91±5.87 
4.18±0.02 
50.06±0.97 
105.48±5.43 
275.97±10.89 
844.64±39.65 
961.77±43.28 
28.99±0.41 
88.72±1.86 
101.03±5.73 
IbD2Tw80 
(IbD 1:1) 
1.68±0.02 
24.29±0.76 
100.03±4.83 
6.92±0.03 
55.30±1.07 
108.68±5.22 
4.45±0.02 
45.65±0.92 
104.45±5.08 
249.69±9.75 
1019.52±50.20 
921.83±40.22 
36.72±0.58 
149.92±6.23 
135.56±7.52 
IbD3Tw80 
(IbD 1:2) 
2.14±0.02 
34.29±0.81 
100.89±3.86 
9.70±0.04 
72.05±1.33 
109.35±5.41 
6.35±0.03 
65.58±1.24 
105.11±5.18 
428.72±20.21 
2930.03±90.14 
505.03±27.82 
47.63±0.90 
325.56±16.13 
56.11±0.90 
IbD4Tw80 
(IbD 1:4) 
1.33±0.02 
18.09±0.62 
100.21±4.37 
6.28±0.03 
46.77±0.80 
109.30±5.11 
3.71±0.02 
37.47±0.76 
104.63±5.03 
170.09±7.88 
562.83±28.74 
565.57±25.38 
17.54±0.63 
58.02±1.21 
58.31±1.08 
IbD5Tw80 
(IbD 1:8) 
1.47±0.01 
49.74±0.82 
99.63±4.73 
12.98±0.06 
92.35±3.25 
110.33±5.36 
8.64±0.04 
82.55±2.87 
106.31±5.06 
1390.84±48.95 
8995.74±110.68 
952.14±48.21 
144.88±7.79 
937.06±43.66 
98.18±4.01 
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Figure 61 DSC thermograms of ibuprofen-DEAE-Dextran conjugates (surfactant solubilization), ibuprofen control, pure 
ibuprofen, DEAE-Dextran and physical mixture of ibuprofen and DEAE-Dextran. 
The DSC thermograms of the nanoconjugates obtained from the hydrotropic complexation 
technique exhibited three peaks at ibuprofen/DEAE-Dextran weight ratios 1:0.5; 1:1 and 1:4 while 
other weight ratios studied exhibited only two peaks as presented in Table 40 and Figure 62. The 
first peak exhibited two minima values of 7.34 °C and 3.62 °C at ibuprofen/DEAE-Dextran weight 
ratio 1:0.5 and 1:2 respectively suggesting formation of multiple complexes.  The second peak which 
was assigned to melting point of ibuprofen decreased to a minimum value of 64.67 °C at 
ibuprofen/DEAE-Dextran ratio of 1:0.5 beyond which it increased steadily. It was opined that lower 
concentration of DEAE-Dextran was required for complexation in this technique and the lower 
melting peak for ibuprofen indicates the amorphous state of the nanoconjugates formed. The 
absence of ibuprofen peaks at weight ratios 1:2 and 1:8 may indicate the formation of eutectic 
mixture as well as formation of multiple complexes. The melting point of nicotinamide was reported 
to be in the range of 128 to 131 °C [84]. The third peak did not vary significantly with increase in 
concentration of DEAE-Dextran. The thermal decomposition peak of ibuprofen at 237.51 °C 
disappeared in all the IbDNic nanoconjugates however the ibuprofen melting peak exhibited higher 
values indicating isothermal stability of the nanoconjugates. 
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Table 40 DSC of ibuprofen-DEAE-Dextran conjugates (hydrotropy), ibuprofen control, pure ibuprofen, DEAE-Dextran and 
physical mixture of ibuprofen and DEAE-Dextran. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Peak (oC) Area (mJ) Delta H (J/g) 
Ibuprofen-reference 76.52±1.42 
193.66±7.73 
83.23±1.78 
243.03±9.57 
80.07±1.94 
237.51±9.93 
949.15±38.72 
309.29±11.21 
118.64±0.96 
2241.34±51.03 
DEAE-Dextran-
reference 
53.55±0.85 
87.43±1.22 
187.42±8.23 
245.83±12.74 
63.97±0.92 
158.87±5.34 
210.60±11.45 
281.53±13.66 
57.86±0.76 
124.05±4.16 
201.54±10.58 
268.50±11.78 
35.16±0.41 
960.30±40.48 
87.74±1.25 
488.852±21.22 
5.10±0.08 
139.17±5.64 
12.72±0.84 
70.84±0.92 
Ibuprofen-DEAE-
Dextran physical 
mixture 
55.30±0.76 
75.83±1.40 
90.83±1.35 
179.65±7.43 
233.64±10.75 
66.17±0.88 
83.83±1.91 
154.50±5.58 
211.36±10.54 
245.06±10.84 
59.58±0.92 
79.99±1.84 
116.86±2.76 
200.58±10.68 
237.63±10.96 
20.57±0.43 
192.03±9.47 
226.48±10.82 
66.68±0.81 
412.78±18.64 
3.37±0.02 
31.48±0.95 
37.13±0.86 
10.93±0.22 
67.67±0.81 
IbNic-control 
(IbD 1:0) 
0.64±0.04 
54.37±1.11 
14.33±0.58 
95.45±2.72 
9.54±0.13 
82.88±2.32 
1663.60±32.78 
10631.82±105.77 
186.92±7.57 
1194.58±58.22 
IbD1Nic 
(IbD 1:0.5) 
 
1.62±0.02 
38.21±0.83 
86.46±2.25 
10.77±0.48 
75.17±1.99 
99.88±2.92 
7.34±0.26 
64.67±1.34 
96.09±2.68 
703.17±28.21 
3805.28±187.35 
249.29±9.56 
93.76±2.44 
507.37±22.16 
33.24±0.74 
IbD2Nic  
(IbD 1:1) 
2.29±0.02 
51.61±1.10 
102.24±5.24 
15.30±0.58 
92.58±2.54 
109.64±5.36 
9.97±0.35 
85.90±2.11 
105.41±5.38 
1383.84±50.14 
7964.04±103.22 
267.82±10.29 
168.76±8.02 
971.22±48.11 
32.66±0.41 
IbD3Nic  
(IbD 1:2) 
0.97±0.01 
96.06±4.87 
6.48±0.23 
107.98±5.65 
3.62±0.03 
104.03±5.23 
213.20±9.22 
805.64±29.22 
28.81±0.31 
108.87±5.79 
IbD4Nic  
(IbD 1:4) 
1.44±0.01 
54.27±1.14 
102.37±5.10 
14.59±0.54 
95.56±2.73 
107.01±5.76 
9.99±0.38 
89.64±2.03 
104.51±5.32 
1781.70±58.36 
10695.82±185.48 
62.53±1.21 
209.61±8.76 
1258.33±49.83 
7.36±0.25 
IbD5Nic  
(IbD 1:8) 
1.38±0.01 
57.01±1.14 
15.84±0.67 
106.89±4.23 
10.90±0.42 
100.52±5.10 
2111.71±84.63 
14607.10±212.23 
224.65±9.78 
1153.93±47.36 
 
 
Figure 62 DSC thermograms of ibuprofen-DEAE-Dextran conjugates (hydrotropy), ibuprofen control, pure ibuprofen, 
DEAE-Dextran and physical mixture of ibuprofen and DEAE-Dextran. 
The thermo-analytical profile of ibuprofen/chitosan nanoconjugates was similar to that of 
ibuprofen/DEAE-Dextran nanoconjugates. Chitosan exhibited a broad melting peak at 115.44 °C with 
enthalpy of 301.02 J/g and an exothermic peak at 318.29 oC with enthalpy of -201.91 J/g. These 
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correspond to the values reported by Silva et al. [85]. They observed the endothermic melting peak 
of chitosan at 112.00 °C while the exothermic peak was at about 311.00 °C which was attributed to 
chitosan degradation. The ibuprofen-chitosan physical mixture exhibited melting peaks at 81.34 °C, 
126.56 °C and 250.30 °C corresponding to the individual components of the nanoconjugates. The 
first peak increased to a maximum value of 9.52 °C at ibuprofen/chitosan weight ratio of 1:0.5 
beyond which it decreased steadily indicating the critical complexation concentration of chitosan. 
IbCh2Melt and IbCh3Melt conjugates showed two endothermic peaks while IbCh1Melt, IbCh4Melt 
and IbCh5Melt showed three peaks (Table 41). The melting peak of ibuprofen in the nanoconjugates 
shifted to higher values in this technique ranging from 80.00 to 93.17  °C with minima values of 
80.00 °C and 80.71 °C at ibuprofen/chitosan weight ratios 1:0.125 and 1:1 respectively suggesting 
formation of multiple complexes (Figures 63 and 64). 
Table 41 DSC of ibuprofen-chitosan conjugates (melt solubilization), ibuprofen control, pure ibuprofen, chitosan and 
physical mixture of ibuprofen and chitosan. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Peak (oC) Area (mJ) Delta H (J/g) 
Ibuprofen-
reference 
76.52±1.42 
193.66±7.73 
83.23±1.78 
243.03±9.57 
80.07±1.94 
237.51±9.93 
949.15±38.72 
309.29±11.21 
118.64±0.96 
2241.34±51.03 
Chitosan-reference 60.44±1.02 
299.84±7.95 
155.57±6.2 
339.81±10.85 
115.44±4.32 
318.39±10.68 
2077.04±45.38 
-1938.38±42.56 
301.02±9.75 
-201.91±9.21 
Ibuprofen-Chitosan 
physical mixture 
75.45±1.30 
104.95±2.94 
250.30±9.82 
85.47±1.88 
153.00±5.96 
267.84±10.11 
81.34±1.54 
126.56±3.68 
262.48±10.35 
581.56±17.56 
111.01±3.02 
59.29±1.14 
67.62±1.12 
12.91±0.49 
6.89±0.23 
IbMelt-control 
(IbCh 1:0) 
1.57±0.04 
52.64±1.08 
12.93±0.58 
97.04±2.64 
8.31±0.23 
89.00±2.32 
1278.28±52.78 
8057.21±105.77 
193.68±7.3 
1220.79±38.22 
IbCh1Melt  
(IbCh 1:0.125) 
0.47±0.02 
45.37±1.57 
98.39±4.62 
11.59±0.54 
87.06±3.58 
108.96±5.84 
7.82±0.36 
80.00±3.65 
104.85±5.22 
1107.72±35.47 
6566.20±80.69 
350.41±18.72 
246.16±7.85 
1459.16±58.32 
77.87±2.65 
IbCh2Melt  
(IbCh 1:0.25) 
0.34±0.01 
52.50±1.97 
13.01±0.61 
93.89±3.86 
8.55±0.33 
85.49±2.06 
1473.09±40.12 
10899.12±120.33 
196.41±7.24 
1453.22±38.62 
IbCh3Melt  
(IbCh 1:0.5) 
0.62±0.02 
61.71±2.08 
13.92±0.69 
101.44±4.36 
9.52±0.42 
93.17±2.55 
1759.81±66.85 
12833.43±115.46 
219.98±7.72 
1604.18±60.31 
IbCh4Melt  
(IbCh 1:1) 
1.13±0.03 
45.10±0.97 
101.56±4.01 
12.50±0.65 
89.17±2.24 
109.35±4.74 
8.26±0.37 
80.71±1.98 
104.90±4.32 
1024.83±32.63 
6245.46±85.30 
237.54±11.25 
133.09±6.12 
811.10±31.26 
30.85±0.68 
IbCh5Melt  
(IbCh 1:2) 
0.06±0.01 
72.84±2.14 
103.68±3.78 
10.31±0.41 
98.17±3.82 
110.83±4.52 
6.30±0.27 
89.20±2.78 
107.92±4.31 
1050.81±34.08 
6174.67±82.33 
193.70±6.55 
134.72±5.96 
791.62±25.68 
24.83±0.85 
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Figure 63 DSC thermograms of ibuprofen-chitosan conjugates (melt solubilization), ibuprofen control, pure ibuprofen, 
chitosan and physical mixture of ibuprofen and chitosan. 
 
Figure 64 DSC melting peak profiles of IbChMelt, IbChNaOH, IbChTw80 and IbChNic nanoconjugates 
The nanoconjugates obtained from the alkaline solubilization technique (IbChNaOH) showed three 
peaks in the range of 2.93 to 6.95 °C; 56.90 to 80.17 °C and 104.35 to 105.20 °C (Table 41 and Figure 
65). The first peak exhibited two minima values of 4.66 °C and 2.93 °C at ibuprofen/chitosan weight 
ratio of 1:2 and 1:8 respectively suggesting formation of multiple complexes. The melting peak of 
ibuprofen shifted to a range of 56.90 to 80.17 °C with minima values of 67.47 °C and 56.90 °C at 
ibuprofen/chitosan weight ratios 1:2 and 1:8 respectively (Figure 65). 
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Table 42 DSC of ibuprofen-chitosan conjugates (solubilization), ibuprofen control, pure ibuprofen, chitosan and physical 
mixture of ibuprofen and chitosan. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Peak (oC) Area (mJ) Delta H (J/g) 
Ibuprofen-reference 76.52±1.42 
193.66±7.73 
83.23±1.78 
243.03±9.57 
80.07±1.94 
237.51±9.93 
949.15±38.72 
309.29±11.21 
118.64±0.96 
2241.34±51.03 
Chitosan-reference 60.44±1.02 
299.84±7.95 
155.57±6.2 
339.81±10.85 
115.44±4.32 
318.39±10.68 
2077.04±45.38 
-1938.38±42.56 
301.02±9.75 
-201.91±9.21 
Ibuprofen-Chitosan 
physical mixture 
75.45±1.30 
104.95±2.94 
250.30±9.82 
85.47±1.88 
153.00±5.96 
267.84±10.11 
81.34±1.54 
126.56±3.68 
262.48±10.35 
581.56±17.56 
111.01±3.02 
59.29±1.14 
67.62±1.12 
12.91±0.49 
6.89±0.23 
IbNaOH-control 
(IbCh 1:0) 
0.54±0.04 
101.07±1.18 
10.48±0.58 
119.18±1.37 
5.91±0.23 
114.02±1.41 
966.66±42.78 
5166.17±58.77 
322.22±14.30 
1722.07±35.37 
IbCh1NaOH  
(IbCh 1:0.5) 
0.15±01 
39.85±0.79 
98.72±5.21 
10.19±0.45 
86.27±2.43 
111.61±5.76 
6.26±0.21 
80.17±1.98 
105.10±4.89 
1001.42±35.14 
6364.10±58.39 
251.75±7.96 
126.76±5.98 
805.58±25.67 
31.87±0.69 
IbCh2NaOH  
(IbCh 1:1) 
0.61±0.03 
39.63±0.73 
100.91±4.72 
7.43±0.22 
76.68±1.81 
110.43±5.66 
4.67±0.14 
68.17±1.27 
104.42±5.03 
502.64±17.21 
3108.43±42.36 
318.21±9.63 
67.02±1.42 
414.46±15.64 
42.43±0.85 
IbCh3NaOH  
(IbCh 1:2) 
0.46±0.02 
41.07±0.88 
99.12±5.06 
7.78±0.26 
75.41±1.58 
110.19±5.21 
4.66±0.18 
67.47±1.13 
104.45±5.36 
520.83±18.69 
3367.61±46.39 
278.46±8.76 
70.38±1.59 
455.04±17.03 
37.63±0.85 
IbCh4NaOH 
(IbCh1:4) 
0.57±0.02 
46.89±0.96 
98.09±4.36 
10.53±0.41 
81.30±1.95 
109.82±5.01 
6.95±0.16 
75.01±1.38 
105.20±4.98 
885.60±28.36 
4552.84±59.36 
440.24±16.38 
150.10±6.32 
771.67±29.56 
74.62±1.52 
IbCh5NaOH  
(IbCh 1:8) 
1.02±0.01 
39.93±0.76 
100.68±4.43 
5.39±0.12 
64.06±1.32 
108.98±4.65 
2.93±0.06 
56.90±1.20 
104.35±5.01 
279.13±8.21 
1530.97±42.58 
441.81±15.21 
31.01±0.65 
170.11±5.98 
49.10±0.87 
 
 
Figure 65 DSC thermograms of ibuprofen-chitosan conjugates (alkaline solubilization), ibuprofen control, pure 
ibuprofen, chitosan and physical mixture of ibuprofen and chitosan. 
The nanoconjugates obtained from the surfactant solubilization technique (IbChTw80) showed three 
peaks in the range of 2.71 to 6.66 °C; 47.77 to 80.31 °C and 103.92 to 105.87 °C (Table 43 and Figure 
66). The first peak increased to two maxima values of 5.54 °C and 6.66 °C at ibuprofen/chitosan 
weight ratios 1:0.5 and 1:1 respectively indicating the formation of multiple complexes. The melting 
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peak of ibuprofen shifted to a range of 47.77 to 80.31 °C in IbChTw80 conjugates with two minima 
values of 47.77 °C and 58.19 °C at ibuprofen/chitosan weight ratios 1:0.125 and 1:0.5 respectively 
(Figure 66).  All the nanoconjugates except IbCh4Tw80 exhibited broad and diffuse peaks with lower 
melting points than raw ibuprofen suggesting the existence of nanoconjugates in the amorphous 
state. 
Table 43 DSC of ibuprofen-chitosan conjugates (solubilization), ibuprofen control, pure ibuprofen, chitosan and physical 
mixture of ibuprofen and chitosan. Each value represents mean ± SD (n = 4). 
Formulation Onset (°C) End (°C) Peak (°C) Area (mJ) Delta H (J/g) 
Ibuprofen-reference 76.52±1.42 
193.66±7.73 
83.23±1.78 
243.03±9.57 
80.07±1.94 
237.51±9.93 
949.15±38.72 
309.29±11.21 
118.64±0.96 
2241.34±51.03 
Chitosan-reference 60.44±1.02 
299.84±7.95 
155.57±6.2 
339.81±10.85 
115.44±4.32 
318.39±10.68 
2077.04±45.38 
-1938.38±42.56 
301.02±9.75 
-201.91±9.21 
Ibuprofen-Chitosan 
physical mixture 
75.45±1.30 
104.95±2.94 
250.30±9.82 
85.47±1.88 
153.00±5.96 
267.84±10.11 
81.34±1.54 
126.56±3.68 
262.48±10.35 
581.56±17.56 
111.01±3.02 
59.29±1.14 
67.62±1.12 
12.91±0.49 
6.89±0.23 
IbTw80-control 
(IbCh 1:0) 
-25.29±0.14 
120.42±1.08 
-7.35±0.22 
131.83±3.64 
-14.15±0.23 
125.11±3.32 
207.06±12.13 
262.84±11.77 
28.76±0.53 
36.51±0.52 
IbCh1Tw80  
(IbCh 1:0.125) 
0.15±0.01 
25.20±0.58 
101.36±4.65 
4.97±0.09 
54.66±1.36 
108.74±5.11 
2.71±0.02 
47.77±1.25 
103.92±5.05 
152.93±5.98 
695.81±18.33 
291.34±7.84 
17.11±0.78 
77.83±1.52 
32.59±0.81 
IbCh2Tw80  
(IbCh 1:0.25) 
0.44±0.01 
46.28±1.08 
101.19±4.98 
8.88±0.19 
75.82±1.36 
111.26±5.09 
5.54±0.16 
64.67±1.09 
105.87±4.86 
363.79±13.65 
2562.82±64.32 
507.23±16.58 
43.31±1.14 
305.10±12.66 
60.38±1.25 
IbCh3Tw80  
(IbCh 1:0.5) 
0.09±0.01 
33.59±0.82 
100.67±5.06 
6.43±0.15 
69.19±1.65 
110.34±5.22 
3.36±0.82 
58.19±1.24 
104.42±5.17 
251.42±7.21 
1595.91±53.69 
303.26±13.25 
30.29±0.75 
192.28±6.18 
36.54±0.81 
IbCh4Tw80  
(IbCh1:1) 
0.01±0.00 
46.77±1.01 
102.43±4.98 
10.50±0.32 
88.32±1.69 
109.93±5.02 
6.66±0.18 
80.31±1.72 
104.74±4.61 
1000.08±47.25 
7070.51±92.03 
142.63±5.36 
123.47±5.23 
872.90±35.67 
17.61±0.85 
IbCh5Tw80  
(IbCh 1:2) 
0.05±0.01 
33.02±0.87 
101.15±5.01 
8.11±0.26 
77.09±1.59 
110.17±5.14 
4.87±0.12 
66.42±1.23 
104.87±4.86 
533.82±17.48 
3942.72±76.38 
420.53±15.42 
100.72±4.86 
743.91±23.54 
79.35±1.52 
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Figure 66 DSC thermograms of ibuprofen-chitosan conjugates (surfactant solubilization), ibuprofen control, pure 
ibuprofen, chitosan and physical mixture of ibuprofen and chitosan. 
Nanoconjugates obtained from the hydrotropic complexation technique showed two peaks 
(IbCh1Nic and IbCh3Nic) however the IbCh2Nic, IbCh4Nic and IbCh5Nic exhibited three peaks as 
presented in Table 44 and Figure 67. The first peak exhibited two minimal values of 3.84 °C and 6.26 
°C at ibuprofen/chitosan weight ratios 1:0.125 and 1:1 respectively suggesting formation of multiple 
complexes. The melting peak of ibuprofen shifted to 83.65 °C and 85.17 °C at ibuprofen/chitosan 
weight ratios 1:0.25 and 1:2 respectively but did not appear at other weight ratios. It was observed 
that the weight ratios without the ibuprofen melting peak exhibited broad and diffuse second peak 
with higher values indicating the formation of stable amorphous product (Figure 64). Similar 
complexation was reported by Oberoi et al. in the preparation of ibuprofen-nicotinamide 
suspensions by solvent evaporation method [84]. 
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Table 44 DSC of ibuprofen-chitosan conjugates (solubilization), ibuprofen control, pure ibuprofen, chitosan and physical 
mixture of ibuprofen and chitosan. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Peak (oC) Area (mJ) Delta H (J/g) 
Ibuprofen-reference 76.52±1.42 
193.66±7.73 
83.23±1.78 
243.03±9.57 
80.07±1.94 
237.51±9.93 
949.15±38.72 
309.29±11.21 
118.64±0.96 
2241.34±51.03 
Chitosan-reference 60.44±1.02 
299.84±7.95 
155.57±6.2 
339.81±10.85 
115.44±4.32 
318.39±10.68 
2077.04±45.38 
-1938.38±42.56 
301.02±9.75 
-201.91±9.21 
Ibuprofen-Chitosan 
physical mixture 
75.45±1.30 
104.95±2.94 
250.30±9.82 
85.47±1.88 
153.00±5.96 
267.84±10.11 
81.34±1.54 
126.56±3.68 
262.48±10.35 
581.56±17.56 
111.01±3.02 
59.29±1.14 
67.62±1.12 
12.91±0.49 
6.89±0.23 
IbNic-control 
(IbCh 1:0) 
0.64±0.04 
54.37±1.11 
14.33±0.58 
95.45±2.72 
9.54±0.13 
82.88±2.32 
1663.60±32.78 
10631.82±105.77 
186.92±7.57 
1194.58±58.22 
IbCh1Nic  
(IbCh 1:0.125) 
0.83±0.04 
101.97±4.93 
6.90±0.25 
113.79±5.26 
3.84±0.15 
108.24±4.73 
404.29±20.36 
1190.10±33.56 
134.76±5.36 
396.70±8.22 
IbCh2Nic  
(IbCh 1:0.25) 
0.19±0.01 
51.84±0.95 
99.90±4.97 
11.27±0.52 
91.33±4.01 
111.68±5.21 
7.14±0.31 
83.65±4.32 
105.07±4.65 
832.41±35.22 
5428.98±72.34 
254.57±11.25 
163.22±6.58 
1064.51±42.33 
49.92±0.85 
IbCh3Nic  
(IbCh 1:0.5) 
0.44±0.02 
101.18±4.89 
11.03±0.51 
127.10±5.87 
7.41±0.21 
116.75±5.74 
1369.36±38.74 
8548.60±73.42 
273.87±10.58 
1709.72±37.28 
IbCh4Nic  
(IbCh1:1) 
1.53±0.05 
108.19±5.18 
10.51±0.48 
116.72±5.29 
6.26±0.20 
112.47±5.37 
563.89±22.64 
3258.61±67.85 
281.95±8.15 
1162.7±32.55 
IbCh5Nic  
(IbCh 1:2) 
0.28±0.01 
48.98±0.92 
101.94±4.72 
10.25±0.43 
92.02±2.23 
109.59±5.16 
6.66±0.18 
85.17±1.82 
105.57±5.06 
946.50±43.17 
5861.76±72.36 
216.32±7.23 
182.10±6.39 
1127.26±35.42 
41.60±0.95 
 
 
Figure 67 DSC thermograms of ibuprofen-chitosan conjugates (hydrotropy), ibuprofen control, pure ibuprofen, chitosan 
and physical mixture of ibuprofen and chitosan. 
The DSC thermograms of ibuprofen-DEAE-Dextran-gellan complex, IbDW-control, pure ibuprofen, 
gellan, DEAE-Dextran and chitosan are shown in Figures 68 and 69; Tables 45 and 46. Pure ibuprofen 
showed a sharp melting peak at 80.37 °C due to the melting of the drug and the second peak at 
237.51 °C due to its decomposition. Gellan and DEAE-Dextran powders exhibited broad melting 
peaks at 127.86 °C and 124.05 °C respectively. The melting peak of ibuprofen decreased in the 
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ternary conjugates to a minimum value of 77.06 °C with decreased intensity at DEAE-Dextran/Gellan 
weight ratio of 75:25 however, the peaks were still broad and diffuse suggesting the amorphous 
nature of the nanoconjugates. The second endothermic peaks observed in the complexes 
correspond to the step of inflection in the thermograms, confirming that the peak was due to the 
decomposition of the complex. 
Table 45 DSC of ibuprofen incorporated into DEAE-Dextran-gellan conjugate in ratios, DG 0:100, DG 25:75, DG 50:50, DG 
75:25 and DG 100:0; pure ibuprofen, gellan and DEAE-Dextran. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Peak (oC) Area (mJ) Delta H (J/g) 
Ibuprofen-reference 76.52±1.42 
193.66±7.73 
83.23±1.78 
243.03±9.57 
80.07±1.94 
237.51±9.93 
949.15±38.72 
309.29±11.21 
118.64±0.96 
2241.34±51.03 
Gellan-reference 77.70±1.55 
246.56±12.37 
186.32±8.76 
270.88±12.86 
127.86±7.43 
264.02±12.75 
1043.54±52.70 
-803.81±40.22 
168.31±8.81 
-129.64±6.5 
DEAE-Dextran-reference 53.55±0.85 
87.43±1.22 
187.42±8.23 
245.83±12.74 
63.97±0.92 
158.87±5.34 
210.60±11.45 
281.53±13.66 
57.86±0.76 
124.05±4.16 
201.54±10.58 
268.50±11.78 
35.16±0.41 
960.30±40.48 
87.74±1.25 
488.852±21.22 
5.10±0.08 
139.17±5.64 
12.72±0.84 
70.84±0.92 
IbDW-pH6 75.89±1.54 
184.30±8.59 
84.31±1.78 
224.45±10.36 
80.67±1.58 
219.59±10.32 
333.87±15.64 
602.20±27.79 
104.33±5.04 
188.18±8.37 
DG 0:100 74.47±1.41 
184.16±8.26 
80.92±1.62 
219.04±10.04 
77.54±1.48 
204.63±9.78 
349.49±16.76 
289.15±12.97 
116.49±5.21 
96.38±4.02 
DG 25:75 73.51±1.22 
244.98±11.21 
81.80±1.48 
252.38±10.97 
78.40±1.17 
246.90±11.04 
293.49±13.05 
133.84±5.26 
97.83±4.18 
44.61±0.54 
DG 50:50 73.39±1.17 
240.91±10.87 
80.51±1.40 
255.61±11.81 
77.38±1.29 
248.64±11.32 
270.97±11.33 
39.52±0.54 
87.41±1.73 
12.74±0.27 
DG 75:25 73.27±1.35 
240.15±11.58 
80.21±1.26 
250.12±11.42 
77.06±1.02 
244.27±10.80 
286.55±12.71 
148.00±5.07 
92.43±3.31 
47.74±0.62 
DG 100:0 76.20±1.21 
177.36±7.07 
82.76±1.54 
229.66±10.86 
79.52±1.37 
221.93±11.31 
373.05±18.95 
711.26±32.45 
109.72±4.78 
209.19±10.52 
 
 
Figure 68 DSC thermograms of ibuprofen incorporated into DEAE-Dextran-gellan conjugate in ratios (a) DG 0:100, (b) DG 
25:75, (c) DG 50:50, (d) DG 75:25, (e) DG 100:0, (f) pure ibuprofen-reference, (g) gellan-reference and (h) DEAE-Dextran-
reference. 
146 | P a g e  
 
The ternary chitosan-ibuprofen-gellan nanoconjugates showed a decrease in the melting peak of 
ibuprofen ranging from 67.01 to 77.18 °C indicating the formation of amorphous nanoconjugates 
(Table 46 and Figure 68). Chitosan exhibited broad melting peak at 115.44 °C. 
Table 46 DSC of ibuprofen incorporated into chitosan-gellan conjugate in ratios, CG 0:100, CG 25:75, CG 50:50, CG 75:25 
and CG 100:0; pure ibuprofen, gellan and chitosan. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Peak (oC) Area (mJ) Delta H (J/g) 
Ibuprofen-reference 
 
76.52±1.42 
193.66±7.73 
83.23±1.78 
243.03±9.57 
80.07±1.94 
237.51±9.93 
949.15±38.72 
309.29±11.21 
118.64±0.96 
2241.34±51.03 
Gellan-reference 77.70±1.55 
246.56±12.37 
186.32±8.76 
270.88±12.86 
127.86±7.43 
264.02±12.75 
1043.54±52.70 
-803.81±40.22 
168.31±8.81 
-129.64±6.5 
Chitosan-reference 60.44±1.02 
299.84±7.95 
155.57±6.2 
339.81±10.85 
115.44±4.32 
318.39±10.68 
2077.04±45.38 
-1938.38±42.56 
301.02±9.75 
-201.91±9.21 
IbDW-pH5 75.89±1.54 
184.30±8.59 
84.31±1.78 
224.45±10.36 
80.67±1.58 
219.59±10.32 
333.87±15.64 
602.20±27.79 
104.33±5.04 
188.18±8.37 
CG 0:100 76.91±1.21 
184.16±8.26 
84.06±1.62 
219.04±10.04 
77.18±1.58 
204.63±9.78 
353.92±13.78 
289.15±12.97 
104.09±4.73 
96.38±4.02 
CG 25:75 57.96±0.78 
193.22±6.62 
77.22±1.36 
220.19±11.03 
71.33±1.07 
197.88±8.26 
158.73±6.26 
66.28±1.04 
52.91±0.65 
22.09±0.21 
CG 50:50 71.92±1.15 
167.83±6.03 
81.24±1.65 
202.65±10.84 
77.15±1.14 
192.73±6.54 
297.75±13.32 
42.71±0.72 
85.07±1.87 
12.20±0.14 
CG 75:25 58.78±0.73 
163.49±5.92 
76.74±1.18 
277.93±12.36 
71.63±1.12 
206.37±10.96 
215.44±10.76 
81.36±1.32 
61.55±0.74 
23.24±0.28 
CG 100:0 57.33±0.86 
167.95±6.34 
73.25±1.10 
260.09±12.25 
67.01±0.92 
221.99±11.23 
68.31±0.96 
451.40±16.13 
17.51±0.21 
115.74±5.62 
 
 
Figure 69 DSC thermograms of ibuprofen incorporated into chitosan-gellan conjugate in ratios (a) CG 0:100, (b) CG 25:75, 
(c) CG 50:50, (d) CG 75:25, (e) CG 100:0, (f) pure ibuprofen-reference, (g) gellan-reference and (h) chitosan-reference. 
2.3.3.10.2. Thermogravimetric analysis (TGA) 
Thermogravimetric analysis (TGA) is a useful thermal analysis technique which measures the 
changes in physical and chemical properties of material as a function of increasing temperature or 
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time. TGA measures the mass of a sample as a function of sample temperature or time. It is used to 
evaluate the mass loss or gain of polymers due to decomposition, oxidation or loss of moisture. The 
thermal stability of the pure reference compounds and nanoconjugates can be interpreted from the 
TGA thermograms. 
The TGA thermograms of pure ibuprofen and ibuprofen control (processed ibuprofen without 
polymer) showed one step of weight loss of 99.5% and 99.3% at 240.76 °C and 104.52 °C 
respectively in Figure 70. DEAE-Dextran showed two steps of weight loss of 6.94% and 67.61% at 
24.94 °C and 272.15 °C respectively while the ibuprofen-DEAE-Dextran physical mixture showed 
three steps of weight loss of 4.13%, 47.92% and 36.17% at 126.01 °C, 218.05 °C and 253.12 °C 
respectively.  The pure ibuprofen exhibited almost 100% degradation. DEAE-Dextran exhibited 88.2% 
degradation, a residue of 11.88% remained after degradation. The IbDMelt conjugates showed one 
step of weight loss of 97.40  to 99.77% at temperatures below 150 °C in the range of 97.17 to 140.34 
°C which has been attributed to weight loss due to free or loosely bound water in the conjugate 
structure [86] in Table 47. The step of inflection decreased with increasing concentration of DEAE-
Dextran up to 0.8%, followed by a final increase. The absence of the decomposition step in the TGA 
curve confirmed the absent decomposition peaks in the DSC thermograms of the nanoconjugates. 
Table 47 TGA of ibuprofen-DEAE-Dextran conjugates (melt solubilization) ibuprofen control, ibuprofen-reference, DEAE-
Dextran-reference and ibuprofen-DEAE-Dextran physical mixture. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Step of inflection (oC) Delta Y (%) 
Ibuprofen-reference 207.81±11.23 247.08±11.87 240.76±12.32 99.50±1.95 
DEAE-Dextran-reference 47.16±0.47 
261.20±11.43 
106.74±4.32 
301.16±15.72 
77.47±1.47 
272.15±12.62 
6.94±0.12 
67.61±0.98 
Ibuprofen-DEAE-Dextran physical mixture 115.93±5.32 
192.74±8.65 
248.94±12.12 
129.68±5.68 
223.95±12.04 
270.55±12.69 
126.01±.47 
218.05±11.95 
253.12±12.48 
4.13±0.02 
47.92±0.52 
36.17±0.34 
IbMelt-control (IbD 1:0) 71.42±0.57 106.88±1.95 104.52±1.87 99.32±1.21 
IbD1Melt (IbD 1:0.5) 93.08±2.68 138.59±5.07 135.77±4.98 96.35±2.78 
IbD2Melt (IbD 1:1) 82.57±2.53 124.39±4.36 121.14±4.21 98.91±2.54 
IbD3Melt (IbD 1:2) 76.53±0.89 114.96±4.51 112.34±4.23 97.40±2.10 
IbD4Melt (IbD 1:4) 66.01±0.64 104.38±2.43 97.17±2.17 97.44±2.23 
IbD5Melt (IbD 1:8) 96.68±1.82 142.55±4.88 140.34±4.58 99.72±1.18 
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Figure 70 TGA thermogram of ibuprofen-DEAE-Dextran conjugates (melt solubilization) (a) IbD1Melt, (b) IbD2Melt, (c) 
IbD3Melt, (d) IbD4Melt, (e) IbD5Melt, (f) IbMelt-control, (g) ibuprofen-reference, (h) DEAE-Dextran-reference and (i) 
ibuprofen-DEAE-Dextran physical mixture. 
Nanoconjugates obtained from the alkaline solubilization technique (IbDNaOH) showed one step of 
weight loss in the range of 97.78  to 99.16% at temperatures below 150 °C which indicated weight 
loss due to free water in the conjugates in Table 48 and Figure 71 [87]. The step of inflection initially 
increased, followed by decrease with increasing DEAE-Dextran concentration. The rate of moisture 
loss was faster in nanoconjugates than the physical mixture.  
Table 48 TGA of ibuprofen-DEAE-Dextran conjugates (solubilization) ibuprofen control, ibuprofen-reference, DEAE-
Dextran-reference and ibuprofen-DEAE-Dextran physical mixture. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Step of inflection (oC) Delta Y (%) 
Ibuprofen-reference 207.81±11.23 247.08±11.87 240.76±12.32 99.50±1.95 
DEAE-Dextran-reference 47.16±0.47 
261.20±11.43 
106.74±4.32 
301.16±15.72 
77.47±1.47 
272.15±12.62 
6.94±0.12 
67.61±0.98 
Ibuprofen-DEAE-Dextran physical mixture 115.93±5.32 
192.74±8.65 
248.94±12.12 
129.68±5.68 
223.95±12.04 
270.55±12.69 
126.01±.47 
218.05±11.95 
253.12±12.48 
4.13±0.02 
47.92±0.52 
36.17±0.34 
IbNaOH-control (IbD 1:0) 71.42±0.57 106.88±1.95 104.52±1.87 99.32±1.21 
IbD1NaOH (IbD 1:0.5) 72.96±0.12 110.94±3.16 106.69±3.34 99.16±0.46 
IbD2NaOH (IbD 1:1) 85.01±1.42 134.02±5.04 130.45±4.65 98.40±2.82 
IbD3NaOH (IbD 1:2) 74.43±1.08 111.17±3.48 108.50±3.21 98.73±2.64 
IbD4NaOH (IbD 1:4) 69.91±0.98 105.33±2.82 102.08±2.64 97.78±2.16 
IbD5NaOH (IbD 1:8) 72.80±1.02 109.08±2.66 106.07±2.48 98.22±2.38 
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Figure 71 TGA thermograms of ibuprofen-DEAE-Dextran conjugates (solubilization) (a) IbD1NaOH, (b) IbD2NaOH, (c) 
IbD3NaOH, (d) IbD4NaOH, (e) IbD5NaOH, (f) IbNaOH-control, (g) ibuprofen-reference, (h) DEAE-Dextran-reference and 
(i) ibuprofen-DEAE-Dextran physical mixture. 
TGA thermograms of nanoconjugates obtained from surfactant solubilization technique are 
presented in Table 49 and Figure 72. The IbDTw80 conjugates showed two steps of weight loss at a 
range of 104.34 to 130.96 °C and 379.29 to 405.62 °C which was close to 429.7 °C, the reported 
weight loss temperature  due to decomposition of Tween 80  [88].  The IbDTw80 conjugates showed 
two steps of weight loss at a range of 104.34 to 130.96 °C and 379.29 to 405.62 °C (Table 49). The 
first weight loss was due to the loss of free water in the conjugates while the second weight loss was 
due to the decomposition of the conjugates [87]. The higher temperature of decomposition of the 
IbDTw80 conjugates compared to ibuprofen was due to the effect of Tween 80 on the conjugates.   
Table 49 TGA of ibuprofen-DEAE-Dextran conjugates (solubilization) ibuprofen control, ibuprofen-reference, DEAE-
Dextran-reference and ibuprofen-DEAE-Dextran physical mixture. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Step of inflection (oC) Delta Y (%) 
Ibuprofen-reference 207.81±11.23 247.08±11.87 240.76±12.32 99.50±1.95 
DEAE-Dextran-reference 47.16±0.47 
261.20±11.43 
106.74±4.32 
301.16±15.72 
77.47±1.47 
272.15±12.62 
6.94±0.12 
67.61±0.98 
Ibuprofen-DEAE-Dextran physical mixture 115.93±5.32 
192.74±8.65 
248.94±12.12 
129.68±5.68 
223.95±12.04 
270.55±12.69 
126.01±.47 
218.05±11.95 
253.12±12.48 
4.13±0.02 
47.92±0.52 
36.17±0.34 
IbTw80-control (IbD 1:0) 71.42±0.57 106.88±1.95 104.52±1.87 99.32±1.21 
IbD1Tw80  
(IbD 1:0.5) 
86.58±1.55 
335.07±14.36 
131.43±4.88 
412.37±20.14 
126.01±3.78 
379.29±16.64 
91.30±1.94 
8.74±0.03 
IbD2Tw80 
(IbD 1:1) 
86.95±1.46 
378.00±15.48 
130.25±5.34 
420.20±22.42 
125.56±4.68 
405.62±21.06 
89.23±1.32 
9.31±0.04 
IbD3Tw80 
(IbD 1:2) 
90.44±1.94 
380.89±16.00 
135.16±5.16 
419.07±21.04 
130.96±4.82 
403.18±20.64 
90.25±1.87 
8.36±0.04 
IbD4Tw80 
(IbD 1:4) 
72.31±0.81 
372.36±17.61 
107.79±4.21 
415.63±20.18 
104.34±4.23 
403.77±21.21 
88.44±1.64 
10.21±0.05 
IbD5Tw80 
(IbD 1:8) 
76.39±0.74 
376.17±16.89 
114.47±4.98 
416.36±22.54 
111.45±5.21 
402.06±21.08 
88.65±1.58 
9.80±0.04 
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Figure 72 TGA thermograms of ibuprofen-DEAE-Dextran conjugates (solubilization) (a) IbD1Tw80, (b) IbD2Tw80, (c) 
IbD3Tw80, (d) IbD4Tw80, (e) IbD5Tw80,  (f) IbTw80-control, (g) ibuprofen-reference, (h) DEAE-Dextran-reference and (i) 
ibuprofen-DEAE-Dextran physical mixture. 
The TGA thermograms of nanoconjugates obtained from the hydrotropic complexation technique 
are presented in Table 50 and Figure 73. The IbDNic conjugates showed one step of weight loss at 
temperatures below 150 °C which indicated weight loss due to free water in the conjugates in Table 
50 and Figure 73 [87]. The step of inflection decreased with increasing concentration of DEAE-
Dextran. The decomposition step was absent in three of the four techniques (except tween 80 
nanoconjugates) suggesting isothermal stability of the nanoconjugates.   
Table 50 TGA of ibuprofen-DEAE-Dextran conjugates (hydrotropy) ibuprofen control, ibuprofen-reference, DEAE-
Dextran-reference and ibuprofen-DEAE-Dextran physical mixture. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Step of inflection (oC) Delta Y (%) 
Ibuprofen-reference 207.81±11.23 247.08±11.87 240.76±12.32 99.50±1.95 
DEAE-Dextran-reference 47.16±0.47 
261.20±11.43 
106.74±4.32 
301.16±15.72 
77.47±1.47 
272.15±12.62 
6.94±0.12 
67.61±0.98 
Ibuprofen-DEAE-Dextran physical mixture 115.93±5.32 
192.74±8.65 
248.94±12.12 
129.68±5.68 
223.95±12.04 
270.55±12.69 
126.01±5.47 
218.05±11.95 
253.12±12.48 
4.13±0.02 
47.92±0.52 
36.17±0.34 
IbNic-control (IbD 1:0) 71.42±0.57 106.88±1.95 104.52±1.87 99.32±1.21 
IbD1Nic (IbD 1:0.5) 90.14±2.04 134.40±4.16 129.34±4.64 99.75±2.68 
IbD2Nic (IbD 1:1) 75.15±0.86 114.82±4.34 110.43±4.26 99.86±2.42 
IbD3Nic (IbD 1:2) 80.94±0.90 123.78±5.42 118.57±5.32 100.88±2.74 
IbD4Nic (IbD 1:4) 80.46±0.72 120.45±5.36 117.26±5.06 98.30±2.48 
IbD5Nic (IbD 1:8) 81.60±0.84 124.16±5.32 120.10±5.18 97.34±2.16 
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Figure 73 TGA thermograms of ibuprofen-DEAE-Dextran conjugates (hydrotropy) (a) IbD1Nic, (b) IbD2Nic, (c) IbD3Nic, (d) 
IbD4Nic, (e) IbD5Nic,  (f) IbNic-control, (g) ibuprofen-reference, (h) DEAE-Dextran-reference and (i) ibuprofen-DEAE-
Dextran physical mixture. 
The TGA thermograms of ibuprofen/chitosan nanoconjugates are similar to the ibuprofen/DEAE- 
Dextran. The thermograms of pure chitosan showed two steps of weight loss of 9.65% and 47.65% 
(total weight loss of 57.00 %) at 57.48 °C and 311.76 °C in Table 50. The 43.00% residue remaining 
could be assigned to the part of chitosan that did not undergo decomposition. The first weight loss 
was due to the loss of free water in the conjugates while the second weight loss was due to the 
decomposition of the conjugates [87]. The ibuprofen-chitosan physical mixture showed three steps 
of weight loss at 27.81 °C, 233.76 °C and 311.89 °C in Figure 74. The first weight loss was due to the 
loss of free water in the conjugates while the second and third weight loss was due to the 
decomposition of the ibuprofen and chitosan components in the physical mixture [87]. The 
nanoconjugates obtained from melt solubilization technique (IbChMelt) showed one step of weight 
loss below 150 °C which indicated weight loss due to free water in the conjugates. 
Table 51 TGA of ibuprofen-chitosan conjugates (melt solubilization) ibuprofen control, ibuprofen-reference, chitosan-
reference and ibuprofen-chitosan physical mixture. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Step of inflection (oC) Delta Y (%) 
Ibuprofen-reference 207.81±11.23 247.08±11.87 240.76±12.32 99.50±1.95 
Chitosan-reference 36.14±0.37 
291.90±14.28 
92.94±0.85 
338.75±16.72 
57.48±0.45 
311.76±15.24 
9.65±0.08 
47.65±0.32 
Ibuprofen-Chitosan physical mixture 27.81±0.22 
203.02±10.55 
293.87±15.21 
63.05±0.58 
235.31±11.23 
342.21±16.34 
27.81±0.22 
233.76±11.45 
311.89±15.22 
3.26±0.01 
61.41±0.44 
20.35±0.18 
IbDW-pH6 (IbCh 1:0)  71.42±0.57 106.88±1.95 104.52±1.87 99.32±1.21 
IbCh1Melt (IbCh 1:0.125) 76.36±1.10 116.36±3.21 111.87±2.05 96.76±1.58 
IbCh2Melt (IbCh 1:0.25) 82.58±1.36 126.70±3.45 121.25±3.27 98.12±1.89 
IbCh3Melt (IbCh 1:0.5) 75.02±1.06 114.54±2.32 110.03±2.21 98.00±1.88 
IbCh4Melt (IbCh 1:1) 75.90±1.12 114.94±2.26 110.90±2.32 95.56±1.74 
IbCh5Melt (IbCh 1:2) 90.43±1.86 136.67±4.73 131.13±4.56 97.29±1.65 
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Figure 74 TGA thermograms of ibuprofen-chitosan conjugates (melt solubilization) (a) IbCh1Melt, (b) IbCh2Melt, (c) 
IbCh3Melt, (d) IbCh4Melt, (e) IbCh5Melt,  (f) IbMelt-control, (g) ibuprofen-reference, (h) chitosan-reference and (i) 
ibuprofen-chitosan physical mixture. 
The nanoconjugates obtained from alkaline solubilization technique (IbChNaOH) showed one step of 
weight loss in the range of 114.07 to 126.91 °C (below 150 °C ) which indicated weight loss due to 
free water in the conjugates in Figure 75 [87].  
Table 52 TGA of ibuprofen-chitosan conjugates (solubilization) ibuprofen control, ibuprofen-reference, chitosan-
reference and ibuprofen-chitosan physical mixture. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Step of inflection (oC) Delta Y (%) 
Ibuprofen-reference 207.81±11.23 247.08±11.87 240.76±12.32 99.50±1.95 
Chitosan-reference 36.14±0.37 
291.90±14.28 
92.94±0.85 
338.75±16.72 
57.48±0.45 
311.76±15.24 
9.65±0.08 
47.65±0.32 
Ibuprofen-Chitosan physical mixture 27.81±0.22 
203.02±10.55 
293.87±15.21 
63.05±0.58 
235.31±11.23 
342.21±16.34 
27.81±0.22 
233.76±11.45 
311.89±15.22 
3.26±0.01 
61.41±0.44 
20.35±0.18 
IbNaOH-control (IbCh 1:0) 71.42±0.57 106.88±1.95 104.52±1.87 99.32±1.21 
IbCh1NaOH (IbCh 1:0.125) 77.45±0.76 119.65±3.54 114.56±2.98 98.08±1.88 
IbCh2NaOH (IbCh 1:0.25) 76.77±0.89 119.00±3.24 114.07±3.26 98.57±1.98 
IbCh3NaOH (IbCh 1:0.5) 80.63±1.14 123.00±3.08 119.17±3.02 97.54±1.95 
IbCh4NaOH (IbCh 1:1) 78.87±0.89 119.89±2.98 116.00±2.89 97.93±1.84 
IbCh5NaOH (IbCh 1:2) 87.37±1.06 132.01±3.25 126.91±3.14 97.84±1.92 
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Figure 75 TGA thermograms of ibuprofen-chitosan conjugates (melt solubilization) (a) IbCh1NaOH, (b) IbCh2NaOH, (c) 
IbCh3NaOH, (d) IbCh4NaOH, (e) IbCh5NaOH,  (f) IbNaOH-control, (g) ibuprofen-reference, (h) chitosan-reference and (i) 
ibuprofen-chitosan physical mixture. 
The IbChTw80 conjugates showed two steps of weight loss at the range of 108.92 to 129.53 °C and 
378.81 to 385.25 °C in Table 53. The first weight loss (range of 90.15 to 90.69%) was due to the loss 
of free water in the conjugates while the second weight loss (range of 6.20 to 7.81%) was due to the 
decomposition of the conjugates in Figure 76. The higher temperature of decomposition of the 
IbChTw80 conjugates compared to ibuprofen showed that the conjugates had a better isothermal 
stability than the pure ibuprofen. 
Table 53 TGA of ibuprofen-chitosan conjugates (solubilization) ibuprofen control, ibuprofen-reference, chitosan-
reference and ibuprofen-chitosan physical mixture. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Step of inflection (oC) Delta Y (%) 
Ibuprofen-reference 207.81±11.23 247.08±11.87 240.76±12.32 99.50±1.95 
Chitosan-reference 36.14±0.37 
291.90±14.28 
92.94±0.85 
338.75±16.72 
57.48±0.45 
311.76±15.24 
9.65±0.08 
47.65±0.32 
Ibuprofen-Chitosan physical mixture 27.81±0.22 
203.02±10.55 
293.87±15.21 
63.05±0.58 
235.31±11.23 
342.21±16.34 
27.81±0.22 
233.76±11.45 
311.89±15.22 
3.26±0.01 
61.41±0.44 
20.35±0.18 
IbTw80-control  (IbCh 1:0) 71.42±0.57 106.88±1.95 104.52±1.87 99.32±1.21 
IbCh1Tw80 
(IbCh 1:0.125) 
73.63±0.65 
351.03±14.32 
113.93±3.06 
404.40±18.32 
108.92±2.89 
378.81±18.64 
90.19±1.72 
6.67±0.05 
IbCh2Tw80  
(IbCh 1:0.25) 
87.35±0.87 
369.44±16.54 
136.05±3.26 
398.49±18.02 
129.53±3.45 
385.25±17.22 
90.64±1.72 
7.55±0.05 
IbCh3Tw80  
(IbCh 1:0.5) 
77.05±0.68 
361.06±17.04 
120.01±3.24 
399.38±16.58 
113.28±2.98 
384.69±16.54 
90.32±1.72 
7.81±0.05 
IbCh4Tw80  
(IbCh 1:1) 
76.04±0.70 
340.46±16.54 
116.75±2.89 
397.47±17.68 
109.73±3.12 
378.88±15.45 
90.15±1.65 
7.64±0.05 
IbCh5Tw80 
(IbCh 1:2) 
77.60±0.72 
357.90±17.84 
118.05±3.08 
391.47±17.45 
112.83±2.54 
379.49±16.88 
90.69±1.74 
6.20±0.06 
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Figure 76 TGA thermogram of ibuprofen-chitosan conjugates (melt solubilization) (a) IbCh1Tw80, (b) IbCh2Tw80, (c) 
IbCh3Tw80, (d) IbCh4Tw80, (e) IbCh5Tw80,  (f) IbTw80-control, (g) ibuprofen-reference, (h) chitosan-reference and (i) 
ibuprofen-chitosan physical mixture. 
The hydrotropic nanoconjugates (IbChNic) showed one step of weight loss in the range of 105.81 to 
122.85 °C (below 150 °C) which indicated weight loss due to free water in the conjugates in Table 54 
and Figure 76. 
Table 54 TGA of ibuprofen-chitosan conjugates (hydrotropy) ibuprofen control, ibuprofen-reference, chitosan-reference 
and ibuprofen-chitosan physical mixture. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Step of inflection (oC) Delta Y (%) 
Ibuprofen-reference 207.81±11.23 247.08±11.87 240.76±12.32 99.50±1.95 
Chitosan-reference 36.14±0.37 
291.90±14.28 
92.94±0.85 
338.75±16.72 
57.48±0.45 
311.76±15.24 
9.65±0.08 
47.65±0.32 
Ibuprofen-Chitosan physical mixture 27.81±0.22 
203.02±10.55 
293.87±15.21 
63.05±0.58 
235.31±11.23 
342.21±16.34 
27.81±0.22 
233.76±11.45 
311.89±15.22 
3.26±0.01 
61.41±0.44 
20.35±0.18 
IbNic (IbCh 1:0) 71.42±0.57 106.88±1.95 104.52±1.87 99.32±1.21 
IbCh1Nic (IbCh 1:0.125) 75.80±1.17 116.45±2.76 111.32±2.85 96.50±1.72 
IbCh2Nic (IbCh 1:0.25) 81.77±1.28 126.54±3.18 120.35±3.22 98.76±1.99 
IbCh3Nic (IbCh 1:0.5) 83.08±1.36 128.76±3.10 122.85±3.15 97.60±1.86 
IbCh4Nic (IbCh1:1) 80.31±1.25 123.97±3.02 118.37±2.98 97.21±1.73 
IbCh5Nic (IbCh 1:2) 71.00±0.62 111.55±2.32 105.89±1.93 98.16±1.61 
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Figure 77 TGA thermograms of ibuprofen-chitosan conjugates (hydrotropy) (a) IbCh1Nic, (b) IbCh2Nic, (c) IbCh3Nic, (d) 
IbCh4Nic, (e) IbCh5Nic,  (f) IbNic-control, (g) ibuprofen-reference, (h) chitosan-reference and (i) ibuprofen-chitosan 
physical mixture. 
The TGA thermograms of ibuprofen-DEAE-Dextran-gellan complex, IbDW-control, pure ibuprofen, 
gellan, DEAE-Dextran and chitosan are shown in Figures 78 and 79; Tables 55 and 56. Ibuprofen and 
gellan powders showed one step of weight loss of 99.5% and 67.4%, at 240.76 °C and 264.91°C 
respectively, predominantly caused by the thermal decomposition of the molecular structure. DEAE-
Dextran showed two steps of weight loss of 6.94% and 67.61% at 24.94 °C and 272.15 °C respectively. 
However, DG 25:75, DG 50:50 and DG 75:25 showed two steps of inflection or weight loss after 150  
°C predominantly caused by the thermal decomposition of the molecular structure. DG 0:100 and 
DG 100:0 with gellan-ibuprofen and DEAE-Dextran-ibuprofen complex respectively showed one step 
weight loss of 99.8% and 99.7% at 206.01 °C and 205.05 °C respectively. It was obvious that the 
nanoconjugates lost moisture faster the the reference ibuprofen and the physical mixture however 
the ternary nanoconjugates retained moisture than the corresponding binary nanoconjugates. 
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Table 55 TGA of ibuprofen incorporated into DEAE-Dextran-gellan conjugate in ratios, DG 0:100, DG 25:75, DG 50:50, DG 
75:25 and DG 100:0; pure ibuprofen, gellan and DEAE-Dextran. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Step of inflection (oC) Delta Y (%) 
Ibuprofen-reference 207.81±11.23 247.08±11.87 240.76±12.32 99.50±1.95 
DEAE-Dextran-reference 47.16±0.47 
261.20±11.43 
106.74±4.32 
301.16±15.72 
77.47±1.47 
272.15±12.62 
6.94±0.12 
67.61±0.98 
Gellan-reference 43.99±0.65 
257.79±12.21 
131.17±4.72 
282.29±12.74 
90.39±3.15 
264.91±12.10 
7.85±0.08 
59.67±0.93 
IbDW-pH6 186.84±7.24 218.10±11.42 214.74±11.25 99.87±2.13 
DG0:100 180.43±8.03 210.96±11.67 206.01±11.22 99.80±2.01 
DG25:75 181.23±8.15 215.41±10.55 206.72±10.39 97.11±1.78 
DG50:50 173.32±8.23 
241.29±11.65 
205.13±10.21 
277.11±12.24 
199.87±9.69 
250.51±11.40 
77.93±1.12 
18.49±0.15 
DG75:25 167.06±7.30 
238.16±11.14 
201.80±9.87 
283.19±12.98 
197.68±8.32 
249.20±11.17 
79.19±1.06 
17.03±0.12 
DG100:0 179.80±8.45 207.68±10.66 205.05±10.24 99.70±2.03 
 
 
Figure 78 TGA thermograms of ibuprofen incorporated into DEAE-Dextran-gellan conjugate in ratios,(a) DG 0:100, (b) DG 
25:75,(c) DG 50:50, (d) DG 75:25, (e) DG 100:0, (f) IbDW-pH6 control, (g) pure ibuprofen-reference, (h) DEAE-Dextran-
reference and (i) gellan-reference. 
The TGA thermograms of Chitosan-ibuprofen-gellan ternary nanoconjugates are presented in Table 
56 and Figure 79.  Pure chitosan reference, showed two steps of weight loss. The first step of weight 
loss of 9.65% at 57.48 °C may be due to loss of free water in the polymer. The second weight loss of 
47.65% observed at 311.76 °C may be attributed to the decomposition of the polymer. CG 0:100, 
CG25:75, CG 50:50 and CG 75:25 showed one step of weight loss after 150 °C, due to the 
decomposition of the molecular structure of the complexes in Figure 79. CG 100:0 showed two steps 
of weight loss of 86.89% and 9.60% at 201.33 °C and 456.51 °C respectively, due to the 
decomposition of the molecular structure. The chitosan-ibuprofen-gellan nanoconjugates lost 
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moisture faster than the pure ibuprofen and the physical mixture however they retained moisture 
than the corresponding binary nanoconjugates.  
Table 56 TGA of ibuprofen incorporated into chitosan-gellan conjugate in ratios, CG 0:100, CG 25:75, CG 50:50, CG 75:25 
and CG 100:0; pure ibuprofen, gellan and chitosan. Each value represents mean ± SD (n = 4). 
Formulation Onset (oC) End (oC) Step of inflection (oC) Delta Y (%) 
Ibuprofen-reference 207.81±11.23 247.08±11.87 240.76±12.32 99.50±1.95 
Chitosan-reference 36.14±0.37 
291.90±14.28 
92.94±0.85 
338.75±16.72 
57.48±0.45 
311.76±15.24 
9.65±0.08 
47.65±0.32 
Gellan-reference 43.99±0.65 
257.79±12.21 
131.17±4.72 
282.29±12.74 
90.39±3.15 
264.91±12.10 
7.85±0.08 
59.67±0.93 
IbDW-pH5 186.84±7.24 218.10±11.42 214.74±11.25 99.87±2.13 
CG 0:100 177.59±6.87 210.62±10.94 205.30±10.77 99.36±1.84 
CG 25:75 159.65±5.86 239.46±11.02 197.16±10.48 90.53±1.73 
CG 50:50 170.87±6.62 212.06±10.71 200.98±10.43 98.59±1.85 
CG 75:25 165.00±6.01 243.87±11.32 203.05±10.76 88.87±1.03 
CG 100:0 170.88±6.44 
436.82±18.32 
215.94±10.52 
468.94±18.45 
201.33±10.73 
456.51±18.21 
86.89±1.27 
9.60±0.05 
 
 
Figure 79 TGA thermograms of ibuprofen incorporated into chitosan-gellan conjugate in ratios, (a) CG 0:100, (b) CG 
25:75, (c) CG 50:50, (d) CG 75:25, (e) CG 100:0, (f) IbDW-pH6 control, (g) pure ibuprofen-reference, (h) chitosan-reference 
and (i) gellan-reference. 
2.3.4. Drug release studies 
The in vitro release profiles of Ibuprofen-DEAE-Dextran conjugates and ibuprofen control in PBS pH 
7.4 at 37 °C are shown in Figure 80 toFigure 83. The release of Ibuprofen from IbDMelt was in the 
range of 37.40 to 65.76%, which was significantly higher (p < 0.05, n = 4) than the release by 
ibuprofen control (30.72%) as shown in Figure 80. Increasing concentration of DEAE-Dextran 
increased rate of ibuprofen release to 65.77 % at 0.2% w/v followed by a decrease up to 45.93 % at 
0.8% w/v with a further increase at higher concentrations of DEAE-Dextran. The order of release of 
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ibuprofen from IbDMelt conjugates at the end of 24 h is as follows: IbD2Melt > IbD5Melt > IbD3Melt 
> IbD4Melt > IbD1Melt > IbMelt-control as shown in Appendix I (Figure 158). The dissolution of 
ibuprofen from the solid dispersion is dependent on the preparation method, proportion and the 
properties of the carriers used in the formulation [90]. Esnaashari et al. studied the drug release 
rates along with the polymer dissolution rates of ibuprofen-polyvinylpyrrolidone (PVP) solid 
dispersions [91]. The authors found that ibuprofen dissolution was greatly enhanced by the 
formation of a solid dispersion (1:4 ratio) with 100% of the drug dissolving within 60 min compared 
with 12.26 and 45.94% at 1 and 24 h respectively in this study. The low dissolution rate in this study 
was ascribed to the strong electrostatic interaction between ibuprofen and DEAE-Dextran which 
retarded the release.   
Two theories have been proposed to justify the higher dissolution rates of solid dispersions. Firstly, 
formation of higher energy metastable states of the components as a function of the carrier system 
and the proportion of the carriers present enhance the dissolution rates [92]. The formation of a 
solid solution of the drug affects the dissolution was the second theory. The melt solubilization 
technique as well as the decrease in particle size to nano dimensions as shown previously (section 
2.3.3.5) suggests a combination of these literature principles. However the stronger affinity between 
ibuprofen and DEAE-Dextran retarded the dissolution rate within 24 h of study. 
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Figure 80 Release profile of ibuprofen from DEAE-Dextran conjugate (melt solubilization). Each data point represents 
mean ± SD (n = 4). 
The release of Ibuprofen from IbDNaOH was in the range of 59.63 to 70.78%, which was significantly 
higher than the release by ibuprofen control (30.72%) in Figure 81. The order of release of ibuprofen 
from IbDNaOH conjugates at 24 h is as follows: IbD3NaOH > IbD2NaOH > IbD1NaOH > IbD4NaOH > 
IbD5NaOH > IbNaOH-control as shown in Appendix I (Figure 158). Dissolution studies of ibuprofen 
polymer conjugates showed an increase in dissolution due to the reduction of the particle size from 
the micrometer range to the nanometer range (section 2.3.3.5), which has been previously reported 
for other poorly soluble drugs such as nitrendipine [93] and deacety mycoepoxydiene [94]. Alkaline 
solubilization of ibuprofen at higher pH values could also contribute to the enhanced dissolution 
rate. 
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Figure 81 Release profile of ibuprofen from DEAE-Dextran conjugates (solubilization). Each data point represents mean ± 
SD (n = 4). 
The release of Ibuprofen from IbDTw80 conjugates was in the range of 74.67 to 85.53%, which was 
significantly higher (p < 0.05, n = 4) than the release by ibuprofen control (30.72%) at the end of 24 h 
in Figure 82. The order of release of ibuprofen from IbDTw80 conjugates at 24 h is as follows: 
IbD4Tw80 > IbD2Tw80 > IbD5Tw80 > IbD3Tw80 > IbD1Tw80 > IbTw80-control as shown in Appendix 
I (Figure 158). Increasing concentration of DEAE-Dextran increased the release of ibuprofen from 
74.67 to 85.53%. However the increase was not statistically significant (p > 0.05, n = 20). Purcaru et 
al. studied the drug release of nimesulide from Tween 80 solutions in combination with buffer (pH 
7.4) [95]. They reported that the release from 1% Tween 80 was instantaneous with drug release of 
78 to 79% after 60 min. However, in this study the release of ibuprofen from tween 80 conjugates 
was 17% after 60 min. It was opined that the affinity between the DEAE-Dextran and ibuprofen 
retarded the release. The solubilizing effect of tween 80 may have been hindered by increased 
degree of disorderliness (entropy) in the mixture due to the presence of the conjugates. 
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Figure 82 Release profile of ibuprofen from DEAE-Dextran conjugates (solubilization). Each data point represents mean ± 
SD (n = 4). 
The release of Ibuprofen from IbDNic conjugates was in the range of 86.53 to 99.72%, which was 
significantly higher (p < 0.05) than the release by ibuprofen control (30.72%) in Figure 83. The order 
of release of ibuprofen from IbDNic conjugates at 24 h is as follows: IbD1Nic > IbD2Nic > IbD4Nic > 
IbD5Nic > IbD3Nic > IbNic-control as shown in Appendix I (Figure 158).  Increasing concentration of 
DEAE-Dextran significantly increased (p < 0.05, n = 20) the release of ibuprofen from the conjugate. 
Nicotinamide acts as water structure disruptors by increasing the solubility which destroys clusters 
of associated water molecules releasing water of solvation [96]. It was opined that the structure 
disruptors (nicotinamide) prevented self aggregation of ibuprofen which led to increase in solubility 
of ibuprofen. In a similar study, Ahuja et al. reported that  higher drug release of rofecoxib was 
observed with urea and nicotinamide systems via their ability to destroy water structure and 
complex formation [39] supporting the findings in this study.   
From the foregoing, it was obvious that the influence of the four different techniques on the in vitro 
release of ibuprofen from the conjugates is in the following order: IbDNic > IbDTw80 > IbDNaOH > 
IbDMelt with maximum release of 99.71, 85.53, 70.78 and 65.77% respectively. 
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Figure 83 Release profile of ibuprofen from DEAE-Dextran conjugates (hydrotropy). Each data point represents mean ± 
SD (n = 4). 
The in vitro release profiles of ibuprofen-chitosan conjugates and dissolution profile of ibuprofen 
control in PBS 7.4 at 37 oC are shown in Figure 84 to Figure 87. The release of Ibuprofen from 
IbChMelt conjugates was in the range of 32.83 to 59.10%, which was significantly higher (p < 0.05, n 
= 4) than the release by ibuprofen control (30.72%) in Figure 84. The order of release of ibuprofen 
from IbChMelt conjugates at 24 h is as follows: IbCh4Melt > IbCh5Melt > IbCh2Melt > IbCh3Melt > 
IbCh1Melt > IbMelt-control as shown in Appendix I (Figure 159). Increasing concentration of 
chitosan significantly increased (p < 0.05, n = 20) the release of ibuprofen from the conjugates. 
Portero et al. studied the effect of chitosan and chitosan glutamate enhancing the dissolution 
properties of nifedipine [97]. Chitosan significantly increased the dissolution of nifedipine. The effect 
was dependent on the polymer: drug mixing weight ratio, the chitosan type and the method 
employed in dispersing the drug in the polymer.  
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Figure 84 Release profile of ibuprofen from chitosan conjugates (melt solubilization). Each data point represents mean ± 
SD (n = 4). 
The release of Ibuprofen from IbChNaOH conjugates was in the range of 57.68 to 66.87%, which was 
significantly higher (p < 0.05, n = 4) than the release by ibuprofen control (30.72%) in Figure 85. The 
order of release of ibuprofen from IbChNaOH conjugates at 24 h is as follows: IbCh1NaOH > 
IbCh2NaOH > IbCh3NaOH > IbCh4NaOH > IbCh5NaOH > IbNaOH-control. There was insignificant 
decrease (p > 0.05, n = 20) in the release of ibuprofen from the conjugates with increase in chitosan 
content.  
 
Figure 85 Release profile of ibuprofen from chitosan conjugates (solubilization). Each data point represents mean ± SD (n 
= 4). 
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The release of Ibuprofen from IbChTw80 conjugates was in the range of 52.01 to 55.93%, which was 
significantly higher (p < 0.05, n = 4) than the release by ibuprofen control (30.72%) in Figure 86. The 
order of release of ibuprofen from IbChTw80 conjugates at 24 h is as follows: IbCh4Tw80 > 
IbCh1Tw80 > IbCh5Tw80 > IbCh2Tw80 > IbCh3Tw80 > IbTw80-control. Chitosan did not significantly 
change (p > 0.05, n = 20) the release of ibuprofen as the concentration of ibuprofen increased.  
 
Figure 86 Release of ibuprofen from chitosan conjugates (solubilization). Each data point represents mean ± SD (n = 4). 
The release of Ibuprofen from IbChNic conjugates was in the range of 97.31 to 99.28%, which was 
significantly higher (p < 0.05, n = 4) than the release by ibuprofen control (30.72%) in Figure 87. The 
order of release of ibuprofen from IbChNic conjugates at 24 h is as follows: IbCh4Nic > IbCh2Nic > 
IbCh3Nic > IbCh1Nic > IbCh5Nic > Ibuprofen control. Chitosan did not significantly (p > 0.05, n = 20) 
change the ibuprofen release with increasing concentration. The initial burst release has been 
reported to be mainly due to weakly bound or adsorbed drug to the large surface of the 
nanoparticles [98]. The solubility and dissolution characteristics are altered by the complexation of 
drugs to suitable carriers due to high solubility of the carrier [99].  
Overall, the effect of the four different techniques on the in vitro release of ibuprofen from the 
conjugates is in the following order: IbChNic > IbChNaOH > IbChMelt> IbChTw80 with maximum 
release of 99.28, 66.87, 59.10 and 55.94% respectively. 
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Figure 87 Release profile of ibuprofen from chitosan conjugates (hydrotropy). Each data point represents mean ± SD (n = 
4). 
The release profile of the complexes and dissolution profile of ibuprofen control in PBS pH 7.4 at 37 
oC are shown in Figure 88. The release of Ibuprofen from DEAE-Dextran-gellan complexes was in the 
range of 56.83 to 95.49%, which was significantly higher (p < 0.05, n = 4) than the release by 
ibuprofen control (30.91%). The order of release of ibuprofen from the DEAE-Dextran-gellan 
complexes at 48 h is as follows: DG 100:0 > DG 0:100 > DG 75:25 > DG 50:50 > DG 25:75 > ibuprofen 
control. The drug release significantly increased (p < 0.05, n = 20) with increase in DEAE-Dextran 
concentration. The individual polymers (DEAE-Dextran and chitosan) gave greater release of 95.49 
and 95.33% respectively than the ternary conjugates (56.83 to 90.38%). Increasing concentration of 
DEAE-Dextran increased the release to an initial maximum followed by an extended release as 
shown in Appendix I (Figure 160). Ternary conjugate containing DG 75:25 weight ratio exhibited the 
highest release of 90.38% (3-fold) compared with ibuprofen control. 
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Figure 88 Release profile of ibuprofen from DEAE-Dextran-Gellan conjugates (ternary). Each data point represents mean 
± SD (n = 4).  
The release profile of the complexes and dissolution profile of ibuprofen control in PBS pH 7.4 at 37 
oC are shown in Figure 89. The release of Ibuprofen from chitosan-gellan complexes was in the range 
of 45.33 to 96.59%, which was significantly higher (p < 0.05, n = 4) than the release by ibuprofen 
control (30.91%). The order of release of ibuprofen at 48 h is as follows: CG 100:0 > CG 0:100 > CG 
75:25 > CG 50:50 > CG 25:75 > ibuprofen control. The ibuprofen release significantly increased (p < 
0.05, n = 20) with increase in chitosan concentration as shown in Appendix I (Figure 160).  
 
Figure 89 Release profile of ibuprofen from Chitosan-Gellan conjugates (ternary). Each data point represents mean ± SD 
(n = 4). 
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2.3.5. Drug release kinetics 
Kinetic or mathematical models are model – dependent methods useful in comparing in vitro 
dissolution profiles. Methods of drug release from nanoparticles include desorption of drug bound 
to the surface; diffusion through the nanoparticle matrix; diffusion through the polymer wall of 
nanocapsules; nanoparticle matrix erosion; or a combined erosion-diffusion process. To analyze the 
drug release mechanism in the complexes, the release data was fitted into different kinetic models: 
zero order, first order, Higuchi plot and Korsemeyer-Peppas (first 60% release) [31]. The parameters 
of the models were obtained by linear regression.  
The drug release kinetics showed that the data were best fitted with the Korsemeyer-Peppas kinetic 
models for ibuprofen control and the IbDMelt conjugates except IbD5Melt which was best fitted 
with the Higuchi plot. Based on Korsemeyer-Peppas equation, values of n = 0.5  refers to Fickian 
diffusion which indicates drug release by diffusion and n = 1 refers to Case II transport which 
indicates drug release by the process of swelling [100]. Values of n between 0.5 and 1 refer to 
anomalous transport mechanism which indicates the superposition of diffusion and swelling 
processes. These extreme values of n are valid for slab geometry (thin films). For spheres which 
represent the particles in this study, different n values have been derived [101-102]. Values of n < 
0.43 refers to Fickian diffusion; 0.43 < n < 0.85 refers to anomalous transport; while n = 0.85 refers 
to Case II transport. 
The the n values obtained (Table 57) indicated that for the conjugates IbD3Melt, IbD5Melt and 
ibuprofen control had n < 0.43, exhibiting Fickian diffusion. For IbD1Melt, IbD2Melt and IbD4Melt, 
the release mechanism was anomalous (non-Fickian) diffusion where diffusion exponent (n) is 0.43 < 
n < 0.85. This can be attributed to presence of unbound drug on the surface of the nanoconjugates.  
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Table 57 Regression coefficient (r) values of different kinetic models and diffusion exponent (n) of Korsemeyer-Peppas 
models for the release of ibuprofen from DEAE-Dextran conjugates (melt solubilization). 
Formulation  Zero order First Order Higuchi Korsemeyer-Peppas 
 R2 R2 R2 R2 n 
IbMelt-control 
(IbD 1:0) 
0.61 0.56 0.80 0.88 0.32 
IbD1Melt (IbD 1:0.5) 0.75 0.51 0.93 0.97 0.51 
IbD2Melt (IbD 1:1) 0.76 0.54 0.93 0.99 0.50 
IbD3Melt (IbD 1:2) 0.56 0.46 0.78 0.92 0.43 
IbD4Melt (IbD 1:4) 0.76 0.54 0.93 0.98 0.54 
IbD5Melt (IbD 1:8) 0.81 0.67 0.94 0.84 0.28 
The data were best fitted with Korsemeyer-Peppas kinetic models for Ibuprofen control and all the 
IbDNaOH conjugates. The n values obtained (Table 58) indicated that for IbD1NaOH, IbD3NaOH, 
IbD4NaOH and IbD5NaOH, the release mechanism was anomalous diffusion where diffusion 
exponent (n) is 0.43 < n < 0.85. IbD2NaOH and Ibuprofen control had n values less than 0.43 
exhibiting Fickian diffusion. 
Table 58 Regression coefficient (r) values of different kinetic models and diffusion exponent (n) of Korsemeyer-Peppas 
models for the release of ibuprofen from DEAE-Dextran conjugates (solubilization). 
Formulation Zero order First Order Higuchi Korsemeyer-Peppas 
 R2 R2 R2 R2 n 
IbNaOH-control 
(IbD 1:0) 
0.61 0.56 0.80 0.88 0.32 
IbD1NaOH (IbD 1:0.5) 0.56 0.46 0.78 0.92 0.44 
IbD2NaOH (IbD 1:1) 0.67 0.53 0.87 0.96 0.37 
IbD3NaOH (IbD 1:2) 0.67 0.48 0.67 0.98 0.54 
IbD4NaOH (IbD 1:4) 0.68 0.52 0.87 0.94 0.51 
IbD5NaOH (IbD 1:8) 0.58 0.44 0.81 0.94 0.47 
 
The data were best fitted with Higuchi kinetic models for all the IbDTw80 conjugates. The n values 
obtained (Table 589) indicated that for all the IbDTw80 nanoconjugates, the release mechanism was 
anomalous (non-Fickian) diffusion where diffusion exponent (n) is 0.43 < n < 0.85. 
Table 59 Regression coefficient (r) values of different kinetic models and diffusion exponent (n) of Korsemeyer-Peppas 
models for the release of ibuprofen from DEAE-Dextran conjugates (solubilization). 
Formulation Zero order First Order Higuchi Korsemeyer-Peppas 
 R2 R2 R2 R2 n 
IbTw80-control 
 (IbD 1:0) 
0.61 0.56 0.80 0.88 0.32 
IbD1Tw80 (IbD 1:0.5) 0.91 0.65 0.99 0.96 0.60 
IbD2Tw80 (IbD 1:1) 0.95 0.66 0.99 0.93 0.60 
IbD3Tw80 (IbD 1:2) 0.89 0.59 0.99 0.98 0.65 
IbD4Tw80 (IbD 1:4) 0.89 0.58 0.99 0.96 0.56 
IbD5Tw80 (IbD 1:8) 0.98 0.74 0.98 0.96 0.57 
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The data were best fitted with the Higuchi kinetic models for IbD1Nic, IbD2Nic and IbD3Nic 
conjugates (lower concentrations of DEAE-Dextran) while IbD4Nic, IbD5Nic and ibuprofen control 
were best fitted with Korsemeyer-Peppas kinetic models.The n values obtained (Table 60) indicated 
that for IbD1Nic, IbD2Nic and IbD3Nic conjugates, the release mechanism was anomalous (non 
Fickian) diffusion where diffusion exponent (n) is 0.43 < n < 0.85, while for IbD4Nic and IbD5Nic a 
Super Case II transport mechanism (where n > 0.85) was exhibited. 
Table 60 Regression coefficient (r) values of different kinetic models and diffusion exponent (n) of Korsemeyer-Peppas 
models for the release of ibuprofen from DEAE-Dextran conjugates (hydrotropy). 
Formulation Zero order First Order Higuchi Korsemeyer-Peppas 
 R2 R2 R2 R2 n 
IbNic-control  
(IbD 1:0) 
0.61 0.56 0.80 0.88 0.32 
IbD1Nic (IbD 1:0.5) 0.86 0.53 0.94 0.86 0.44 
IbD2Nic (IbD 1:1) 0.81 0.45 0.90 0.79 0.48 
IbD3Nic (IbD 1:2) 0.79 0.51 0.92 0.88 0.49 
IbD4Nic (IbD 1:4) 0.35 0.26 0.59 0.95 1.15 
IbD5Nic (IbD 1:8) 0.34 0.27 0.58 0.99 0.98 
 
The data were best fitted with the Korsemeyer-Peppas kinetic models for all the IbChMelt 
conjugates except IbCh4Melt which fitted the Higuchi kinetic model. The n values obtained (Table 
61) indicated that for IbCh2Melt, IbCh3Melt, IbCh4Melt and IbCh5Melt nanoconjugates, the release 
mechanism was anomalous (non Fickian) diffusion where diffusion exponent (n) is 0.43 < n < 0.85. 
The IbCh1Melt nanoconjugate and ibuprofen control had n values less than 0.43 exhibiting Fickian 
diffusion.  
Table 61 Regression coefficient (r) values of different kinetic models and diffusion exponent (n) of Korsemeyer-Peppas 
models for the release of ibuprofen from chitosan conjugates (melt solubilization). 
Formulation  Zero order First Order Higuchi Korsemeyer-Peppas 
 R2 R2 R2 R2 n 
IbMelt-control  
(IbCh 1:0) 
0.61 0.56 0.80 0.88 0.32 
IbCh1Melt  
(IbCh 1:0.125) 
0.67 0.47 0.86 0.91 0.37 
IbCh2Melt  
(IbCh 1:0.25) 
0.64 0.48 0.84 0.93 0.51 
IbCh3Melt (IbCh 1:0.5) 0.58 0.44 0.81 0.94 0.47 
IbCh4Melt (IbCh 1:1) 0.87 0.63 0.98 0.94 0.47 
IbCh5Melt (IbCh 1:2) 0.81 0.59 0.95 0.97 0.51 
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The data were best fitted with the Korsemeyer-Peppas kinetic models for ibuprofen control and all 
the IbChNaOH conjugates.The n values obtained (Table 62) indicated that for all the IbChNaOH 
conjugates,the release mechanism was anomalous (non Fickian) diffusion where diffusion exponent 
(n) is 0.43 < n < 0.85.  
Table 62 Regression coefficient (r) values of different kinetic models and diffusion exponent (n) of Korsemeyer-Peppas 
models for the release of ibuprofen from Chitosan conjugates (solubilization). 
Formulation  Zero order First Order Higuchi Korsemeyer-Peppas 
 R2 R2 R2 R2 n 
IbNaOH-control 
(IbCh 1:0) 
0.61 0.56 0.80 0.88 0.32 
IbCh1NaOH  
(IbCh 1:0.125) 
0.67 0.45 0.87 0.98 0.65 
IbCh2NaOH  
(IbCh 1:0.25) 
0.74 0.54 0.91 0.94 0.57 
IbCh3NaOH 
(IbCh 1:0.5) 
0.71 0.50 0.90 0.96 0.52 
IbCh4NaOH (IbCh 1:1) 0.81 0.58 0.95 0.96 0.50 
IbCh5NaOH (IbCh 1:2) 0.76 0.54 0.93 0.96 0.49 
 
The data were best fitted with the Higuchi kinetic models for IbCh2Tw80, IbCh3Tw80, IbCh4Tw80 
and IbCh5Tw80 conjugates while IbCh1Tw80 was best fitted with Korsemeyer-Peppas kinetic 
models. The n values obtained indicated that for IbCh1Tw80, IbCh2Tw80, IbCh3Tw80 and 
IbCh5Tw80 conjugates, the release mechanism was anomalous (non Fickian) diffusion where 
diffusion exponent (n) is 0.43 < n < 0.85. The IbCh4Tw80 conjugate had n < 0.43 exhibiting Fickian 
diffusion. 
Table 63 Regression coefficient (r) values of different kinetic models and diffusion exponent (n) of Korsemeyer-Peppas 
models for the release of ibuprofen from Chitosan conjugates (solubilization). 
Formulation  Zero order First Order Higuchi Korsemeyer-Peppas 
 R2 R2 R2 R2 n 
IbTw80-control  
(IbCh 1:0) 
0.61 0.56 0.80 0.88 0.32 
IbCh1Tw80  
(IbCh 1:0.125) 
0.82 0.59 0.96 0.99 0.46 
IbCh2Tw80 
(IbCh 1:0.25) 
0.90 0.65 0.99 0.97 0.54 
IbCh3Tw80  
(IbCh 1:0.5) 
0.90 0.68 0.99 0.98 0.46 
IbCh4Tw80 (IbCh 1:1) 0.89 0.68 0.99 0.95 0.41 
IbCh5Tw80 (IbCh 1:2) 0.88 0.69 0.98 0.96 0.43 
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The data were best fitted with the Higuchi kinetic models for IbCh1Nic and IbCh2Nic conjugates 
(lower concentrations of DEAE-Dextran), while IbCh3Nic, IbCh4Nic, IbCh5Nic and ibuprofen control 
were best fitted with Korsemeyer-Peppas kinetic models.The n values obtained (Table 64) indicated 
that for all the IbChNic conjugates, the dominant release mechanism was anomalous (non Fickian) 
diffusion where diffusion exponent (n) is 0.43 < n < 0.85.  
Table 64 Regression coefficient (r) values of different kinetic models and diffusion exponent (n) of Korsemeyer-Peppas 
models for the release of ibuprofen from Chitosan conjugates (hydrotropy). 
Formulation Zero order First Order Higuchi Korsemeyer-Peppas 
 R2 R2 R2 R2 n 
IbNic-control  
(IbCh 1:0) 
0.61 0.56 0.80 0.88 0.32 
IbCh1Nic  
(IbCh 1:0.125) 
0.95 0.64 0.98 0.91 0.53 
IbCh2Nic (IbCh 1:0.25) 0.91 0.59 0.99 0.97 0.56 
IbCh3Nic (IbCh 1:0.5) 0.57 0.47 0.78 0.99 0.48 
IbCh4Nic (IbCh 1:1) 0.57 0.43 0.79 0.99 0.64 
IbCh5Nic (IbCh 1:2) 0.45 0.35 0.67 0.98 0.65 
 
Drug release kinetics showed that the data were best fitted with the Korsemeyer-Peppas models for 
all the ibuprofen-DEAE-Dextran-gellan complexes and ibuprofen control. The n values obtained 
(Table 65) indicated that for the complexes (DG 0:100, DG 25:75 and DG 100:0) and ibuprofen 
control, the release mechanism was anomalous (non-Fickian) diffusion where diffusion exponent (n) 
is 0.43 < n < 0.85; DG 50:50 exhibited Fickian diffusion (n < 0.43) while DG 75:25 exhibited Super 
case II transport (n > 0.85). 
Table 65 Regression coefficient (r) values of different kinetic models and diffusion exponent (n) of Korsemeyer-Peppas 
models for the release of ibuprofen from DEAE-Dextran-Gellan conjugates. 
Formulation Zero order First Order   Higuchi Korsemeyer-Peppas 
 R2 R2 R2 R2 n 
IbDW-control 0.54 0.34 0.74 0.85 0.81 
DG 0:100 0.54 0.39 0.75 0.96 0.64 
DG 25:75 0.71 0.47 0.88 0.92 0.47 
DG 50:50 0.62 0.43 0.81 0.89 0.41 
DG 75:25 0.64 0.36 0.83 0.94 0.90 
DG 100:0 0.47 0.36 0.69 0.96 0.68 
 
Drug release kinetics showed that the data were best fitted with the Korsemeyer-Peppas models for 
all the ibuprofen-chitosan-gellan complexes. The n values obtained (Table 66) indicated that for the 
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complexes CG 0:100, CG 50:50 and CG 75:25, the release mechanism was by anomalous (non-
Fickian) diffusion where diffusion exponent (n) is 0.5 < n < 1; CG 25:75 was by Fickian diffusion (n < 
0.43), while CG 100:0 exhibited Super case II transport (n > 0.85). 
Table 66 Regression coefficient (r) values of different kinetic models and diffusion exponent (n) of Korsemeyer-Peppas 
models for the release of ibuprofen from Chitosan-Gellan conjugates. 
Formulation Zero order First Order Higuchi Korsemeyer-Peppas 
 R2 R2 R2 R2 n 
IbDW-control 0.54 0.34 0.74 0.85 0.82 
CG 0:100 0.45 0.34 0.66 0.96 0.68 
CG 25:75 0.46 0.36 0.67 0.86 0.39 
CG 50:50 0.67 0.44 0.86 0.95 0.51 
CG 75:25 0.60 0.40 0.80 0.91 0.78 
CG 100:0 0.31 0.23 0.52 0.98 0.95 
 
2.3.6. Similarity factor 
The f2 similarity factor was used to compare the drug release profiles of processed ibuprofen control 
(reference) with ibuprofen-DEAE-Dextran or ibuprofen-chitosan nanoconjugates (tests) and the 
mean f2 data was presented in Tables 102 and 103. The f2 values were in the range of 45.27 to 79.53 
for the IbDMelt nanoconjugates. Three nanoconjugates IbD1Melt, IbD3Melt and IbD4Melt were 
higher than the limit value of 50, suggesting a similarity between the test and reference drug release 
profiles. The IbD2Melt and IbD5Melt were lower than the limit value of 50 suggesting dissimilarity 
between the drug release profiles. The f2 values obtained for the IbDNaOH conjugates were lower 
than limit value of 50 (f2 values in the range of 42.38 to 49.41) suggesting dissimilarity of the drug 
release profiles of IbDNaOH conjugates compared to the control. The f2 values obtained for the 
IbDTw80 conjugates were lower than limit value of 50 (f2 values in the range of 35.60 to 40.38) 
suggesting dissimilarity of the drug release profiles of IbDTw80 conjugates compared to the control. 
This implied that the nanoconjugates were not identical with the control. The f2 values obtained for 
the IbDNic conjugates were lower than limit value of 50 (f2 values in the range of 30.61 to 35.21) 
suggesting dissimilarity of the drug release profiles of IbDNic conjugates compared to the control. 
The f2 values obtained were higher than limit value of 50 (f2 values in the range of 49.81 to 95.17) 
except IbCh4Melt suggesting similarity of the drug release profiles of IbChMelt conjugates compared 
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to the control. The f2 values obtained were lower than limit value of 50 (f2 values in the range of 
44.60 to 50.92) except IbCh5NaOH (higher concentration of chitosan) suggesting dissimilarity of the 
drug release profiles of IbChNaOH conjugates compared to the control. The f2 values obtained were 
higher than limit value of 50 (f2 values in the range of 52.35 to 55.96) suggesting similarity of the 
drug release profiles of IbChTw80 conjugates compared to the control. The f2 values obtained were 
lower than limit value of 50 (f2 values in the range of 30.75 to 31.38) suggesting dissimilarity of the 
drug release profiles of IbChNic conjugates compared to the control. 
For the ibuprofen loaded DEAEDextran-Gellan nanoconjugates, all the similarity f2 values obtained 
were lower than the limit value of 50 except DG 25:75 (f2 = 53.02) suggesting dissimilarity of the drug 
release profiles of the conjugates compared with ibuprofen control shown in Table 104. All the 
similarity f2 factor values obtained for the ibuprofen loaded Chitosan-Gellan nanocongates were 
lower than the limit value of 50 except CG 25:75 (f2 = 65.46) suggesting dissimilarity of the drug 
release profiles of the conjugates compared with ibuprofen control (Table 104). 
2.4. Conclusion 
Ibuprofen-polymer binary and ternary nanoconjugates have been prepared from ibuprofen and 
DEAE-Dextran or chitosan and gellan respectively using five techniques. The nanoconjugates were 
characterized using particle size analysis and zeta potential, SEM, FTIR, NMR, DSC and TGA. It was 
evident that conjugation occurred between ibuprofen and each of the polymers via electrostatic and 
hydrophobic interaction as well as hydrogen bonding. The conjugation efficiency was above 89% in 
all techniques employed. All the techniques used in this study decreased the particle size of 
ibuprofen to nanometre ranges in the order IbDTw80 < IbDNic < IbDNaOH < IbDMelt; IbChTw80 < 
IbChMelt < IbChNic < IbChNaOH. The conjugates where spherical particles presented either as 
discrete, or in aggregates with particle sizes within nanometre range and a few in the micrometre 
range as evidenced by the SEM micrographs. The DSC thermograms of the conjugates revealed that 
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lower concentrations (up to 1:1 weight ratio) of the polymer reduced the crystallinity of the 
ibuprofen to 50.99% with respect to melting peaks suggesting increased solubility of the conjugates.  
The hydrotropic conjugation technique exhibited almost complete release profile (99.71 and 
99.28%) at 0.1% DEAE-Dextran and 0.2% chitosan respectively. The least release profile was 
exhibited by the melt solubilization technique for DEAE-Dextran and surfactant solubilization for 
chitosan. Fickian and non-Fickian anomalous mechanisms were deduced for the drug release of 
ibuprofen from the conjugates. In conclusion the five techniques used in this study, successfully 
reduced the particle size of ibuprofen to nanometre range and enhanced the in vitro drug release of 
ibuprofen without the use of organic solvents.  
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CHAPTER THREE 
3.0. Formulation and characterization of Ibuprofen – Polymer ternary 
nanoconjugate hydrogels 
3.1. Introduction 
Hydrogels are three-dimensional hydrophilic polymeric networks with tendency to absorb large 
quantity of water or biological fluids and thus resembling biological tissues [1]. The polymeric 
networks are made up of homopolymers or copolymers and the presence of chemical or physical 
crosslinks renders them insoluble. They exhibit thermodynamic compatibility with water which aids 
their swelling in aqueous media [1].They are classified  based on the nature of their side groups as 
neutral or ionic and based on the physical structures of their networks as amorphous, 
semicrystalline, hydrogen bonded or supermolecular structures [1-2]. Other categories include: 
physiologically responsive hydrogels whose polymer complexes can be broken or networks swollen 
due to changing external environment such as pH, ionic strength, changes in concentration of 
glucose, temperature and electromagnetic radiation [3]. Environmental sensitive hydrogels are also 
referred to as ‘intelligent’ or ‘smart’ hydrogels [4]. They are ideal candidates for developing self 
regulated drug delivery systems [5]. The disadvantage of these smart hydrogels is their slow 
response time; therefore fast acting gels are necessary. 
Hydrogels may require crosslinking to prevent matrix erosion which may affect their solubility. 
Chemical hydrogels are formed by irreversible covalent crosslinking. Crosslinking reagents in trace 
quantities are toxic (glutaraldehyde, epichlorohydrin) [6] and if drug is added before the cross linking 
step, the crosslinker can affect the integrity of the drug entrapped. This has led to the crosslinker 
being replaced by polyelectrolyte complexes since they crosslink by ionic linkages or direct physical 
interactions [7]. Various forces such as van der Waals, electrostatic attraction and hydrogen have 
been reported to be responsible for the physical interaction of polymer chains. These physical 
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hydrogels or polyelectrolyte complex gels are formed by the interaction of positively charged 
polymer with an oppositely charged polyelectrolyte. Positively charged chitosan has been used to 
form polyelectrolyte complex gels by electrostatic interaction with negatively charged 
polyelectrolytes [8]. Saleem et al. reported a non-Fickian diffusion mechanism first order release of 
diltiazem hydrochloride from chitosan-carboxymethylcellulose sodium PEC hydrogel [8].  
Hydrogels have been used extensively for the controlled release of drugs, bioadhesives and 
targetable devices of therapeutic agents [7]. Hydrogels are used as delivery devices to various sites 
such as oral, ocular, nasal, gastrointestinal tract, transdermal and subcutaneous applications. Patel 
and Amiji developed cationic hydrogels composed of freeze-dried chitosan-poly (ethylene oxide) 
(PEO) semi-interpenetrating polymeric network (IPN) loaded with amoxicillin and metronidazole for 
site specific antibiotic delivery [9]. A fast release of the entrapped antibiotics was achieved from 
simulated gastric fluid (SGF) of more than 65% and 59% of amoxicillin and metronidazole 
respectively from the hydrogels after 2 h in SGF.  However, potential applications of polyelectrolyte 
complex hydrogels for controlled drug release are still limited [10]. 
Gellan gum is a linear anionic polysaccharide gelling agent produced by Sphingomonas elodea. It 
consists of tetrasaccharide repeating units of glucose, glucuronic acid and rhamnose in the 2:1:1 
ratio [11]. Gellan can form solid transparent gels at concentrations as low as 0.1% [12]. Gelation of 
gellan is either temperature dependent or cation induced. As temperature decreases, there is a coil 
to double helix transition forming a gel based on pH and ionic strength of the solution. The process 
of  gelation starts with the gellan coil molecules forming double helices with the reduction in 
temperature; and helices aggregate subsequently forming junction zones, leading to system gelation 
[13]. Diethylaminoethyl-Dextran (DEAE-Dextran) is a water soluble polycationic derivative of Dextran 
produced by reacting diethylaminoethyl chloride with Dextran. There is no report showing that 
DEAE-Dextran form gels or films.  
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Gellan gum has been used in controlled release hydrogel with scleroglucan [14]. Theophylline was 
used as the model poorly soluble drug in the preparation of the gellan/scleroglucan hydrogel. The 
controlled delivery system formed exhibited the capability of responding to different environmental 
conditions with potentials for specific applications such as implants for drug delivery. However, little 
information has been focussed on the preparation and characterization of gellan gum and DEAE-
Dextran complex gel. The purpose of this research was to design and develop hydrogel by 
polyelectrolyte complexation of gellan gum and DEAE-Dextran. Poorly soluble drug ibuprofen was 
incorporated as the model drug, to form drug-polymer conjugate and drug-polymer-polymer 
conjugate. 
Ibuprofen is a non-steroidal anti-inflammatory drug used in the treatment of rheumatoid arthritis. It 
is an anionic drug with poor water solubility. Oral delivery of ibuprofen gives side effects such as 
gastric ulceration and bleeding, therefore, topical and transdermal delivery could be alternative 
routes to minimize the gastrointestinal side effects of ibuprofen. Topical (gels) and transdermal 
(dermal patches) improve patient compliance due to reduced dosage frequency. The poor 
permeability of ibuprofen at the skin surface due to the formidable barrier property of the stratum 
corneum may be overcome by the use of drug carriers and penetration enhancers. In this work, a 
series of polymer complexes were prepared in form of hydrogels as carriers for incorporating the 
poorly soluble drug. The complexes were fully characterized and the in vitro drug release evaluated. 
The aim of this study was to develop and characterize a novel PEC hydrogel from gellan gum and 
DEAE-Dextran as a drug carrier for ibuprofen. This research also intends to investigate the effect of 
the PEC on the physicochemical and drug release of ibuprofen from the hydrogel. 
3.2. Materials and methods 
3.2.1. Materials 
Ibuprofen (purchased from Fagron, UK), gellan gum (Phytagel®) and DEAE-Dextran hydrochloride 
(purchased from Sigma-Aldrich, UK), were used as supplied in this study. 
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3.2.2.  Preparation of binary and ternary nanoconjugate hydrogels 
Gellan reference hydrogel (G) was prepared by dispersing 2% gellan powder in distilled water while 
under magnetic stirring until homogeneous and heated up to 90 °C. The pH was adjusted to 6 with 
NaOH (Mettler Toledo pH meter) and left to cool. 
The plain binary hydrogel was prepared by dispersing 2% gellan in distilled water while stirring until 
homogeneous and heated up to 90 °C (Jenway 1000 hotplate and stirrer). The gellan solution was 
transferred into DEAE-Dextran solution at different mixing ratios (2:0.125, 2:0.25, 2:0.5 and 2:1) at 
the same temperature under continuous magnetic stirring. The resulting composite polyelectrolyte 
complex hydrogels were adjusted to pH 6 (Mettler Toledo pH meter) with NaOH and further left to 
cool. These samples will be referred to GDD 2:0.125, GDD 2:0.25, GDD 2:0.5 and GDD 2:1 (Table 67). 
The samples were stored at room temperature until analysis. 
Table 67 Composition of plain gellan and gellan-DEAE-Dextran hydrogels. 
Sample Gellan (%w/v) DEAE-Dextran (%w/v) 
G  2.0 - 
GDD 2:0.125 2.0 0.125 
GDD 2:0.25 2.0 0.25 
GDD 2:0.5 2.0 0.5 
GDD 2:1 2.0 1.0 
All samples were made up to 100 g with distilled water. 
The drug loaded reference hydrogel was prepared by solubilizing 1% ibuprofen in 1 M NaOH. This 
solution was added drop-wisely to a 2% gellan dispersed in distilled water while under magnetic 
stirring at 90 °C (Jenway 1000 hotplate and stirrer).The pH was adjusted to 6 with NaOH (Mettler 
Toledo pH meter). The mixture was continuously stirred and left to cool and referred to as Glb. 
The drug loaded ternary hydrogel was prepared by solubilizing 1% of ibuprofen in 5 mL NaOH. It was 
added drop wise to 2% gellan dispersed in distilled water while stirring at 90 °C (Jenway 1000 
hotplate and stirrer). This was transferred into DEAE-Dextran solution at different mixing ratios 
(2:0.125, 2:0.25, 2:0.5 and 2:1) at the same temperature under continuous magnetic stirring. The 
resulting polyelectrolyte complex (loaded with ibuprofen) hydrogels were adjusted to pH 6 (Mettler 
Toledo pH meter) with NaOH (referred to as GIbDD 2:0.125, GIbDD 2:0.25, GIbDD 2:0.5 and GIbDD 
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2:1 shown in Table 68. The mixture was continuously stirred and left to cool. The samples were 
stored at room temperature until analysis. 
Table 68 Composition of ibuprofen loaded gellan and gellan-DEAE-Dextran gels. 
Sample Ibuprofen 
(%w/v) 
Gellan 
(%w/v) 
DEAE-Dextran 
(%w/v) 
GIb - 2.0 - 
GIbDD 2:0.125 1.0 2.0 0.125 
GIbDD 2:0.25 1.0 2.0 0.25 
GIbDD 2:0.5 1.0 2.0 0.5 
GIbDD 2:1 1.0 2.0 1.0 
All samples were made up to 100 g with distilled water. 
3.2.3. Physicochemical characterization of the plain and drug loaded hydrogels 
3.2.3.1. pH 
One gram (1 g) of gel was dispersed in 100 mL of distilled water and stirred for 2 h. The pH of each 
formulation was determined by a pH meter (Mettler Toledo). All measurements were an average of 
four determinations and expressed as mean ± S.D. 
3.2.3.2. Morphology and size – Scanning electron microscopy 
The surface morphologies of the polymeric hydrogels were examined by a Carl Zeiss SEM EVO High 
Definition 15 (Carl Zeiss, Germany) scanning electron microscope using variable pressure technology 
at low voltages with beam deceleration and high definition backscattered electron (BSE) imaging. 
The hydrogel samples were mounted on double sided carbon tabs that were previously secured to 
aluminium stubs and then analysed at different magnifications and a pressure of 10 Pa. The 
accelerating voltage was 10 KV with probe current of 400 pA. 
3.2.3.3. Spectroscopic analysis - Fourier Transform Infra-red 
The spectra of samples were acquired by a Precisely Spectrum One FTIR spectrometer (PerkinElmer, 
USA) fitted with a Universal ATR Sampling Accessory. The hydrogels were mounted directly on the 
diamond surface and the arm was placed over it by applying enough pressure in the range of 100 to 
120 units. The spectrum was recorded in the wavelength region of 4000 to 650 cm-1.  All spectra 
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were then collected at an average of 16 scans at a resolution of 4 cm-1. All measurements were 
taken in replicates of four determinations. 
3.2.3.4. Thermal studies 
3.2.3.4.1. Differential scanning calorimetry 
DSC was performed using Perkin Elmer Jade DSC machine in conjunction with a Perkin Elmer 
Intracooler SP cooling Accessory (Perkin Elmer, USA) to study the thermal characteristics of 
polymeric hydrogels. The polymeric hydrogel samples of mass 3 mg (±0.5 mg) were heated in 
hermetically sealed aluminium pans under nitrogen flow (40 mL/min) at a scanning rate of 20 ˚C/min 
from 30 to 300 ˚C. Empty aluminium pan was used as a reference pan. Zinc and indium were used as 
the standard reference materials to calibrate the DSC instrument. All measurements were an 
average of four determinations and expressed as mean ± S.D. 
3.2.3.4.2. Thermogravimetric analysis  
Mass changes as a function of temperature in a controlled chamber were studied using Pyris 1 
Thermogravimetric Analyser (Perkin Elmer, USA). The weight of the empty reference pan placed in 
the crucible was zeroed and then removed. Samples of known weight 17 mg (±3 mg) were placed in 
aluminium pans and measurements performed at a scanning rate of 10 ˚C/min in the range of 25 to 
500 ˚C.  All measurements were an average of four determinations and expressed as mean ± S.D. 
3.2.4. Rheological studies of hydrogels  
3.2.4.1. Oscillatory measurements  
Dynamic rheological properties of the plain and drug loaded polymeric complex hydrogels were 
evaluated using a Physica MCR501 rheometer (Anton Paar, Austria) using cone and plate geometry 
(CP50 with 1° angle) in oscillatory mode at 32 °C. Tests were conducted in controlled strain 
amplitude performed within the linear viscoelastic region (LVR) so that the storage (G') and loss (G") 
moduli were independent of strain. A strain sweep measurement between 0.1 and 100% was 
185 | P a g e  
 
conducted first at a frequency of 1 Hz for plain and 1% w/v ibuprofen loaded gellan and gellan-DEAE-
Dextran complex hydrogels at a strain value which was within the linear viscoelastic region for both 
samples was selected for the subsequent frequency sweeps. The strain value selected for all 
polymeric complex hydrogels was 1%. Frequency sweeps at this constant strain were then 
conducted between 0.01 to 50 Hz and a solvent trap was used to prevent sample dehydration during 
the test. All tests were done in replicate of four determinations using fresh sample for each test and 
expressed as mean ± S.D. The rheological parameters examined were processed with pre-installed 
Physica software provided with the rheometer. The flow test was also conducted. 
3.2.4.2. Determination of sol-gel temperature 
The dynamic rheological characterisation of the plain and drug loaded polymeric hydrogel samples 
was evaluated using Physica MCR 501 Rheometer (Anton Paar, Austria) using cone and plate 
geometry (CP50 with 1o angle) in oscillatory mode. Tests were conducted in controlled strain 
amplitude performed within the linear viscoelastic range (LVR) so that the storage (G′) and loss (Gʺ) 
moduli were independent of strain. The tests were carried out at low oscillation frequency of 1 Hz. 
The polymeric complex hydrogel solutions were analysed just after preparation at 90 °C. The hot 
polymeric complex hydrogel solutions were transferred onto the rheometer plate which was 
preheated to 90 °C.The polymeric complex hydrogel solution tests started with the cooling step from 
90 to 15 °C at the rate 2 °C/min. The thermo reversibility of the gels was also studied by increasing 
the temperature from 15 to 90 °C the heating step followed the cooling step at the same conditions 
in the temperature range 15 to 90 °C also at the rate 2 °C/min. A solvent trap was used to prevent 
sample dehydration during the test. All tests were done in replicate of four determinations using 
fresh sample for each test and expressed as mean ± S.D. The data acquired was analysed with pre-
installed Physica software provided with the rheometer. 
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3.2.5. Swelling kinetics 
About 500 mg of polymeric complex hydrogel was carefully weighed and dried in an oven at 60 °C till 
constant weight was achieved. The dried polymeric gel was accurately weighed and immersed in 5ml 
of PBS (pH 7.4) at 37 °C (B Braun Certomat WR Shaker Waterbath, Germany). At predetermined 
intervals, swollen gels were taken out, and the excess surface water removed by blotting with filter 
paper. This was then weighed on a balance. The following equation (equation 1) was used to 
determine the swelling ratio of the gel.  
                                                                                         (1) 
 Where Wd is the weight of dry gel and Ws is the weight of the swollen gel. All measurements were 
an average of four determinations and expressed as mean ± S.D. 
3.2.6. Drug release from the binary and ternary nanoconjugate hydrogels 
Franz cell (Permegear, USA) with diameter 11.28 mm, surface area 1.00 cm2 and receptor volume of 
8 mL was used in this study. Polymeric complex hydrogel of mass 0.5 g was placed into the donor 
chamber on the stratum corneum of the excised pig abdominal skin, with the dermal side facing the 
receptor compartment. The pig abdominal skin was obtained from freshly killed animals in a local 
slaughterhouse (Leicester, UK). After cleaning, full thickness, non-dermatomed skin (about 1.1 mm) 
was removed with a scapel, cut into squares (2.5 x 2.5 cm) were kept in sealed plastic bags then 
stored at -20 °C until ready for use. The samples were thawed 2 h prior to the experiment [15].  The 
pig abdominal skin was conditioned by immersing in receptor medium (PBS with pH 7.4) for 30 min 
and blotted dry prior to use. At a constant temperature of 32 °C (+0.5 °C) which corresponds to the 
skin surface temperature in vivo, 0.2 mL samples were withdrawn at specified collection intervals 
from the receptor fluid via the sampling port over a period of 24 h. 0.2 mL of the receptor fluid was 
replaced via the sampling port to the receptor chamber. The top of the donor compartment of the 
Franz diffusion cells were occluded with Parafilm® to minimise evaporation. The concentrations of 
the active drug released from the gel were determined by UV (ThermoFischer Evolution 60 UV-
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Visible Spectrophotometer, UK) after appropriate dilutions at 264 nm wavelength and passing 
through 0.45 µm filter (Sartorius, Germany). All measurements were an average of four 
determinations and expressed as mean ± S.D. 
3.2.7. Drug release kinetics 
Data obtained from in vitro release studies were fitted to various kinetic equations. The kinetic 
models used are zero order, first order, Higuchi and Korsemeyer-Peppas equation.  
The zero order rate equation (2) describes the systems were the drug release rate is independent of 
its concentration [16]. The cumulative % drug release vs. time plot is made. 
                          (2)  
Where k0 is zero order rate constant expressed in units of concentration/time and t is the time. 
The first order rate equation (3) describes the release from the systems where release rate is 
concentration dependent [17]. The log cumulative % drug release vs. time plot is made. 
                                                                                (3) 
Where C0 is the initial concentration of drug and K is first order constant. 
Higuchi described the release of drugs from insoluble matrix as a square root of time dependent 
process based on Fickian diffusion: equation (4) [18]. The cumulative % drug release vs. square root 
of time is made.  
                                                                                                                                  (4)  
Where K, is the constant and it reflects the design variables of the system. 
Korsemeyer et al. derived a simple relationship which described drug release from a polymeric 
system: equation (5). To find out the mechanism of drug release, first 60 % drug release data was 
fitted in Korsemeyer-Peppas model: 
         
                                                                                                                   (5)  
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Where Mt/M∞ is a fraction of drug released at time t, K is the rate constant and n is the release 
exponent. The n value is used to characterize different release mechanisms [19]. The log cumulative 
% drug release vs. log time plot is made. The criterion for selecting the appropriate model is the 
highest R2 value which indicates linearity of dissolution data [20]. 
3.2.8. Similarity factors 
The similarity fit factor denoted f2 was used to compare the dissolution profiles of the ibuprofen 
loaded gellan-DEAE-Dextran (GIbDD) complex hydrogels (test) and GIb hydrogel (reference). The 
similarity f2 factor is defined by equation 6 proposed by Moore and Flanner [21]: 
 
              
 
 
            –    
 
          
                                                    (6) 
Where n is the number of dissolution sample times, and Rt and Tt are the individual or mean percent 
dissolved at each time point, t, for the reference and test dissolution profiles, respectively. The f2 
value greater than 50 suggests that the two profiles are similar. The f2 value of 100 suggests that the 
test and the reference profiles are identical and as the value becomes smaller the dissimilarity 
between release profiles increases [22]. 
3.2.9. Statistical analysis 
Quantitative data are presented as mean ± standard deviation. The significance of the differences 
between means was assessed using Analysis of Variance (ANOVA) and Post hoc Tukey Test with a 
statistical significance level set at p < 0.05 using IBM SPSS® (Statistical Package for Social Science) 20. 
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3.3. Results and Discussions 
3.3.1. Preparation and optimization of plain and drug loaded binary and ternary 
hydrogels 
The hydrogel formulations were optimized in the preliminary studies with respect to polymer 
concentration, mixing ratio, ibuprofen concentration, pH and temperature. The choice of 2% gellan 
was based on preliminary studies results of its comparison with 1% gellan gel. Polymer 
concentration has been reported to influence the helix content in gellan solutions with increased 
concentration forming stronger physical crosslinking [23]. Gellan gum has the ability to undergo 
physical gelation. It swells when dispersed in water and on application of heat up to 90 °C; forming a 
clear and transparent solution (sol). Subsequent decrease in temperature transformed the sol to gel, 
thus gellan gel was formed. When the temperature of the gellan solution is decreased, the gellan 
chains undergo a conformational thermo-reversible change from random coil to double helices [24]. 
The aggregation of the double helices forms a three dimensional network by hydrogen bonding with 
water. DEAE-Dextran solution, a positively charged polymer, was added to gellan solution 
(negatively charged polymer) at 90 °C to form polyelectrolyte complex GDD gels of different mixing 
ratios. It was observed that after the addition of DEAE-Dextran, the GDD hydrogels were still formed 
in response to temperature decrease. 
 Ibuprofen was initially dissolved in sodium hydroxide NaOH (basic medium) to form anionic drug 
solute. The ionized drug solution was mixed with negatively charged gellan polyelectrolyte solution 
at 90 °C. This mixture was added to an oppositely charged DEAE-Dextran solution forming drug-
polyelectrolyte electrostatic complex gels. 
Pure gellan hydrogel (G) prepared had the highest transparency when visualized and smoothness. 
On addition of ibuprofen to gellan gel, the GIb gels remained transparent. The plain and drug loaded 
polyelectrolyte complex (PEC) gels formed opaque gels. The opacity of the gel increased with 
increasing concentration of oppositely charged DEAE-Dextran. All the gels were uniform in 
190 | P a g e  
 
consistency and showed no appreciable particulate matter (free from grittiness). It is important for 
any topical formulation to be free from grittiness.  
3.3.2. Physicochemical characteristics of plain and drug loaded nanoconjugate 
hydrogels 
3.3.2.1. pH 
The pH of plain and ibuprofen loaded gellan polymeric complex gels was presented in Figure 90 and 
Table 105 in the Appendix I.  
 
Figure 90 The pH of plain and ibuprofen loaded polymeric complex hydrogels. Each data point represents mean ± SD (n = 
4). 
It is important for the gels to be maintained at a stable pH to achieve the homogeneous distribution 
of ibuprofen in the gel matrix. The pH of pure gellan gel (G) was 6.27 and it ranged from 6.04 to 6.20 
for Gellan-DEAE-Dextran complex gels. While the pH ranged from 5.90 to 5.95 for the ibuprofen 
loaded Gellan-DEAE-Dextran complex gels and 5.99 for GIb gels. The addition of ibuprofen caused a 
little decrease in pH. The pH of the final gels was adjusted to pH 6, which explains why all the gels 
were about pH 6. 
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3.3.2.2. Morphology and size – Scanning electron microscopy  
The morphology of plain and drug loaded hydrogels was analyzed by SEM. The surface micrographs 
of plain and ibuprofen loaded Gellan-DEAE-Dextran PEC hydrogels are presented in Figure 91 and 92. 
The micrograph of plain gellan reference (G) gel showed strand-like smooth compact structured 
surface while the GDD gels showed crinkled rough surfaces in Figure 91. 
 
Figure 91 Scanning electron micrograph  of  gellan and gellan-DEAE-Dextran complex gels (A) plain gelan G, (B) gellan-
DEAE-Dextran complex gel GDD 2:0.125, (C) GDD 2:0.25, (D) GDD 2:0.5 and  (E) GDD 2:1 
The ibuprofen loaded gellan GIb gel showed whitish ibuprofen dispersed through the gel while the 
GIbDD complex gels showed almost sphere-like shapes on the surface of their meshwork in Figure 
92. The complex aggregate observed was due to the presence of ibuprofen and DEAE-Dextran in the 
gel matrix. The spherical patches increased in size and sphericalness in the micrometre range with 
A B 
C D 
E 
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increasing concentration of DEAE-Dextran. The spherical patch sizes exhibited were 43.67 ± 9.13 µm 
(GIbDD 2:0.125), 33.26 ± 9.27 µm (GIbDD 2:0.25), 42.58 ± 6.68 µm (GIbDD 2:0.5) and 82.85 ± 8.13 
µm (GIbDD 2:1). 
 
Figure 92 Scanning electron micrographs of  ibuprofen loaded gellan and gellan-DEAE-Dextran complex gels (A) 
ibuprofen loaded GIb, (B) ibuprofen loaded gellan-DEAE-Dextran GIbDD 2:0.125, (C) GIbDD 2:0.25, (D) GIbDD 2:0.5,  (E) 
GIbDD 2:1. 
3.3.2.3. Spectroscopic studies – Fourier Transform Infra-Red (FTIR) 
The FTIR spectra of pure ibuprofen, gellan gum, DEAE-Dextran, and the complex gel formulations 
were obtained and shown in Figure 93 and 94 with band positions shown in Table 69 and 70. 
Gellan showed significant peaks at 3306 cm-1, 1602 cm-1, 1408 cm-1 and 1020 cm-1. The peak 
assignments of gellan has also been described by Sudhamani et al. [25]. The peak at 3306 cm-1 is 
A B 
C D 
E 
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assigned to hydroxyl stretching. Gellan gum has hydroxyl and carboxyl groups in its structure capable 
of undergoing a nucleophilic substitution reaction with DEAE-Dextran as described for the 
methacrylation of gellan gum (GG-MA) with the most favourable reaction being with the carboxyl 
group [26]. The peaks at 1602 cm-1 and 1408 cm-1 are assigned to the characteristic absorption band 
of carboxyl group in gellan gum [27]. The peak at 1020 cm-1 is assigned to C-O stretching. Pure DEAE-
Dextran showed significant peaks at 3295 cm-1, 2921 cm-1, 1641 cm-1, 1342 cm-1 and 1007 cm-1. Pure 
DEAE-Dextran showed N-H deformation vibration at 1641 cm-1. This peak is assigned to the free N-H 
group present on DEAE-Dextran. The peaks at 2921 cm-1 and 3295 cm-1 are assigned to N-H 
stretching and C-H stretching vibrations. The peaks at 1342 cm-1 and 1007 cm-1 are assigned to 
methyne C-H bending and C-N stretching respectively. The peaks at 3318 cm-1, 2163 cm-1, 2080 cm-1 
and 1601 cm-1 in pure gellan shifted to 3285 cm-1, 2214 cm-1, 2108 cm-1 and 1638 cm-1 in the plain 
gellan reference G hydrogel. The peaks at 2897 cm-1, 2324 cm-1, 2018 cm-1, 1974 cm-1, 1403 cm-1, 
1295 cm-1, 1198 cm-1, 1021 cm-1, 891 cm-1, 836 cm-1 and 806 cm-1 in gellan disappeared in the gellan 
reference G hydrogel. 
The -OH stretching peak at 3318 cm-1 in pure gellan and at 3309 cm-1 in DEAE-Dextran shifted to a 
range of 3277 to 3285 cm-1 in the GDD hydrogels. The N-H deformation peak at 1644 cm-1 in DEAE-
Dextran and carboxyl group peak at 1601 cm-1 in gellan shifted to a range of 1631 to 1638 cm-1 in 
GDD gels. Additional peak at 1491 cm-1 was exhibited in GDD 2:0.125 and GDD 2:0.25 hydrogels. The 
C-C stretching peak at 1456 cm-1 in DEAE-Dextran shifted to 1491 cm-1 in the hydrogels with lower 
concentrations of DEAE-Dextran. The peak at 1491 cm-1 disappeared in GDD complex hydrogels with 
high concentrations of DEAE-Dextran in GDD 2:0.5 and GDD 2:1 hydrogels. Features of DEAE-Dextran 
became increasingly prominent in the complex gels with increasing concentration of DEAE-Dextran. 
GDD 2:0.5 and GDD 2:1 showed additional peaks at 1071 cm-1, 1238 cm-1, 1293 cm-1, 1370 cm-1 and 
1411 cm-1 contributed by gellan and DEAE-Dextran powders. The C-H stretching peak at 2922 cm-1 in 
DEAE-Dextran shifted to 2929 cm-1 and 2941 cm-1 in GDD 2:0.5 and GDD 2:1 hydrogels. The shifts and 
disappearances in peak suggest an interaction between gellan and DEAE-Dextran. 
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Figure 93 The FTIR spectra gellan and gellan-DEAE-Dextran PEC gels (a) plain gellan gel G (b) gellan-DEAE-Dextran gel 
GDD 2:0.125 (c) GDD 2:0.25 (d) GDD 2:0.5 (e) GDD 2:1 (f) gellan powder-reference (g) DEAE-Dextran powder-reference. 
Table 69 FTIR spectral characteristics of gellan and plain gellan-DEAE-Dextran complex gels. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Gellan-reference 3318 2897 
2324 
2163 
2080 
2018 
1974 
1601 
1403 
1295 
1198 
1019 
891 
836 
806 
DEAE-Dextran 
reference 
3309 2922 
2656 
2487 
2287 
2245 
2161 
2145 
2081 
2018 
2010 
1981 
1644 
1456 
1399 
1343 
1269 
1144 
1102 
1007 
 
915 
844 
797 
760 
G  3285 2214 2108 1638   
GDD 2:0.125  3285 2099 
2003 
1988 1638 1491  
GDD 2:0.25 3286 2213 
2170 
2100 
1988 
1638 1491  
GDD 2:0.5 3277 2929 
2382 
2322 
2170 
2099 
1964 
1631 
1410 
1370 
1340 
1293 
1238 
1150 
1103 
1071 
1035 
946 
920 
GDD 2:1 3902 
3284 
2941 
2382 
2147 
2113 
1988 
1634 
1411 
1369 
1340 
1293 
1238 
1151 
1103 
1071 
1017 
 
The bands assigned as the  finger prints of ibuprofen in literature include 2992 cm-1, 1706 cm-1 
(carboxylic acid), 1230 cm-1  and 779 cm-1 [28-29]. The peak at 2992 cm-1 is assigned to the C-H 
stretching. The peak at 1706 cm-1 is assigned to strong carbonyl band absorbance which corresponds 
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to the carboxyl group present in ibuprofen. The peaks at 1230 cm-1 and 779 cm-1 are assigned to 
skeletal C-C vibration and aromatic C-H bending. The other peaks in the region 1200 to 1000 cm-1 are 
contributions from the benzene ring. All these major peaks in ibuprofen were absent in the GIb and 
GIbDD gels.  Ibuprofen loaded gellan gel GIb exhibited new peaks at 3902 cm-1, 3749 cm-1,2383 cm-1, 
2126 cm-1, 1637 cm-1 and 1491 cm-1. The C=O, C=C and C-C stretching peaks at 1710 cm-1 (carbonyl), 
1563 cm-1 and 1229 cm-1  for pure ibuprofen disappeared in the spectra of ibuprofen loaded GIb and 
GIbDD hydrogels. This suggests a new product has been formed based on interaction of ibuprofen 
with the polymers as confirmed by the DSC thermograms of the complex gels exhibiting a single 
melting peak.  
The peaks at 3318 cm-1 in pure gellan and at 3309 cm-1 DEAE-Dextran shifted to a range of 3296 to 
3320 cm-1 in the GIbDD gels.The N-H deformation peak at 1644 cm-1 in DEAE-Dextran and carboxyl 
peak at 1601 cm-1 in gellan shifted to a range of 1635 to 1637 cm-1 in the GIbDD hydrogels.  
 
 
Figure 94 The FTIR spectra of ibuprofen incorporated into polymer complex gels (a) ibuprofen loaded gellan gel GIb (b) 
ibuprofen gellan-DEAE-Dextran complex gel GIbDD 2:0.125 (c) GIbDD 2:0.25 (d) GIbDD 2:0.5 (e) GIbDD 2:1 (f) Ibuprofen 
powder-reference (g) gellan powder-reference (h) DEAE-Dextran powder-reference. 
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Table 70 Spectral characteristics at various wavelengths for gellan, DEAE-Dextran and ibuprofen complex GIbDD 
hydrogels. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Ibuprofen-reference 3088 
3044 
3015 
2991 
2980 
 
2954 
2922 
2868 
2851 
2728 
2631 
2601 
2542 
2203 
2163 
2144 
2115 
2079 
1911 
1887 
1803 
1706 
1563 
1507 
1461 
1451 
1442 
1418 
1379 
1365 
1329 
1321 
1305 
1268 
1229 
1183 
1168 
1123 
1092 
1073 
1068 
1008 
969 
935 
880 
865 
849 
834 
820 
810 
779 
746 
690 
667 
Gellan-reference 3318 2897 
2324 
2163 
2080 
2018 
1974 
1601 
1403 
1295 
1198 
1019 
891 
836 
806 
DEAE-Dextran 
reference 
3309 
2922 
 
2656 
2487 
2287 
2240 
2161 
2145 
2081 
2018 
2010 
1981 
1644 
1456 
1399 
1343 
1269 
1144 
1102 
1007 
 
915 
844 
797 
760 
GIb  3902 
3749 
3284 
2383 
2126 1637 
1491 
1473 
1396 
1368 
GIbDD 2:0.125  3314 2147 
2109 
1984 
1974 
1635 
1461 
1396 
1230 
1152 
1041 
GIbDD 2:0.25 3305 2128  1635 
1459 
1396 
1151 
1105 
1042 
GIbDD 2:0.5 3296 2362 
2109 
 1635 
1397 
1151 1041 
GIbDD 2:1 3320 2150 1957 1637 
1396 
1151 1015 
3.3.2.4. Thermal analysis 
3.3.2.4.1. Differential scanning calorimetry 
The DSC thermal characteristics of plain (G) and binary (GDD) hydrogels were compared with pure 
gellan and DEAE-Dextran and presented in Figure 137 and Table 90. Pure gellan powder exhibited a 
broad melting peak at 127.86 °C and exothermic decomposition peak at 254.84 °C. DEAE-Dextran 
showed a small peak at 57.26 °C which indicated its glass transition endotherm (Tg); a broad 
endothermic peak at 124.05 °C due to its amorphous characteristic; a small peak at 201.21 °C and a 
final peak at 268.50 °C attributed to the decomposition of DEAE-Dextran. 
The DSC thermograms of hydrogels exhibited one endothermic melting peak for plain reference 
gellan hydrogel (G) at 114.2 °C and the GDD hydrogels ranged from 99.8 to 115.3 °C shown in Table 
71 which indicated that the two polymers merged into one peak. This was a shift to lower values 
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from the melting peak shown by gellan powder reference at 127.9 °C, DEAE-Dextran powder 
reference at 124.1 °C which suggested the miscibility or compatibility of gellan and DEAE-Dextran.  
Table 71 DSC of plain gellan and gellan - DEAE-Dextran PEC gels. Each value represents mean ± SD (n = 4). 
Formulation Onset (°C) Peak (°C) End (°C) Delta H (J/g) Area (mJ) 
Gellan-reference 77.70±1.55 
246.56±12.37 
127.86±7.43 
264.02±12.75 
186.32±8.76 
270.88±12.86 
168.31±8.81 
-129.64±6.5 
1043.54±52.70 
-803.81±40.22 
DEAE-Dextran-
reference 
53.55±0.85 
87.43±1.22 
187.42±8.23 
245.83±12.74 
57.86±0.76 
124.05±4.16 
201.54±10.58 
268.50±11.78 
63.97±0.92 
158.87±5.34 
210.60±11.45 
281.53±13.66 
5.10±0.08 
139.17±5.64 
12.72±0.84 
70.84±0.92 
35.16±0.41 
960.30±40.48 
87.74±1.25 
488.852±21.22 
G  98.13±3.21 114.15±5.17 119.56±4.78 1392.94± 57.51 3900.23±208.43 
GDD 2:0.125  101.62±4.32 115.26±4.96 121.60±6.38 1535.61±74.38 5067.50±312.19 
GDD 2:0.25 101.68±4.28 112.11±4.35 120.70±5.86 1324.11±43.10 4237.14±261.76 
GDD 2:0.5 101.89±3.84 114.94±5.08 128.60±5.45 1092.03±41.22 3494.47±188.73 
GDD 2:1 70.75±1.67 99.83±3.36 113.26±4.20 299.34±18.78 927.96±38.04 
 
 
Figure 95 DSC thermograms of gellan and gellan-DEAE-Dextran PEC gels (a) plain gellan reference G (b) GDD 2:0.125 (c) 
GDD 2:0.25 (d) GDD 2:0.5 (e) GDD 2:1 (f) gellan powder-reference (g) DEAE-Dextran powder-reference. 
The melting peak and enthalpy change profiles of plain and ibuprofen loaded binary and ternary 
hydrogels were presented in Figures 96 and 97 respectively.  The melting peak profile of GDD 
hydrogels exhibited two maxima values at 0.125 and 0.5% of DEAE-Dextran with increasing DEAE-
Dextran concentration. While the melting peak profile of GIbDD hydrogels initially increased to 
maximum value at 0.125% DEAE-Dextran and then decreased with increasing DEAE-Dextran 
concentration. The DSC enthalpy profiles of GDD and GIbDD hydrogels initially increased to 
maximum values at 0.125% and then decreased steadily with increasing DEAE-Dextran 
concentration. 
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Figure 96 DSC melting peak profile of plain and ibuprofen loaded gellan and gellan - DEAE-Dextran PEC gels. Each data 
point represents mean ± SD (n = 4). 
 
Figure 97 DSC enthalpy profile of plain and ibuprofen loaded gellan and gellan - DEAE-Dextran PEC gels. Each data point 
represents mean ± SD (n = 4). 
DSC thermograms of ibuprofen loaded gellan, gellan-DEAE-Dextran hydrogels were presented in 
Figure 142 and Table 9272. The DSC thermograms of Ibuprofen showed characteristic sharp 
endothermic peak at 80.07 °C suggesting its crystallinity, with enthalpy of fusion of 118.64 J/g. This 
melting peak is higher than the literature value for pure ibuprofen in the range of 75 to 78 °C [30]. 
This could be due to some impurity in the ibuprofen sample however in a similar study, Kumar et al. 
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reported that the melting peak of ibuprofen was 82.76 °C [31], while gellan and DEAE-Dextran 
showed endothermic peaks at 127.86 °C and 124.05 °C respectively. The endothermic peaks were 
exhibited by GIb at 107.9 °C and the GIbDD gels ranged from 100.4 to 112.3 °C as shown in Table 72. 
The sharp endothermic peak exhibited by ibuprofen at 82.7 °C corresponding to its melting point 
completely disappeared in the ibuprofen loaded gellan GIb and GIbDD complex hydrogels shown in 
Figure 98 suggesting an interaction between the drug and the polymer. 
Table 72 DSC of ibuprofen loaded polymer complex (Gellan-DEAE-Dextran) gels. Each value represents mean ± SD (n = 4) 
Formulation Onset (°C) Peak (°C) End (°C) Delta H (J/g) Area (mJ) 
Ibuprofen-
reference 
76.85±0.64 
236.27±11.36 
82.69±2.46 
264.63±19.41 
86.79±3.27 
273.47±17.20 
92.90±4.32 
203.71±18.79 
826.37±55.04 
1753.15±74.65 
Gellan-reference 77.70±1.55 
246.56±12.37 
127.86±7.43 
264.02±12.75 
186.32±8.76 
270.88±12.86 
168.31±8.81 
-129.64±6.5 
1043.54±52.70 
-803.81±40.22 
DEAE-Dextran-
reference 
53.55±0.85 
87.43±1.22 
187.42±8.23 
245.83±12.74 
57.86±0.76 
124.05±4.16 
201.54±10.58 
268.50±11.78 
63.97±0.92 
158.87±5.34 
210.60±11.45 
281.53±13.66 
5.10±0.08 
139.17±5.64 
12.72±0.84 
70.84±0.92 
35.16±0.41 
960.30±40.48 
87.74±1.25 
488.852±21.22 
GIb  95.14±3.87 107.88±4.10 115.67±4.75 745.30±37.45 2161.36±91.94 
GIbDD 2:0.125  101.64±4.06 112.27±4.68 119.57±5.32 1156.40±43.70 3469.19±188.52 
GIbDD 2:0.25 101.87±4.62 112.11±4.85 118.52±5.41 1060.11±45.25 2968.32±146.37 
GIbDD 2:0.5 96.45±3.82 107.72±4.96 114.36±4.96 749.15±39.04 2172.54±112.74 
GIbDD 2:1 78.66±1.79 100.41±4.21 107.72±4.65 374.65±21.96 1086.49±48.36 
 
 
Figure 98 DSC thermograms of ibuprofen incorporated into polymer complex gels (a) ibuprofen loaded gellan GIb (b) 
ibuprofen loaded gellan-DEAE-Dextran GIbDD 2:0.125 (c) GIbDD 2:0.25 (d) GIbDD 2:0.5 (e) GIbDD 2:1 (f) Ibuprofen 
powder-reference (g) gellan powder-reference (h) DEAE-Dextran powder-reference. 
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3.3.2.4.2. Thermogravimetric analysis 
TGA analysis was conducted to examine the thermal stability of the polymer gels as presented in 
Figure 99 and 100; Table 73 andTable 74. Gellan powder showed two steps of inflection at 90.4 °C 
and 264.9 °C with corresponding weight losses of 7.9% and 59.7%. DEAE-Dextran showed two steps 
of inflection at 77.47 °C and 272.15 °C with corresponding weight losses of 6.94% and 67.61%. The 
first weight loss below 150 °C was attributed to loss of free or loosely bound water while the second 
weight loss was due to the decomposition of the polymers. The plain gellan reference G hydrogel 
showed two steps of inflection at 100 °C and 257 °C with corresponding weight losses of 97.17%, and 
2.14% respectively. The GDD gels also exhibited two steps of inflection ranging from 106.5 °C to 
108.7 °C and 251.8 °C to 258.3 °C; with corresponding weight losses ranging from 97.20 to 97.70% 
and from 2.00 to 2.80%. The total weight loss exhibited by G hydrogel was 99.30% and for GDD gels 
was in the range of 99.60 to 100%. The prepared hydrogels lost their high moisture content faster 
when compared to the individual polymer powders. It showed that the hydrogels main constituent 
was water. The plain gellan G gel was able to withstand more heat when compared to the GDD 
complex gels. 
Table 73 TGA of plain gellan and gellan-DEAE-Dextran PEC hydrogels. Each value represents mean ± SD (n = 4). 
Formulation Onset (°C) End (°C) Step of inflection (°C) Delta Y (%) 
Gellan-reference 43.99 ±0.65 
257.79 ±12.21 
131.17 ±4.72 
282.29 ±12.74 
90.39 ±3.15 
264.91 ±12.10 
7.85 ±0.08 
59.67 ±0.93 
DEAE-Dextran-reference 47.16 ±0.47 
261.20 ±11.43 
106.74 ±4.32 
301.16 ±15.72 
77.47 ±1.47 
272.15 ±12.62 
6.94 ±0.12 
67.61 ±0.98 
G  59.47 ±0.56 
253.10 ±12.11 
133.66 ±2.07 
280.60 ±13.18 
100.00 ±3.78 
257.03 ±12.65 
97.17 ±3.12 
2.14 ±0.01 
GDD 2:0.125  69.75 ±1.05 
237.64 ±12.25 
122.59 ±5.13 
281.77 ±13.65 
107.86 ±4.19 
251.77 ±13.18 
97.34 ±3.24 
2.37 ±0.01 
GDD 2:0.25 71.78 ±1.13 
241.82 ±12.54 
116.47 ±4.62 
280.15 ±12.68 
107.14 ±4.02 
251.68 ±12.95 
97.18 ±2.98 
2.43 ±0.01 
GDD 2:0.5 70.79 ±1.05 
233.80 ±11.63 
116.12 ±4.55 
293.20 ±12.76 
108.69 ±4.18 
254.19 ±12.74 
97.70 ±2.66 
2.76 ±0.02 
GDD 2:1 71.59 ±1.12 
235.33 ±10.86 
115.74 ±4.31 
299.01 ±12.84 
106.51 ±3.94 
258.31 ±12.46 
97.74 ±3.40 
2.02 ±0.01 
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Figure 99 TGA thermogram of plain gellan and gellan-DEAE-Dextran PEC gels (a) plain gellan reference G (b) gellan-DEAE-
Dextran complex GDD 2:0.125 (c) GDD 2:0.25 (d) GDD 2:0.5 (e) GDD 2:1 (f) gellan powder-reference (g) DEAE-Dextran 
powder-reference. 
Ibuprofen exhibited one step of inflection at 240.76 ˚C attributed to the heat of decomposition of 
the drug or disintegration of the molecular chains with a complete weight loss of 99.50%; while 
gellan and DEAE-Dextran powder reference exhibited two steps of inflection with a total weight loss 
of 67.52% and 74.55% respectively. The ibuprofen loaded gellan GIb gel showed two steps of 
inflection at 91.9 °C, and 282.8 °C with corresponding weight losses of 94.60%, and 4.10% 
respectively. The GIbDD gels also exhibited two steps of inflection ranging from 86.4 to 109.6 °C and 
246.8 to 256.5 °C; with corresponding weight losses ranging from 94.60 to 96.70% and from 2.60 to 
4.00%. The first high percentage weight loss was due to loss of loosely bound water in the hydrogel 
while the second low percentage weight loss was due to decomposition of the polymer complexes. 
The GIb hydrogel was able to withstand more heat than the GIbDD complex hydrogels. 
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Table 74 TGA of ibuprofen incorporated into gellan and gellan-DEAE-Dextran PEC hydrogels. Each value represents mean 
± SD (n = 4). 
Formulation Onset (°C) End (°C) Inflection step (°C) Delta Y (%) 
GIb  55.94 ±0.82 
270.43 ±12.31 
105.00 ±3.96 
303.73 ±13.66 
91.86 ±3.14 
282.82 ±12.75 
94.58 ±3.06 
4.11 ±0.02 
GIbDD 2:0.125  60.09 ±0.74 
228.55 ±11.16 
131.44 ±4.87 
275.73 ±12.25 
101.47 ±3.78 
249.75 ±11.62 
95.44 ±3.12 
2.36 ±0.01 
GIbDD 2:0.25 67.81 ±0.71 
236.72 ±11.40 
120.64 ±4.62 
274.85 ±12.14 
103.04 ±3.22 
254.67 ±11.70 
95.60 ±2.98 
2.90 ±0.01 
GIbDD 2:0.5 52.61 ±0.61 
231.68 ±11.24 
127.61 ±4.88 
294.82 ±12.67 
86.44 ±2.35 
246.79 ±10.94 
96.67 ±2.86 
3.28 ±0.02 
GIbDD 2:1 69.06 ±0.66 
209.81 ±11.10 
119.75 ±4.32 
358.79 ±13.48 
109.63 ±3.47 
256.52 ±11.02 
94.56 ±2.74 
4.04 ±0.02 
Ibuprofen-reference 207.81 ±11.23 247.08 ±11.87 240.76 ±12.32 99.50 ±1.95 
Gellan-reference 43.99 ±0.65 
257.79 ±12.21 
131.17±4.72 
282.29±12.74 
90.39 ±3.15 
264.91 ±12.10 
7.85 ±0.08 
59.67 ±0.93 
DEAE-Dextran-reference 47.16 ±0.47 
261.20 ±11.43 
106.74 ±4.32 
301.16 ±15.72 
77.47 ±1.47 
272.15 ±12.62 
6.94 ±0.12 
67.61 ±0.98 
 
 
Figure 100 TGA thermograms of ibuprofen incorporated into polymer complex gels (a) ibuprofen loaded gellan GIb (b) 
ibuprofen loaded gellan-DEAE-Dextran GIbDD 2:0.125 (c) GIbDD 2:0.25 (d) GIbDD 2:0.5 (e) GIbDD 2:1 (f) Ibuprofen 
powder-reference (g) gellan powder-reference (h) DEAE-Dextran powder-reference. 
3.3.3. Rheological studies 
3.3.3.1. Oscillatory measurements 
Rheology is the science of the deformation and flow of matter.  It is useful in the monitoring of 
gelation (crosslinking) and microstuctural changes in a material allowing materials to be probed in 
‘at rest’ conditions without disruption of the microstructure [32]. Rheological studies were carried 
out on all formulations of gellan, plain GDD complex and ibuprofen loaded polymer GIbDD complex 
hydrogels. It measured the viscoelastic response of the gels to an applied strain. 
Rheological properties are used to describe the flow characteristics and textural behaviour of 
materials. The storage modulus – elastic part (G′), loss modulus - viscous part (G"), complex viscosity 
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(η*) and loss tangent (δ) were measured in oscillation mode. The storage or elastic modulus is the 
measure of how structured a material is and its ability of the material to store energy. The loss or 
viscous modulus is the ability of the material to dissipate energy. The loss tangent is the ratio of 
energy lost to energy stored, in the cyclic deformation (the ratio of G"/ G′). When tan δ < 1 (because 
G′ > G") means a prevalent elastic behaviour and or gel state. 
The strain amplitude values were verified to ensure that all the rheological measurements were 
performed within the viscoelastic range, with the storage (G′) and the loss (G") moduli being 
independent of the strain [33]. The linear viscoelastic region can be observed in Figure 101 where G′ 
and G" are both linear across the strain range 0.1 to 50% suggesting that a strain of 1% could be 
used for all gellan hydrogel formulations measurements. G′ and G" are linear up to about 50%. 
Beyond the linear viscoelastic (LVE) range, the G′ and G" abruptly decreased indicating that the 
structural breakdown occurred as a consequence of large deformations imposed [34]. The results 
showed that G′ > G" for all samples in the LVE range exhibiting prevalence of the elastic behaviour 
over the viscous behaviour. 
 
 
Figure 101 Strain amplitude sweeps of G′ and G" with linearity at strain of 1% for plain gellan reference G hydrogel. 
After the gels linear viscoelastic range was defined by a strain sweep, the gels were further 
characterized using frequency sweep. Figures 102 to 105 below showed the behaviour of viscoelastic 
parameters G′, G", η* and tan δ when subjected to frequency oscillation sweep across a frequency 
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range of 0.1 to 50 Hz at a strain of 1% at 32 °C for plain gellan gel, gellan-DEAE-Dextran GDD complex 
gels and ibuprofen loaded GIbDD complex gels. Figures 102 and 103 showed an increase in G′ and G" 
of the hydrogels as the frequency increased across the frequency range. The storage modulus G′ 
solid-like characteristics of all the hydrogels tested; predominated over the loss modulus G" liquid-
like characteristics. 
The GDD complex gels exhibited  an increase in G′ (elastic modulus) in ascending order through G < 
GDD 2:1 < GDD 2:0.125 < GDD 2:0.25 < GDD 2:0.5 with GDD 2:0.5 exhibiting the highest G′ value 
(elasticity) at frequency of 1 Hz mid way  through the frequency sweep shown in Figure 102A. Across 
the frequency range, G′ increased sharply from 0.05 to 1 Hz (at low frequency) and slowly increased 
till 50 Hz for G, GDD 2:0.125 and GDD 2:0.25 gels; while G′ increased steadily across the frequency 
range for GDD 2:0.5 and GDD 2:0.1. The plain gellan G, GDD 2:0.125 and GDD 2:0.25 (lower 
concentrations of DEAE-Dextran) hydrogels required a higher frequency to assume the solid-like 
state characterized by the sharp increase in G′ to achieve a similar response when compared to the 
GDD 2:0.5 and GDD 2:0.1 (higher concentrations of DEAE-Dextran) hydrogels. 
 Addition of ibuprofen to plain gellan G gel, the G′ of GIb gel was higher when compared to plain G 
gel at low frequency from 0.05 to 1 Hz, and the G′ of GIb gel became lower than G gel at higher 
frequency between 1 and 50 Hz. While with GIbDD complex gel, the G′ increased across the 
frequency range of 0.05 to 50 Hz in ascending order through  GIb < GIbDD 2:0.125 <  GIbDD 2:0.25 < 
GIbDD 2:0.5 < GIbDD2:1 shown in Figure 102B. The addition of DEAE-Dextran increased the elasticity 
of the gels as the concentration of DEAE-Dextran increased which suggests the enhancement of their 
elasticity and a clear indication of the improvement on the three dimensional network stability.  The 
formulations with lesser G′ showed a less solid-like behaviour, hence are less elastic in viscoelastic 
character. A near plateau was achieved for all the hydrogels towards the end of the frequency range 
(50 Hz) suggesting a stable polymer network. 
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Figure 102 Storage modulus profiles across a frequency range of 0.01 to 50 Hz at 32°C for (A) plain gellan G and GDD 
complex gels and (B) Ibuprofen loaded gellan GIb and GIbDD complex gels. Each data point represents mean ± S.D (n = 
4). 
The GDD complex gels exhibited an increase in G" in ascending order through G < GDD 2:1 < GDD 
2:0.125 < GDD 2:0.25 < GDD 2:0.5; with GDD 2:0.5 exhibiting the highest G" value (viscous) at 
frequency of 1 Hz shown in Figure 103A. Across the frequency range, G" increased sharply from 0.05 
to 1Hz and slowly increased till 50 Hz for G, GDD 2:0.125 and GDD 2:0.25 gels; while G" increased 
steadily across the frequency range for GDD 2:0.5 and GDD 2:1. In the GIbDD complex gels, the G" 
increased slowly across the frequency range of 0.05 to 50Hz in ascending order through G < GIbDD 
2:0.125 < GIbDD 2:0.25 < GIbDD 2:0.5 < GIbDD2:1 shown in Figure 103B. The addition of DEAE-
Dextran increased the storage moduli of ibuprofen loaded GIbDD complex gels with increasing 
concentration of DEAE-Dextran. 
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Figure 103 Loss modulus profiles across a frequency range of 0.01 to 50 Hz at 32 °C for (A) plain gellan G and GDD 
complex gels and (B) Ibuprofen loaded gellan GIb and GIbDD complex gels. Each data point represents mean ± S.D (n=4). 
The flow behaviour of the gels in Figure 104A and 104B showed that for G, and low concentrations 
of DEAE-Dextran GDD 2:0.125 and GDD 2:0.25 gels, there was an initial increase in complex viscosity 
followed by a decrease across the frequency range while complex viscosity for GDD 2:0.5, GDD 2:1 
and GIbDD gels decreased steadily across the frequency, suggesting pseudoplastic behaviour. 
With reference to GDD complex gels, complex viscosity increased in ascending order through G < 
GDD 2:1 < GDD 2:0.125 < GDD 2:0.25 < GDD 2:0.5; with GDD 2:0.5 exhibiting the highest complex 
viscosity trend shown in Figure 104A. Complex viscosity decreased across the frequency range in 
ibuprofen loaded GIbDD complex gels. In GIbDD complex gels, complex viscosity increased in 
ascending order through GIb < GIbDD 2:0.125 < GIbDD 2:0.25 < GIbDD 2:0.5 < GIbDD 2:1; with GIbDD 
2:1 exhibiting the highest complex viscosity trend shown in Figure 104B. These results showed an 
increase in the complex viscosity frequency sweep profiles as DEAE-Dextran content was increased.  
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Figure 104 Complex viscosity profiles across a frequency range of 0.01 to 50 Hz at 32 °C for (A) plain gellan G and GDD 
complex gels and (B) Ibuprofen loaded gellan GIb and GIbDD gels. Each data point represents mean ± S.D (n = 4). 
Tan delta (δ) is the ratio of energy loss to energy stored which gives the overall viscoelasticity of the 
sample [35]. Therefore as tan δ becomes smaller, the elasticity of the material increases, but the 
viscous behaviour is reduced [36]. 
The tan δ frequency sweep profiles for all the formulations were below 1 (Figure 105A and Figure 
105B) indicating that all samples were gels with dominant elastic (solid like) behaviour [37]. Tan δ 
remained almost constant near 0.1 for all the plain and ibuprofen loaded gellan-DEAE-Dextran 
complex gels. Addition of DEAE-Dextran slightly increased the tan δ values of GDD and GIbDD gels as 
the concentration of DEAE-Dextran increased. This indicated a more solid-like state resulting in a 
decrease in tan δ. Generally, frequency sweeps of the tested plain and ibuprofen loaded complex 
gels showed typical gel behaviour  [38] with G′ greater than G” and tan δ well below 1.  
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Figure 105 Tan delta profiles across a frequency range of 0.01 to 50 Hz at 32°C for (A) Gellan G and GDD complex gels 
and (B) Ibuprofen loaded gellan GIb and GIbDD complex gels. Each data point represents mean ± S.D (n = 4). 
The flow behaviour of plain gellan G hydrogel is shown in Figure 106. The viscosity of gellan G 
hydrogel decreased with increase in shear rate which indicated a pseudoplastic behaviour (shear 
thinning). The plain gellan G gel gave a flow like behaviour with increasing shear rate exhibiting 
hysteresis (thixotropy) on return, this suggests that the structures of the samples were broken and 
did not fully recover to the original state. The increase in shear rate permanently destroyed the 
sample structures. This was observed in all the batches including the reference gel formulations. The 
area between the curves is an indication of the extent of thixotropy. The larger the curve, the more 
thixotropic the sample is. Thixotropic materials lose their structure during shear, and rebuild it on 
standing. This behaviour is an important parameter in the ability of the gel to be easily applied to a 
surface (through structure breakdown in spreading) and then rebuild its structure and viscosity so 
that it does not drip and run. 
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Figure 106 Viscosity curve against shear rate with hysteresis (thixotropy) for plain gellan G hydrogel. 
3.3.3.2. Determination of sol-gel temperature 
A gel is a three dimensional network formed once the polymer reaches the critical gelation 
concentration. Polymer gel formed was monitored from the viscoelastic functions (G′, Gʺ and tan δ) 
of the material developed at the gel point. Sol-gel transition point such as a particular temperature 
or volume concentration is an important parameter used in characterizing gel formation. In physical 
gels, the sol-gel transition is often reversible due to van der Waals forces or hydrogen bonding being 
employed in binding polymer chains together to form a gel network [39]. Existence of hysteresis in 
the melting process of reversible physical gels complicates the investigation of the gelation process 
and gel structure [40]. To determine the sol-gel transition point, the sudden loss of flow is the most 
common indication since the viscoelastic property change abruptly from liquid like state to a solid 
like state at gelation point [41]. Therefore the sol-gel transition is determined from rheological 
characterization since it coincides with the point at which G′ intersects Gʺ. It can also be determined 
based on Winter-Chambon criterion [42], where the gel point is the time at which G′(ω) and Gʺ(ω) 
follow the power law Gʹ = kʹ ωn  and Gʺ = kʺ ωn (G′ and Gʺ were proportional to ωn over a wide range 
of temperature and frequency). Here, n denotes the exponent, ω is the angular frequency, k′ and kʺ 
are proportionality constants. Four ways from which the gelling time can be determined was also 
described by Ross-Murphy [43]: (i) when viscosity becomes infinite in a steady shear test (ii) when G′ 
diverges from a characteristic “signal noise”, (iii) when Gʺ shows a maximum, and (iv) when G′ = Gʺ 
(tan δ = 1.0) during time evolution of both moduli in gel cure experiment. 
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Gellan gum forms strong gels at very low concentrations (0.05% w/v) [44]. Gellan gelation can be 
induced by increasing the temperature of the concentrated gellan gum solution up to 90 °C. A 
decrease in temperature to 32.5 ± 2.5 °C leads to a conformational change of the chains from 
random coils to double helices (coil-helix transition). The rearrangement of the double helices occurs 
which leads to the formation of ordered junction zones (sol-gel-transition) [24]. Ultimately, a 
thermo-reversible hydrogel is formed. Addition of mono and divalent cations to gel solutions gives a 
much stronger physical thermo-reversible gel [45]. The gel formed is heat resistant and its gel 
strength is less dependent on pH compared to other common polysaccharides [46]. Gellan forms 
Ca2+ mediated junction zones by cross linking two double helices [47]. 
Gellan solutions undergo thermally induced sol-gel transition. The solution is a sol at high 
temperature and a gel when the solution is cooled. The traditional mechanism proposed for the sol-
gel transition of gellan gum is based on a ‘random coil’ to ‘double helix’ transition followed by ‘helix 
to helix aggregation’, involving weak interactions such as Van der Waals forces and hydrogen bonds 
[48]. Existence of thermal hysteresis between gelation and melting was reported since aggregation 
stabilizes the helices to temperatures higher than those at which they form on cooling [49]. 
Figures 107 to 110 showed the temperature sweep profile of G′ and Gʺ with cooling from 90 to 15 °C 
and heating from 15 to 90 °C for G, GIb, GDD, GIbDD gels. During the cooling cycle for plain gellan G 
gel in Figure 107, the gels generally exhibited an increase in G′ and Gʺ from 90 to 76.8 °C until a 
plateau was reached.  
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Figure 107 Temperature sweep profile of heating and cooling curves of plain gellan G hydrogel. 
The plateau was maintained across a large temperature range from 76.8 to 38.8 °C until a lower 
temperature was reached, then the elastic and storage modulus started to decrease from 37.8 °C, 
until they reached the values (15 °C) close to the value recorded at the beginning of the heating 
cycle. This indicated that the liquid solution turned into solid-like gel in the vicinity of 38 °C. 
During the heating cycle, the gels generally exhibited a decrease in G′ and Gʺ from 15 to 27.1 °C. This 
was followed by a sharp increase from 27.1 to 39.1 °C, until a plateau is reached and the values are 
maintained till the end of the heating cycle at 90 °C. The sharp increase of the moduli at 27 °C, 
indicated thermoreversibility with a tendency of the gel to return to liquid state.This similar 
observation was reported by Moura et al. in the rheological study of chitosan solution at 
physiological pH exhibiting gelation at 50 °C which was thermoreversible [34].  G′ and G” crossover 
was not observed during the heating and cooling cycles of the complex gels. This was expected 
10
3
10
4
10
5
10
6
Pa
G'
G''
1
10
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100°C
Temperature T
Rheoplus
Anton Paar GmbH
2%Gellan-control 1
CP25-1/TG-SN6344; d=0.047 mm
G' Storage Modulus
G'' Loss Modulus
(ii) Heating 
(i) Cooling G′ 
(i) Cooling Gʺ 
(ii) Heating 
212 | P a g e  
 
because G′ > Gʺ throughout the cycles and the elastic properties dominated.  For cross-linked gels, G′ 
and Gʺ are very high and are nearly parallel to each other [50]. This was observed for G, GIb in Figure 
108, GDD and GIbDD complex hydrogels in Figure 109 and Figure 110 respectively, which indicated 
that they are hydrogels with highly cross-linked polymer networks.  
Gels cross-linked with genipin also showed this rheological pattern [50]. Hysteresis effect was 
observed when the gels where first subjected to the cooling phase and then the heating phase. This 
indicated an irreversible break down in structure of the gels. 
 
Figure 108 Temperature sweep profile of heating and cooling curves of GIb hydrogel. 
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Figure 109 Temperature sweep profile of heating and cooling curves of GDD hydrogel 
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Figure 110 Temperature sweep profile of heating and cooling curves of GIbDD hydrogel. 
3.3.4. Swelling kinetics 
The swelling behaviour of the hydrogels was assessed by immersing the hydrogels in PBS (pH 7.4) at 
37 °C. Hydrogels are crosslinked macromolecular network with swelling capabilities in aqueous 
media or biological fluids. Due to the high water content of the hydrogel formulations and their 
ability to retain great quantities of water, the gels were initially weighed and dried to constant 
weight before starting the swelling tests.  
Plain gellan reference G gel increased in swelling with increasing contact time in PBS pH 7.4 up to 
0.47 times its dried weight without losing its physical integrity at the end of 48 h in Figure 111. The 
general trend is that the swelling increased with time and the swelling ratio of the gels reached 
equilibrium at 6 h. The swelling ratio ranged from 0.53 to 0.59 times its dried weight in PBS pH 7.4 at 
37 °C for the GDD gels. The addition of DEAE-Dextran to gellan GDD complex gels significantly 
10
3
10
4
10
5
10
6
Pa
G'
G''
1
10
0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100°C
Temperature T
Rheoplus
Anton Paar GmbH
GIbDD-run2 1
CP25-1/TG-SN6344; d=0.047 mm
G' Storage Modulus
G'' Loss Modulus
(i) Cooling G′ 
(ii) Heating 
(i) Cooling Gʺ 
(ii) Heating 
215 | P a g e  
 
increased (p < 0.05, n = 4) swelling ratio when compared to the plain gellan reference G gel. The 
swelling behavioural pattern showed a steady increase in swelling ratio in the GDD complex as the 
concentration of DEAE-Dextran increased. Therefore, the swelling ratio was increased by the 
addition of DEAE-Dextran.  
 
Figure 111  The swelling kinetics of gellan and gellan-DEAE-Dextran complex gels. Each data point represents mean ± S.D 
(n = 4). 
The ibuprofen loaded plain gellan GIb had a swelling ratio of 0.52, while for the GIbDD complex gels 
the swelling ratio ranged from 0.77 to 1.61 times its dried weight in PBS pH 7.4 at 37 °C in Figure 
112. The addition of DEAE-Dextran to GIb gel (GIbDD complex gels) significantly increased (p < 0.05, 
n = 4) swelling ratio when compared to the GIb gel. The swelling behavioural pattern showed that a 
steady increase in swelling ratio in GIbDD complex gels as the concentration of DEAE-Dextran 
increased. The incorporation of ibuprofen (GIb and GIbDD complex gels) significantly increased (p < 
0.05, n = 4) the swelling of the gels when compared with G and GDD gels without ibuprofen. The 
swollen hydrogels maintained their gel integrity till the end of 48 h. 
The swelling of hydrogels has been reported to be affected by crosslinking ratio. Highly cross-linked 
hydrogels exhibit tighter structure with less swelling when compared with lower cross-linked 
hydrogels [7]. The swelling ratio is thus lowered by the hindering of the polymer chains by 
crosslinking. Plain gellan reference G gel exhibited the highest physical crosslinking of its polymer 
network when compared with GDD complex and ibuprofen loaded complex GIbDD gels. The addition 
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of DEAE-Dextran and ibuprofen lowered the crosslinking ratios of the polymer network of the plain 
gellan G hydrogels.  
 
Figure 112 The swelling kinetics of ibuprofen loaded gellan and gellan-DEAE-Dextran complex gels. Each data point 
represents mean ± S.D (n = 4). 
3.3.5. Drug release from the binary and ternary nanoconjugate hydrogels 
The release of drug from hydrogels is governed by its ability to act as a permeable membrane or 
matrix. The release profile of ibuprofen from gellan, gellan-DEAE-Dextran complex GIbDD hydrogels 
and commercial ibuprofen gel was presented in Figure 113. 
The drug release profile of ibuprofen from the hydrogels was divided into three phases. Within the 
first hour, there was a steady rate of release of ibuprofen from GIb (31.98%), GIbDD gels (34.58 to 
67.18%) and commercial ibuprofen gel (40.44%) shown in Figures 161 to 163 in the Appendix. The 
release rate reduced between 1 and 4 h. There was a similar trend of release between 4 and 48 h. 
The drug release profile showed that the maximum ibuprofen released from GIb gels was 85.67%; 
ranged from 94.33% to 97.13% for GIbDD gels and 77.17% for commercial ibuprofen gel (Figure 
113). Ibuprofen release from commercial ibuprofen gel was significantly reduced (p < 0.05, n = 4) 
when compared to plain gellan GIb gel and gellan-DEAE-Dextran GIbDD complex gels. At 48 h, the 
release exhibited were in the increasing order from commercial ibuprofen gel < GIb < GIbDD 2:1 < 
GIbDD 2:0.5 < GIbDD 2:0.25 < GIbDD 2:0.125 with GIbDD 2:0.125 showing the highest drug release. 
The DEAE-Dextran concentration that gave the highest release was 0.125%. DEAE-Dextran initially 
increased then decreased the release of ibuprofen from the hydrogels at the rate of 2.97% per unit 
0 
0.4 
0.8 
1.2 
1.6 
0 4 8 12 16 20 24 28 32 36 40 44 48 
Sw
e
lli
n
g 
ra
ti
o
 
Time / hours 
GIb 
GIbDD 2:0.125 
GIbDD 2:0.25 
GIbDD 2:0.5 
GIbDD 2:1 
217 | P a g e  
 
weight (R2 = 0.97) shown in Figure 114. The combination of gellan and DEAE-Dextran influenced the 
drug release of ibuprofen which suggested a synergistic effect of the two polymers.  
The drug release pattern showed an initial burst release up to 6 h and slower release rate up to 48 h.  
The initial burst effect may be attributed to the diffusion of the drug caused by rapid gel swelling and 
also the release of the drug adsorbed towards the surface of the gel matrix [51]. The formation of 
polyelectrolyte complex hydrogels (PEC) could have enhanced the release of ibuprofen over time. 
The degree of swelling of the hydrogels influenced the diffusional properties of the solute through 
the hydrogel.  This was confirmed by the drug release studies which showed a significantly higher (p 
< 0.05, n = 20) drug release for the GIbDD complex gels when compared to GIb gel.  
 
 
Figure 113 Ibuprofen release from gellan, gellan-DEAE-Dextran complex and commercial ibuprofen gels. Each data point 
represents mean ± S.D (n = 4). 
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Figure 114 Effect of DEAE-Dextran on the release profile of ibuprofen from the conjugate hydrogels. Each data point 
represents mean ± S.D (n = 4). 
3.3.6. Drug release kinetics 
The drug release kinetics data based on the kinetic models is shown in Table 75. The data was best 
fitted with the Korsemeyer-Peppas models for GIb, GIbDD and commercial ibuprofen gels. The 
classification of diffusional exponent (n) based on release behaviour of bioactive agent from the 
hydrogel systems described by Lowman is as follows: Fickian diffusion (n = 0.5); anomalous transport 
system - Fickian diffusion and polymer relaxation (0.5 < n < 1); case II transport system - polymer 
relaxation (n = 1); super case II transport system – zero order release and plasticization at gel layer (n 
> 1) [52]. The n values obtained shown in Table 75 indicated that for GIbDD 2:0.125, GIbDD 2:0.25 
and GIbDD 2:0.5 (where n < 0. 5) Fickian diffusion was exhibited, for commercial ibuprofen gel the 
release mechanism was anomalous (non-Fickian) diffusion where diffusion exponent (n) is 0. 5 < n < 
1, while in the absence of DEAE-Dextran, GIb and GIbDD 2:1 gels (higher concentration of DEAE-
Dextran) the release mechanism was a Super Case II transport mechanism (where n > 1). The Super 
Case II release kinetics of GIb and GIbDD 2:1 gel is a strong indication of zero order release 
mechanism. In controlled drug release, zero order is the ideal with advantage of delivering drug at a 
constant rate which gives a predictable bioavailabilty.  
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Table 75 Regression coefficient (r) values of different kinetic models and diffusion exponent (n) of Korsemeyer-Peppas 
models for the ibuprofen loaded gellan, gellan-DEAE-Dextran complex gels and branded ibuprofen gel.  
Formulation Zero order First Order Higuchi Korsemeyer-Peppas 
 R2 R2 R2 R2 n 
GIb 0.47 0.21 0.67 0.81 1.31 
GIbDD 2:0.125 0.60 0.47 0.79 0.90 0.38 
GIbDD 2:0.25 0.62 0.45 0.81 0.89 0.43 
GIbDD 2:0.5 0.61 0.47 0.80 0.91 0.23 
GIbDD 2:1 0.30 0.15 0.47 0.90 1.96 
Commercial Ibuprofen gel  0.42 0.22 0.61 0.76 0.74 
 
3.3.7. Similarity of drug release profiles (Similarity factor f2) 
All the similarity (f2) values of GIbDD complex hydrogels were higher than the limit value of 50 (f2 
values ranging from 68.97 to 74.60 in Table 106) suggesting a similarity between the ibuprofen 
loaded (GIbDD ternary) complex and the ibuprofen loaded plain gellan (GIb binary) hydrogels. The f2 
values increased with increase in concentration of DEAE-Dextran in the complex. 
3.4. Conclusion 
Polyelectrolyte complex nanoconjugate hydrogels were prepared by in situ interaction between 
gellan gum and different concentrations of oppositely charged DEAE-Dextran. The plain PEC 
hydrogels were further loaded with solubilized ibuprofen. The DSC thermograms exhibited the 
disappearance of the melting peak of ibuprofen suggesting an interaction between ibuprofen and 
the polymers. This was confirmed by the FTIR spectra, where the major peaks of ibuprofen were 
absent. The TGA of the hydrogels showed that the the binary GIb (282.8 °C) had higher 
decomposition temperature than the ternary GIbDD complex (246.8 to 256.5 °C) gels suggesting 
greater thermal stability. The release of ibuprofen from the gels increased steadily with time to 
100% at the end of 48 hours. This correlates with the rheological findings which showed 
pseudoplastic behaviour.  The lowest concentration of DEAE-Dextran (GIbDD 2:0.125) used in this 
study, increased the release of ibuprofen by 13.4%. Higher concentrations of DEAE-Dextran 
decreased the release profile steadily. It follows that DEAE-Dextran has potentials in the formulation 
of modified (extended) release of hydrogels. The drug release kinetics fitted into different models 
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suggests a combination of mechanisms of release including Fickian, anomalous and Super Case II 
transport. However, diffusion from the hydrogel is more dominant than discrete particle dissolution 
mechanism. 
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CHAPTER FOUR 
4.0. Preparation and characterization of composite and bilayer 
polymer films 
4.1.  Introduction 
There is ongoing research on the preparation of films using natural and synthetic polymers to 
improve their bioavailability and expand their use as biomaterials. Biodegradable polymer films are 
made from biopolymers which include polysaccharides, lipids and proteins. These films have been 
exploited for their controlled drug release potential based on  softness, absorbency and high surface 
area characteristics [1]. Due to their biodegradability, biocompatibility and non-toxicity, they have 
advantages over synthetic polymers and are fast replacing them. The release profile of naproxen 
from the three polymers (poly (lactide-co-glycolide) PLGA, poly (D, L-lactide) PDLLA and poly (ɛ-
caprolactone) PCL studied, exhibited two-stage release model: release by diffusion followed by zero 
order release due to polymer erosion. Polymer films and coatings have been used to modulate 
surface properties of biomaterials and a reservoir for drug [1]. 
Methods developed for fabrication of polymer films include solvent evaporation method used in the 
development of curcumin loaded hydroxyl propyl methylcellulose - ethyl cellulose polymeric films 
[2] and layer-by-layer method in the preparation of gentamicin and cefazolin loaded poly-L-
lysine/poly-L-(glutamic acid) multilayer nanofilms [3]. Solvent casting is the most popular and an old 
film making technique which dates back up to a century ago. It involves the suspension or 
dissolution of Active Pharmaceutical Ingredients (APIs) in a solution of polymers, plasticizers and 
other excipients in a volatile solvent such as water or ethanol, casting on a surface and drying to 
remove the solvent. Layer-by-Layer (LbL) films were first developed by Decher [4]. He proposed a 
method for the preparation of thin films based on alternate and repeated adsorption of polycations 
and polyanions on the surface of a solid substrate from the solution with washing steps. LbL is not 
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only based on electrostatic forces but also hydrogen bonding, covalent bonding and biological 
affinity [5]. Polyelectrolyte multi layer films has been developed for drug delivery with advantages 
which include: drug molecules acting as functional drugs or components of the film, with the 
tendency to form stable crosslinking structure with other film components; possibility of achieving 
sustained drug release; potential of protecting drug molecules from losing their biological activities; 
simplicity of the film preparation process which can be automated [3]. Kawashima et al. developed a 
polyelectrolyte (PEC) film by reacting theophylline granules coated with sodium tripolyphosphate 
and chitosan [6]. Drug release from the coated granules followed zero order kinetics with significant 
reduction compared with that of original granules. Pang et al. fabricated ibuprofen loaded PLGA 
polymeric films dissolved in tetrahydrofuran solvent by spreading PLGA-ibuprofen solution on non 
solvent surface [7]. The films with higher concentrations of ibuprofen prepared had convex 
patterned surfaces due to surface tension when the phase separation moved to the surface of the 
polymer solution. 
Gellan gum is a water soluble polysaccharide consisting of a tetrasaccharide repeat units of two D-
glucose, one L-rhamnose and one D-glucuronic acid connected by glycosidic bonds [8]. It is produced 
by the fermentation of Sphingomonas elodea ATCC 31461 [9] (formerly referred to as Pseudomonas 
elodea). Gellan gum is finding increasing applications in the pharmaceutical and biotechnology 
industry based on its good film-forming properties [10] exhibited by the preparation of gellan-gelatin 
composite films with improved mechanical properties and potential to be used as packing or coating 
materials;  and drug release [11]. Agnihotri et al. prepared cephalexin loaded gellan gum beads with 
spherical shaped beads with average size of 925 to 1183 µm and higher release rates achieved by 
beads prepared in acidic pH media [11]. The authors found that it was important to use the 
combination of calcium and zinc cations to give uniform sized beads with sustained drug release. 
Gellan gum has been found to be of use in oral sustained delivery in the formulation of cimetidine 
loaded gellan in situ gel with in vitro release profile following root-time kinetics over a period of 6 h 
[12], in the development of methylprednisolone loaded gellan based systems for sustained release 
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for ophthalmic drug delivery [13], in the preparation of amoxicillin loaded gellan beads prepared by 
ionic gelation with the release kinetics following the diffusion model [14] and floating in situ gelling 
for controlled delivery of ramipril with good fit to the zero order and Korsemeyer Peppas model 
exhibiting Fickian diffusion mechanism [15]. The mechanical and water vapour properties of edible 
gellan films have been investigated [16]. It was found that the mechanical properties of the film 
were adversely affected by high water activity. Gellan film has been used to produce regenerative 
barrier membrane with the 2% gellan film exhibiting better film integrity in the bone defect in rats 
healing after two months and good cell separation ability [17]. The choice of exploiting gellan further 
is based on its cheapness, biodegradable, easy gel and film forming characteristics 
Diethylaminoethyl-Dextran (DEAE-Dextran) is a polycationic derivative of Dextran produced by 
reacting diethylaminoethyl chloride with Dextran. It is freely soluble in water and salt solutions and 
biodegradable [18]. There is no report showing that DEAE-Dextran form films or gels but have been 
found to possess bioadhesive properties in the preparation of laminin treated DEAE-Dextran where 
laminin binds readily with it [19]. Its polycationic nature is being explored in this study in 
combination with gellan at different mixing ratio without the use of crosslinking agents and toxic 
solvents with potential to form polyelectrolyte films with the desired properties.  
In this study, single, composite and bilayer gellan - DEAE-Dextran films; and ibuprofen-loaded films 
were prepared and characterized with the objective of its future application of biodegradable films 
in the transdermal delivery of ibuprofen. The synergistic potential of incorporating DEAE-Dextran 
into gellan in view of improving their physicochemical properties was exploited and the mode of 
preparation (composite and electrostatic layer-by-layer) where compared. The in vitro drug release 
study of ibuprofen from gellan films and its polyelectrolyte complex and bilayer composite films 
were evaluated. 
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4.2. Materials and methods 
4.2.1. Materials 
Ibuprofen (purchased from Fagron, UK), gellan (Phytagel®), DEAE-Dextran hydrochloride and glycerol 
(all purchased from Sigma-Aldrich, UK) were used as supplied. 
4.2.2. Preparation of plain composite and bilayer films 
The method of preparing composite gellan films by Yang and Paulson was modified in this study. 2% 
w/v of gellan was dispersed in distilled water and 3% v/v of glycerol (at 60% w/w 
plasticizer/(plasticizer + polymer) [16] was added under magnetic stirring and heated at 80 to 90°C 
until it became a transparent solution coded G film. Gellan-glycerol solution was added to DEAE-
Dextran solution at different mixing ratios (2:0.125, 2:0.25, 2:0.5 and 2:1) under magnetic stirring 
and heated up to 90 ˚C until homogenous mix was achieved. The resulting binary composite 
polyelectrolyte complex film forming mixtures were adjusted to pH 6.0 (Mettler Toledo pH meter) 
with sodium hydroxide NaOH coded GDD 2:0.125, GDD 2:0.25, GDD 2:0.5 and GDD 2:1 shown in 
Table 76. 
The hot film forming mixtures of gellan and gellan - DEAE-Dextran composite polyelectrolyte 
complexes were placed individually under vacuum for 30 sec to remove air bubbles and 30 g was 
immediately poured into a 12 cm square petri dish (casting method). The petri dishes were placed in 
the oven overnight at 40 ˚C. The dried films were peeled out from the plates and stored in a 
desiccator prior to analysis. 
Bilayer polyelectrolyte complex films were formed with gellan films as base component. Already 
prepared gellan films were immersed into varying concentrations of oppositely charged DEAE-
Dextran solutions for about 5 min on each side  and dried again overnight in the oven (layer by layer 
immersion) coded G/DDB 2:0.125, G/DDB 2:0.25, G/DDB 2:0.5 and G/DDB 2:1 shown in Table 77. 
The DEAE-Dextran solutions were kept at room temperature while being used as immersion liquid. 
 
227 | P a g e  
 
Table 76 Composition of gellan and gellan-DEAE-Dextran composite films. 
Sample  Gellan 
(%w/v) 
DEAE-Dextran 
(%w/v) 
Glycerol 
(%v/v) 
Distilled 
Water (%) 
G  2.0 - 3.0 to 100 
GDD 2:0.125 2.0 0.125 3.0 to 100 
GDD 2:0.25 2.0 0.25 3.0 to 100 
GDD 2:0.5 2.0 0.5 3.0 to 100 
GDD 2:1 2.0 1.0 3.0 to 100 
 
Table 77 Composition of gellan-DEAE-Dextran bilayer films. 
Sample Gellan 
(%w/v) 
DEAE-Dextran 
(%w/v) 
Glycerol 
(%v/v) 
Distilled 
Water (%) 
G/DDB 2:0.125 2.0 0.125 3.0 to 100 
G/DDB 2:0.25 2.0 0.25 3.0 to 100 
G/DDB  2:0.5 2.0 0.5 3.0 to 100 
G/DDB  2:1 2.0 1.0 3.0 to 100 
 
4.2.3. Preparation of drug loaded composite and bilayer films 
2% w/v of gellan was dispersed in distilled water and 3% v/v of glycerol (at 60% w/w 
plasticizer/(plasticizer + polymer) [16] was added under magnetic stirring and heated between 80  
and 90 ˚C until it became a transparent solution. 1% w/v of ibuprofen was dissolved in 5 mL of 1 M 
NaOH, added to the polymer solution at same temperature, adjusted to pH 6.0 and coded GIb film. 
2% w/v of gellan and 3% w/v  of glycerol in 50 mL distilled water under stirring and heated between 
80 and 90 ˚C until it became a transparent solution. 1% w/v of ibuprofen was dissolved in 5mL of 1 M 
NaOH and added to the hot solution. 1% w/v of DEAE-Dextran was dispersed in 25 mL of distilled 
water, adjusted to pH 6 with NaOH  and heated up to 90 ˚C. The gellan-ibuprofen solution was 
transferred into the DEAE-Dextran solution at different mixing ratios of gellan to DEAE-Dextran 
(2:0.125, 2:0.25, 2:0.5 and 2:1) under continuous magnetic stirring until homogenous mix was 
achieved. The resulting composite polyelectrolyte complex (loaded with ibuprofen) film forming 
solutions were adjusted to pH 6 (Mettler Toledo pH meter) with NaOH coded GIbDD 2:0.125, GIbDD 
2:0.25, GIbDD 2:0.5 and GIbDD 2:1 shown in Table 78. 
The hot film forming solutions of gellan and gellan - DEAE-Dextran composite polyelectrolyte 
complexes loaded with ibuprofen were placed under vacuum for 30 sec to remove air bubbles and 
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30 g was immediately transferred into a 12 cm square petri dish (casting method). The petri dishes 
were placed in the oven overnight at 40˚C. The dried films were peeled out from the plates and 
stored in a desiccator. 
Bilayer polyelectrolyte complex films were formed with gellan loaded with ibuprofen films as base 
component. Already prepared gellan-ibuprofen films were immersed into varying concentrations of 
oppositely charged DEAE-Dextran solutions adjusted to pH 6 (Mettler Toledo pH meter) for about 5 
min on each side and dried again overnight in the oven (layer by layer immersion) coded GIb/DDB 
2:0.125, GIb/DDB 2:0.25, GIb/DDB 2:0.5 and GIb/DDB 2:1 shown in Table 79. The DEAE-Dextran 
solutions were kept at room temperature while being used as immersion liquid. 
Table 78 Composition of ibuprofen loaded gellan and gellan-DEAE-Dextran composite films. 
Code Ibuprofen 
(%w/v) 
Gellan 
(%w/v) 
DEAE-Dextran 
(%w/v) 
Glycerol 
(%v/v) 
Distilled 
Water (%) 
GIb - 2.0 - 3.0 to 100 
GIbDD 2:0.125 1.0 2.0 0.125 3.0 to 100 
GIbDD 2:0.25 1.0 2.0 0.25 3.0 to 100 
GIbDD 2:0.5 - 2.0 0.5 3.0 to 100 
GIbDD 2:1 1.0 2.0 1.0 3.0 to 100 
 
Table 79 Composition of ibuprofen loaded gellan and gellan-DEAE-Dextran bilayer films. 
Code Ibuprofen 
(%w/v) 
Gellan 
(%w/v) 
DEAE-Dextran 
(%w/v) 
Glycerol 
(%v/v) 
Distilled 
Water (%) 
GIb/DDB 2:0.125 1.0 2.0 0.125 3.0 to 100 
GIb/DDB 2:0.25 1.0 2.0 0.25 3.0 to 100 
GIb/DDB 2:0.5 1.0 2.0 0.5 3.0 to 100 
GIb/DDB 2:1 1.0 2.0 1.0 3.0 to 100 
4.2.4. Physicochemical characterization of the composite and bilayer films 
4.2.4.1. Morphology and size studies  
4.2.4.1.1. Scanning electron microscopy 
The surface and cross-sectional morphologies of gellan (pure and blend) films and ibuprofen loaded 
films were observed by a Carl Zeiss SEM EVO High Definition 15 scanning electron microscope (Carl 
Zeiss, Germany) using variable pressure technology at low voltages with beam deceleration and high 
definition backscattered electron (BSE) imaging. The film samples were mounted on double sided 
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carbon tabs that were previously secured to aluminium stubs and then analysed at different 
magnifications and a pressure of 10 Pa. The accelerating voltage was 10 KV with probe current of 
400 pA. The particle sizes on the surface and cross section of the films were determined. 
4.2.4.1.2. Atomic force microscopy 
The surface topographies of the films were observed using an Agilent Technologies 5420 Scanning 
Probe Microscope/ Atomic Force Microscopy (Agilent Technologies Inc., USA).  The AFM mapping 
was performed in a contact mode with a cantilever. The measurements were carried out in ambient 
conditions at a scan speed of 10.01 lines/second, and a resolution of 256 µm together with the scan 
area of size 20 x 20 µm. 
4.2.4.2. Film thickness measurements 
The thickness of the film samples was measured using a thickness micrometer screw gauge (Draper 
Expert, UK) micrometer to the nearest 0.01 mm. Thickness measurements were taken at six different 
locations on each sample and the average value was taken as the mean thickness of the film. 
4.2.4.3. Mechanical properties of films 
Tensile strength (TS), percentage tensile elongation (TE) at break and elastic modulus (EM) of the 
film were determined at 21 ± 1˚C using Zwick Roell Materials Tester (Zwick GmbH & Co AG Ulm, 
Germany)  according to ASTM standard method D882 [21]. Strips of dimension 10 x 2.5 cm were cut 
from films and mounted between the grips of the machine. The initial grip separation and cross head 
speed were set to 80 mm and 40 mm/min respectively. A computer with Zwick TestXpert II software 
was used to record the stress-strain curves. Elastic modulus, tensile strength and elongation were 
calculated from the slope of the linear part of the stress-strain curve, the maximum stress and 
percentage elongation at break respectively. All measurements were an average of four 
determinations and expressed as mean ± S.D. 
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4.2.5. Spectroscopic analysis - Fourier Transform Infrared 
FTIR was conducted using Perkin-Elmer Precisely Spectrum One FTIR Spectrometer and a Universal 
ATR Sampling Accessory (Perkin Elmer, USA). The films were mounted directly on the diamond 
surface and the arm was placed over it by applying enough pressure in the range of 100 to 120. The 
spectrum was recorded in the wavelength region of 4000 to 650 cm-1.  All spectra were then 
collected at an average of 16 scans at a resolution of 4 cm-1. All measurements were taken in 
replicates of four determinations. 
4.2.6. Thermal analysis  
4.2.6.1. Differential scanning calorimetry 
DSC was performed using Perkin Elmer Jade DSC machine in conjunction with a Perkin Elmer 
Intracooler SP cooling Accessory (Perkin Elmer, USA) to study the thermal behaviour of the 
ibuprofen powder, polymer powders and polymer films. The samples were prepared from several 
pieces cut from the polymer film to a mass ranging between 5 to 10 mg. The samples were heated in 
hermetically sealed aluminium pans under nitrogen flow (40 mL/min) at a scanning rate of 20˚C/min 
from 30 to 300 ˚C. Empty aluminium pan was used as a reference pan. Indium was used as the 
standard reference material to calibrate the DSC instrument. All measurements were an average of 
four determinations and expressed as mean ± S.D. 
4.2.6.2. Thermogravimetric analysis 
TGA was performed using Perkin Elmer Pyris 1 Thermogravimetric Analyser (Perkin Elmer, USA) to 
monitor the mass of the films as a function of temperature or time as the sample specimen is 
subjected to a controlled temperature program in a controlled atmosphere. The weight of the empty 
reference pan placed in the crucible was zeroed and then removed. The samples of known weight 
between 5 to 10 mg were placed in aluminium pans and measurements performed at a scanning 
rate of 10 ˚C/min from 25 to 500 ˚C. All measurements were an average of four determinations and 
expressed as mean ± S.D. 
231 | P a g e  
 
4.2.7. Swelling kinetics 
Dried films (1.5 x 1.5 cm) were carefully weighed and immersed in 5mL of PBS 7.4 at 37 ˚C (B Braun 
Certomat WR Shaker Waterbath Germany). At predetermined intervals, swollen films were taken 
out, and the excess was blotted with filter paper at the surface. This was then weighed on a balance. 
The swelling ratio of the film was determined using the following equation (equation 1): 
                                                                                     (1) 
Where Wd is the weight of dry film and Ws is the weight of the swollen film. All data were averages 
of four independent experiments expressed as mean ± S.D. 
4.2.8. Drug release profile from bilayer films 
The concentration of pure ibuprofen (secondary standard) was derived from a calibration model 
constructed with the average of six independent measurements. The concentrations of ibuprofen 
were derived from this calibration curve. Thereafter, the dissolution profile of the ibuprofen-loaded 
films was studied using the USP dissolution method. 
Dried films (4 x 4 cm) were placed in 900 mL of PBS pH 7.4, rotated at 50 rpm and maintained at 32 ± 
0.5 °C using Pharma Test PT DT7 USP Apparatus II Dissolution Test Instrument – paddle method 
(Pharma Test Ltd, Germany). At pre-determined time intervals 5, 10, 15, 20, 30, 60, 90, 120 min, 4, 6 
and 24 h, 5 mL aliquots were withdrawn and replaced with 5 mL PBS pH 7.4. Drug concentrations 
were quantified using UV (ThermoFischer Evolution 60S UV-Visible Spectrophotometer, UK) at 264 
nm wavelength after passing through 0.45 µm filter (Sartorius, Germany). All measurements were an 
average of four determinations and expressed as mean ± S.D. 
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4.2.9. Drug release kinetics  
Data obtained from in vitro release studies were fitted to various kinetic equations. The kinetic 
models used are zero order, first order, Higuchi and Korsemeyer Peppas equation.  
The zero order rate equation (2) describes the systems were the drug release rate is independent of 
its concentration [22]. The cumulative % drug release vs. time plot is made. 
                          (2)  
Where k0 is zero order rate constant expressed in units of concentration/time and t is the time. 
The first order rate equation (3) describes the release from the systems where release rate is 
concentration dependent [23]. The log cumulative % drug release vs. time plot is made. 
                                                                                (3) 
Where C0 is the initial concentration of drug and K is first order constant. 
Higuchi described the release of drugs from insoluble matrix as a square root of time dependent 
process based on Fickian diffusion: equation (4) [24]. The cumulative % drug release vs. square root 
of time is made.  
                                                                                                                                  (4)  
Where K, is the constant and it reflects the design variables of the system. 
Korsemeyer et al. derived a simple relationship which described drug release from a polymeric 
system: equation (5). To find out the mechanism of drug release, first 60 % drug release data was 
fitted in Korsemeyer-Peppas model: 
         
                                                                                                                   (5)  
Where Mt/M∞ is a fraction of drug released at time t, K is the rate constant and n is the release 
exponent. The n value is used to characterize different release mechanisms [25]. The log cumulative 
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% drug release vs. log time plot is made. The criterion for selecting the appropriate model is the 
highest R2 value which indicates linearity of dissolution data [26]. 
4.2.10.  Similarity factors 
The similarity fit factor denoted f2 was used to compare the dissolution profiles of the ibuprofen 
loaded gellan - DEAE-Dextran (GIbDD) composite or bilayer (GIb/DDB) films (test) and GIb binary film 
(reference). The similarity f2 factor is defined by equation 6 proposed by Moore and Flanner [27]: 
 
              
 
 
            –    
 
          
                                                    (6) 
Where n is the number of dissolution sample times, and Rt and Tt are the individual or mean percent 
dissolved at each time point, t, for the reference and test dissolution profiles, respectively. The f2 
value greater than 50 suggests that the two profiles are similar. The f2 value of 100 suggests that the 
test and the reference profiles are identical and as the value becomes smaller the dissimilarity 
between release profiles increases [28]. 
4.2.11.  Statistical analysis 
Quantitative data are expressed as mean ± standard deviation (S.D). The significance of the 
differences between means was assessed using Analysis of Variance (ANOVA) and Post hoc Tukey 
Test with a statistical significance level set at p < 0.05 using IBM SPSS® (Statistical Package for Social 
Science) 20. 
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4.3. Results and discussions 
4.3.1. Preparation and optimization of plain and drug loaded composite and bilayer 
films 
The basic constituents of films include polymers, solvents, plasticizers and cross-linking agents. 
Gellan and DEAE-Dextran composite films were prepared by casting method from aqueous solution 
without the use of organic toxic solvents and cross-linking agents since both polymers are soluble in 
hot water (above 90 °C) and cold water respectively. The amount of gellan used in the mixing ratio 
was fixed at 2% based on preliminary optimization studies done. The 2% gellan film was found to 
have better mechanical properties when compared with the 1% gellan film, hence its selection. A 
varying concentration range of 0.125 to 1% of DEAE-Dextran was used to study the effect of its 
increasing concentration on the films formed.  Due to the poor mechanical properties of biopolymer 
films, hydrophobic materials and plasticizers have been incorporated to improve their mechanical 
properties [16]. Glycerol was incorporated as plasticizer to provide elasticity for the films based on 
the proposition Yang and Paulson of using 60% w/w plasticizer: (plasticizer + polymer) as the lowest 
effective concentration, therefore  used in this ratio in the formulation 3% glycerol: 2% gellan + 3% 
glycerol. The authors found that below that proposed concentration, the films were found to be 
brittle and difficult to handle, while when it exceeds its compatibility limit, it exhibits white residues 
on the surface. Plasticizers increase the flexibility and workability of the polymers; and degradability 
of biodegradable polymers in preparation of polymer films [29]. Pure gellan films (G) prepared had 
the highest transparency when visualized and smoothness. The smoothness is a desired property 
since the formulation can maintain a smooth and uniform surface when applied to the skin. There 
was reduced clarity and transparency when gellan solution was reacted with oppositely charged 
DEAE-Dextran at different mixing ratios to form the polyelectrolyte complex (PEC) composite films 
(GDD). The increasing concentration of DEAE-Dextran decreased the clarity and transparency of the 
films. Increased concentration of DEAE-Dextran increased crosslinking efficiency. This was supported 
by Yang et al. report that films with a higher crosslinking degree tend to exhibit an increase in 
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opacity due to a decrease in polymer inter-chain spacing, which allows less light to pass through it 
[30]. 
In the preparation of PEC bilayer films, gellan films were used as the base component since DEAE-
Dextran does not form films on its own even at high concentrations from results of preliminary 
studies. Bilayer films formed by immersing fixed concentration of gellan (2%) films into varying 
concentrations of DEAE-Dextran were transparent with glossy, smooth but sticky surfaces. The 
stickiness of the surfaces increased with increasing concentration of DEAE-Dextran solutions. This 
shows potential bioadhesive properties with potential applications in transdermal patches. 
The conformational transition from coil to helix structure could be used to describe the mechanism 
of formation of gellan films. The choice of heating up to 90 °C is based on the finding that gellan gum 
is stable at higher temperatures with maintained strength at 90 °C [31]. Sanderson and Clark 
reported that the melting temperature can be below or above 100 °C, depending on the conditions 
of gel formation [8]. Brittle films are thus formed by gellan due to tight packing of gellan chains. 
When gellan was loaded with ibuprofen solubilized in NaOH (GIb), it remained transparent. The PEC-
ibuprofen loaded (GIbDD) changed from opaque film forming mixtures which indicated formation of 
two-phase structure and turned back to translucent films after evaporation. This similar occurrence 
was reported by Ma and McHugh in the preparation of PLGA-acetone-naproxen films due to the 
formation of two-phase structure while opaque and finally reverting back to clear state at the end of 
the solidification process [32]. Bierhalz et al. also reported an increase in film opacity on 
incorporation of natamycin into alginate/pectin films related to the low water solubility of naproxen 
[32]. An increase in opacity due to addition of hydrophobic substances was also reported by Yang 
and Paulson [16]. The authors also opined in their further work that films with a higher crosslinking 
degree tend to exhibit an increase in opacity due to a decrease in polymer inter-chain spacing which 
allows less light to pass through [30]. The use of a crosslinker was avoided in this study; rather an 
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oppositely charged polyelectrolyte (DEAE-Dextran) to gellan was used in the preparation of film 
which showed an increase in opacity as DEAE-Dextran was increased.  
4.3.2. Physicochemical characterization and mechanical properties of plain and 
Ibuprofen loaded composite and bilayer films 
4.3.2.1. Morphology and size studies  
4.3.2.1.1. Scanning electron microscopy of plain and Ibuprofen loaded composite and 
bilayer films 
Scanning electron microscopy (SEM) was used to investigate the differences in film morphology due 
to method of preparation (composite and bilayer) and addition of ibuprofen to plain films. SEM 
micrographs of the surface and cross sectional of the composite and bilayer films with and without 
ibuprofen were presented in Figure 115 to 117. 
Plain gellan (G) film exhibited a smooth and homogenous surface and cross section with a 
continuous and compact matrix in Figure 115. Similar report was made by Chang et al. about gellan 
films exhibiting smooth and dense morphological structures required to prevent apical migration of 
fibroblasts into bony defects in the development of regenerative barrier membrane [17]. 
                                                                                
Figure 115 Scanning electron micrographs of gellan films (A) surface of plain gellan G film (B) cross section of G film. 
Gellan-DEAE-Dextran (GDD) PEC composite films exhibited increased surface irregularity and cross 
section morphologies with the addition of increasing concentration of DEAE-Dextran in Figure 116. 
While the gellan-DEAE-Dextran (G/DDB) PEC bilayer films exhibited smooth and homogenous 
A B 
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surfaces due to the DEAE-Dextran coat on the surface of the films in Figure 117. The cross section of 
the G/DDB bilayer films was homogenous. 
 
Figure 116 Scanning electron micrographs of gellan-DEAE-Dextran composite films (A) surface of GDD 2:0.125 (B) cross-
section of 2:0.125 (C) surface of GIbDD 2:0.25  (D) cross-section of GIbDD 2:0.25 (E) surface of GIbDD 2:0.5 (F) cross-
section of GIbDD 2:0.5 (G) surface of GIbDD 2:1 (H) cross-section of GIbDD 2:1. 
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Figure 117 Scanning electron micrographs of gellan-DEAE-Dextran PEC bilayer films (A) surface of G/DDB 2:0.125 (B) 
cross-section of G/DDB 2:0.125  (C) surface of G/DDB 2:0.25 (D) cross-section of G/DDB 2:0.25  (E) surface of G/DDB 2:0.5 
(F) cross-section of G/DDB 2:0.5 (G) surface of G/DDB 2:1 and (H) cross-section of G/DDB 2:1. 
The effect of the incorporation of ibuprofen into the films was evaluated by the scanning electron 
microscopy (SEM). The surface and cross sectional micrographs of the prepared films are presented 
in Figures 118 to 120.   
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Figure 118 Scanning electron micrographs of ibuprofen loaded gellan binary film (A) surface morphology of GIb (B) cross-
section of GIb 
The incorporation of ibuprofen caused changes on the film surfaces with GIb and GIbDD showing 
clearly visible spheres with concentric layers dispersed throughout the film matrix and particle sizes 
of 7.85 µm and 7.79 to 3.71 µm respectively. The particle sizes of the spheres on the surfaces of the 
GIbDD films decreased with increasing concentration of DEAE-Dextran. Bierhalz et al. reported 
observing the crystals of natamycin on the film surface compared to the control films which had 
homogenous film surfaces [33]. There are more concentric layers round the spheres in the ibuprofen 
loaded complex films (GIbDD) in Figure 119 when compared with GIb films in Figure 118, indicating 
that extra layers where formed by addition of DEAE-Dextran. The particle sizes of GIbDD films were 
smaller compared to GIb films. The cross section of the films exhibited spherical patterns disperse 
along its plane with particle sizes in the range of 2.56 to 4.12 µm. Ibuprofen dissolved completely in 
sodium hydroxide as molecular state, hence the drug was distributed homogenously in the formed 
films. 
 
A B 
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Figure 119 Scanning electron micrographs of ibuprofen loaded gellan-DEAE-Dextran complex composite films (A) surface 
of GIbDD 2:0.125  (B) cross-section of GIbDD 2:0.125  (C) surface of GIbDD 2:0.25  (D) cross-section of GIbDD 2:0.25 (E) 
surface of GIbDD 2:0.5  (F) cross-section of GIbDD 2:0.5 (G) surface of GIbDD 2:1  (H) cross-section of GIbDD 2:1. 
The GIb/DDB films in Figure 120 showed less spherical patterns on the surface with somewhat 
empty pores which may have been caused by the diffusion of Ibuprofen out of the gellan base layer 
while being immersed in DEAE-Dextran solutions. The depletion was also exhibited along the cross 
section of the Ibuprofen loaded bilayer films. The particle sizes of spheres on the surface of GIb/DDB 
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films were in the range of 217 to 3446 nm with GIb/DDB film only in the micrometer range. The 
particle sizes decreased with increasing concentration of DEAE-Dextran.  
 
Figure 120 Scanning electron micrographs of ibuprofen loaded gellan-DEAE-Dextran complex bilayer films (A) surface of 
GIb/DDB 2:0.125 (B) cross-section of GIb/DDB 2:0.125 (C) surface of GIb/DDB 2:0.25 (D) cross-section of GIb/DDB 2:0.25 
(E) surface of GIb/DDB 2:0.5  (F) cross-section of GIb/DDB 2:0.5 (G) surface of GIb/DDB 2:1  (H) cross-section of GIb/DDB 
2:1. 
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The particle sizes exhibited on the surfaces of GIb/DDB bilayer films were smaller when compared to 
particle sizes on GIb and GIbDD composite films. The particle sizes of the composite and bilayer films 
were significantly reduced (p < 0.05, n = 4) when compared to raw ibuprofen crystals of 31.42 µm. 
4.3.2.1.2. Atomic force microscopy (AFM) 
Atomic Force Microscopy (AFM) is a characterization technique that can provide direct spatial 
mapping of surface topography and surface heterogeneity with nanometer resolution [34]. The AFM 
imaging of the films was done under contact mode with intrinsic challenges which include: difficulty 
in achieving ultimate high resolution; transient stick-and-slip caused by lateral force which may lead 
to sample damage. These problems are overcome by the introduction of Acoustic AC mode which 
removes the tip or sample degradation effects and makes it a good technique of imaging polymers.  
The topography retrace images of G and GDD films are shown in Figures 121 and 122. The G film 
image exhibited a gellan rich surface while the GDD 2:0.5 film (representative) showed a gellan-
DEAE-Dextran rich surface. 
 
Figure 121 Topography retrace image of plain gellan G film. 
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Figure 122 Topography retrace image of gellan-DEAE-Dextran GDD 2:0.5 composite film. 
The topography retrace images of GIb and GIbDD 2:0.5 composite films are shown in Figure 123 and 
124. The GIb image exhibited one concentric layer (gellan) round the core (ibuprofen) of the sphere 
formed in the film while two concentric layers were formed round the GIbDD sphere depicting a 
core (ibuprofen) surrounded by two shells (first is DEAE-Dextran, followed by the gellan coat). These 
images were similar to those exhibited by SEM micrographs of the films. The topography first trace, 
amplitude and phase trace images of the films were presented in Figures 164 to 166 in the Appendix 
I. 
 
Figure 123 Topography retrace image of ibuprofen loaded gellan GIb film. 
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Figure 124 Topography retrace image of ibuprofen loaded gellan-DEAE-Dextran GIbDD 2:0.5 composite film. 
4.3.2.2. Film thickness 
The results of the average film thickness of the plain composite and bilayer films were presented in 
Table 80. The thickness of  plain gellan reference G (2% gellan) film  was 0.062 mm. Chang et al. 
reported the thickness of 2% gellan film prepared without plasticizer (glycerol) to be 0.034 mm 
[17].The thickness of the films prepared ranged from 0.082 to 0.167mm for the composite GDD 
films. The values indicated that there was a significant increase in thickness of the films on addition 
of DEAE-Dextran to the formulations. The GDD composite films were thus significantly higher than 
the plain gellan G film (p < 0.05, n = 6). 
The profile of the thickness of the films was presented in Figure 125. There was an increase in 
thickness of GDD composite films with increasing DEAE-Dextran concentration and were greater 
than the baseline G film with thickness 0.062 mm. The increase in thickness is expected as the 
increase in polymer concentration leads to higher solution viscosity.  
 The G/DDB PEC bilayer films formed ranged from 0.060 to 0.073 mm.  There was an initial increase 
and a decrease with increasing concentration of DEAE-Dextran. The statistical analysis of the film 
thickness results showed that the addition of DEAE-Dextran to the plain gellan G film did not 
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significantly change the thickness of the G/DDB bilayer films (p > 0.05, n = 6). However, the GDD 
composite films were significantly thicker than the G/DDB bilayer films (p < 0.05, n = 6).  
Table 80  The thickness of gellan films. Each value represents mean ± S.D (n = 6) 
Formulation Film Thickness (mm) Mean ± S.D 
G  0.062±0.004 
GDD 2:0.125 0.082±0.004 
GDD 2:0.25 0.097±0.008 
GDD 2:0.5 0.138±0.010 
GDD 2:1 0.167±0.008 
G/DDB 2:0.125 0.073±0.008 
G/DDB 2:0.25 0.062±0.004 
G/DDB 2:0.5 0.060±0.001 
G/DDB 2:1 0.065±0.005 
 
 
Figure 125 Film thickness of GDD composite and G/DDB bilayer films. Each data point represents mean ± S.D (n = 6). 
The profile of the ibuprofen loaded composite and bilayer film thickness was presented in Figure 
126. The thickness of the films prepared ranged from 0.097 to 0.117 mm for the ibuprofen loaded 
composite films shown in Table 81. The thickness of film increased with increasing concentration of 
DEAE-Dextran in the films except the thickness decreased to a minimum at low concentration of 
DEAE-Dextran at 2:0.25 gellan-DEAE-Dextran weight ratio. The GIbDD ibuprofen loaded composite 
films formed were significantly thicker (p < 0.05, n = 6) than the baseline ibuprofen loaded film (GIb) 
with thickness of 0.078 mm. The addition of ibuprofen to the formulations changed the thickness of 
the films significantly. Similar values were reported for gellan films loaded with ascorbic acid with 
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thickness in the range of 0.085 (±0.005 mm) [35]. The GIb/DDB PEC bilayer films had a thickness of 
0.072 (±0.005 mm). The GIb/DDB ibuprofen loaded bilayer films formed were thinner than the single 
component ibuprofen loaded film (GIb). The GIbDD ibuprofen loaded composite films were 
significantly thicker (p < 0.05, n = 6) than the GIb/DDB ibuprofen loaded bilayer films. 
Table 81  The thickness of ibuprofen loaded gellan, gellan-DEAE-Dextran composite and bilayer films. Each value 
represents mean ± S.D (n = 6). 
Formulation Film Thickness (mm) 
GIb 0.078±0.004 
GIbDD 2:0.125 0.100±0.006 
GIbDD 2:0.25 0.097±0.008 
GIbDD 2:0.5 0.110±0.006 
GIbDD 2:1 0.117±0.005 
GIb/DDB 2:0.125 0.077±0.005 
GIb/DDB 2:0.25 0.067±0.005 
GIb/DDB 2:0.5 0.072±0.007 
GIb/DDB 2:1 0.072±0.007 
 
 
Figure 126 Film thickness of GIbDD composite and GIb/DDB bilayer films. Each data point represents mean ± S.D (n = 6).  
4.3.2.3. Mechanical properties 
The effects of DEAE-Dextran concentration on the mechanical properties of gellan films were 
evaluated. The mechanical properties of gellan, gellan-DEAE-Dextran composite and bilayer films 
were shown in Table 82 and 83.   
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The tensile strength of the films which indicated the films resistance to abrasion for plain gellan G 
film was 17.14 MPa, while GDD composite films ranged from 0.60 to 16.26 MPa. The addition of 
DEAE-Dextran to gellan decreased the tensile strength of the composite blend films. Statistical 
analysis indicated that lower concentrations of DEAE-Dextran (0.125 and 0.25%) did not cause 
significant reduction (p > 0.05, n = 4) in the tensile strength of GDD 2:0.125 and GDD 2:0.25 
compared to the plain gellan G film. However, higher concentrations of DEAE-Dextran (0.5 and 1.0 
%) caused significant reduction (p < 0.05) in the tensile strength of GDD 2:0.5 and GDD 2:1 film. This 
could be due to the interaction between DEAE-Dextran and gellan which resulted in a more flexible 
film. Comparable values were reported by Lee et al. which ranged from 12.4 to 59 MPa for 
gellan/gelatin composite films with the tensile strength decreasing linearly as the gelatin ratio 
increased [10]. The tensile strength of the G/DDB bilayer films ranged from 11.98 to 20.33 MPa with 
G/DDB 2:0.125 and G/DDB 2:0.5 exhibiting higher tensile strength than G single component film. The 
addition of DEAE-Dextran in the bilayer method did not significantly change (p > 0.05, n = 4) the 
tensile strength of the films when compared to the plain gellan G film. The tensile strength profile in 
Figure 127 showed that the G/DDB bilayer film exhibited two maxima values at 0.125 and 0.5% 
DEAE-Dextran as the concentration of DEAE-Dextran increased. The G/DDB bilayer films exhibited 
significantly higher (p < 0.05, n = 4) tensile strength than their corresponding GDD composite films. 
Table 82 Mechanical properties of gellan and gellan-DEAE-Dextran PEC composite films. Each value represents mean ± 
SD (n = 4). 
Formulation Tensile strength(MPa) Percentage Tensile Elongation (%) Elastic Modulus (MPa) 
G  17.14±2.43 19.53±2.35 742.00±40.93 
GDD 2:0.125  16.26±2.13 13.90±2.30 480.67±86.64 
GDD 2:0.25 10.88±1.74 20.23±1.59 201.33±17.90 
GDD 2:0.5 6.32±0.62 18.63±3.45 22.23±4.02 
GDD 2:1 0.60±0.07 9.37±0.91 17.80±5.27 
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Table 83 Mechanical properties of gellan and gellan-DEAE-Dextran PEC bilayer films. Each value represents mean ± SD (n 
= 4). 
Formulation Tensile strength 
(MPa) 
Percentage Tensile 
Elongation (%) 
Elastic Modulus (MPa) 
G  17.14±2.43 19.53±2.35 742.00±40.93 
G/DDB 2:0.125  20.33±3.25 2.33±0.10 927.00±105.24 
G/DDB 2:0.25 12.91±1.62 1.00±0.05 1206.67±166.23 
G/DDB 2:0.5 19.36±2.78 1.37±0.12 1212.00±100.02 
G/DDB 2:1 11.98±1.42 0.80±0.06 1261.67±106.89 
 
 
Figure 127 Effect of DEAE-Dextran concentration on the tensile strength of gellan and gellan-DEAE-Dextran PEC 
composite and bilayer films. Each data point represents mean ± SD (n = 4). 
The percentage tensile elongation which indicated the flexibility of the films was 19.53% for G film; 
ranged from 9.37 to 20.23% for GDD films and from 0.88 to 2.33% for G/DDB films. The addition of 
DEAE-Dextran to the GDD films did not cause significant change (p > 0.05, n = 4) except with the 
higher concentration (GDD 2:1) when compared to plain gellan G film. The GDD 2:0.25 composite 
film was the only mixing ratio which exhibited a higher tensile elongation than gellan film. 
 G/DDB bilayer films were less flexible with significantly reduced (p < 0.05, n = 4) tensile elongation 
when compared with the GDD composite films. The profile in Figure 128 showed that the tensile 
elongation of GDD composite film initially decreased then increased and finally decreased as DEAE-
Dextran concentration increased. While G/DDB bilayer films decreased as the DEAE-Dextran 
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increased. This suggests that the incorporation of DEAE-Dextran reduced the flexibility and increased 
brittleness of gellan composite and bilayer films.  
 
Figure 128 Effect of DEAE-Dextran concentration on the percentage tensile elongation of gellan and gellan-DEAE-Dextran 
PEC composite and bilayer films. Each data point represents mean ± SD (n = 4). 
Young’s modulus also known as elastic modulus is used to measure the stiffness of an elastic 
material. Stiffness is the capacity of a material to resist deformation in the elastic range.  The elastic 
modulus was 742 MPa for G film; ranged from 17.80 to 480.67 MPa for GDD films and 927 to 
1261.67 MPa for G/DDB films in Figure 129. Lower concentrations of DEAE-Dextran (0.125 and 
0.25%) did not cause significant reduction (p > 0.05, n = 4) in the elastic modulus of GDD 2:0.125 and 
GDD 2:0.25 compared to the plain gellan G film. However, higher concentrations of DEAE-Dextran 
(0.5 and 1.0%) caused significant reduction (p < 0.05, n = 4) in the elastic modulus of GDD 2:0.5 and 
GDD 2:1 film. The G/DDB films had significantly higher (p < 0.05, n = 4) elastic modulus values than G 
and GDD films. The higher elastic modulus values exhibit greater stiffness when compared to lower 
elastic modulus values characteristic of softer films. The GDD composite films showed the lowest 
value in tensile strength and elastic modulus but highest percentage tensile elongation. This can be 
attributed to the presence of DEAE-Dextran; where the gellan-DEAE-Dextran bonds reduced the 
intermolecular forces along polymer chains, which reduced the elastic modulus and increased the 
percentage tensile elongation.  The GDD composite films were weaker and more flexible when 
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compared to G/DDB bilayer films. Mechanical strength is increased by increasing the cross linking 
density leading to stronger films being formed. However, with increase in cross linking density, there 
is a decrease in percentage elongation of the films resulting in brittleness.  
 
Figure 129 Effect of DEAE-Dextran concentration on the elastic modulus of gellan and gellan-DEAE-Dextran PEC 
composite and bilayer films. Each data point represents mean ± SD (n = 4). 
The mechanical properties of ibuprofen loaded gellan, gellan-DEAE-Dextran composite and bilayer 
films were shown in Table 84 and 85.  
Table 84 Mechanical properties of drug loaded gellan composite films. Each value represents mean ± SD (n = 4). 
Formulation Tensile strength 
(MPa) 
Percentage Tensile 
Elongation (%) 
Elastic Modulus (MPa) 
G  17.14±2.43 19.53±2.35 742.00±40.93 
GIb  7.61±0.53 21.93±1.05 462.33±44.92 
GIbDD 2:0.125  3.31±0.14 20.23±4.27 245.67±22.27 
GIbDD 2:0.25 5.62±0.58 18.93±2.47 341.67±45.28 
GIbDD 2:0.5 5.24±0.42 20.17±0.86 342.33±36.14 
GIbDD 2:1 4.14±0.37 22.4±1.74 185.00±21.63 
 
Table 85 Mechanical properties of drug loaded gellan bilayer films. Each value represents mean ± SD (n = 4). 
Formulation Tensile strength 
(MPa) 
Percentage Tensile 
Elongation (%) 
Elastic Modulus (MPa) 
GIb  7.61±0.53 21.93±1.05 462.33±44.92 
GIb/DDB 2:0.125  28.66±3.94 5.33±0.15 1149.33±97.08 
GIb/DDB 2:0.25 10.91±1.12 1.10±0.35 1142.50±94.00 
GIb/DDB 2:0.5 19.69±2.58 2.50±0.70 1036.00±95.66 
GIb/DDB 2:1 24.67±2.71 2.63±0.26 179.00±6.57 
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The tensile strength GIb film was 7.61 MPa, while GIbDD composite films ranged from 3.31 to 5.62 
MPa. The incorporation of ibuprofen into gellan significantly decreased (p < 0.05, n = 4) the tensile 
strength of the drug loaded gellan (GIb) and GIbDD composite films. The decrease in tensile strength 
may be due to the incorporated ibuprofen  causing changes in the polymeric structure [33]. Bierhalz 
et al. reported a reduction in tensile strength on incorporation of natamycin into alginate/pectin 
composite films which may be attributed to modifications in the polymeric structure [33]. The 
tensile strength of the GIb/DDB bilayer films ranged from 10.91 to 28.66 MPa exhibiting significantly 
higher (p < 0.05, n = 4) tensile strength than GIb and GIbDD films in Figure 130. The bilayer films may 
have more linear and organized chain, giving more energetic crosslinking and higher cohesive forces 
between the chains.  
 
Figure 130 Effect of DEAE-Dextran concentration on the tensile strength of ibuprofen loaded gellan and gellan-DEAE-
Dextran PEC composite and bilayer films. Each data point represents mean ± SD (n = 4). 
The percentage tensile elongation which indicated the flexibility of the films was 21.93% for GIb film; 
ranged from 18.93 to 22.40% for GIbDD films and from 1.10 to 5.33% for GIb/DDB films in Figure 
131. GIb/DDB films were less flexible than the GIb and the GIbDD films.  The brittleness of the 
GIb/DDB films which was as low as 1.1% may be due to drying of the films twice (double heat 
treatment) before and after immersion during the bilayer preparation.  
 
0 
5 
10 
15 
20 
25 
30 
35 
0 0.2 0.4 0.6 0.8 1 
Te
n
si
le
 s
tr
e
n
gt
h
 (
M
P
a)
 
DEAE-Dextran concentration (%w/v) 
GIbDD 
Gib/DDB 
252 | P a g e  
 
 
Figure 131 Effect of DEAE-Dextran concentration on the percentage tensile elongation of ibuprofen loaded gellan and 
gellan-DEAE-Dextran PEC composite and bilayer films. Each data point represents mean ± SD (n = 4). 
The elastic modulus was 462.33 MPa for GIb film; ranged from 185.00 to 342.33 MPa for GIbDD films 
and 179.00 to 1149.33 MPa for GIb/DDB films in Figure 132. The GIb/DDB films except GIb/DDB 2:1 
had higher elastic modulus values than GIb and GIbDD films. The addition of ibuprofen resulted in 
decreased elastic modulus values of GIb and GIbDD 2:0.125 when compared to plain G and GDD 
2:0.125 films. However, the effect of addition of ibuprofen on higher mixing ratios of gellan-DEAE-
Dextran (GIbDD 2:0.25, GIbDD 2:0.5 and GIbDD 2:1) resulted in significant increase (p < 0.05, n = 4) 
in elastic modulus values when compared to the plain GDD films. The mechanical properties of 
gellan film were improved when loaded with ibuprofen by the bilayer immersion method GIb/DDB 
films but they exhibited low tensile elongation values caused by the effect of heat during the two 
drying stages.  
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Figure 132 Effect of DEAE-Dextran concentration on the elastic modulus of ibuprofen loaded gellan and gellan-DEAE-
Dextran PEC composite and bilayer films. Each data point represents mean ± SD (n = 4). 
4.3.3. Spectroscopic studies of plain and ibuprofen loaded composite and bilayer films - 
Fourier Transform Infrared 
To investigate possible chemical or physical interaction between ibuprofen and excipients, the 
functional groups exhibited by the plain and drug loaded composite and bilayer film were studied by 
the FTIR spectrometry technique. Figure 133 shows the FTIR spectra of gellan, DEAE-Dextran; gellan 
and GDD films. Gellan powder showed significant peaks at 3318 cm-1, 2897 cm-1, 1601 cm-1 and 1403 
cm-1 presented in Tables 86 and 87. The broad absorption band at 3318 cm-1 is assigned to the 
stretching –OH groups in gellan. The peak at 2897 cm-1 is due to the stretching vibrations of the –CH2 
group [11]. The peaks at 1601 cm-1 and 1403 cm-1 are assigned to the characteristic absorption band 
of carboxyl group in gellan  [36]. Due to the presence of free carboxylate groups in gellan, it becomes 
anionic with characteristic property of undergoing ionic gelation.  
The C-O stretching peak at 1021 cm-1 for pure gellan powder shifted to a higher peak at 1030 cm-1 in 
plain gellan G film, from 1027 to 1029 cm-1  in GDD films; and from 1016 to 1028 cm-1 in G/DDB films 
shown in Figures 133 and 134.  
The N-H deformation peak at 1644 cm-1 and 1007 cm-1 C-N stretching peak in DEAE-Dextran powder 
disappeared in the spectra of the GDD PEC composite films and G/DDB bilayer films. A new peak at 
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1551 cm-1 corresponding to secondary -NH2 group was observed in the GDD 2:0.5 films. The peak at 
994 cm-1 seen in G and GDD films disappeared in the G/DDB films. The O-H peak at 3318 cm-1 in pure 
gellan and at 3309 cm-1 DEAE-Dextran shifted to a range of 3283 cm-1 and 3293 cm-1 in the GDD films; 
and a range of 3277 to 3288 cm-1 in the G/DDB films. Similar shifts from peak at 3273 cm-1 for gellan  
to a range of 3223 to 3229 cm-1 for the blends were reported in gellan and PVA blends suggesting 
interactions in the blends [37]. Contributions from the components (gellan and DEAE-Dextran) could 
be easily seen with slight variations in the GDD complex films at a range of 2926 to 2932 cm-1 (from 
2922 cm-1  in DEAE-Dextran), 1966 to 1977 cm-1 (from 1981 cm-1  in DEAE-Dextran), 1609 cm-1 (from 
1601 cm-1  in gellan), 1408 cm-1 (from 1403 cm-1 in gellan), 1148 cm-1 (from 1144 cm-1 in DEAE-
Dextran). The shifts and disappearances in peaks show there is a possible interaction between the 
two polymers.   
Table 86 Spectral characteristics of gellan and gellan – DEAE-Dextran PEC composite films. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Gellan-reference 3318 2897 
2324 
2163 
2080 
2018 
1974 
1601 
1403 
1295 
1198 
1019 
891 
836 
806 
DEAE-Dextran-
reference 
3309 2922 
2656 
2487 
2287 
2240 
2161 
2145 
2081 
2018 
2010 
1981 
 
1644 
1456 
1399 
1343 
1269 
1144 
1102 
1007 
 
915 
844 
797 
760 
G  3296 2929 
2884 
2163 
2087 
2020 
1977 
1609 
1408 
1338 
1235 
1148 
1105 
1029 
993 
922 
847 
812 
 
GDD 2:0.125 3289 2932 
2883 
2186 
2163 
2140 
2081 
2019 
1976 
1966 
1609 
1408 
1338 
1235 
1148 
1106 
1028 
993 
922 
849 
813 
GDD 2:0.25 3289 2932 
2883 
2186 
2163 
2080 
2046 
2019 
1976 
1966 
1609 
1408 
1338 
1235 
1148 
1106 
1028 
 
993 
922 
849 
813 
 
GDD 2:0.5 
 
 
 
3283 
 
 
 
2925 
2883 
2339 
2232 
2164 
2139 
2080 
1976 
1609 
1551 
1408 
1338 
1235 
1149 
1105 
1028 
994 
922 
849 
812 
GDD 2:1 3293 2926 
2883 
2165 
2180 
1977 
1609 
1408 
1339 
1236 
1149 
1105 
1028 
923 
886 
848 
785 
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Figure 133 The FTIR spectra of gellan and PEC composite films (a) G , (b) GDD 2:0.125 , (c) GDD 2:0.25, (d) GDD 2:0.5, (e) 
GDD 2:1, (f) Gellan powder-reference and (g) DEAE-Dextran powder-reference. 
Table 87 Spectral characteristics of gellan and gellan – DEAE-Dextran PEC bilayer films. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Gellan-reference 3318 2897 
2324 
2163 
2080 
2018 
1974 
1601 
1403 
1295 
1198 
1019 
891 
836 
806 
DEAE-Dextran-
reference 
3309 2922 
2656 
2487 
2287 
2240 
2161 
2145 
2081 
2018 
2010 
1981 
1644 
1456 
1399 
1343 
1269 
1144 
1102 
1007 
 
915 
844 
797 
760 
G  3296 2929 
2884 
2163 
2087 
2020 
1977 
1609 
1408 
1338 
1235 
1148 
1105 
1029 
993 
922 
847 
812 
 
G/DDB 2:0.125 3287 2923 
2883 
2191 
2163 
2147 
2103 
2051 
2019 
1999 
1979 
1607 
1405 
1338 
1292 
1233 
1149 
1105 
1026 
 
 
922 
841 
812 
G/DDB 2:0.25 3288 2922 
2884 
2323 
2195 
2175 
2163 
2136 
2115 
2048 
2015 
1987 
1967 
1606 
1405 
1338 
1293 
1234 
1148 
1101 
1069 
1025 
922 
837 
872 
 
G/DDB 2:0.5 3289 
 
 
 
2924 
2884 
2283 
2203 
2164 
2147 
2103 
2051 
2015 
1987 
1967 
1606 
1406 
1338 
1293 
1237 
1149 
1105 
1024 
 
922 
840 
812 
G/DDB 2:1 3273 
2922 
 
2884 
2307 
2212 
2165 
2151 
2049 
2016 
1986 
1606 
1404 
1338 
1236 
1148 
1103 
1070 
1016 
923 
837 
812 
675 
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Figure 134 The FTIR spectra of bilayer films  (a) G/DDB 2:0.125 , (b) G/DDB 2:0.25, (c) G/DDB 2:0.5,  (d) G/DDB 2:1, (e) 
Gellan powder-reference and (f) DEAE-Dextran powder-reference. 
The FTIR spectra of pure ibuprofen, gellan, DEAE-Dextran; ibuprofen loaded gellan - DEAE-Dextran 
composite and bilayer films is shown in Figures 135 and 136. Gellan showed significant peaks at 
3318 cm-1, 2897 cm-1, 1601 cm-1 and 1403 cm-1 presented in Tables 88 and 89. The broad absorption 
band at 3318 cm-1 is assigned to the stretching –OH groups in gellan. The peak at 2897 cm-1 is due to 
the stretching vibrations of the –CH2 group [11]. Pure DEAE-Dextran showed N-H deformation 
vibration at 1644 cm-1. This peak is assigned to the free N-H group present on DEAE-Dextran. The 
peaks at 2921 cm-1 and 3295 cm-1 are assigned to N-H stretching and C-H stretching vibrations. The 
peaks at 1606 cm-1 and 1408 cm-1 are assigned to the characteristic absorption band of carboxyl 
group in gellan in literature [36]. The bands assigned as the  finger prints of ibuprofen in literature 
include 2992 cm-1, 1706 cm-1, 1230 cm-1  and 779 cm-1 [38-39]. The FTIR spectra of GIb film showed 
the disappearances of 1403 cm-1   peak of gellan, strong carbonyl absorbance at 1706 cm-1 and 1230 
cm-1 peaks of ibuprofen. Instead, a new –NH2 group peak at 1512 cm
-1 was observed. Contributions 
from ibuprofen and gellan were observed in the GIb complex with slight variations. The C-O 
stretching peak at 1021 cm-1 for pure gellan powder shifted to 1028 cm-1 in GIb, 1032 cm-1 in GIbDD 
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composite films and a range of 1008 cm-1 to 1023 cm-1 in GIb/DDB bilayer films. The shifts and 
disappearances in peaks show there is a possible hydrophobic interaction between gellan and 
ibuprofen.  
The C=O and C-C stretching peak at 1710 cm-1 (carbonyl) and 1229 cm-1 for pure ibuprofen 
disappeared in the spectra of ibuprofen loaded films GIbDD composite and GIb/DDB bilayer films 
which suggests a possible electrostatic interaction forming a carboxylate. The N-H deformation peak 
at 1644 cm-1 in DEAE-Dextran powder disappeared in the spectra of ibuprofen loaded films GIbDD 
composite and GIb/DDB bilayer films. The peak at 1608 cm-1 disappeared in the GIbDD 2:0.125 
composite, GIb/DDB 2:0.5 and GIb/DDB 2:1 bilayer films. The peak at 3318 cm-1 in pure gellan and 
3309 cm-1 in DEAE-Dextran shifted to a range of 3299 to 3307 cm-1 in the GIbDD films; and a range of 
3288 to 3308 cm-1. While in gellan, a peak was observed at 2827 cm-1 and in DEAE-Dextran, at 2927 
cm-1, GIbDD films exhibited two single peaks at 2927 cm-1 and 2881 cm-1.  Similar shifts from 2927 
cm-1 in gellan and 2938 cm-1 in PVA to a single peak at 2934 cm-1 in the blend were reported in gellan 
and PVA blends confirming the interaction of different OH groups in the gellan and DEAE-Dextran 
complex [37]. 
The new peak at 1512 cm-1 may be attributed to the asymmetric stretching vibration of COO- since 
carboxylic acid salts exhibit strong characteristic COO- band in the region of  1650 to 1550 cm-1  
suggesting the peak of carboxylate ion [40]. This suggests that carboxylate ion may be forming a 
complex with the amine group of DEAE-Dextran. This result shows that polyelectrolyte complex was 
formed. 
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Table 88 Spectral characteristics of ibuprofen loaded gellan and gellan – DEAE-Dextran PEC composite films. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Ibuprofen-
reference 
3088 
3044 
3015 
2991 
2980 
2954 
2922 
2868 
2851 
2728 
2631 
2601 
2542 
2203 
2163 
2144 
2115 
2079 
1911 
1887 
1803 
1706 
1563 
1507 
1461 
1451 
1442 
1418 
1379 
1365 
1329 
1321 
1305 
1268 
1229 
1183 
1168 
1123 
1092 
1073 
1068 
1008 
969 
935 
880 
865 
849 
834 
820 
810 
779 
746 
690 
667 
Gellan-reference 3318 2897 
2324 
2163 
2080 
2018 
1974 
1601 
1403 
1295 
1198 
1019 
891 
836 
806 
DEAE-Dextran-
reference 
3309 2922 
2656 
2487 
2287 
2240 
2161 
2145 
2081 
2018 
2010 
1981 
 
1644 
1456 
1399 
1343 
1269 
1144 
1102 
1007 
 
915 
844 
797 
760 
GIb 3294 2932 
2880 
2340 
2163 
2080 
2047 
1976 
1608 
1564 
1512 
1455 
1396 
1364 
1289 
1192 
1099 
1028 
991 
922 
850 
812 
 
GIbDD 2:0.125 3307 2928 
2872 
2344 
2187 
2163 
2079 
1981 
1906 
1563 
1512 
1456 
1395 
1364 
1287 
1195 
1099 
1032 
992 
923 
885 
850 
GIbDD 2:0.25 3305 2930 
2881 
2324 
2163 
2140 
2078 
2018 
1982 
 
1607 
1564 
1512 
1455 
1395 
1364 
1288 
1193 
1098 
1032 
992 
922 
887 
849 
814 
GIbDD 2:0.5 3307 2927 
2881 
2322 
2163 
2108 
2017 
1977 
1948 
1607 
1565 
1512 
1455 
1395 
1364 
1288 
1201 
1147 
1108 
1032 
922 
889 
849 
812 
GIbDD 2:1 3299 2928 
2882 
2339 
2163 
2079 
2019 
1977 
1916 
1607 
1566 
1511 
1456 
1394 
1363 
1288 
1240 
1203 
1149 
1106 
1032 
922 
886 
849 
811 
259 | P a g e  
 
 
Figure 135 The FTIR spectra ibuprofen loaded composite films (a) GIb , (b) GIbDD 2:0.125, (c) GIbDD 2:0.25, (d) GIbDD 
2:0.5,  (e) GIbDD 2:1, (f) Ibuprofen powder-reference. (g) Gellan powder-reference and (h) DEAE-Dextran powder-
reference. 
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Table 89 Spectral characteristics of ibuprofen loaded gellan and gellan – DEAE-Dextran PEC bilayer films. 
Formulation Position of absorption band (Wavenumber) / cm-1 
Ibuprofen-
reference 
3088 
3044 
3015 
2991 
2980 
 
2954 
2922 
2868 
2851 
2728 
2631 
2601 
2542 
 
2203 
2163 
2144 
2115 
2079 
1911 
1887 
1803 
1706 
 
1563 
1507 
1461 
1451 
1442 
1418 
1379 
1365 
1329 
1321 
1305 
1268 
1229 
1183 
1168 
1123 
1092 
1073 
1068 
1008 
969 
935 
880 
865 
849 
834 
820 
810 
779 
746 
690 
667 
Gellan-reference 3318 2897 
2324 
2163 
2080 
2018 
1974 
1601 
1403 
1295 
1198 
1019 
891 
836 
806 
DEAE-Dextran-
reference 
3309 2922 
2656 
2487 
2287 
2240 
2161 
2145 
2081 
2018 
2010 
1981 
 
1644 
1456 
1399 
1343 
1269 
1144 
1102 
1007 
 
915 
844 
797 
760 
GIb 3294 2932 
2880 
2340 
2163 
2080 
2047 
1976 
1608 
1564 
1512 
1455 
1396 
1364 
1289 
1192 
1099 
1028 
991 
922 
850 
812 
 
GIb/DDB 2:0.125 3308 2925 
2325 
2191 
2165 
2146 
2080 
2009 
1987 
1905 
1606 
1579 
1567 
1512 
1454 
1394 
1364 
1290 
1237 
1149 
1105 
1023 
922 
890 
850 
812 
GIb/DD 2:0.25 3301 2927 
2285 
2162 
 
2064 
2009 
1987 
 
1606 
1510 
1454 
1394 
1362 
1290 
1238 
1150 
1106 
1019 
922 
891 
841 
811 
674 
GIb/DDB 2:0.5 3302 2953 
2927 
2870 
2324 
2192 
2162 
2145 
2118 
2049 
2017 
1982 
 
1567 
1511 
1455 
1393 
1362 
1285 
1150 
1107 
1012 
921 
887 
853 
673 
GIb/DDB 2:1 3288 2953 
2923 
2326 
2187 
2161 
2137 
2064 
2050 
2009 
1986 
1703 
 
1567 
1511 
1461 
1385 
 
1362 
1283 
1150 
1110 
1008 
921 
886 
852 
754 
672 
665 
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Figure 136 The FTIR spectra of  ibuprofen loaded bilayer films (a) GIb/DDB 2:0.125, (b) GIb/DDB 2:0.25, (c) GIb/DDB 
2:0.5, (d) GIb/DDB 2:1, (e) Ibuprofen powder-reference, (f) Gellan powder-reference and  (g) DEAE-Dextran powder-
reference. 
4.3.4. Thermal analysis 
4.3.4.1.  Differential scanning calorimetry (DSC) 
DSC analysis was conducted to examine the thermal behaviour of gellan, GDD composite and G/DDB 
bilayer films and further study polymer-polymer and drug-polymer interaction. Therefore, the DSC 
thermal characteristics of G, GDD composite and G/DDB bilayer films were compared with pure 
gellan and DEAE-Dextran and presented in Figure 137; Table 90 and 91. Pure gellan powder 
exhibited a broad melting peak at 127.86 °C and exothermic decomposition peak at 254.84 °C. DEAE-
Dextran showed a glass transition endotherm (Tg) at 57.26 °C; a broad endothermic peak at 124.05 
°C due to its amorphous characteristic; a small peak at 201.21 °C and a final peak at 268.50 °C 
attributed to the decomposition of DEAE-Dextran. 
Representative DSC thermograms and their derivatives of G, GDD and G/DDB films were presented 
in Figure 138. The DSC thermogram exhibited endothermic melting peak for G film at 127.81 ˚C, GDD 
films ranged from 125.70 to 140.83 ˚C while for G/DDB films, ranged from 125.21 to 135.20 ˚C. The 
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DSC curve of plain gellan G film exhibited an exothermic peak at 255.89 ˚C which indicated the 
decomposition of the polymer presented in Figure 138A and this corresponds to the step of 
inflection on the TGA curve in Figure 146. The GDD films showed exothermic peaks at 254.81 to 
261.63 ˚C while G/DDB films ranged from 264.34 to 266.59 ˚C caused by the thermal degradation of 
the films.  The G/DDB films were thermally more stable than the G and GDD films. The DSC melting 
profile of GDD was presented in Figure 139 with an initial decrease, an increase, a decrease and 
finally an increase in melting point as the DEAE-Dextran concentration increased. The melting point 
profile of G/DDB exhibited an initial decrease and then increase with increasing DEAE-Dextran 
concentration. The enthalpy change profile of GDD in Figure 140 exhibited an initial decrease and a 
further increased as DEAE-Dextran concentration increased. The enthalpy change profile of G/DDB 
exhibited a steady increase in enthalpy change as DEAE-Dextran concentration increased.  
 
Figure 137 DSC thermograms of gellan and composite films (a) G , (b) GDD 2:0.125 , (c) GDD 2:0.25, (d) GDD 2:0.5, (e) 
GDD 2:1, (f) Gellan powder-reference and (g) DEAE-Dextran powder-reference. 
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Table 90 DSC of plain gellan and gellan-DEAE-Dextran PEC composite films. Each value represents mean ± SD (n = 4). 
Formulation Onset (°C) Peak (°C) End (°C) Delta H (J/g) Area (mJ) 
Gellan-reference 77.70±1.55 
246.56±12.37 
127.86±7.43 
264.02±12.75 
186.32±8.76 
270.88±12.86 
168.31±8.81 
-129.64±6.5 
1043.54±52.70 
-803.81±40.22 
DEAE-Dextran-
reference 
53.55±0.85 
87.43±1.22 
187.42±8.23 
245.83±12.74 
57.86±0.76 
124.05±4.16 
201.54±10.58 
268.50±11.78 
63.97±0.92 
158.87±5.34 
210.60±11.45 
281.53±13.66 
5.10±0.08 
139.17±5.64 
12.72±0.84 
70.84±0.92 
35.16±0.41 
960.30±40.48 
87.74±1.25 
488.852±21.22 
G  77.66±2.33 
253.70±8.23 
127.81±4.27 
255.89±10.68 
174.79±7.43 
262.69±11.57 
71.60±1.38 
137.33±5.14 
862.87±38.36 
789.62±31.54 
GDD 2:0.125  76.18±1.35 
259.07±8.20 
125.70±5.63 
261.63±11.77 
166.60±6.86 
267.61±11.48 
179.94±6.17 
99.92±2.79 
1025.65±52.66 
569.50±0.95 
GDD 2:0.25 96.24±2.23 
249.54±9.44 
138.55±5.33 
256.21±12.37 
178.88±6.94 
265.88±11.92 
122.06±4.76 
207.19±8.13 
805.57±38.73 
1367.49±62.46 
GDD 2:0.5 90.96±2.15 
250.46±8.77 
135.98±5.12 
255.88±10.66 
176.05±6.35 
267.74±10.93 
125.66±4.48 
161.91±5.70 
804.21±35.73 
1036.22±58.41 
GDD 2:1 93.75±1.11 
245.23±9.66 
140.83±5.14 
254.84±11.05 
182.79±7.12 
270.22±12.11 
116.87±4.66 
181.70±6.88 
666.16±22.46 
1035.68±14.21 
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Figure 138 DSC/DTG thermograms of (A) G, (B) GDD and (C) G/DDB films. 
A 
B 
C 
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Figure 139 DSC melting peak profiles of GDD and G/DDB films. Each data point represents mean ± S.D (n = 4). 
 
Figure 140 DSC enthalpy change profiles of GDD and G/DDB films. Each data point represents mean ± S.D (n = 4). 
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Figure 141 DSC thermograms of bilayer films  (a) G/DDB 2:0.125 , (b) G/DDB 2:0.25, (c) G/DDB 2:0.5,  (d) G/DDB 2:1, (e) 
Gellan powder-reference and (f) DEAE-Dextran powder-reference. 
Table 91 DSC of plain gellan and gellan-DEAE-Dextran PEC bilayer films. Each value represents mean ± SD (n = 4). 
Formulation Onset (°C) Peak (°C) End (°C) Delta H (J/g) Area (mJ) 
Gellan-reference 77.70±1.55 
246.56±12.37 
127.86±7.43 
264.02±12.75 
186.32±8.76 
270.88±12.86 
168.31±8.81 
-129.64±6.5 
1043.54±52.70 
-803.81±40.22 
DEAE-Dextran-
reference 
53.55±0.85 
87.43±1.22 
187.42±8.23 
245.83±12.74 
57.86±0.76 
124.05±4.16 
201.54±10.58 
268.50±11.78 
63.97±0.92 
158.87±5.34 
210.60±11.45 
281.53±13.66 
5.10±0.08 
139.17±5.64 
12.72±0.84 
70.84±0.92 
35.16±0.41 
960.30±40.48 
87.74±1.25 
488.852±21.22 
G  77.66±2.33 
253.70±8.23 
127.81±4.27 
255.89±10.68 
174.79±7.43 
262.69±11.57 
71.60±1.38 
137.33±5.14 
862.87±38.36 
789.62±31.54 
G/DDB 2:0.125  75.51±2.26 
244.56±7.08 
125.21±4.32 
265.78±10.96 
166.82±6.24 
269.95±12.11 
79.12±1.57 
14.08±0.07 
419.31±13.89 
76.03±1.95 
G/DDB 2:0.25 78.39±2.15 
261.28±9.31 
129.15±5.33 
264.34±12.37 
173.18±6.52 
269.46±12.86 
88.94±2.89 
25.77±0.58 
498.05±19.73 
144.36±5.55 
G/DDB 2:0.5 76.63±1.85 
245.28±8.77 
135.48±5.49 
266.84±12.66 
180.17±7.22 
273.21±12.93 
119.26±3.48 
10.81±0.07 
878.85±25.73 
63.76±1.41 
G/DDB 2:1 79.96±1.11 
246.51±11.65 
135.50±5.14 
266.59±12.05 
181.27±7.58 
271.09±13.11 
143.49±5.66 
3.75±0.08 
947.02±29.13 
24.77±0.21 
 
DSC thermograms of ibuprofen loaded gellan, gellan-DEAE-Dextran composite and bilayer films as 
presented in Figure 142 and 143; Table 92 and 93. The DSC thermograms of Ibuprofen showed 
characteristic sharp endothermic peak at 80.07 °C suggesting its crystallinity, with enthalpy of fusion 
of 118.64 J/g. This melting peak is higher than the literature value for pure ibuprofen in the range of 
75 to 78 °C [41]. This could be due to some impurity in the ibuprofen sample however in a similar 
study, Kumar et al. reported that the melting peak of ibuprofen was 82.76 °C [42], while gellan and 
DEAE-Dextran showed endothermic peaks at 127.86 °C and 124.05 °C respectively. The variation in 
267 | P a g e  
 
the reported ibuprofen melting peak compared to the compedial values could be due to the 
presence of impurities in the sample. 
The ibuprofen peak was not observed in the thermograms of the films, which suggested a complete 
solubilization of the drug in the polymers with loss of crystallinity. This similar trend was observed by 
Barriero-Iglesias where the peak of camptothecin completely disappeared in the thermograms of its 
conjugate films [43]. The melting peak of ibuprofen disappeared in all the film blends incorporated 
with ibuprofen suggesting an interaction between ibuprofen and gellan (GIb) in the binary 
conjugate; between ibuprofen, gellan and DEAE-Dextran in the ternary conjugate GIbDD and 
GIb/DDB (PEC) films. The DSC thermograms of the components of the drug loaded films were shown 
to be compatible since a single melt peak was observed [44]. It also suggests that ibuprofen was 
uniformly dispersed in an amorphous state in the film. The melting peak of GIb film was 142.17 ˚C; 
ranged from 131.87 to 142.40 ˚C for GIbDD films and from 124.28 to 139.16 ˚C for GIb/DDB bilayer 
films in Table 93 and Figure 145. The presence of DEAE-Dextran increased the melting point of the 
binary complex GIb film; ternary complexes GIbDD composite and bilayer films when compared with 
the single component G film. The DSC of gellan and PVA blends exhibiting single melt temperature 
that shifted to higher temperature with increasing amount of PVA had been reported [37]. 
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Figure 142 DSC thermograms of ibuprofen loaded composite films (a) GIb, (b) GIbDD 2:0.125, (c) GIbDD 2:0.25, (d) GIbDD 
2:0.5, (e) GIbDD 2:1, (f) Ibuprofen powder-reference. (g) Gellan powder-reference and (h) DEAE-Dextran powder-
reference. 
Table 92 DSC of ibuprofen loaded gellan and gellan-DEAE-Dextran PEC composite films. Each value represents mean ± SD 
(n = 4). 
Formulation Onset (°C) Peak (°C) End (°C) Delta H (J/g) Area (mJ) 
Ibuprofen-
reference 
76.85±0.64 
236.27±11.36 
82.69±2.46 
264.63±19.41 
86.79±3.27 
273.47±17.20 
92.90±4.32 
203.71±18.79 
826.37±55.04 
1753.15±74.65 
Gellan-reference 77.70±1.55 
246.56±12.37 
127.86±7.43 
264.02±12.75 
186.32±8.76 
270.88±12.86 
168.31±8.81 
-129.64±6.5 
1043.54±52.70 
-803.81±40.22 
DEAE-Dextran-
reference 
87.43±1.22 
187.42±8.23 
245.83±12.74 
124.05±4.16 
201.54±10.58 
268.50±11.78 
158.87±5.34 
210.60±11.45 
281.53±13.66 
139.17±5.64 
12.72±0.84 
70.84±0.92 
960.30±40.48 
87.74±1.25 
488.852±21.22 
G  77.66±2.33 
253.70±8.23 
127.81±4.27 
255.89±10.68 
174.79±7.43 
262.69±11.57 
71.60±1.38 
137.33±5.14 
862.87±38.36 
789.62±31.54 
GIb  79.90±1.22 
253.62±9.08 
142.77±6.36 
257.24±10.13 
190.10±8.32 
268.05±10.21 
182.22±5.43 
202.21±8.15 
902.01±42.76 
1000.93±50.89 
GIbDD 2:0.125  96.38±3.41 
253.95±8.31 
142.40±6.64 
258.01±11.37 
187.59±7.55 
270.64±10.86 
105.80±3.89 
237.38±9.08 
677.15±28.73 
1519.22±63.55 
GIbDD 2:0.25 87.85±2.85 
255.41±9.77 
131.87±5.49 
269.00±12.54 
173.03±6.22 
258.70±11.93 
140.95±4.42 
153.02±5.70 
817.51±35.73 
887.52±38.44 
GIbDD 2:0.5 80.83±3.15 
255.70±8.65 
132.81±5.14 
259.25±11.05 
176.84±6.59 
269.31±12.07 
98.15±3.46 
149.43±5.34 
559.43±27.12 
851.76±34.21 
GIbDD 2:1 91.08±2.31 
254.43±9.38 
140.30±4.86 
259.98±12.01 
192.15±7.55 
268.74±13.43 
74.21±1.82 
156.58±7.31 
452.70±25.61 
955.19±46.44 
 
The DSC curves of ibuprofen, gellan gum and DEAE-Dextran powders showed exothermic peaks at 
264.63 ˚C, 264.02 ˚C and 268.50 ˚C respectively attributed to the disintegration of the molecular 
chains, which corresponds to the step of inflection on the TGA curve. The GIb film showed 
exothermic peak at 257.24 ˚C; from 258.01 to 269.00 ˚C for the GIbDD films while G/DDB films 
ranged from 264.34 to 266.59 ˚C caused by the thermal degradation of the films. The GIbDD and 
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GIb/DDB films were thermally more stable than the G films since they withstand more heat. The DSC 
profile of GIbDD films in Figure 143 exhibited a decrease in melting point up to 0.6% followed by 
increase as DEAE-Dextran concentration increased; and the profile of GIb/DDB exhibited an initial 
decrease, an increase and then a further increase as DEAE-Dextran concentration increased. The 
enthalpy change profile of GIbDD in Figure 143 exhibited an initial decrease, increase and a further 
decrease as DEAE-Dextran concentration increased; and the profile of GIb/DDB exhibited a decrease 
up to 0.5 % and a further increase as the DEAE-Dextran concentration increased. 
 
Figure 143 DSC melting peak profiles of GIbDD and GIb/DDB films. Each data point represents mean ± S.D (n = 4). 
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Figure 144 DSC enthalpy changes of GIbDD and GIb/DDB films. Each data point represents mean ± S.D (n = 4). 
 
 
Figure 145 DSC thermograms of ibuprofen loaded bilayer films (a) GIb/DDB 2:0.125, (b) GIb/DDB 2:0.25, (c) GIb/DDB 
2:0.5, (d) GIb/DDB 2:1 (e) Ibuprofen powder-reference, (f) Gellan powder-reference and  (g) DEAE-Dextran powder-
reference. 
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Table 93 DSC of ibuprofen loaded gellan and gellan-DEAE-Dextran PEC bilayer films. Each value represents mean ± SD (n 
= 4). 
Formulation Onset (°C) Peak (°C) End (°C) Delta H (J/g) Area (mJ) 
Ibuprofen-reference 76.85±0.64 
236.27±11.36 
82.69±2.46 
264.63±19.41 
86.79±3.27 
273.47±17.20 
92.90±4.32 
203.71±18.79 
826.37±55.04 
1753.15±74.65 
Gellan-reference 77.70±1.55 
246.56±12.37 
127.86±7.43 
264.02±12.75 
186.32±8.76 
270.88±12.86 
168.31±8.81 
-129.64±6.5 
1043.54±52.70 
-803.81±40.22 
DEAE-Dextran-
reference 
87.43±1.22 
187.42±8.23 
245.83±12.74 
124.05±4.16 
201.54±10.58 
268.50±11.78 
158.87±5.34 
210.60±11.45 
281.53±13.66 
139.17±5.64 
12.72±0.84 
70.84±0.92 
960.30±40.48 
87.74±1.25 
488.852±21.22 
GIb  79.90±1.22 
253.62±9.08 
142.77±6.36 
257.24±10.13 
190.10±8.32 
268.05±10.21 
182.22±5.43 
202.21±8.15 
902.01±42.76 
1000.93±50.89 
GIb/DDB 2:0.125  78.77±1.51 
260.55±8.89 
133.63±4.72 
264.46±10.60 
178.75±7.55 
272.68±11.06 
113.58±4.02 
96.99±2.97 
681.47±25.65 
581.19±23.42 
GIb/DDB 2:0.25 81.04±2.62 
259.73±9.61 
139.16±5.31 
264.10±11.54 
186.14±6.22 
269.78±11.68 
105.53±3.58 
44.41±0.70 
664.72±25.21 
279.78±12.56 
GIb/DDB 2:0.5 75.91±1.26 
262.58±9.52 
131.08±5.39 
265.07±12.38 
176.29±6.42 
272.04±12.03 
142.45±4.32 
11.88±0.32 
854.69±37.32 
71.25±1.53 
GIb/DDB 2:1 73.46±1.36 
244.80±9.37 
124.28±4.54 
252.33±9.38 
167.21±6.35 
263.16±11.59 
189.88±6.49 
24.91±0.51 
895.30±35.38 
139.55±4.71 
 
4.3.4.2. Thermogravimetric analysis 
TGA complements the DSC technique since they are both thermal analysis technique useful in the 
detection of the inter-atomic and inter/-intra- molecular interactions in relation to external change 
in temperature. The complimentary data obtained allows differentiation between endothermic and 
exothermic events which have no associated weight loss (melting and crystallization) and those 
which involve a weight loss (degradation). TGA analysis was conducted to examine the thermal 
stability and degradation characteristics of the plain composite and bilayer films as presented in 
Figure 146 and 147; Table 93 and 95. The onset temperature denotes the temperature at which 
weight loss begins while the step of inflection point indicates the point of the greatest rate of change 
of the weight loss curve. The G film showed three steps of inflection at 24.99 ˚C, 184.59 ˚C and 
250.62 ˚C with corresponding weight losses of 10.17%, 40.41% and 35.27% respectively and total 
weight loss of 85.85%. The first weight loss was due to the loss of water in the films while the second 
and third weight loss was due to the decomposition of the films. The third weight loss at 250.62 ˚C 
can be correlated to its DSC exothermic peak at 255.89 ˚C in Figure 136 which suggests 
decomposition of the films.  
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The GDD films in Figure 146 exhibited three steps of inflection denoting three distinct thermal 
events. The total weight loss in Table 94 was in the range of 80.93 to 88.50% with an initial decrease, 
an increase and a further decrease with increasing DEAE-Dextran concentration. The residual weight 
left in the range of 18.07 to 11.50% could be attributed to the residual left from the complex. The 
temperature at which the films decomposed was in the range of 250.62 to 309.64 ˚C which 
increased with increasing DEAE-Dextran concentration. It showed that GDD 2:1 with highest 
concentration was the most thermally stable film. This suggests that addition of DEAE-Dextran 
increased the thermal stability of the composite films. 
 
Figure 146 TGA thermograms of gellan and PEC composite films (a) G, (b) GDD 2:0.125, (c) GDD 2:0.25, (d) GDD 2:0.5, (e) 
GDD 2:1, (f) Gellan powder-reference and (g) DEAE-Dextran powder-reference. 
Table 94 TGA of gellan and gellan-DEAE-Dextran PEC composite films. Each value represents mean ± SD (n = 4) 
Formulation Onset (°C) End (°C) Step of inflection (°C) Delta Y (%) 
Gellan-reference 43.99±0.65 
257.79±12.21 
131.17±4.72 
282.29±12.74 
90.39±3.15 
264.91±12.10 
7.85±0.08 
59.67±0.93 
DEAE-Dextran-reference 47.16±0.47 
261.20±11.43 
106.74±4.32 
301.16±15.72 
77.47±1.47 
272.15±12.62 
6.94±0.12 
67.61±0.98 
G  24.99±0.56 
158.64±5.21 
233.83±10.27 
176.56±7.31 
204.82±10.32 
275.67±12.53 
24.99±0.56 
184.91±8.73 
250.62±11.47 
10.17±0.33 
40.41±1.05 
35.27±0.98 
GDD 2:0.125  27.37±0.65 
158.66±5.14 
236.20±10.54 
133.51±7.65 
211.12±9.52 
274.80±12.18 
27.37±0.65 
194.98±9.73 
252.15±11.04 
10.46±0.36 
27.89±0.65 
42.48±1.13 
GDD 2:0.25 42.73±0.97 
168.02±5.31 
240.42±10.13 
85.71±1.93 
214.89±9.66 
278.04±12.38 
65.25±1.08 
199.88±9.41 
255.22±11.44 
13.67±0.72 
45.79±1.28 
29.39±0.84 
GDD 2:0.5 26.26±0.67 
164.13±6.15 
239.73±10.21 
126.51±4.43 
214.30±9.32 
292.60±13.58 
26.26±0.67 
196.53±8.87 
258.33±11.25 
13.38±0.59 
44.75±1.47 
27.47±0.75 
GDD 2:1 36.62±0.98 
158.54±5.75 
290.80±13.15 
76.68±1.46 
259.18±13.32 
357.26±16.28 
40.23±1.04 
189.16±8.96 
309.64±15.81 
7.28±0.48 
61.10±1.46 
13.42±0.43 
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The G/DDB PEC films in Figure 1468 exhibited three steps of inflection denoting three distinct 
thermal events except G/DDB 2:1 which exhibited two steps. The total weight loss in Table 95 was in 
the range of 77.16 to 89.26% with a maxima value at 0.25% DEAE-Dextran and a further decrease 
with increase in DEAE-Dextran concentration. The weight loss in the range of 251.18 to 255.20 ˚C 
attributed to decomposition, exhibited increase in weight loss with increase in DEAE-Dextran except 
G/DDB 2:1 which was least the thermally stable film. This suggests that addition of DEAE-Dextran 
increased the thermal stability of the films up to 0.8%. 
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Figure 147 TGA/DTG thermograms of (A) G, (B) GDD and (C) G/DDB Films. 
A 
B 
C 
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Figure 148 TGA thermograms of  bilayer films  (a) G/DDB 2:0.125, (b) G/DDB 2:0.25, (c) G/DDB 2:0.5,  (d) G/DDB 2:1, (e) 
Gellan powder-reference and (f) DEAE-Dextran powder-reference. 
Table 95 TGA of gellan and gellan-DEAE-Dextran PEC bilayer films. Each value represents mean ± SD (n = 4). 
Formulation Onset (˚C) End (˚C) Step of inflection (˚C) Delta Y (%) 
Gellan-reference 43.99±0.65 
257.79±12.21 
131.17±4.72 
282.29±12.74 
90.39±3.15 
264.91±12.10 
7.85±0.08 
59.67±0.93 
DEAE-Dextran-reference 47.16±0.47 
261.20±11.43 
106.74±4.32 
301.16±15.72 
77.47±1.47 
272.15±12.62 
6.94±0.12 
67.61±0.98 
G  24.99±0.56 
158.64±5.21 
233.83±10.27 
176.56±7.31 
204.82±10.32 
275.67±12.53 
24.99±0.56 
184.91±8.73 
250.62±11.47 
10.17±0.33 
40.41±1.05 
35.27±0.98 
G/DDB 2:0.125  26.43±0.97 
148.67±5.32 
233.06±10.45 
124.51±5.56 
198.46±9.25 
277.49±12.36 
26.43±0.97 
176.14±7.37 
252.17±11.24 
6.95±0.21 
16.12±0.56 
58.66±1.23 
G/DDB 2:0.25 26.27±0.78 
146.32±5.40 
238.49±10.35 
89.46±2.95 
203.89±9.25 
275.23±12.07 
34.87±0.86 
180.88±8.32 
253.94±12.03 
14.78±0.52 
17.09±0.67 
57.39±1.14 
G/DDB 2:0.5 26.33±0.52 
166.90±6.26 
234.53±10.16 
149.61±4.12 
210.75±9.73 
284.13±12.85 
26.33±0.52 
212.59±9.96 
255.20±11.52 
8.29±0.24 
11.69±0.47 
57.18±1.25 
G/DDB 2:1 25.59±0.47 
228.95±9.57 
151.36±5.87 
277.92±12.23 
25.59±0.47 
251.18±10.69 
8.69±0.48 
68.68±1.64 
 
TGA thermograms of ibuprofen loaded composite and bilayer films were presented in Figure 149 
and 150; Table 97 and 97. Ibuprofen exhibited one step of inflection at 240.76 ˚C attributed to the 
heat of decomposition of the drug  with a complete weight loss of 99.50%; while gellan and DEAE-
Dextran powder reference exhibited two steps of inflection with a total weight loss of 67.52% and 
74.55% respectively. The GIb film showed two steps of inflection at 41.24 ˚C and 201.63 ˚C with 
corresponding weight losses of 8.81%, and 78.99% respectively and total weight loss of 87.80% in 
Table 96. The first weight loss was due to the loss of free water in the films while the second weight 
loss was due to the decomposition of the films. The addition of Ibuprofen to the film GIb exhibited 
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lower temperature of decomposition at 201.63 ˚C compared to G film at 250.62 ˚C suggesting 
reduced thermal stability of the GIb film. The GIbDD films in Figure 149 exhibited three steps of 
inflection denoting three distinct thermal events in the range of 25.98 to 29.54 ˚C; 195.97 to 199.4 ˚C 
and 451.62 to 456.20 ˚C. The total weight loss was in the range of 83.15% and 86.65% exhibiting two 
minima values with increasing DEAE-Dextran concentration. The marked increase in the second 
decomposition temperature to about 450 ˚C suggests that the addition of DEAE-Dextran to form the 
ternary complex further increased the thermal stability of GIbDD films greatly. 
 
Figure 149 TGA thermograms of ibuprofen loaded composite films (a) GIb, (b) GIbDD 2:0.125, (c) GIbDD 2:0.25, (d) 
GIbDD 2:0.5, (e) GIbDD 2:1, (f) Ibuprofen powder-reference. (g) Gellan powder-reference and (h) DEAE-Dextran-
reference. 
Table 96 TGA of ibuprofen loaded gellan and gellan-DEAE-Dextran PEC composite films. Each value represents mean ± 
SD (n = 4). 
Formulation Onset (˚C) End (˚C) Step of inflection (˚C) Delta Y (%) 
Ibuprofen-reference 207.81 ±11.23 247.08±11.87 240.76±12.32 99.50±1.95 
Gellan-reference 43.99±0.65 
257.79±12.21 
131.17±4.72 
282.29±12.74 
90.39±3.15 
264.91±12.10 
7.85±0.08 
59.67±0.93 
DEAE-Dextran-reference 47.16±0.47 
261.20±11.43 
106.74±4.32 
301.16±15.72 
77.47±1.47 
272.15±12.62 
6.94±0.12 
67.61±0.98 
G  24.99±0.56 
158.64±5.21 
233.83±10.27 
176.56±7.31 
204.82±10.32 
275.67±12.53 
24.99±0.56 
184.91±8.73 
250.62±11.47 
10.17±0.33 
40.41±1.05 
35.27±0.98 
GIb  39.52±0.87 
167.81±6.45 
57.53±1.24 
241.04±11.62 
41.24±1.21 
201.63±9.37 
8.81±0.27 
78.99±1.06 
GIbDD 2:0.125  26.41±0.56 
164.89±5.71 
416.43±33.42 
127.47±4.86 
245.20±10.54 
468.12±35.37 
26.41±0.56 
199.34±9.47 
455.69±34.32 
7.89±0.41 
68.54±1.25 
9.10±0.37 
GIbDD 2:0.25 25.98±0.97 
164.74±6.28 
421.21±32.76 
122.65±5.21 
252.36±10.73 
475.82±36.74 
25.98±0.97 
197.99±10.36 
461.06±35.28 
9.61±0.29 
68.34±1.52 
7.89±0.18 
GIbDD 2:0.5 26.25±0.61 
162.83±6.45 
413.66±32.31 
125.12±5.74 
260.14±14.23 
482.96±37.58 
26.25±0.61 
195.97±10.87 
456.20±35.25 
10.28±0.37 
69.35±1.12 
7.02±0.22 
GIbDD 2:1 29.54±0.73 
167.20±6.75 
404.08±31.03 
126.51±4.67 
273.22±12.64 
475.98±37.11 
29.54±0.73 
199.17±10.96 
451.62±34.19 
8.77±0.43 
68.99±0.21 
5.39±0.12 
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The GIb/DDB films in Figure 150 exhibited three steps of inflection denoting three distinct thermal 
events in the range of 22.87 to 26.33 ˚C; 188.50 to 197.99 ˚C and 250.24 to 257.53 ˚C. The total 
weight loss was in the range of 77.22 to 81.60% which exhibited decrease with increasing DEAE-
Dextran concentration.  
 
Figure 150 TGA thermograms of  ibuprofen loaded bilayer films (a) GIb, (b) GIb/DDB 2:0.125, (c) GIb/DDB 2:0.25, (d) 
GIb/DDB 2:0.5, (e) GIb/DDB 2:1 (f) Ibuprofen powder-reference, (g) Gellan powder-reference and (h) DEAE-Dextran 
powder-reference. 
Table 97 TGA of ibuprofen loaded gellan and gellan-DEAE-Dextran PEC bilayer films. Each value represents mean ± SD (n 
= 4). 
Formulation Onset (˚C) End (˚C) Step of inflection (˚C) Delta Y (%) 
Ibuprofen-reference 207.81±11.23 247.08±11.87 240.76±12.32 99.50±1.95 
Gellan-reference 43.99±0.65 
257.79±12.21 
131.17±4.72 
282.29±12.74 
90.39±3.15 
264.91±12.10 
7.85±0.08 
59.67±0.93 
DEAE-Dextran-reference 47.16±0.47 
261.20±11.43 
106.74±4.32 
301.16±15.72 
77.47±1.47 
272.15±12.62 
6.94±0.12 
67.61±0.98 
GIb  
 
39.52±0.87 
167.81±6.45 
57.53±1.24 
241.04±11.62 
41.24±1.21 
201.63±9.37 
8.81±0.27 
78.99±1.06 
GIb/DDB 2:0.125  24.85±0.78 
192.14±5.71 
125.37±4.68 
285.26±12.54 
24.85±0.78 
251.30±10.73 
8.33±0.41 
73.27±1.21 
GIb/DDB 2:0.25 25.98±0.97 
164.74±6.28 
231.17±10.64 
122.65±5.21 
252.36±10.73 
281.28±12.47 
25.98±0.97 
197.99±10.36 
252.30±10.82 
14.78±0.58 
17.09±0.52 
48.44±0.98 
GIb/DDB 2:0.5 26.33±0.52 
166.90±6.45 
229.13±10.17 
149.61±5.74 
210.75±14.23 
285.99±13.85 
26.33±0.52 
194.51±10.87 
250.24±11.27 
10.28±0.37 
17.58±0.43 
52.54±0.56 
GIb/DDB 2:1 22.87±0.56 
157.68±5.88 
239.93±31.03 
42.49±4.67 
207.64±13.71 
285.32±37.11 
22.87±0.56 
188.50±9.28 
257.53±14.11 
7.30±0.35 
16.89±0.67 
53.03±0.61 
4.3.5. Swelling kinetics 
An important property of biopolymer film is the swelling ratio which gives the amount of water 
absorbed by films. The polymer films were subjected to swelling tests in PBS pH 7.4. The results 
were presented in Figures 151 and 152. Gellan film increased in swelling with increasing contact 
time in PBS pH 7.4. The hydrophilic nature of gellan polysaccharide makes it readily absorb water 
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which results in changes of its structure. The films reached equilibrium at 6 h as shown in Figure 151 
and 152. 
The swelling ratio ranged from 2.65 to 3.27 times its dried weight in PBS pH 7.4 at 37 ˚C for GDD 
films; 3.59 to 3.98 times for G/DDB films. The average equilibrium swelling ratio (SR) of G film was 
2.58 ± 0.03. Statistical analysis showed that the addition of DEAE-Dextran to gellan significantly 
increased (p < 0.05, n = 4) the swelling ratio of the GDD and G/DDB films. The swelling ratio 
increased in the order: GDD 2:0.25 > GDD 2:0.125 > GDD 2:0.5 > GDD 2:1 > G for GDD films. The 
swelling ratio increased in the order: G/DDB 2:0.25 > G/DDB 2:0.125 > G/DDB 2:0.5 > G/DDB 2:1 > G 
for G/DDB films. The same trend or profile was observed in the composite and bilayer films. The 
swelling behavioural pattern showed a higher swelling ratio in the G/DDB complexes when 
compared with the GDD films indicating a higher capability to retain water. In the G/DDB and GDD 
complex films, the polymer network is loose with more hydrodynamic free volume with capacity to 
absorb more water leading to higher swelling.  
 
Figure 151 The swelling ratio of gellan and GDD composite films in PBS pH 7.4 at 37oC. Each data point represents mean 
± SD (n = 4). 
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Figure 152 The swelling ratio of gellan and G/DDB bilayer films in PBS pH 7.4 at 37 ˚C. Each data point represents mean ± 
SD (n = 4). 
The swelling of the drug loaded films reached equilibrium at 6 h in Figure 153 and 154. The swelling 
ratio ranged from 4.37 to 6.84 times its dried weight in PBS pH 7.4 at 37 ˚C for GIbDD films; 4.67 to 
5.10 times for GIb/DDB films. The average equilibrium swelling ratio (SR) of GIb film was 2.85 
(±0.12). The swelling ratio increased in the order: GIbDD 2:0.25 > GIbDD 2:0.125 > GIbDD 2:0.5 > 
GIbDD 2:1 > GIb for GIbDD composite films. The swelling ratio increased in the order: GIb/DDB 
2:0.25 > GIb/DDB 2:0.125 > GIb/DDB 2:0.5 > GIb/DDB 2:1 > GIb for GIb/DDB bilayer films. The 
swelling behavioural pattern showed a higher swelling ratio in the GIbDD composite films when 
compared with the GIb/DDB bilayer films. It also showed that incorporation of ibuprofen 
significantly increased (p < 0.05, n = 4) the swelling of the films when compared with films without 
the drug. In the drug loaded complexes, the polymer network is loose with more hydrodynamic free 
volume with capacity to absorb more water leading to higher swelling.  
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Figure 153 The swelling ratio of ibuprofen loaded gellan and gellan-DEAE-Dextran PEC composite films in PBS pH 7.4 at 
37 ˚C. Each data point represents mean ± SD (n = 4). 
 
Figure 154 The swelling ratio of ibuprofen loaded gellan and gellan-DEAE-Dextran PEC bilayer films in PBS pH 7.4 at 37˚C. 
Each data point represents mean ± SD (n = 4). 
4.3.6. Drug release from composite and bilayer films  
The release profiles of ibuprofen from gellan, gellan-DEAE-Dextran composite and bilayer complex 
films in PBS pH 7.4 are shown in Figures 155 and 156 respectively. Drug release from matrices is 
preceded by polymer hydration. Hydration of the polymeric films in the dissolution medium 
triggered the release of ibuprofen from the film. The drug release profile of ibuprofen from the 
composite and bilayer films was divided into three phases shown in Figures 166 to 172 in the 
Appendix I. The cumulative release of ibuprofen from GIb films (50.61%) was lower than the ternary 
complex GIbDD composite films (69.59 to 79.44%). An increased rate of release was exhibited by the 
GIbDD films compared with the GIb films within the first 30 min. The GIb films maintained a constant 
release rate which slowly increased beyond 2 h. The third phase of drug release between 2 and 24 h 
showed a steady increase from 2 to 4 h and a further constant rate of release up to 24 h. The drug 
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release profile from the bilayer films within the first 30 min showed a slow release rate which 
continued till 24 h. The maximum ibuprofen released from GIb films was 71.52%; of the range of 
80.49 to 99.76% for GIbDD films of the range 31.8 to 47.37% for GIb/DDB films. The statistical 
analysis of the drug release profiles indicated that for GIbDD films, the ibuprofen release significantly 
increased (p < 0.05, n = 4) with increase in DEAE-Dextran concentration. Bajpai et al. studied the 
release of potassium nitrate from alginate/pectin beads and also observed that the release rate of 
potassium nitrate increased with increase in pectin concentration [45].  Ibuprofen release from 
GIb/DDB films was significantly reduced (p < 0.05, n = 4) when compared to GIb and GIbDD films. In 
the GIb/DDB films, a considerable amount of ibuprofen was washed out during the bilayer formation 
process when the films were immersed in DEAE-Dextran solutions. Part of ibuprofen migrated into 
the DEAE-Dextran solution during the process.  This was evident from the SEM micrographs in Figure 
119 where empty pores showing depletion of ibuprofen on the surface morphology of the films 
were observed. The release profiles of the GIb, GIbDD and GIb/DDB films exhibited burst release 
from the films. The initial burst release could be due to the ibuprofen molecules being physically and 
chemically entrapped. This similar initial burst release trend was reported by Yan et al. where there 
was burst release of Rhodamine B from nanoporous polymer (N-vinylpyrrolidinone and 
dipentaerythritol penta/hexa-acrylate) thin film [46]. This may be due to increased swelling ratio of 
the films and fast dissolution of the weakly incorporated ibuprofen in the film matrix resulting in 
rapid release of ibuprofen into the buffer medium. The slow ibuprofen release rate in the later stage 
may be related to the chemical bonding between ibuprofen and DEAE-Dextran, therefore the drug 
release rate was controlled by the equilibrium between bonding with DEAE-Dextran and dissolution 
in aqueous medium. At the last plateau stage, the release was quite slow and maintained the release 
up to 24 h. 
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Figure 155 Release profile of ibuprofen from Gellan, Gellan-DEAE-Dextran composite films in PBS pH 7.4. Each data point 
represents mean ± SD (n = 4). 
 
Figure 156 Release profile of ibuprofen from Gellan, Gellan-DEAE-Dextran complex bilayer films in PBS pH 7.4. Each data 
point represents mean ± SD (n = 4). 
4.3.7. Drug release kinetics 
To examine the drug release kinetics, the data were fitted to models representing zero order (Q v/s 
t), first order (Log Q0 – Q) v/s t), Higuchi (Q v/s t
0.5) and Korsemeyer-Peppas (Log Q v/s Log t). The 
data was best fitted with the Korsemeyer-Peppas models for GIb, GIbDD and GIb/DDB films. The 
diffusional exponents (n) values obtained are shown in Table 98 and 99 for GIb, GIbDD and GIb/DDB 
films.  
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For GIb, GIbDD 2:0.25 composite and GIb/DDB bilayer films the release mechanisms exhibited were 
Fickian (n < 0.5); therefore the release rate was linear to t0.5. While GIbDD 2:0.125, GIbDD 2:0.5 and 
GIbDD 2:1 composite films exhibited non-Fickian diffusion where diffusion exponent (n) is 0.5 < n < 
1, therefore anomalous transport or polymer relaxation was the predominating mechanism [47]. 
Here, the diffusion rate of the solvent and the relaxation of the polymeric chains are of the same 
order of magnitude; and a deviation from the Fickian behaviour. Ozdemir and Floros also observed 
an anomalous diffusion mechanism for whey protein films with potassium sorbate [48]. This was 
also observed by Bierhalz et al. for alginate/pectin films with natamycin [33] 
Table 98 Regression coefficient (r) values of different kinetic models and diffusion exponent (n) of Korsemeyer-Peppas 
models for the release of ibuprofen from Gellan, Gellan-DEAE-Dextran complex composite films in PBS pH 7.4.  
Formulation Zero order First Order Higuchi Korsemeyer-Peppas 
 R2 R2 R2 R2 n 
GIb  0.45 0.42 0.72 0.85 0.078 
GIbDD 2:0.125  0.20 0.15 0.39 0.99 0.633 
GIbDD 2:0.25 0.38 0.32 0.63 0.99 0.271 
GIbDD 2:0.5 0.39 0.35 0.65 1.00 0.901 
GIbDD 2:1 0.29 0.22 0.51 1.00 0.941 
 
Table 99 Regression coefficient (r) values of different kinetic models and diffusion exponent (n) of Korsemeyer-Peppas 
models for the release of ibuprofen from Gellan, Gellan-DEAE-Dextran complex bilayer films in PBS pH 7.4.  
Formulation Zero order First Order Higuchi Korsemeyer-Peppas 
 R2 R2 R2 R2 n 
GIb  0.45 0.42 0.72 0.85 0.078 
GIb/DDB 2:0.125  0.49 0.45 0.75 0.97 0.076 
GIb/DDB 2:0.25 0.29 0.26 0.53 0.85 0.076 
GIb/DDB 2:0.5 0.69 0.65 0.89 0.94 0.071 
GIb/DDB 2:1 0.36 0.30 0.61 0.87 0.120 
4.3.8. Similarity of drug release profiles (Similarity factor f2) 
Comparing the drug release profile of GIbDD (ternary) composite films with the GIb (binary) films 
based on model independent similarity factor, the f2 values obtained were in the range of 52.32 to 
76.11, decreasing with increase in concentration of DEAE-Dextran shown in Table 107. All the f2 
values were above the limit value of 50 suggesting that the drug release from the GIbDD composite 
films were similar to that of the GIb films. However, for the GIb/DDB bilayer films, the f2 values of 
GIb/DDB 2:0.125 and GIb/DDB 2:0.5 films were lower than the limit value 50 (45.00 and 49.81 in 
Table 108) suggesting dissimilarity in the drug release profiles while GIb/DDB 2:0.25 and GIb/DDB 
2:1 were above 50 suggesting similarity in the profiles. 
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4.4. Conclusion 
A novel pharmaceutical nanoconjugate film was prepared by simple aqueous cast method to form 
composite films from electrostatic interaction between gellan and DEAE-Dextran. The bilayer films 
were formed by immersion of gellan films into DEAE-Dextran solutions. The inclusion of DEAE-
Dextran produced weaker and less flexible films than the control gellan film. The DSC and TGA 
thermograms confirmed the formation of a single eutectic product which was evidenced by single 
endothermic peak. The swelling behavioural pattern showed a higher swelling ratio in the G/DDB 
complexes when compared with the GDD films.  The gellan and PEC films loaded with ibuprofen 
showed layered spheres on the surface morphology suggesting inclusion of ibuprofen in the PEC 
nanoconjugates. This was confirmed by the FTIR findings which showed the disappearance of 
ibuprofen peaks in the spectra of the binary and ternary complexes suggesting electrostatic and 
hydrophobic interaction as well as hydrogen bonding between ibuprofen and the polymers. The 
GIbDD complexes showed higher swelling ratio compared with the GIb/DDB films indicating a 
possible mechanism of release of ibuprofen from the conjugate film. The maximum ibuprofen 
released from GIb, GIbDD and GIb/DDB films were 71.52%, 99.76% and 47.37% respectively. The 
most prominent release mechanisms were Fickian diffusion and anomalous mechanisms. Overall, 
the nanoconjugate composite films produced a near complete release (99.76%) compared with the 
control film within 48h. It was concluded that the nanoconjugate composite films demonstrated 
potential application in the delivery of poorly soluble drugs.  
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CHAPTER FIVE 
5.0. Recommended future works  
 The stability studies of the nanoconjugates, hydrogels and films will be carried out to 
determine the stability and predict the shelf life of the products. 
 The effects of different pHs on the swelling kinetics of the hydrogels and films will be 
studied. 
 The effects of pH and ionic strength on the drug release profiles of the nanoconjugate 
products will be studied.  
 The potential mucoadhesive performance of the bilayer films based on the presence of the 
DEAE-Dextran will be investigated using a texture analyzer. 
 Scaling up of production batches. 
 Finally, the efficacy studies of the hydrogels will be evaluated based on animal models/ 
invitro test to determine the mechanism of enhanced effect of their analgesic and anti-
inflammatory properties. 
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6.0. Appendix I 
Table 100 Particle size measurements from SEM images of IbDMelt, IbDNaOH, IbDTw80 and IbDNic nanoconjugates. 
Concentration code  Particle size measurements from SEM (nm) 
 IbDMelt IbDNaOH IbDTw80 IbDNic 
1 170.67±34.15 364.90±6.34 111.6±6.56 77.52±8.55 
2 295.87±73.54 108.40±1.32 101.88±16.16 108.73±3.56 
3 315.33±63.09 249.73±34.21 62.72±3.88 150.93±5.00 
4 807.10±89.41 89.93±6.44 51.03±10.31 161.90±18.23 
5 122.73±14.00 60.36±6.77 38.76±4.73 162.73±5.34 
 
Table 101 Particle size measurements from SEM images of IbDMelt, IbDNaOH, IbDTw80 and IbDNic nanoconjugates. 
Concentration code  Particle size measurements from SEM (nm) 
 IbChMelt IbChNaOH IbChTw80 IbChNic 
1 261.27±22.15 6320.00±170.00 166.20±42.88 114.83±9.60 
2 303.13±37.50 2300.00±920.00 221.93±58.91 191.00±22.10 
3 405.07±48.26 8050.00±2430.00 379.43±21.81 197.07±26.27 
4 433.63±13.78 9290.00±1280.00 395.37±17.81 385.83±30.02 
5 602.37±119.86 9840.00±700.00 498.87 ±160.20 2.60±0.40 
 
 
Figure 157 Calibration curve for ibuprofen at 264 nm. Each data point represents mean ± SD (n = 10). 
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Figure 158 Effect of DEAEDextran on the release of ibuprofen from the conjugates at 24 h. 
 
Figure 159 Effect of chitosan on the release of ibuprofen from the conjugates at 24 h. 
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Figure 160 Effect of polymer concentrations on ibuprofen release from the ternary conjugates. 
Table 102 Similarity factor f2 for ibuprofen control versus ibuprofen – DEAE-Dextran conjugates. 
Concentration code  f2 – Similarity factor 
 IbDMelt IbDNaOH IbDTw80 IbDNic 
1 79.53 45.94 40.38 30.61 
2 45.27 43.83 38.22 31.08 
3 51.19 42.38 36.54 35.21 
4 63.08 43.92 35.60 31.34 
5 48.95 49.41 38.54 32.34 
 
Table 103 Similarity factor f2 for ibuprofen control versus ibuprofen – chitosan conjugates. 
Concentration code  f2 – Similarity factor 
 IbChMelt IbChNaOH IbChTw80 IbChNic 
1 95.17 44.60 54.18 31.17 
2 73.78 46.03 55.96 31.10 
3 78.58 48.49 55.35 31.16 
4 49.81 49.79 52.35 30.75 
5 61.76 50.92 54.30 31.38 
 
Table 104 Similarity factor f2 for ibuprofen control versus ibuprofen loaded DEAE-Dextran-gellan (DG) or chitosan/gellan 
(CG) conjugates. 
Mixing ratio f2 – Similarity factor 
 DG CG 
0:100 33.38 34.73 
25:75 53.02 65.46 
50:50 47.62 34.18 
75:25 35.11 34.27 
100:0 33.32 32.96 
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Table 105 The pH of polymeric complex hydrogels. Each value represents mean ± SD (n = 4). 
Formulation pH 
G  6.27±0.12 
GDD 2:0.125  6.12±0.28 
GDD 2:0.25 6.20±0.07 
GDD 2:0.5 6.04±0.08 
GDD 2:1 6.17±0.14 
GIb  5.99±0.14 
GIbDD 2:0.125  5.92±0.04 
GIbDD 2:0.25 5.93±0.06 
GIbDD 2:0.5 5.90±0.08 
GIbDD 2:1 5.95±0.04 
 
 
Figure 161 Release profile of ibuprofen from GIb and GIbDD complex hydrogels within the first hour. 
 
Figure 162 Release profile of ibuprofen from GIb and GIbDD complex hydrogels between 1 and 4 h. 
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Figure 163 Release profile of ibuprofen from GIb and GIbDD complex hydrogels between 4 and 48 h. 
Table 106 Similarity factor f2 for GIb versus GIbDD complex hydrogels. 
Formulation f2 – Similarity factor 
GIbDD 2:0.125  68.97 
GIbDD 2:0.25 70.64 
GIbDD 2:0.5 71.48 
GIbDD 2:1 74.60 
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Figure 164 Topography trace images for (A) plain gellan G (B) composite GDD (C) ibuprofen loaded gellan GIb and (D) 
ibuprofen loaded composite GIbDD films. 
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Figure 165 Amplitude trace images for (A) plain gellan G (B) composite GDD (C) ibuprofen loaded gellan GIb and (D) 
ibuprofen loaded composite GIbDD films. 
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Figure 166 Phase trace images for (A) plain gellan G (B) composite GDD (C) ibuprofen loaded gellan GIb and (D) 
ibuprofen loaded composite GIbDD films. 
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Figure 167 Release profile of ibuprofen from GIb and GIbDD complex composite films within the first 30 min. 
 
Figure 168 Release profile of ibuprofen from GIb and GIbDD complex composite films from 30 to 120 min. 
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Figure 169 Release profile of ibuprofen from GIb and GIbDD complex composite films from 120 to 1440 min. 
 
Figure 170 Release profile of ibuprofen from GIb and GIbDD complex bilayer films within the first 30 min. 
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Figure 171 Release profile of ibuprofen from GIb and GIbDD complex bilayer films from 30 to 120 min. 
 
Figure 172 Release profile of ibuprofen from GIb and GIbDD complex bilayer films from 120 to 1440 min. 
Table 107 Similarity factor f2 for GIb versus GIbDD composite films.  
Formulation f2 – Similarity factor 
GIbDD 2:0.125  76.11 
GIbDD 2:0.25 58.95 
GIbDD 2:0.5 53.43 
GIbDD 2:1 52.32 
Table 108 Similarity factor f2 for GIb versus GIb/DDB bilayer films. 
Formulation f2 – Similarity factor 
GIb/DDB 2:0.125  45.00 
GIb/DDB 2:0.25 50.81 
GIb/DDB 2:0.5 49.81 
GIb/DDB 2:1 55.67 
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6.1. Appendix II APS poster presentation at the University of 
Nottingham UK (September 2012) 
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AAPS Abstract poster presentation at San Anthonio Texas (November 2013) 
 
